WO2018013589A1 - Methods and compositions for thymic transplantation - Google Patents
Methods and compositions for thymic transplantation Download PDFInfo
- Publication number
- WO2018013589A1 WO2018013589A1 PCT/US2017/041566 US2017041566W WO2018013589A1 WO 2018013589 A1 WO2018013589 A1 WO 2018013589A1 US 2017041566 W US2017041566 W US 2017041566W WO 2018013589 A1 WO2018013589 A1 WO 2018013589A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- thymic
- factor
- cells
- function
- Prior art date
Links
- 230000002992 thymic effect Effects 0.000 title claims abstract description 662
- 238000000034 method Methods 0.000 title claims abstract description 220
- 239000000203 mixture Substances 0.000 title claims description 28
- 238000002054 transplantation Methods 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims description 341
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 265
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 claims description 209
- 210000001541 thymus gland Anatomy 0.000 claims description 154
- 108091008874 T cell receptors Proteins 0.000 claims description 113
- 230000007423 decrease Effects 0.000 claims description 96
- 230000000694 effects Effects 0.000 claims description 91
- -1 by at least 10% Chemical compound 0.000 claims description 88
- 238000011282 treatment Methods 0.000 claims description 73
- 230000035755 proliferation Effects 0.000 claims description 55
- 238000002360 preparation method Methods 0.000 claims description 52
- 230000001965 increasing effect Effects 0.000 claims description 48
- 102000000588 Interleukin-2 Human genes 0.000 claims description 45
- 108010002350 Interleukin-2 Proteins 0.000 claims description 43
- 230000003247 decreasing effect Effects 0.000 claims description 39
- 210000002536 stromal cell Anatomy 0.000 claims description 39
- 230000013632 homeostatic process Effects 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 210000001789 adipocyte Anatomy 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 30
- 239000003102 growth factor Substances 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 26
- 239000003550 marker Substances 0.000 claims description 25
- 230000006378 damage Effects 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 238000004458 analytical method Methods 0.000 claims description 18
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 17
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 17
- 230000012292 cell migration Effects 0.000 claims description 16
- 210000003289 regulatory T cell Anatomy 0.000 claims description 16
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 15
- 238000010186 staining Methods 0.000 claims description 15
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 14
- 230000001413 cellular effect Effects 0.000 claims description 14
- 230000009758 senescence Effects 0.000 claims description 14
- 238000003556 assay Methods 0.000 claims description 13
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 12
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 12
- 238000002604 ultrasonography Methods 0.000 claims description 12
- 208000014674 injury Diseases 0.000 claims description 11
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000000724 thymus hormone Substances 0.000 claims description 9
- 238000012879 PET imaging Methods 0.000 claims description 8
- 230000006052 T cell proliferation Effects 0.000 claims description 8
- 238000009826 distribution Methods 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 239000011324 bead Substances 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 6
- 230000002093 peripheral effect Effects 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 230000004907 flux Effects 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 claims description 3
- 108010003422 Circulating Thymic Factor Proteins 0.000 claims description 3
- 238000001516 cell proliferation assay Methods 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 230000003190 augmentative effect Effects 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 230000009258 tissue cross reactivity Effects 0.000 claims 1
- 238000011124 ex vivo culture Methods 0.000 abstract description 3
- 230000006870 function Effects 0.000 description 517
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 110
- 230000012010 growth Effects 0.000 description 86
- 230000014509 gene expression Effects 0.000 description 77
- 108090000765 processed proteins & peptides Proteins 0.000 description 75
- 108090000623 proteins and genes Proteins 0.000 description 73
- 239000003446 ligand Substances 0.000 description 71
- 239000003795 chemical substances by application Substances 0.000 description 66
- 102000005962 receptors Human genes 0.000 description 62
- 108020003175 receptors Proteins 0.000 description 62
- 102000004196 processed proteins & peptides Human genes 0.000 description 56
- 229920001184 polypeptide Polymers 0.000 description 51
- 108020004999 messenger RNA Proteins 0.000 description 50
- 230000009368 gene silencing by RNA Effects 0.000 description 43
- 239000000523 sample Substances 0.000 description 42
- 108091030071 RNAI Proteins 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 41
- 206010028980 Neoplasm Diseases 0.000 description 39
- 239000003814 drug Substances 0.000 description 39
- 210000001519 tissue Anatomy 0.000 description 38
- 102000004190 Enzymes Human genes 0.000 description 37
- 108090000790 Enzymes Proteins 0.000 description 37
- 229940088598 enzyme Drugs 0.000 description 37
- 238000013518 transcription Methods 0.000 description 35
- 230000035897 transcription Effects 0.000 description 35
- 238000011269 treatment regimen Methods 0.000 description 34
- 229940088597 hormone Drugs 0.000 description 30
- 239000005556 hormone Substances 0.000 description 30
- 150000007523 nucleic acids Chemical class 0.000 description 30
- 238000004113 cell culture Methods 0.000 description 29
- 238000011161 development Methods 0.000 description 29
- 230000018109 developmental process Effects 0.000 description 29
- 229940124597 therapeutic agent Drugs 0.000 description 29
- 102000035195 Peptidases Human genes 0.000 description 28
- 108091005804 Peptidases Proteins 0.000 description 28
- 230000001973 epigenetic effect Effects 0.000 description 28
- 210000004443 dendritic cell Anatomy 0.000 description 27
- 230000002441 reversible effect Effects 0.000 description 27
- 102100023471 E-selectin Human genes 0.000 description 23
- 102100020880 Kit ligand Human genes 0.000 description 23
- 201000011510 cancer Diseases 0.000 description 23
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 23
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 22
- 210000004379 membrane Anatomy 0.000 description 22
- 239000012528 membrane Substances 0.000 description 22
- 102000039446 nucleic acids Human genes 0.000 description 22
- 108020004707 nucleic acids Proteins 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- 230000005012 migration Effects 0.000 description 21
- 238000013508 migration Methods 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 230000001086 cytosolic effect Effects 0.000 description 20
- 210000002919 epithelial cell Anatomy 0.000 description 20
- 102000040945 Transcription factor Human genes 0.000 description 18
- 108091023040 Transcription factor Proteins 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- 230000009466 transformation Effects 0.000 description 18
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 17
- 108010024212 E-Selectin Proteins 0.000 description 17
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 17
- 102000016267 Leptin Human genes 0.000 description 17
- 108010092277 Leptin Proteins 0.000 description 17
- 230000004069 differentiation Effects 0.000 description 17
- 229940039781 leptin Drugs 0.000 description 17
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 17
- 102000019034 Chemokines Human genes 0.000 description 16
- 108010012236 Chemokines Proteins 0.000 description 16
- 108010036466 E2F2 Transcription Factor Proteins 0.000 description 16
- 102100024024 Transcription factor E2F2 Human genes 0.000 description 16
- 108060003393 Granulin Proteins 0.000 description 14
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 239000004365 Protease Substances 0.000 description 14
- 102000006255 nuclear receptors Human genes 0.000 description 14
- 108020004017 nuclear receptors Proteins 0.000 description 14
- 235000019833 protease Nutrition 0.000 description 14
- 235000019419 proteases Nutrition 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 102000000844 Cell Surface Receptors Human genes 0.000 description 13
- 108010001857 Cell Surface Receptors Proteins 0.000 description 13
- 108010002586 Interleukin-7 Proteins 0.000 description 13
- 102100021592 Interleukin-7 Human genes 0.000 description 13
- 101150010310 WNT-4 gene Proteins 0.000 description 13
- 102000052548 Wnt-4 Human genes 0.000 description 13
- 108700020984 Wnt-4 Proteins 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 13
- 238000003384 imaging method Methods 0.000 description 13
- 230000006872 improvement Effects 0.000 description 13
- 108700028369 Alleles Proteins 0.000 description 12
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 12
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 12
- 102000012004 Ghrelin Human genes 0.000 description 12
- 101800001586 Ghrelin Proteins 0.000 description 12
- 108090001005 Interleukin-6 Proteins 0.000 description 12
- 101710177504 Kit ligand Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 210000004180 plasmocyte Anatomy 0.000 description 12
- 150000003384 small molecules Chemical class 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 11
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 11
- 102100030704 Interleukin-21 Human genes 0.000 description 11
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 11
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 11
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 11
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 11
- 101150113268 ghrl gene Proteins 0.000 description 11
- 108010074108 interleukin-21 Proteins 0.000 description 11
- 125000005647 linker group Chemical group 0.000 description 11
- 210000002220 organoid Anatomy 0.000 description 11
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 10
- 108010065805 Interleukin-12 Proteins 0.000 description 10
- 102000013462 Interleukin-12 Human genes 0.000 description 10
- 102000003810 Interleukin-18 Human genes 0.000 description 10
- 108090000171 Interleukin-18 Proteins 0.000 description 10
- 108010047118 Wnt Receptors Proteins 0.000 description 10
- 102000006757 Wnt Receptors Human genes 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000001054 cortical effect Effects 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 10
- 102100036465 Autoimmune regulator Human genes 0.000 description 9
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 9
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 9
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 9
- 206010028289 Muscle atrophy Diseases 0.000 description 9
- 102000014128 RANK Ligand Human genes 0.000 description 9
- 108010025832 RANK Ligand Proteins 0.000 description 9
- 108020004459 Small interfering RNA Proteins 0.000 description 9
- 230000005867 T cell response Effects 0.000 description 9
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 230000004075 alteration Effects 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 108091023037 Aptamer Proteins 0.000 description 8
- 101001042337 Burkholderia plantarii Lipase-specific foldase Proteins 0.000 description 8
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 8
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 8
- 108020005004 Guide RNA Proteins 0.000 description 8
- 108010033040 Histones Proteins 0.000 description 8
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 description 8
- 102000026633 IL6 Human genes 0.000 description 8
- 102000003812 Interleukin-15 Human genes 0.000 description 8
- 108090000172 Interleukin-15 Proteins 0.000 description 8
- 102100030703 Interleukin-22 Human genes 0.000 description 8
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 8
- 108010074109 interleukin-22 Proteins 0.000 description 8
- 210000003071 memory t lymphocyte Anatomy 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 101100510263 Caenorhabditis elegans klf-3 gene Proteins 0.000 description 7
- 101100193633 Danio rerio rag2 gene Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 101150095289 FGF7 gene Proteins 0.000 description 7
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 7
- 108010075704 HLA-A Antigens Proteins 0.000 description 7
- 108010058597 HLA-DR Antigens Proteins 0.000 description 7
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 7
- 101000904150 Homo sapiens Transcription factor E2F3 Proteins 0.000 description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 7
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 7
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 description 7
- 108010016731 PPAR gamma Proteins 0.000 description 7
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 7
- 102100024819 Prolactin Human genes 0.000 description 7
- 108010057464 Prolactin Proteins 0.000 description 7
- 108091027967 Small hairpin RNA Proteins 0.000 description 7
- 102100024027 Transcription factor E2F3 Human genes 0.000 description 7
- 230000003915 cell function Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000002595 magnetic resonance imaging Methods 0.000 description 7
- 239000002679 microRNA Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 229940097325 prolactin Drugs 0.000 description 7
- 239000004055 small Interfering RNA Substances 0.000 description 7
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 6
- 101150042405 CCN1 gene Proteins 0.000 description 6
- 102100027207 CD27 antigen Human genes 0.000 description 6
- 102100025221 CD70 antigen Human genes 0.000 description 6
- 108091033409 CRISPR Proteins 0.000 description 6
- 101150066398 CXCR4 gene Proteins 0.000 description 6
- 108050007957 Cadherin Proteins 0.000 description 6
- 102000000905 Cadherin Human genes 0.000 description 6
- 208000020446 Cardiac disease Diseases 0.000 description 6
- 101150050722 Crlf2 gene Proteins 0.000 description 6
- 101100179523 Danio rerio ihhb gene Proteins 0.000 description 6
- 101100522258 Danio rerio ptmaa gene Proteins 0.000 description 6
- 101150059401 EGR2 gene Proteins 0.000 description 6
- 101150000195 EGR3 gene Proteins 0.000 description 6
- 108010055334 EphB2 Receptor Proteins 0.000 description 6
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 6
- 101150002545 Fzd9 gene Proteins 0.000 description 6
- 101150005295 GATA2 gene Proteins 0.000 description 6
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 6
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 6
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 6
- 108010058607 HLA-B Antigens Proteins 0.000 description 6
- 108010052199 HLA-C Antigens Proteins 0.000 description 6
- 108010010378 HLA-DP Antigens Proteins 0.000 description 6
- 102000015789 HLA-DP Antigens Human genes 0.000 description 6
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 6
- 108010024164 HLA-G Antigens Proteins 0.000 description 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 6
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 6
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 6
- 101000895882 Homo sapiens Transcription factor E2F4 Proteins 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 108010065637 Interleukin-23 Proteins 0.000 description 6
- 102000013264 Interleukin-23 Human genes 0.000 description 6
- 101100013967 Mus musculus Gata3 gene Proteins 0.000 description 6
- 101100153533 Mus musculus Ltbr gene Proteins 0.000 description 6
- 101100371162 Mus musculus Tslp gene Proteins 0.000 description 6
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 6
- 101150045905 NFAT5 gene Proteins 0.000 description 6
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 101150082969 SELP gene Proteins 0.000 description 6
- 101150099493 STAT3 gene Proteins 0.000 description 6
- 101150036293 Selenop gene Proteins 0.000 description 6
- 108010016283 TCF Transcription Factors Proteins 0.000 description 6
- 102000000479 TCF Transcription Factors Human genes 0.000 description 6
- 101150093886 TGFBR2 gene Proteins 0.000 description 6
- 101150082269 TSHB gene Proteins 0.000 description 6
- 101150014014 Traf6 gene Proteins 0.000 description 6
- 102100021783 Transcription factor E2F4 Human genes 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000004154 complement system Effects 0.000 description 6
- 238000002591 computed tomography Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 101150057053 fzd2 gene Proteins 0.000 description 6
- 101150047767 fzd4 gene Proteins 0.000 description 6
- 101150110248 fzd5 gene Proteins 0.000 description 6
- 101150074034 fzd8 gene Proteins 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000010362 genome editing Methods 0.000 description 6
- 238000011194 good manufacturing practice Methods 0.000 description 6
- 208000019622 heart disease Diseases 0.000 description 6
- 101150010866 ihh gene Proteins 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 230000002452 interceptive effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 101150054513 ptmA gene Proteins 0.000 description 6
- 230000008707 rearrangement Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102000003390 tumor necrosis factor Human genes 0.000 description 6
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 5
- 102100032912 CD44 antigen Human genes 0.000 description 5
- 101150017002 CD44 gene Proteins 0.000 description 5
- 238000010446 CRISPR interference Methods 0.000 description 5
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 5
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 5
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 5
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 5
- 108010035766 P-Selectin Proteins 0.000 description 5
- 102100023472 P-selectin Human genes 0.000 description 5
- 108010078233 Thymalfasin Proteins 0.000 description 5
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000002489 hematologic effect Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 108091070501 miRNA Proteins 0.000 description 5
- 201000000585 muscular atrophy Diseases 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 5
- 229960004231 thymalfasin Drugs 0.000 description 5
- 206010046766 uterine cancer Diseases 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 102000001398 Granzyme Human genes 0.000 description 4
- 108060005986 Granzyme Proteins 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 102100031258 HLA class II histocompatibility antigen, DM beta chain Human genes 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 4
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 4
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 102100030590 Mothers against decapentaplegic homolog 6 Human genes 0.000 description 4
- 101710143114 Mothers against decapentaplegic homolog 6 Proteins 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 102100038803 Somatotropin Human genes 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 101150081494 TMPO gene Proteins 0.000 description 4
- 102100029530 Thyrotropin subunit beta Human genes 0.000 description 4
- 101710087584 Thyrotropin subunit beta Proteins 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 230000005784 autoimmunity Effects 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 230000037180 bone health Effects 0.000 description 4
- 230000037118 bone strength Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 210000003244 etp Anatomy 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000020763 muscle atrophy Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 3
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 108090000056 Complement factor B Proteins 0.000 description 3
- 102000003712 Complement factor B Human genes 0.000 description 3
- 230000007067 DNA methylation Effects 0.000 description 3
- 101100203200 Danio rerio shha gene Proteins 0.000 description 3
- 102100023371 Forkhead box protein N1 Human genes 0.000 description 3
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 3
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 description 3
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 3
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 3
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 3
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 description 3
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 description 3
- 102100028640 HLA class II histocompatibility antigen, DR beta 5 chain Human genes 0.000 description 3
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 3
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 3
- 108010050568 HLA-DM antigens Proteins 0.000 description 3
- 108010093061 HLA-DPA1 antigen Proteins 0.000 description 3
- 108010047762 HLA-DQ8 antigen Proteins 0.000 description 3
- 108010067148 HLA-DQbeta antigen Proteins 0.000 description 3
- 108010064885 HLA-DR3 Antigen Proteins 0.000 description 3
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 3
- 108010061311 HLA-DRB3 Chains Proteins 0.000 description 3
- 108010040960 HLA-DRB4 Chains Proteins 0.000 description 3
- 108010016996 HLA-DRB5 Chains Proteins 0.000 description 3
- 101150074628 HLA-E gene Proteins 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 3
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 3
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 3
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 3
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 3
- 101000907576 Homo sapiens Forkhead box protein N1 Proteins 0.000 description 3
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 3
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 description 3
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 3
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 3
- 108091058560 IL8 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 102100026236 Interleukin-8 Human genes 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 102000003959 Lymphotoxin-beta Human genes 0.000 description 3
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 description 3
- 102100035721 Syndecan-1 Human genes 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 101150067309 bmp4 gene Proteins 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000011748 cell maturation Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000009850 completed effect Effects 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 210000001808 exosome Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000002501 natural regulatory T cell Anatomy 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000026267 regulation of growth Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 101150088976 shh gene Proteins 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000011191 terminal modification Methods 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- SUHQNCLNRUAGOO-KQCZLNONSA-N (4s,5r,6r,7s,8r)-4,6,7,8,9-pentahydroxy-5-[(2-hydroxyacetyl)amino]-2-oxononanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](NC(=O)CO)[C@@H](O)CC(=O)C(O)=O SUHQNCLNRUAGOO-KQCZLNONSA-N 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 101150030271 AXIN1 gene Proteins 0.000 description 2
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 102000051172 Axin Human genes 0.000 description 2
- 108700012045 Axin Proteins 0.000 description 2
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 102100026167 Fez family zinc finger protein 2 Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 2
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 244000060234 Gmelina philippensis Species 0.000 description 2
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 description 2
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 2
- 108010022839 HLA-B47 antigen Proteins 0.000 description 2
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 2
- 108010051539 HLA-DR2 Antigen Proteins 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 102000011787 Histone Methyltransferases Human genes 0.000 description 2
- 108010036115 Histone Methyltransferases Proteins 0.000 description 2
- 108010016918 Histone-Lysine N-Methyltransferase Proteins 0.000 description 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 2
- 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 2
- 102100027770 Histone-lysine N-methyltransferase KMT5B Human genes 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 2
- 101000912440 Homo sapiens Fez family zinc finger protein 2 Proteins 0.000 description 2
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 2
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 2
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 2
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 description 2
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 2
- 101000634835 Homo sapiens M1-specific T cell receptor alpha chain Proteins 0.000 description 2
- 101000634836 Homo sapiens T cell receptor alpha chain MC.7.G5 Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 101150106931 IFNG gene Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 2
- 101150073396 LTA gene Proteins 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 101710096379 Lysine-specific histone demethylase 1 Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 206010027076 Mediastinal mass Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102000003800 Selectins Human genes 0.000 description 2
- 108090000184 Selectins Proteins 0.000 description 2
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 2
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 208000010183 Thymus Hyperplasia Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229960003603 decitabine Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- PFRGXCVKLLPLIP-UHFFFAOYSA-N diallyl disulfide Chemical compound C=CCSSCC=C PFRGXCVKLLPLIP-UHFFFAOYSA-N 0.000 description 2
- 210000003317 double-positive, alpha-beta immature T lymphocyte Anatomy 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000011223 gene expression profiling Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 108091088477 miR-29a stem-loop Proteins 0.000 description 2
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 description 2
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 description 2
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000007030 peptide scission Effects 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 description 2
- 229960002232 sodium phenylbutyrate Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- DTTONLKLWRTCAB-UDFURZHRSA-N (1s,3e,5r,7r)-3-[(3,4-dihydroxyphenyl)-hydroxymethylidene]-6,6-dimethyl-5,7-bis(3-methylbut-2-enyl)-1-[(2s)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]bicyclo[3.3.1]nonane-2,4,9-trione Chemical compound O=C([C@@]1(C(C)(C)[C@H](CC=C(C)C)C[C@](C2=O)(C1=O)C[C@H](CC=C(C)C)C(C)=C)CC=C(C)C)\C2=C(\O)C1=CC=C(O)C(O)=C1 DTTONLKLWRTCAB-UDFURZHRSA-N 0.000 description 1
- CQERVFFAOOUFEQ-UHFFFAOYSA-N (5-bromo-3-pyridinyl)-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone Chemical compound BrC1=CN=CC(C(=O)N2CCC(CC2)N2CCCC2)=C1 CQERVFFAOOUFEQ-UHFFFAOYSA-N 0.000 description 1
- UIDRIVJQZGXVCM-XVFCMESISA-N 1-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-sulfanyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound S[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 UIDRIVJQZGXVCM-XVFCMESISA-N 0.000 description 1
- MUSPKJVFRAYWAR-XVFCMESISA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)S[C@H]1N1C(=O)NC(=O)C=C1 MUSPKJVFRAYWAR-XVFCMESISA-N 0.000 description 1
- WXRGFPHDRFQODR-ICLZECGLSA-N 1-[3-[[(2R,3S,4R,5R)-5-(4-amino-7-pyrrolo[2,3-d]pyrimidinyl)-3,4-dihydroxy-2-oxolanyl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea Chemical compound C([C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C2=NC=NC(N)=C2C=C1)O)N(C(C)C)CCCNC(=O)NC1=CC=C(C(C)(C)C)C=C1 WXRGFPHDRFQODR-ICLZECGLSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- FXPLCAKVOYHAJA-UHFFFAOYSA-N 2-(4-carboxypyridin-2-yl)pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(C=2N=CC=C(C=2)C(O)=O)=C1 FXPLCAKVOYHAJA-UHFFFAOYSA-N 0.000 description 1
- FADQCEBBTITJBI-UHFFFAOYSA-N 2-[(2-methoxyphenyl)methoxymethyl]oxirane Chemical compound COC1=CC=CC=C1COCC1OC1 FADQCEBBTITJBI-UHFFFAOYSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- BGTXMQUSDNMLDW-AEHJODJJSA-N 2-amino-9-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F BGTXMQUSDNMLDW-AEHJODJJSA-N 0.000 description 1
- OMKHWTRUYNAGFG-IEBDPFPHSA-N 3-deazaneplanocin a Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1C=C(CO)[C@@H](O)[C@H]1O OMKHWTRUYNAGFG-IEBDPFPHSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- AULLUGALUBVBDD-UHFFFAOYSA-N 7-[2-[2-(dimethylamino)ethoxy]ethoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-(1-methyl-4-piperidinyl)-4-quinazolinamine Chemical compound N1=C(N2CCN(C)CCC2)N=C2C=C(OCCOCCN(C)C)C(OC)=CC2=C1NC1CCN(C)CC1 AULLUGALUBVBDD-UHFFFAOYSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- OJSXICLEROKMBP-FFUDWAICSA-N 869705-22-6 Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OJSXICLEROKMBP-FFUDWAICSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 101100218322 Arabidopsis thaliana ATXR3 gene Proteins 0.000 description 1
- 241000180579 Arca Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 108010017079 CCR6 Receptors Proteins 0.000 description 1
- 102000004288 CCR6 Receptors Human genes 0.000 description 1
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 210000003751 DN2 alpha-beta immature T lymphocyte Anatomy 0.000 description 1
- 210000001086 DN3 alpha-beta immature T lymphocyte Anatomy 0.000 description 1
- 210000001570 DN4 alpha-beta immature T lymphocyte Anatomy 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical class C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- QDKLRKZQSOQWJQ-JGWHSXGBSA-N Garcinol Natural products O=C([C@@]1(C(C)(C)[C@@H](CC=C(C)C)C[C@](C=2O)(C1=O)C[C@H](CC=C(C)C)C(C)=C)CC=C(C)C)C=2C(=O)C1=CC=C(O)C(O)=C1 QDKLRKZQSOQWJQ-JGWHSXGBSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102100033107 Growth factor receptor-bound protein 7 Human genes 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 102100031180 Hereditary hemochromatosis protein Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 102100039999 Histone deacetylase 2 Human genes 0.000 description 1
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 1
- 102100035042 Histone-lysine N-methyltransferase EHMT2 Human genes 0.000 description 1
- 108091016367 Histone-lysine N-methyltransferase EHMT2 Proteins 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 102100028998 Histone-lysine N-methyltransferase SUV39H1 Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000871022 Homo sapiens Growth factor receptor-bound protein 7 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000993059 Homo sapiens Hereditary hemochromatosis protein Proteins 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 1
- 101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 1
- 101000696705 Homo sapiens Histone-lysine N-methyltransferase SUV39H1 Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101001139146 Homo sapiens Krueppel-like factor 2 Proteins 0.000 description 1
- 101000708645 Homo sapiens N-lysine methyltransferase SMYD2 Proteins 0.000 description 1
- 101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 description 1
- 101000709248 Homo sapiens NAD-dependent protein deacetylase sirtuin-7 Proteins 0.000 description 1
- 101000616727 Homo sapiens NAD-dependent protein deacylase sirtuin-5, mitochondrial Proteins 0.000 description 1
- 101000863629 Homo sapiens NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Proteins 0.000 description 1
- 101000866971 Homo sapiens Putative HLA class I histocompatibility antigen, alpha chain H Proteins 0.000 description 1
- 101100149326 Homo sapiens SETD2 gene Proteins 0.000 description 1
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
- 108010018976 Interleukin-8A Receptors Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102000005712 Keratin-8 Human genes 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 description 1
- 102100020675 Krueppel-like factor 2 Human genes 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 108050008120 Lysine methyltransferases Proteins 0.000 description 1
- 102000000717 Lysine methyltransferases Human genes 0.000 description 1
- 102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100125257 Mus musculus Hoxa3 gene Proteins 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- LZHSWRWIMQRTOP-UHFFFAOYSA-N N-(furan-2-ylmethyl)-3-[4-[methyl(propyl)amino]-6-(trifluoromethyl)pyrimidin-2-yl]sulfanylpropanamide Chemical compound CCCN(C)C1=NC(=NC(=C1)C(F)(F)F)SCCC(=O)NCC2=CC=CO2 LZHSWRWIMQRTOP-UHFFFAOYSA-N 0.000 description 1
- 102100032806 N-lysine methyltransferase SMYD2 Human genes 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- 102100022913 NAD-dependent protein deacetylase sirtuin-2 Human genes 0.000 description 1
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 description 1
- 102100021840 NAD-dependent protein deacetylase sirtuin-6 Human genes 0.000 description 1
- 102100034376 NAD-dependent protein deacetylase sirtuin-7 Human genes 0.000 description 1
- 102100021839 NAD-dependent protein deacylase sirtuin-5, mitochondrial Human genes 0.000 description 1
- 102100030709 NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Human genes 0.000 description 1
- 101150061038 NLRP3 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 101800000590 Obestatin Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101100533304 Plasmodium falciparum (isolate 3D7) SETVS gene Proteins 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 1
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108050007775 Protein-lysine N-methyltransferases Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 101150117538 Set2 gene Proteins 0.000 description 1
- 206010040628 Sialoadenitis Diseases 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 108010041216 Sirtuin 2 Proteins 0.000 description 1
- 108010041218 Sirtuin 3 Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 206010052645 Thymus hypoplasia Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
- 102100035100 Transcription factor p65 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
- 229950010221 alexidine Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
- 229940098166 bactrim Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000000453 cell autonomous effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 201000007750 congenital bile acid synthesis defect Diseases 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002435 cytoreductive effect Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- LMFLOMBYUXRHIL-UHFFFAOYSA-N garcifuran-A Natural products COC1=C(O)C(OC)=CC(C=2C(=C3C=COC3=CC=2)O)=C1 LMFLOMBYUXRHIL-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- GRBCIRZXESZBGJ-UHFFFAOYSA-N guttiferone F Natural products CC(=CCCC(C(=C)C)C12CC(CC=C(C)C)C(C)(C)C(CC=C(C)C)(C(=O)C(=C1O)C(=O)c3ccc(O)c(O)c3)C2=O)C GRBCIRZXESZBGJ-UHFFFAOYSA-N 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000012735 histological processing Methods 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000002861 immature t-cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000002602 induced regulatory T cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000020061 kirsch Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002479 lipoplex Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 238000012083 mass cytometry Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- LIBVHXXKHSODII-UHFFFAOYSA-N n-cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-n-[2-[2-(5-hydroxy-3-oxo-4h-1,4-benzoxazin-8-yl)ethylamino]ethyl]propanamide Chemical compound C1=2OCC(=O)NC=2C(O)=CC=C1CCNCCN(C(=O)CCNCCC=1C=C(Cl)C(Cl)=CC=1)C1CCCCC1 LIBVHXXKHSODII-UHFFFAOYSA-N 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000016021 phenotype Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 description 1
- 102000028499 poly(A) binding Human genes 0.000 description 1
- 108091023021 poly(A) binding Proteins 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 210000005211 primary lymphoid organ Anatomy 0.000 description 1
- 210000001978 pro-t lymphocyte Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000018448 secretion by cell Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000001050 sialadenitis Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 230000010741 sumoylation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000005029 transcription elongation Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229940065658 vidaza Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/065—Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Definitions
- the thymus is a specialized primary lymphoid organ of the immune system, responsible for the development, selection and maturation of T cells.
- the thymus provides an inductive environment for development of T cells from hematopoietic progenitor cells.
- thymic stromal cells allow for the selection of a functional and self-tolerant T cell repertoire.
- the thymus is largest and most active during the neonatal and pre-adolescent periods. By the early teens, the thymus begins to atrophy and thymic stroma is mostly replaced by adipose tissue.
- the invention features methods for producing (e.g., making/providing) a cell (e.g., a cell or population of cells, e.g., tissue or organoid) having a thymic function. Also featured are methods of evaluating the cell having thymic function. Also featured are methods of
- the invention also features methods for modulating (e.g., in vivo or ex-vivo) thymic function, e.g., for decreasing or reversing thymic involution, improving thymic function, treating thymic damage, or treating conditions or diseases related to thymic function, in a subject (e.g., a human or an agricultural animal).
- the invention also features methods for treating physiological senescence and age associated diseases in a subject.
- the invention features methods of providing (e.g., making/providing) a thymic culture.
- the method includes: contacting a source cell (e.g., a population of cells, e.g., cells isolated from a thymus tissue or T cells of a subject, e.g., a cell described herein) with one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more) thymic function modulator described herein; and culturing the cell (e.g., a population of cells) under conditions sufficient to produce a cell (e.g., population of cells) with thymic function (e.g., cells having one or more marker of thymus function described herein).
- a source cell e.g., a population of cells, e.g., cells isolated from a thymus tissue or T cells of a subject, e.g., a cell described herein
- thymic function
- the cultured cell has at least one (at least 2, 3, 4, 5, 6, 7) increased marker of thymus function relative to the source cell (e.g., increased by at least 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 80%, 90%, 100% or more).
- the invention features methods of producing (e.g., making/providing) a cell having a thymic function.
- the method includes:
- thymic function modulator e.g., a thymic function modulator described herein
- the method further comprises expanding, selecting, and/or purifying the cell having the thymic function from (b).
- the method comprises purifying the cell (e.g., population of cells) having the thymic function, e.g., from the thymic function modulator. In embodiments, the method comprises selecting the cell (e.g., population of cells) having the thymic function.
- the purification or selection step comprises using a fluorescently labeled molecule (e.g., antibody or fragment thereof and/or a dye) that binds to one or more cell surface markers for thymic function.
- the purification or selection step comprises using fluorescence activated cell sorting (FACS).
- FACS fluorescence activated cell sorting
- the purification or selection step comprises using a bead (e.g., magnetic bead) coated with an antibody (or fragment thereof) that binds to one or more cell surface markers for thymic function.
- the method comprises expanding the cell (e.g., population of cells) having the thymic function.
- the expansion comprising increasing the number of the cells by at least about 2-fold, e.g., at least about 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 50-, 100-, 1000-, 10 4 -, 10 5 -fold, or more.
- the method further comprises producing a preparation, e.g.,
- the thymic function modulator is present in the preparation at a concentration of less than 15% by weight, e.g., less than 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, 0.01%, or less. In embodiments, the thymic function modulator is present at no less than 0.005% (by weight) in the preparation.
- the preparation comprises 10 6 -10 10 cells, e.g., 10 7 -10 10 cells, 10 8 -10 10 cells, 10 9 -10 10 cells, 10 6 -10 7 cells, 10 6 -10 8 cells, 10 6 -10 9 cells,
- the preparation comprises a tissue or an organoid.
- ex-vivo reaction mixture is prepared according to Good Manufacturing Practice (GMP).
- GMP Good Manufacturing Practice
- one or more of the expansion, selection, and/or purification of the cell(s) is according to Good Manufacturing Practice (GMP).
- the method further comprises evaluating one or more thymic functions (e.g., thymic functions described herein) of the cell preparation.
- the cell(s) having the thymic function has one or more markers of thymic function described herein.
- the cell(s) having the thymic function has at least one (at least 2, 3, 4, 5, 6, 7) increased marker of thymus function relative to the source cell (e.g., increased by at least 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 80%, 90%, 100% or more).
- the method further comprises administering the cell or preparation to a subject in need thereof.
- the subject is the same subject from which the source cell is derived. In embodiments, the subject is a different subject from the subject from which the source cell is derived.
- the method further comprises sending the produced cell(s) or preparation to a health care provider or hospital. In embodiments, the method comprises receiving the source cell from a health care provider or hospital.
- the method comprises one or more steps as described herein, where instead of, or in addition to, contacting a source cell with a thymic function modulator, the method comprises applying a force, e.g., physical/mechanical force (e.g., stress or strain), to the source cell, e.g., to generate/produce a cell having thymic structure/function (e.g., improved thymic structure/function compared to the source cell prior to the application of the force).
- the source cell can comprise a single cell or multiple cells, e.g., tissue and/or organ.
- the force comprises a shear force and/or a stretching force. Additional embodiments are described herein.
- the method comprises one or more steps as described herein, where instead of, or in addition to, contacting a source cell with a thymic function modulator, the method comprises contacting the source cell with a sample from a subject, e.g., a subject younger than 50 years of age (e.g., younger than 50, 40, 30, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or younger).
- the source cell and the sample are derived from the same subject.
- the source cell and the sample are derived from different subjects.
- the sample comprises blood, plasma, and/or one or more factors derived from the blood or plasma of the subject.
- the invention features an ex vivo reaction mixture comprising a source cell and a thymic function modulator, wherein the source cell is derived from a sample from a subject.
- the sample comprises a cell/tissue sample (e.g., biopsy, blood, or lymph sample) from the subject.
- a cell/tissue sample e.g., biopsy, blood, or lymph sample
- the sample comprises/is a biopsy from a thymus and/or surrounding tissue(s).
- the subject is a subject described herein.
- composition e.g., pharmaceutical composition
- the invention features a composition (e.g., pharmaceutical
- preparation e.g., purified preparation
- a cell(s) having thymic function described herein e.g., produced by a method described herein.
- the composition comprises a thymic function modulator, e.g., present at a concentration of at least 0.001% by weight (e.g., at least 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, or more).
- the composition comprises a trace amount of a thymic function modulator, e.g., wherein the thymic function modulator is present at a concentration of less than 1% by weight, e.g., less than 0.5%, 0.1%, 0.05%, 0.01%, or less.
- the invention features a method of:
- thymus function e.g., decreasing, reversing, or preventing thymic involution, treating a thymic injury, treating a thymus related disease or condition (e.g., aging-related disease or condition), or replacing/augmenting thymic function
- thymus function e.g., decreasing, reversing, or preventing thymic involution, treating a thymic injury, treating a thymus related disease or condition (e.g., aging-related disease or condition), or replacing/augmenting thymic function
- senescence or non-aging associated senescence e.g., reversing, reducing the rate of, or delaying physiological senescence
- the method includes administering to the subject a thymic culture described herein or a cell or preparation thereof having thymic function as described herein, thereby performing one or more of (i)-(vii) in the subject.
- the method comprises administering a cell (e.g., population of cells) having thymic function or preparation thereof described herein to the subject.
- a cell e.g., population of cells
- the cell e.g., population of cells having thymic function or preparation thereof is produced using a method described herein.
- the method includes:
- a source cell from a subject e.g., a population of cells, e.g., cells isolated from a thymus tissue or T cells of the subject, e.g., a cell described herein
- a subject e.g., a population of cells, e.g., cells isolated from a thymus tissue or T cells of the subject, e.g., a cell described herein
- thymic function modulator described herein;
- culturing the cell e.g., a population of cells
- thymic function e.g., an improved thymic function described herein (e.g., cells having one or more marker of thymus function described herein);
- d) administering the cell (e.g., population of cells), having improved thymic function to a subject in need thereof (e.g., who may be the same or a different subject than the subject from which the source cell is provided in (a)).
- the cell e.g., population of cells
- the cultured cell, the cell(s) having thymic function, or preparation thereof has at least one (at least 2, 3, 4, 5, 6, 7) increased marker of thymus function described herein relative to the source cell (e.g., increased by at least 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 80%, 90%, 100% or more).
- the cell is from the same subject that is receiving the treatment for any of (i)-(vii), e.g., the cell is an autologous cell.
- the method further incudes obtaining the cell (e.g., population of cells) from the same subject.
- the cell is from a different subject, e.g., the cell is an allogeneic cell.
- the method further incudes obtaining the cell (e.g., population of cells) from a different subject.
- the source cell is a thymic cell.
- the thymic cell is a cortical thymic epithelial cell, a medullar thymic epithelial cell, a thymic stromal cell, or a dendritic cell (e.g., conventional dendritic cell (also called myeloid dendritic cell) or a plasmacytoid dendritic cell).
- the source cell is a population of cells, a tissue, and/or an organ/organoid.
- the source cell is a thymus tissue, thymus organ, or part of a thymus organ.
- the source cell is not a thymic cell.
- the cell is an epithelial cell or a fibroblast cell.
- the epithelial cell or fibroblast cell is contacted with a thymic transformation agent that induces a thymic gene expression profile or a thymic function.
- a thymic gene expression profile comprises the expression of two or more of the genes described in Table 2 or Table 4.
- a thymic function comprises extent of thymic involution, thymic damage, thymic regeneration, decrease/reverse in thymic involution or damage, increased or decreased T cell exhaustion, memory T cell response, tumor infiltrating lymphocyte activity, increased or decreased T cell diversity, increased or decreased T cell repertoire diversity, and/or increased or decreased T cell clonality.
- a thymic transformation agent comprises a nucleic acid molecule, a peptide, an antibody molecule (e.g., an antibody or antigen binding fragment thereof), or a small molecule that induces a thymic gene expression profile or other marker of thymic function in a cell or a population of cells, wherein the cell is not derived from the thymus.
- a thymic transformation agent is a thymic function modulator.
- a thymic transformation agent is a nucleic acid molecule, e.g., a synthetic mRNA, encoding a transcription factor, e.g., FOXN1.
- the thymic transformation agent can be characterized by one or more, e.g., one, two, three, four, or all, of the following:
- cortical TECs e.g., as assessed by imaging or histological analysis of surface markers, e.g., K5 and/or K8 staining;
- changes in gene expression profiles that indicate enhanced cell function or expansion of epithelial cells e.g., expression of AIRE, FEZF2, FOXN1 of medullary TECs; e.g., as assayed by gene expression profiling techniques such as arrays, RT-PCR); and/or
- a thymic transformation agent can be identified by the assays as described herein. Evaluating thymic function (e.g., thymic involution)
- the method further includes assessing one or more markers of thymic structure/function (e.g., one or markers of thymus involution).
- the one or more markers are assessed in the cell, or population of cells, after culturing the cell(s) and prior to administering the cell(s), culture, or preparation thereof to a subject.
- the marker of thymic structure/function comprises the formation of a plasma cell, development of an antigen- specific T cell, and/or formation of a thymic organoid.
- the marker of thymic structure/function comprises the formation of, or modulation (e.g., increase or decrease) in quantity, size, function, and/or distribution of, Hassall' s corpuscles in the cell(s)/tissue(s)/organoid(s), compared to before the culture step(s).
- a change in Hassall' s corpuscles can be detected histologically and/or through a thymus exosome profile, e.g., as described in Skogberg et al. J. Immunol.
- the one or more markers of thymic structure or function are assessed after administering the cell(s), culture, or preparation thereof to a subject.
- the methods include identifying the presence of a thymus tissue after treatment in subjects where no thymus or thymus tissue was detectable prior to treatment.
- the method includes measuring the size (e.g., length, width, and/or thickness), opacity, and/or density of the anterior mediastinal shadow, e.g., to assess a decrease or a reverse in thymic involution.
- measuring the size of the anterior mediastinal shadow includes measuring the length, measuring the width, and/or measuring the thickness of the anterior mediastinal shadow.
- the size, opacity, and/or density of the anterior mediastinal shadow determined from an imaging technique. Examples of imaging techniques include ultrasound, X-ray, CAT scan, MRI, or PET (e.g., FDG avidity via PET).
- a decrease or reverse in thymic involution is characterized by an increase, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or more, in size (e.g., length and/or width) of the anterior mediastinal shadow, as compared to a reference size of the anterior mediastinal shadow.
- a decrease or reverse in thymic involution is characterized by an increase, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or more increase, in the density of the anterior mediastinal shadow, as compared to a reference density of the anterior mediastinal shadow.
- a decrease or reverse in thymic involution is characterized by an increase, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or more increase, in the opacity of the anterior mediastinal shadow, as compared to a reference opacity of the anterior mediastinal shadow.
- the reference size, density, and/or opacity of the anterior mediastinal shadow is the size, density, and/or opacity of the anterior mediastinal shadow in the subject prior to administration of the thymic function modulator.
- the method includes assessing one or more markers of thymic structure/function (e.g., thymic involution).
- the marker of thymic structure/function e.g., thymic involution
- the marker of thymic structure/function is selected from: the level of stromal cells; the level of non-stromal cells; the level of adipocytes; the level of non-adipocytes; T cell diversity; TCR repertoire diversity; T cell clonality; or T cell diversity and T cell clonality.
- an improvement in thymic structure/function is characterized by a decrease in the level or number of adipocytes, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more decrease, e.g., as compared to prior to treatment.
- a an improvement in thymic structure/function is characterized by a increase in the level or number of non- adipocytes, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more decrease, e.g., as compared to prior to treatment.
- an improvement in thymic structure/function is characterized by an increase in T cell diversity, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more increase in T cell diversity, e.g., as compared to prior to treatment.
- an improvement in thymic structure/function is characterized by an increase in TCR repertoire diversity, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more increase in TCR repertoire diversity, e.g., as compared to prior to treatment.
- an improvement in thymic structure/function is characterized by a decrease in T cell clonality, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more decrease in T cell clonality, e.g., as compared to prior to treatment.
- an improvement in thymic structure/function is characterized by an increase in T cell clonality, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more increase in T cell clonality, e.g., as compared to prior to treatment.
- an improvement in thymic structure/function is characterized by an increase in T cell or TCR repertoire diversity, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more increase in T cell or TCR repertoire diversity, and a decrease or increase in T cell clonality, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more decrease or increase in T cell clonality, e.g., as compared to prior to treatment.
- an increase in T cell or TCR repertoire diversity e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more increase in T cell clonality, e.g., as compared to prior to treatment.
- the method further comprises administering a second therapeutic agent or procedure.
- the second therapeutic agent or procedure is chosen from one or more of thymic function modulator, chemo therapeutic, antimicrobial, a cell based therapy, a cell or organ transplant (e.g., stem cell transplant), a radiation procedure, a surgical procedure, an immunomodulatory agent (e.g., an inhibitor of an inhibitory molecule, immune checkpoint inhibitor), a vaccine, or an immunotherapy (e.g., cellular immunotherapy).
- the second therapeutic agent is one or more thymic function modulator, e.g., thymic function modulator described herein.
- the thymic function modulator is an agent that modulates, e.g., increases or decreases, thymic function.
- the thymic function modulator can decrease or reverse thymic involution (e.g., decreasing the rate of thymic involution) in a subject.
- the cell culture, cell(s), or preparation thereof is administered to the subject when one or more of the following is observed: one or more markers of thymic structure/function (e.g., an increase in one or more markers of thymic structure/function relative to the source cell); formation of a plasma cell; development of an antigen-specific T cell; and/or formation of a thymic organoid.
- one or more markers of thymic structure/function e.g., an increase in one or more markers of thymic structure/function relative to the source cell
- formation of a plasma cell e.g., an increase in one or more markers of thymic structure/function relative to the source cell
- formation of a plasma cell e.g., a plasma cell
- development of an antigen-specific T cell e.g., an increase in one or more markers of thymic structure/function relative to the source cell
- formation of a plasma cell e.g., a plasma cell
- the cell culture, cell(s), or preparation thereof is administered in a single dose. In embodiments, the cell culture, cell(s), or preparation thereof is administered in multiple doses (e.g., two or more, three or more, four or more, or five or more doses). In embodiments, the time interval between each dose is at least 1 week, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8 weeks, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months, or more.
- the cell culture, cell(s), or preparation thereof is administered subcutaneously, intravenously, intramuscularly, intrasternally, intraperitoneally, into a thymus, e.g., via infusion, implantation, or injection.
- the cell culture, cell(s), or preparation thereof is administered through a device, e.g., implantable device.
- the cell culture, cell(s), or preparation thereof is administered using an infusion technique, e.g., as described in Rosenberg et ah, New Eng. J. of Med. 319: 1676, 1988.
- the cell culture/cells(s)/preparation thereof is administered at a dose of about 10 4 to 10 10 cells/kg body weight, e.g., 10 4 to 10 8 cells/kg body weight, e.g., 10 5 to 10 6 cells/kg body weight, including all integer values within those ranges. In embodiments, the cell culture/cells(s)/preparation thereof is administered multiple times at these doses.
- the cell culture/cell(s)/preparation is administered in combination with the second therapeutic agent (e.g., thymic function modulator) or procedure (e.g., transplant, e.g., cell transplant or thymus transplant).
- the cell culture/cell(s)/preparation and the second therapeutic agent are administered concurrently or sequentially, in the same or in separate compositions.
- the cell culture/cell(s)/preparation is administered concurrently or sequentially with the second procedure.
- the cell culture/cell(s)/preparation is administered prior to (e.g., at least 2 hours after, e.g., at least 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, 4 weeks, 1 month, 2 months, or more before) administration of the second therapeutic agent or procedure.
- the cell culture/cell(s)/preparation is administered after (e.g., at least 2 hours after, e.g., at least 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, 4 weeks, 1 month, 2 months, or more after) administration of the second therapeutic agent or procedure.
- the cell culture/cell(s)/preparation is administered after (e.g., at least 2 hours after, e.g., at least 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, 4 weeks, 1 month, 2 months, or more after) administration of the second therapeutic agent or procedure.
- the cell culture/cell(s)/preparation is administered after (e.g., at least 2 hours after, e.g., at least 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 1 day
- culture/cell(s)/preparation and the second therapeutic agent or procedure are administered concurrently, e.g., within 2 days (e.g., within 2 days, 1.5 day, 1 day, 24 hours, 12 hours, 6 hours, 4 hours, 2 hours, 1 hour, or less) of each other.
- the second therapeutic agent (e.g., thymic function modulator) is administered in a single dose. In some embodiments, the second therapeutic agent (e.g., thymic function modulator) is administered in multiple, e.g., two or more, doses. In one embodiment, the second therapeutic agent (e.g., thymic function modulator) is administered once a day, once every two days, once every 5 days, once a week, once every other week, or once a month. In one embodiment, multiple doses of the second therapeutic agent (e.g., thymic function modulator) are administered over a period of 1 month, 2 months, 3 months, 4 months, 6 months, or more. In another embodiment, multiple doses of the second therapeutic agent (e.g., thymic function modulator) are administered over a period of 4 weeks, 3 weeks, 2 weeks, 1 week, 6 days, 5 days, 4 days, 3 days or less.
- the second therapeutic agent comprises more than one agent (e.g., a first agent, a second agent, or more agents).
- a first treatment regimen comprising one or more doses of a first thymic function modulator and a second treatment regimen comprising one or more doses of a second thymic function modulator are administered simultaneously or sequentially to the subject.
- the first treatment regimen and the second treatment regimen are administered simultaneously.
- the first treatment regimen and the second treatment regimen are overlapping.
- the first treatment regimen is initiated prior to, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, the initiation of the second treatment regimen.
- the second treatment regimen is initiated prior, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, to the initiation of the first treatment regimen.
- the first treatment regimen is completed prior to, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, initiation of the second treatment regimen.
- the second treatment regimen is completed prior to, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, the initiation of the first treatment regimen.
- a first treatment regimen comprising one or more doses of a first thymic function modulator and one or more additional treatment regimens, e.g., a second, third, fourth, or fifth treatment regimen, wherein each additional treatment regimen comprises one or more doses of an additional thymic function modulator, e.g., second, third, fourth, or fifth thymic function modulator, are administered simultaneously or sequentially to the subject.
- the first treatment regimen and the one or more, e.g., second, third, fourth, or fifth, treatment regimens are administered simultaneously.
- the first treatment regimen and the one or more, e.g., second, third, fourth, or fifth, treatment regimens are overlapping.
- the one (e.g., the first) treatment regimen is initiated prior to, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, the initiation of another (e.g., the second, third, fourth, and/or fifth) treatment regimen.
- the one (e.g., the first) treatment regimen is completed prior to, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, the initiation of another (e.g., the second, third, fourth, and/or fifth) treatment regimen.
- the cell culture/cell(s)/preparation can be administered before the initial dose of the thymic function modulator, after the initial dose but before the last dose of the thymic function modulator, or after the last dose of the thymic function modulator.
- the method further includes monitoring the subject for one or more of the following: anterior mediastinal shadow size (e.g., length, width, and/or thickness); anterior mediastinal shadow density; anterior mediastinal shadow opacity; level of adipocytes and/or non-adipocytes; level of stromal and/or non-stromal cells; T cell clonality; T cell diversity or TCR repertoire diversity; or T cell clonality and T cell diversity or TCR repertoire diversity.
- anterior mediastinal shadow size e.g., length, width, and/or thickness
- anterior mediastinal shadow density e.g., anterior mediastinal shadow density
- anterior mediastinal shadow opacity e.g., level of adipocytes and/or non-adipocytes
- level of stromal and/or non-stromal cells e.g., T cell clonality and T cell diversity or TCR repertoire diversity.
- doses of the cell culture/cell(s)/preparation are administered until one or more of the following occurs in the subject: an increase in a parameter associated with anterior mediastinal shadow (e.g., size, density, and/or opacity); an increase in the level of non- adipocyte cells and/or a decrease in adipocyte cells; an increase in the level of stromal cells and/or a decrease in the level of non-stromal cells; a decrease in T cell clonality; an increase in T cell diversity or TCR repertoire diversity; or a decrease in T cell clonality and an increase in T cell diversity or TCR repertoire diversity.
- a parameter associated with anterior mediastinal shadow e.g., size, density, and/or opacity
- an increase in the level of non- adipocyte cells and/or a decrease in adipocyte cells e.g., an increase in the level of stromal cells and/or a decrease in the level of non-stromal cells
- five or fewer (e.g., five, four, three, two, or one) doses of the cell culture/cell(s)/preparation are administered, and doses of the second therapeutic agent (e.g., thymic function modulator) are administered until one or more of the following occurs in the subject: an increase in a parameter associated with anterior mediastinal shadow (e.g., size, density, and/or opacity); an increase in the level of non-adipocyte cells and/or a decrease in adipocyte cells; an increase in the level of stromal cells and/or a decrease in the level of non- stromal cells; a decrease in T cell clonality; an increase in T cell diversity or TCR repertoire diversity; or a decrease in T cell clonality and an increase in T cell diversity or TCR repertoire diversity.
- a parameter associated with anterior mediastinal shadow e.g., size, density, and/or opacity
- the second therapeutic agent e.g., thymic function modulator
- the second therapeutic agent is administered intravenously.
- the second therapeutic agent e.g., thymic function modulator
- the second therapeutic agent e.g., thymic function modulator
- the second therapeutic agent is administered intrathymically. In embodiments where more than one thymic function modulator is administered, one thymic function modulator is administered intravenously and another thymic function modulator is administered intrathymically.
- the second therapeutic agent e.g., thymic function modulator
- an additional therapeutic agent is selected from: an immunomodulatory agent, an antimicrobial, or a chemotherapy.
- the second therapeutic agent e.g., thymic function modulator
- an additional treatment e.g., a radiation or surgery.
- the thymic function modulator increases or decreases the expression or activity of a thymic function factor described herein.
- the thymic function factor can be characterized by one or more, e.g., one, two, three, four, five, or all, of the following:
- stromal cells or non-adipocyte cells increases the proliferation or cell count of stromal cells or non-adipocyte cells (e.g., as assessed by proliferation assays, e.g., Ki67 staining), e.g., by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, or more.
- stromal/non- stromal cellular balance in the thymus e.g., as assessed by ultrasound, histological analysis, or FDG avidity via PET imaging
- an increase or decrease in the ratio of stromal to non-stromal cells e.g., an increase of decrease in the ratio of thymic epithelial cells to thymocytes, or an increase or decrease in the ratio of adipocytes to thymocytes
- thymic hormone increases thymic hormonal production and/or levels; wherein the thymic hormone is associated with thymic size, e.g., thymulin (e.g., as assessed by rosette inhibition assay, e.g., as described in Consolini et al.), e.g., by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, or more.
- thymulin e.g., as assessed by rosette inhibition assay, e.g., as described in Consolini et al.
- peripheral T cell phenotype e.g., measuring changes in thymic emigrant profile (e.g., as assessed by comparing levels of different T cell populations, e.g., comparing percentages of T cells and clonal populations of T cells with unique TCRs that are FoxP3 positive, e.g., Tregs)
- the thymic function factor comprises a T cell growth factor, a T cell growth factor receptor, a T cell proliferation factor, a T cell migration factor, a T cell activity factor, a thymic epithelial cell (TEC) proliferation factor, a thymic epithelial cell (TEC) growth factor, a thymic epithelial cell (TEC) growth factor receptor, a thymic epithelial cell (TEC) function factor, or a thymus homeostasis factor.
- the thymic function modulator increases or decreases the expression or activity of one or more thymic function factors described herein, e.g., listed in Table 1.
- the T cell growth factor is selected from BMP4, Bmprla, CD70, Cldn4, DM, Egrl, Egr2, Egr3, EphB2, Flt3, Flt3L, Foxol, FoxP3, Gata2, Gata3, Gfil, Ghrl (ghrelin), GnRH, Icaml, Id3, Ifnarl, IL-2, IL-6, IL-7, IL-12b (IL12 p40 subunit), IL- 15, IL-18, IL-21, IFNy, K , Klf3, Lefl, leptin, Lif, Nfat5, Nfatcl, Notch 1, Prolactin, Ragl, Rag2, Runxl, Satbl, SCF (K ), Shh (T-cell), Tcfl, TCR (e.g., a TCR comprising an alpha and a beta chain, a TCR comprising a gamma chain and a delta chain, a TCR comprising
- the T cell growth factor receptor is selected from CD 127 (non- soluble IL-7R), CD27, Crlf2 (TSLP-R), Fzdl, FzdlO, Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7, Fzd8, Fzd9, Ihh, Ptchl, and Ptch2, or IL-7R alpha.
- the T cell growth factor is selected from at least one of Flt3, Flt3L, Foxol, FoxP3, Gfil, Ghrl (ghrelin), GnRH, Icaml, Id3, Ifnarl, IL-2, IL-6, IL-7, IL-12b (IL12 p40 subunit), IL-15, IL-18, IL-21, Kitl, Klf3, Lefl, leptin, Lif, and SCF (Kitl).
- the T cell growth factor is selected from at least one of IL-7, IL-21, Delta-like 4 (DLL4), Flt3L, SCF (Kitl), and miR-29a.
- the T cell growth factor may also include at least one selected from IL-15, IL-2, IL-12, IL-18, and IFNy.
- the T cell migration factor is selected from CC119, Ccl21, CCL25, Ccr7, Ccr9, Cxcll2, Cxcr4, S 1PR1 (S 1P1), Sele (E-selectin, CD62E, ELAM-1, or LECAM2), Sell (CD62L), Selp (P-selectin), CCL20, CCR6, CXCLl-3, CXCR2, IL8, CXCR1, CCL2, CCL4, CCL5, CCL22, CXCL8, or CXCL10.
- the T cell activity factor is E2F2.
- the TEC proliferation factor is selected from Cyr61, E2F2 (TEC), IGF-1, IL-22, IL-23, or KGF (Fgf7).
- the TEC growth factor is selected from Atf3, BMP4 (TEC), Cbx4, Cdh5 (VE cadherin), E2F3, E2F4, Foxnl, Fspl, Fstll, Isll, Kl (Klotho), Ltbr, NFkB l,
- the TEC growth factor enhances thymus function by modulating, e.g., increasing, e.g., enhancing, proliferation, survival and/or generation of thymic epithelial cells.
- the TEC growth factor is selected from at least one of FGF21, FGF7 (KGF), FGF8, FGF10, IL-22, Wnt4, Bmp4, RANKL, LTa, CL40L, Foxnl, leptin, IGF-1, GH, (Ghrl) ghrelin, GnRH, and NGF.
- the TEC growth factor receptor is selected from Bmpr2, Fgfr2, or bmprla (TEC).
- the thymic function factor is selected from AIRE, beta(5t)/Psmbl 1, Fezf2, HLA (e.g., an HLA molecule described herein, e.g., HLA-A, HLA-B, HLA-B27, HLA- B47, HLA-C, HLA-E, HLA-F, HLA-G, p2-microglobulin, HLA-DM (e.g., HLA-DMA1 and/or HLA-DMB 1), HLA-DO (e.g., HLA-DOA1 and/or HLA-DOB 1), HLA-DP (e.g., HLA-DPA1 and/or HLA-DPB l), HLA-DQ (e.g., HLA-DQAl and/or HLA-DQB l), HLA-DQ2, HLA-DQ8, HLA-DR (e.g., HLA-DRA, HLA-DRB 1, HLA-DRB3, H
- lymphotoxin-a lymphotoxin- ⁇
- lymphotoxin- ⁇ lymphotoxin- ⁇
- Prssl6 Prssl6
- the thymus homeostasis factor is selected from 1 lb-HSD2, AR, ASC, Axin, Fgf21, IL10, IL2 (stroma), Leptin (TEC), Meisl, or NLRP3.
- the thymic function factor comprises Cd44, gpl30, hGH (GH1 and GH2), Nfkb2, Ptma (thymosin alpha- 1), Smad4, Smad6, or Tmpo (thymopeotin).
- the thymic function factor comprises a chemokine (e.g., secreted chemokine), cytoplasmic protein, enzyme (e.g., phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound ligand, non-secreted ligand, or secreted ligand), matrix protein, transcription factor, or receptor (e.g., cell surface receptor or nuclear receptor).
- chemokine e.g., secreted chemokine
- cytoplasmic protein enzyme
- enzyme e.g., phosphatase, protease, or proteinase
- hormone e.g., secreted hormone
- ligand e.g., membrane bound ligand, non-secreted ligand, or secreted ligand
- matrix protein e.g., transcription factor, or receptor (e.g., cell surface receptor or nuclear receptor).
- the chemokine is selected from Ccl21, CCL25, or Cxcll2. In embodiments, the secreted chemokine is Cxcll2.
- the cytoplasmic protein is selected from ASC, Axin, or Fspl.
- the enzyme is selected from Cbx4, Kl (Klotho), Ragl, Rag2, Sin/Polr3e, Tmpo (thymopoetin), Traf6, Pten, Prssl6, or beta(5t)/Psmbl l.
- the enzyme comprises a phosphatase, e.g., Pten.
- the enzyme comprises a protease, e.g., Prssl6.
- the enzyme comprises a proteinase, e.g., beta(5t)/Psmbl l.
- the hormone e.g., secreted hormone
- the hormone is selected from GnRH, hGH (GH1 and GH2), leptin, leptin (TEC), prolactin, Ptma (thymosin alpha-1), Tshb (thyrotropin (beta chain)), or Ghrl (ghrelin).
- the secreted hormone encodes a preprotein, e.g., a ghrelin-obestatin preprotein.
- the ligand is a secreted ligand.
- the ligand e.g., secreted ligand, is selected from SCF (Kitl), BMP4, BMP4 (TEC), Ccll9, Cyr61, D114, Fstll, Fgf21, IGF-1, Ihh, IL10, IL-12b (IL12 p40 subunit), IL-15, IL18, IL2, IL2 (stroma), IL21, IL-22, IL23, IL6, IL-7, KGF (Fgf7), Lif, Shh (T-cell), Shh (TEC), Tslp, Wnt3a, Wnt3a (TEC), Wnt4, Wn4 (TEC), Kitl, or Flt3L.
- the ligand is a non-secreted ligand, e.g., membrane bound ligand.
- the ligand e.g., non-secreted ligand, e.g., membrane bound ligand, is selected from 1 lb-HSD2, CD70, Icaml, RANKL, Tbata, Vcaml, SCF (Kitl), K , or Flt3L.
- the matrix protein is Satbl.
- the receptor is selected from TCR (e.g., a TCR comprising an alpha and a beta chain, a TCR comprising a gamma chain and a delta chain, a TCR comprising a CD3 chain, a TCR comprising a zeta chain, a TCR comprising a complementarity determining region, and a TCR comprising a T cell co-receptor (e.g., CD4 or CD8)), AR, Bmprla, Bmprla (TEC), Bmpr2, Ccr7, Ccr9, CD127 (non-soluble IL-7R), CD27, Cd44, Cdh5 (VE cadherin), Cldn4, Crlf2 (TSLP-R), Cxcr4, EphB2, Fgfr2, Flt3, Fzdl, FzdlO, Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7, Fzd8, Fzd9,
- TCR
- IL7Ralpha, Ltbr Major Histocompatibility Complexes
- Class I MHC molecule e.g., comprising one or more polypeptides encoded by a HLA-A, HLA-B, HLA-C, HLA-G, and/or HLA-E gene
- Class II MHC molecule e.g., comprising one or more
- MHC III Class III MHC molecule
- a TCR includes a TCR that binds to an epitope presented on an MHCI molecule, an epitope presented on an MHCII molecule, or an epitope presented on an MHCIII molecule).
- the transcription factor is PPARgamma, AIRE, Atf3, E2F2, E2F2 (TEC), E2F3, E2F4, Egrl, Egr2, Egr3, Fezf2, Foxnl, Foxol, FoxP3, Gata2, Gata3, Gfil, Id3, l, Klf3, Lefl, Meisl, Nfat5, Nfatcl, NFkB l, Runxl, Smad4, Smad6, Stat3, Tbxl, Tcfl, Zfp3611, Zfp3612, or Nfkb2.
- the thymic function factor is a positive regulator of a thymic function, e.g., the thymic function factor is selected from Shh (T-cell), E2F2, CD70, Cldn4, DM, Egrl, Egr2, Egr3, EphB2, Flt3, Flt3L, Foxol, FoxP3, Gata3, Gfil, Ghrl (ghrelin), GnRH, Icaml, Id3, Ifnarl, IL-12b (IL12 p40 subunit), IL-15, IL18, IL2, IL21, IL-7, K , Lefl, leptin, Nfat5, Nfatcl, Notchl, prolactin, Ragl, Rag2, Runxl, Satbl, SCF (KM), Tcfl, Tshb (thyrotropin beta chain), Tslp, Vcaml, Wnt3a, Wnt4, Zfp3611, Zfp3612
- the positive regulator of thymic function comprises a T-cell growth factor, e.g., BMP4, Klf3, Shh (T-cell), IL6, CD70, Cldn4, D114, Egrl, Egr2, Egr3, EphB2, Flt3, Flt3L, Foxol, FoxP3, Gata3, Gfil, Ghrl (ghrelin), GnRH, Icaml, Id3, Ifnarl, IL-12b (IL12 p40 subunit), IL-15, IL18, IL2, IL21, IL-7, KM, Lefl, leptin, Nfat5, Nfatcl, Notchl, prolactin, Ragl, Rag2, Runxl, Satbl, SCF (KM), Tcfl, Tshb (thyrotropin beta chain), Tslp, Vcaml, Wnt3a, Wnt4, Zfp3611, or Zfp3612.
- T-cell growth factor e
- the positive regulator of thymic function comprises a T-cell activity factor, e.g., E2F2.
- the positive regulator of thymic function comprises a T-cell growth factor receptor, e.g., Ihh, CD 127 (non-soluble IL-7R), CD27, Crlf2 (TSLP-R), Fzdl, FzdlO, Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7, Fzd8, Fzd9, Ptchl, Ptch2, or IL-7Ralpha.
- the positive regulator of thymic function comprises a T-cell migration factor, e.g., Ccll9, Ccl21, CCL25, Ccr7, Ccr9, Cxcll2, Cxcr4, S 1PR1 (S 1P1), Sele (E- selectin, CD62E, ELAM-1, or LECAM2), Sell (CD62L), or Selp (P-selectin).
- the positive regulator of thymic function comprises a TEC function factor, e.g., AIRE, beta(5t)/Psmbl 1, Fezf2, or Prssl6.
- the positive regulator of thymic function comprises a TEC growth factor, e.g., Isll, BMP4 (TEC), Cbx4, Cdh5 (VE cadherin), E2F3, Foxnl, Fspl, Kl (Klotho), Ltbr, NFkB l, Pten, RANK, RANKL, Shh (TEC), Sin/Polr3e, Stat3, Tnfrsfl la/RANK, Traf6, Wnt3a (TEC), or Wnt4 (TEC).
- the positive regulator of thymic function comprises a TEC growth factor receptor, e.g., Bmpr2, Fgfr2, or Bmprla (TEC).
- the positive regulator of thymic function comprises a TEC proliferation factor, e.g., Cyr61, E2F2 (TEC), IGF-1, IL-22, IL-23, or KGF (Fgf7).
- the positive regulator of thymic function comprises a thymus homeostasis factor, e.g., l lb-HSD2, Fgf21, IL10, IL2 (stroma), Leptin (TEC), or Meisl.
- the thymic function factor is a negative regulator of a thymic function, e.g., the thymic function factor is selected from Shh, Bmprla, Gata2, Lif, Atf3, E2F4, PPARgamma, Tbata, Tbxl, Tgfbr2, AR, ASC, Axin, NLRP3, gpl30, Tnfrsfl lb, E2F2, BMP4, Ihh, or IL6.
- the negative regulator of thymic function comprises a T-cell growth factor, e.g., BMP4, Shh (T-cell), Bmprla, Gata2, IL6, or Lif.
- the negative regulator of thymic function comprises a TEC growth factor, e.g., Atf3, E2F4, PPARgamma, Tbata, Tbxl, Tgfbr2, or Tnfrsf 1 lb.
- the negative regulator of thymic function comprises a thymus homeostasis factor, e.g., AR, ASC, Axin, or NLRP3.
- the negative regulator of thymic function comprises a T-cell activity factor, e.g., E2F2.
- the thymic function factor is a positive and/or negative regulator of a thymic function, e.g., the thymic function factor is selected from BMP4, IL6, Ihh, E2F2, or Shh (T-cell).
- the thymic function factor is selected from TCR (e.g., a TCR comprising an alpha and a beta chain, a TCR comprising a gamma chain and a delta chain, a TCR comprising a CD3 chain, a TCR comprising a zeta chain, a TCR comprising a
- TCR comprising a T cell co-receptor (e.g., CD4 or CD8)), BMP4, BMP4 (TEC), Bmprla (TEC), Bmpr2, Ccl21, CCL25, CD127 (non-soluble IL- 7R), Cxcll2, D114, E2F2 (TEC), E2F3, Fgf21, Flt3L, Foxnl, Ghrl (ghrelin), GnRH, hGH (GH1 and GH2), IL10, IL21, IL-22, IL-23, IL-7, IL-7Ralpha, KGF (Fgf7), Kitl, leptin, leptin (TEC), prolactin, Ptma (thymosin alpha- 1), or SCF (Kitl).
- T cell co-receptor e.g., CD4 or CD8
- BMP4 TEC
- Bmprla TEC
- Bmpr2 Ccl21, CCL25,
- a TCR includes a TCR that binds to an epitope presented on an MHCI molecule, an epitope presented on an MHCII molecule, or an epitope presented on an MHCIII molecule Thymic Function Modulators
- an agent that modulates, e.g., increases or decreases, thymic function is also referred to as a thymic function modulator.
- the thymic function modulator increases or decreases the expression or activity of one or more thymic function factors described herein.
- the thymic function modulator is itself a thymic function factor (or fragment thereof), e.g., a thymic function factor described herein, e.g., in Table 1.
- the thymic function modulator comprises a nucleic acid molecule (e.g., DNA, mRNA or an inhibitory RNA), a peptide, an antibody molecule (e.g., an antibody or antigen binding fragment thereof), or a small molecule.
- a nucleic acid molecule e.g., DNA, mRNA or an inhibitory RNA
- a peptide e.g., an antibody or antigen binding fragment thereof
- an antibody molecule e.g., an antibody or antigen binding fragment thereof
- the thymic function modulator increases the expression or activity of one or more thymic function factors described herein, e.g., listed in Table 1.
- the increase in expression or activity of the one or more thymic function factors is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, increased as compared to a reference expression or activity level of the one or more thymic function factors.
- the reference expression or activity level is the expression or activity level of the one or more thymic function factors prior to administration of the thymic function modulator.
- the thymic function modulator decreases the expression or activity of one or more thymic function factors described herein, e.g., listed Table 1.
- the decrease in expression or activity of one or more thymic function factors is at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, decreased as compared to a reference expression or activity level of the one or more thymic function factors.
- the reference expression or activity level is the expression or activity level of the one or more thymic function factors prior to administration of the thymic function modulator.
- the thymic function modulator comprises a nucleic acid molecule. In one embodiment, the thymic function modulator comprises a DNA molecule or a RNA molecule. In one embodiment, the thymic function modulator comprises a RNA molecule, e.g., an inhibitory RNA or an RNA therapeutic that encodes a protein. In one embodiment, the thymic function modulator comprises an inhibitory or agonistic antibody.
- the thymic function modulator comprises an mRNA molecule (e.g., an RNA therapeutic) that encodes one or more of the thymic function factors described herein, e.g., listed in Table 1, or a functional fragment thereof.
- the mRNA molecule encodes an amino acid sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to an amino acid sequence listed in Table 1, or a functional fragment thereof.
- the mRNA molecule encodes an amino acid sequence that differs by no more than 20, 10, 5, 4, 3, 2, or 1 amino acids to an amino acid sequence listed in Table 1.
- the mRNA molecule encodes an amino acid sequence comprising an amino acid sequence listed in Table 1, or a functional fragment thereof.
- the thymic function modulator comprises an inhibitory RNA, e.g., an interfering RNA (RNAi) molecule.
- RNAi interfering RNA
- the RNAi molecule is selected from a siRNA, a short hairpin RNA, or a microRNA.
- the interfering RNA molecule decreases or inhibits expression of one or more of the thymic function factors listed in Table 1.
- the thymic function modulator comprises an mRNA molecule that encodes an antibody molecule (e.g., an antibody or an antigen binding fragment thereof) that targets (e.g., specifically binds to) one or more of the thymic function factors described herein, e.g., listed in Table 1.
- an antibody molecule e.g., an antibody or an antigen binding fragment thereof
- targets e.g., specifically binds to
- the thymic function modulator comprises a guide RNA sequence that enables CRISPR-mediated gene editing of one or more of the thymic function factors described herein, e.g., listed in Table 1.
- the thymic function modulator comprises an mRNA molecule that encodes a zinc finger nuclease (ZFN) that targets (e.g., cleaves) the sequence encoding one or more thymic function factors described herein, e.g., listed in Table 1.
- ZFN zinc finger nuclease
- the thymic function modulator comprises an epigenetic modifying agent, e.g., an epigenetic modifying agent described herein.
- one or more additional thymic function modulators e.g., one, two, three, four, or five additional thymic function modulators (e.g., a second, third, fourth, fifth or sixth thymic function modulator) is administered to the subject.
- additional thymic function modulators e.g., one, two, three, four, or five additional thymic function modulators (e.g., a second, third, fourth, fifth or sixth thymic function modulator) is administered to the subject.
- the one or more of the thymic function modulators increase or decrease the expression or activity level of the same type of thymic function factor, e.g., a T cell growth factor, a T cell growth factor receptor, a T cell proliferation factor, a T cell migration factor, a T cell activity factor, a TEC proliferation factor, a TEC growth factor, a TEC growth factor receptor, a TEC function factor, or a thymus homeostasis factor.
- a T cell growth factor e.g., a T cell growth factor, a T cell growth factor receptor, a T cell proliferation factor, a T cell migration factor, a T cell activity factor, a TEC proliferation factor, a TEC growth factor, a TEC growth factor receptor, a TEC function factor, or a thymus homeostasis factor.
- two thymic function modulators are administered, and both thymic function modulators increase or decrease the expression or activity level of a T cell growth factor.
- two or more of the thymic function modulators increase or decrease the expression or activity level of different types of thymic function factors, e.g., a T cell growth factor, a T cell growth factor receptor, a T cell proliferation factor, a T cell migration factor, a T cell activity factor, a TEC proliferation factor, a TEC growth factor, a TEC growth factor receptor, a TEC function factor, or a thymus homeostasis factor.
- thymic function factors e.g., a T cell growth factor, a T cell growth factor receptor, a T cell proliferation factor, a T cell migration factor, a T cell activity factor, a TEC proliferation factor, a TEC growth factor, a TEC growth factor receptor, a TEC function factor, or a thymus homeostasis factor.
- two thymic function modulators are administered, and one thymic function modulator increases or decreases the expression or activity level of a T cell growth factor while the other thymic function modulator increases or decreases the expression or activity level of a TEC proliferation factor.
- the one or more thymic function modulators increase or decrease the expression or activity level of a thymic function factor described herein, e.g., listed in Table 1.
- administering two or more thymic function modulators results in a synergistic effect.
- a synergistic effect is observed when the effect of the two or more thymic function modulators is greater than the additive effect observed of each of the thymic function modulators.
- the method includes administering a first and a second thymic function modulator.
- the first and second thymic function modulators are formulated in separate dosage forms.
- the first and second thymic function modulators are formulated in the same dosage form.
- the first and second thymic function modulators are coupled by a covalent bond, a non-covalent bond, or a chemical linkage.
- the first and second thymic modulators are separated by a linker.
- the first and second thymic function modulators are each mRNA molecules (e.g., encoding a thymic function factor or functional fragment thereof). In one embodiment, the first and second thymic function modulators are coupled by a phosphodiester bond. In one embodiment, the first and second thymic function modulators are translated into a single polypeptide (e.g., a chimeric polypeptide or a polypeptide that can be cleaved into two polypeptides). In one embodiment, the first and second thymic function modulators are separated by a peptide cleavage site. In one embodiment, the first thymic function modulator is translated into a first polypeptide and the second thymic function modulator is translated into a second polypeptide.
- the first and second thymic function modulators are each interfering RNA molecules (e.g., a siRNA, a shRNA, or a miRNA).
- the first and second thymic function modulators are each siRNAs, and wherein the first and second thymic function modulators are coupled by a linker, e.g., a peptide linkage or a chemical linkage, e.g., as described herein.
- the method includes administering more than one (e.g., two, three, four, five, or more) thymic function modulator.
- the more than one (e.g., two, three, four, five, or more) thymic function modulators are formulated in separate dosage forms.
- the more than one (e.g., two, three, four, five, or more) thymic function modulators are formulated in the same dosage form.
- the more than one (e.g., two, three, four, five, or more) thymic function modulators are coupled to each other by a covalent bond, a non-covalent bond, or a chemical linkage.
- the more than one (e.g., two, three, four, five, or more) thymic modulators are separated from each other by a linker.
- the more than one (e.g., two, three, four, five, or more) thymic function modulators are each mRNA molecules (e.g., encoding a thymic function factor or functional fragment thereof). In one embodiment, the more than one (e.g., two, three, four, five, or more) thymic function modulators are coupled to each other by a phosphodiester bond. In one embodiment, the more than one (e.g., two, three, four, five, or more) thymic function modulators are translated into a single polypeptide (e.g., a chimeric polypeptide or a polypeptide that can be cleaved into multiple polypeptides).
- a single polypeptide e.g., a chimeric polypeptide or a polypeptide that can be cleaved into multiple polypeptides.
- the more than one (e.g., two, three, four, five, or more) thymic function modulators are separated from each other by a peptide cleavage site.
- each thymic function modulator is translated into a polypeptide.
- the more than one (e.g., two, three, four, five, or more) thymic function modulators are each interfering RNA molecules (e.g., a siRNA, a shRNA, or a miRNA).
- the more than one (e.g., two, three, four, five, or more) thymic function modulators are each siRNAs, and each of the thymic function modulators are coupled by a linker, e.g., a peptide linkage or a chemical linkage, e.g., as described herein.
- the physiological senescence is associated with one or more of muscle atrophy/degeneration; decrease in bone health (e.g., bone strength and/or density); immunosenescence (e.g., decrease in immune responsiveness); cardiac disease; uncontrolled cell growth (e.g., tumorigenesis).
- bone health e.g., bone strength and/or density
- immunosenescence e.g., decrease in immune responsiveness
- cardiac disease e.g., tumorigenesis
- a subject experiencing physiological senescence has a disease or condition associated with muscle atrophy/degeneration; decrease in bone health (e.g., bone strength and/or density); immunosenescence (e.g., decrease in immune responsiveness); cardiac disease; uncontrolled cell growth (e.g., tumorigenesis).
- a disease or condition associated with muscle atrophy/degeneration e.g., bone strength and/or density
- immunosenescence e.g., decrease in immune responsiveness
- cardiac disease e.g., tumorigenesis
- the subject has a muscular degenerative disorder (e.g., a myopathy, muscle wasting, or sarcopenia); amyotrophic lateral sclerosis (ALS); osteoporosis and related diseases; a cardiac disease (e.g., myocardial infarction, atherosclerosis); a cancer (e.g., a solid cancer, such as uterine cancer, colon cancer, ovarian cancer, rectal cancer, skin cancer, stomach cancer, lung cancer, non-small cell carcinoma of the lung, breast cancer, cancer of the small intestine, testicular cancer, cancer of the anal region, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, rectal cancer, renal-cell carcinoma, liver cancer, cancer of the esophagus, melanoma, cutaneous or intraocular malignant melanoma, uterine cancer, brain cancer, brain stem glioma, pituitary adenoma, Kaposi's sarcoma
- plasmablastic lymphoma and plasmacytoid dendritic cell neoplasm
- a metabolic disease e.g., diabetes, e.g., type I diabetes, or obesity.
- the method further includes monitoring the muscle function, bone health, cardiac health, and/or immune responsiveness of the subject.
- the injury is induced by a disease, a drug treatment, irradiation, or other environmental factor.
- the injury is induced by drug is a cytoreductive or chemotherapeutic drug.
- the injury is an acute injury. In other embodiments, the injury is a chronic injury. Enhancing/decreasing immune response
- the immune response comprises an anti-cancer immune response, a vaccine response, or an immune response to an infection (e.g., chronic infection).
- the cancer is selected from a hematological cancer or a solid cancer such as lung cancer, non-small cell lung cancer (NSCLC), skin cancer, melanoma, cervical cancer, uterine cancer, ovarian cancer, breast cancer, pancreatic cancer, stomach cancer, esophageal cancer, colorectal cancer, liver cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, sarcoma, lymphoma, and brain cancer.
- the method comprises administering the thymic function modulator in combination with an immunotherapy, e.g., cancer immunotherapy, e.g., cancer immunotherapy described herein.
- the infection is a chronic infection or an acute infection.
- the infection is a bacterial or viral infection.
- the infectious disease is a bacterial infection.
- the infectious disease is a viral infection.
- the infection is a chronic infection or an acute infection.
- the infection is a parasitic infection.
- the method comprises inducing negative selection in the subject, e.g., inducing clonal deletion and/or inducing Treg generation in the subject. In embodiments, the method prevents rejection of a transplant in the subject.
- the autoimmune disease is rheumatoid arthritis, j venile oligoarthritis, collagen-induced arthritis, adjuvant-induced arthritis, Sjogren's syndrome, multiple sclerosis, experimental autoimmune encephalomyelitis, inflammatory bowel disease (for example, Crohn's disease, ulcerative colitis), autoimmune gastric atrophy, pemphigus vulgaris, psoriasis, vitiligo, type 1 diabetes, non-obese diabetes, myasthenia gravis, Grave's disease, Hashimoto's thyroiditis, sclerosing cholangitis, sclerosing sialadenitis, systemic lupus erythematosis, autoimmune thrombocytopenia purpura, Goodpasture's syndrome, Addison's disease, systemic sclerosis, polymyositis, dermatomyositis, autoimmune hemolytic anemia, or pernicious anemia.
- inflammatory bowel disease for example,
- the transplant comprises a cell or organ transplant.
- the cell comprises a stem cell, e.g., hematopoietic stem cell and/or mesenchymal stem cell.
- the organ comprises a lung, heart, eye, liver, or kidney.
- the thymic involution is caused by aging, a drug or treatment, and/or a disease.
- the drug or treatment comprises a chemotherapy, radiation, or immunotherapy.
- the disease comprises a cancer or an infection, e.g., chronic or acute infection.
- the cancer is selected from a hematological cancer or a solid cancer, e.g., a hematological or solid cancer described herein, e.g., lung cancer, non-small cell lung cancer (NSCLC), skin cancer, melanoma, cervical cancer, uterine cancer, ovarian cancer, breast cancer, pancreatic cancer, stomach cancer, esophageal cancer, colorectal cancer, liver cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, sarcoma, lymphoma, or brain cancer.
- a hematological cancer or a solid cancer described herein e.g., lung cancer, non-small cell lung cancer (NSCLC), skin cancer, melanoma, cervical cancer, uterine cancer, ovarian cancer, breast cancer, pancreatic cancer, stomach cancer, esophageal cancer, colorectal cancer, liver cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, sarcoma, lymphoma, or brain cancer.
- the infection is a bacterial infection or a viral infection.
- the subject e.g., subject from which the source cell is derived and/or subject to be administered a therapy described herein, e.g., a cell culture/cell(s)/preparation described herein and/or other therapy described herein
- physiological senescence comprises muscle atrophy/degeneration, inadequate bone strength/density, immunosenescence (age-related decrease in immune responsiveness or menopause), or cardiac disease.
- the subject has a disease or condition associated with muscle atrophy/degeneration, inadequate bone strength/density, immunosenescence (age-related decrease in immune responsiveness or menopause), or cardiac disease.
- the subject has an acute thymic injury.
- the subject has drug or radiation induced thymic damage.
- the subject is an adult subject, e.g., a geriatric subject, e.g., a subject older than 60, 65, 70, 75, 80, 85, 90.
- the subject is a juvenile subject, e.g., less than 18 years old.
- the subject does not have a detectable thymus before treatment.
- the subject has an implanted thymus tissue, e.g., has an implanted thymus.
- the subject has had a thymic transplant.
- the subject has undergone, is undergoing, or will undergo a cell (e.g., stem cell, e.g., hematopoietic stem cell) transplant.
- a cell e.g., stem cell, e.g., hematopoietic stem cell
- the disclosure relates to methods of generating and/or enhancing thymic function in cells ex vivo as well as treatment comprising use of such ex vivo thymic cultures.
- the disclosure also relates to compositions comprising cells (e.g., tissues) having thymic function, e.g., cells that were generated using an ex vivo method, and methods of use.
- cells e.g., tissues
- thymic function modulators improve one or more functions of the thymus and can, e.g., lead to rejuvenation of thymus activity.
- thymic function modulators and/or cells generated using thymic function modulators are useful for treating diseases and conditions associated with a loss or reduction of thymic activity.
- a reduction in thymic activity can occur, e.g., due to age (e.g., thymic involution) or stresses (e.g., trauma, drug effects, and diseases).
- diseases and conditions can be related to or include: physiological senescence, autoimmunity, cardiac disease, cancer, infectious disease, muscle
- Atrophy/degeneration decrease in bone health, immunosenescence, thymic injury, and other diseases/conditions described herein.
- therapeutic methods for decreasing or reversing thymic involution are also featured herein.
- methods of enhancing the function/lifetime of a thymus transplant are described in greater detail herein.
- thymic function modulator is an agent that modulates, e.g., increases or decreases, thymic function. Determination of thymic function is described herein, e.g., in the "Measurement of thymus function” section. Thymic function modulators are described in greater detail herein, e.g., in the "Thymic function modulators” section.
- thymic function factor is a molecule, e.g., protein, peptide, polypeptide, or nucleic acid molecule (e.g., oligonucleotide, e.g., DNA, RNA, or mRNA, or gene), that is associated with thymic function.
- expression e.g., high
- Thymic function factors are described in greater detail herein, e.g., in the "Thymic function factors" section.
- an "antibody molecule” is a protein that includes at least one
- an antibody molecule can include a heavy (H) chain variable region (abbreviated herein as VH), and a light (L) chain variable region: (abbreviated herein as VL).
- VH heavy chain variable region
- L light chain variable region
- an antibody includes two heavy (H) chain variable regions and two light (L) chain variable regions.
- antibody molecule encompasses antigen-binding fragments of antibodies (e.g., single chain antibodies, Fab and sFab fragments, F(ab') 2, Fd fragments, Fv fragments, scFv, and domain antibodies (dAb) fragments as well as complete antibodies.
- antibodies can have the structural features of IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof).
- antibodies are recombinant human or humanized antibodies.
- a "combination therapy" or “administered in combination” means that two (or more) different agents or treatments are administered to a subject as part of a defined treatment regimen for a particular disease or condition.
- the treatment regimen defines the doses and periodicity of administration of each agent such that the effects of the separate agents on the subject overlap.
- the delivery of the two or more agents is simultaneous or concurrent and the agents may be co-formulated.
- the two or more agents are not co-formulated and are administered in a sequential manner as part of a prescribed regimen.
- administration of two or more agents or treatments in combination is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one agent or treatment delivered alone or in the absence of the other.
- the effect of the two treatments can be partially additive, wholly additive, or greater than additive (e.g., synergistic). Sequential or substantially simultaneous
- each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues.
- the therapeutic agents can be administered by the same route or by different routes.
- a first therapeutic agent of the combination may be administered by intravenous injection while a second therapeutic agent of the combination may be
- composition refers to a medicinal or pharmaceutical formulation that contains one or more active ingredient as well as one or more excipients and diluents to enable the active ingredient(s) suitable for the method of
- the pharmaceutical composition of the present invention includes
- a pharmaceutical composition or pharmaceutical preparation is a composition or preparation produced under good manufacturing practices (GMP) conditions, having pharmacological activity or other direct effect in the mitigation, treatment, or prevention of disease, and/or a finished dosage form or formulation thereof and is for human use.
- GMP good manufacturing practices
- the terms “increasing” and “decreasing” refer to modulating resulting in, respectively, greater or lesser amounts, function or activity of a metric relative to a reference.
- the amount of a marker of thymic function may be increased or decreased in a subject by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% or more relative to the amount of the marker prior to administration.
- the metric is measured subsequent to administration at a time that the administration has had the recited effect, e.g., at least one week, one month, 3 months, 6 months, after a treatment regimen (e.g., a therapy described herein) has begun.
- a treatment regimen e.g., a therapy described herein
- Treatment and “treating,” as used herein, refer to the medical management of a subject with the intent to improve, ameliorate, stabilize, prevent or cure a disease, pathological condition, or disorder.
- This term includes active treatment (treatment directed to improve the disease, pathological condition, or disorder), causal treatment (treatment directed to the cause of the associated disease, pathological condition, or disorder), palliative treatment (treatment designed for the relief of symptoms), preventative treatment (treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder); and supportive treatment (treatment employed to supplement another therapy).
- synergy or “synergistic” means a more than additive effect of a combination of two or more agents (e.g., a combination therapy described herein) compared to their individual effects.
- synergistic activity is present when a first agent produces a detectable level of an output X, a second agent produces a detectable level of the output X, and the first and second agents together produce a more-than-additive level of the output X.
- thymic capability refers to the ability to carry out one or more thymic functions, e.g., the presence of a cell or tissue that has a thymic function, e.g., a thymic cell or tissue.
- the thymic cell or tissue comprises a thymocyte, epithelial thymic cell (e.g., of the cortex or medulla), stromal cell and/or a dendritic cell (e.g., a conventional dendritic cell or a plasmacytoid dendritic cell).
- the thymic cell or tissue can be autologous or allogeneic.
- the thymic cell or tissue can be suitable for implantation.
- the thymic cell or tissue has been implanted in a subject.
- the thymic cell or tissue is cultured ex vivo prior to implantation into a subject, e.g., using a method described herein, e.g., in the "Ex Vivo Manipulation Methods" section herein.
- the thymic cell or tissue is evaluated by assessing certain thymic activities, functions, markers or characteristics, e.g., using a method described herein, e.g., in the "Measurement of thymus function" section herein.
- peptide linker refers to an amino acid sequence (e.g., synthetic amino acid sequence) that connects or links two polypeptide sequences, e.g., that links two polypeptide domains.
- synthetic refers to amino acid sequences that are not naturally occurring.
- peptide linkers connect two amino acid sequences via peptide bonds, e.g., in a linear sequence.
- a peptide linker connects a biologically active moiety to a second moiety in a linear sequence.
- a peptide linker connects two biologically active moieties.
- the terms "linked,” “fused”, or “fusion”, are used interchangeably. These terms refer to the joining together of two more elements or components, by whatever means including chemical conjugation or recombinant means. Any method of chemical conjugation (e.g., using heterobifunctional crosslinking agents) can be used.
- two or more molecules e.g., nucleic acid molecules (e.g., mRNAs or inhibitory nucleic acid molecules), small molecules, and/or peptides/polypeptides can be linked, e.g., using a linker, e.g., chemical linker or peptide linker.
- genetic fusion refers to the co-linear, covalent linkage or attachment of two or more proteins, polypeptides, or fragments thereof via their individual peptide backbones, e.g., through genetic expression of a single polynucleotide molecule encoding those proteins, polypeptides, or fragments. Such genetic fusion results in the expression of a single contiguous genetic sequence.
- Exemplary genetic fusions are in frame, i.e., two or more open reading frames (ORFs) are fused to form a continuous longer O F, in a manner that maintains the correct reading frame of the original ORFs.
- the resulting recombinant fusion protein is a single polypeptide containing two or more protein segments that correspond to polypeptides encoded by the original ORFs (which segments are not normally so joined in nature).
- the single polypeptide is cleaved during processing to yield dimeric molecules comprising two polypeptide chains.
- Percent identity in the context of two or more polypeptide sequences or nucleic acids refers to two or more sequences that are the same. Two sequences are "substantially identical" if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (e.g., at least 60% identity, e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity, e.g., over a specified region, or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using a sequence comparison algorithms or by manual alignment and visual inspection.
- the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length.
- sequence comparison typically one sequence acts as a reference sequence, to which test sequences are compared.
- test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated.
- sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
- Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, (1970) J.
- BLAST and BLAST 2.0 algorithms Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402; and Altschul et al., (1990) J. Mol. Biol. 215:403-410, respectively.
- Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
- the percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller, (1988) Comput. Appl. Biosci. 4: 11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
- the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (1970) J. Mol. Biol.
- thymic function ex vivo e.g., in a cell, organ, or organoid culture.
- methods of decreasing or reversing thymic involution comprising culturing a cell under conditions that improve thymic function, e.g, and subsequently administering the cultured cell to a subject in need thereof.
- a source cell e.g., population of cells, e.g., cells isolated from a thymus tissue, or T cells
- a thymic function modulator e.g., described herein.
- the source cell(s) is cultured under conditions sufficient to produce a cell(s) with improved thymic function.
- the cell(s) having improved thymic function can be administered to a subject, e.g., alone or in combination with a thymic function modulator or other therapy/agent described herein.
- the cell(s) can be administered at a dosage or dosage frequency described herein, e.g., 10 4 to 10 9 cells/kg body weight, e.g., 10 5 to 10 6 cells/kg body weight, including all integer values within those ranges.
- the cell(s) can also be administered multiple times at these dosages.
- the cells can be administered by using infusion techniques that are known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319: 1676, 1988).
- the cells can be autologous or allogeneic.
- the source cells can be thymic cells, e.g., epithelial thymic cells (e.g., of the cortex or medulla), stromal cells, and/or dendritic cells (e.g., conventional dendritic cells or plasmacytoid dendritic cells).
- Conventional dendritic cells also called myeloid dendritic cells
- dendritic cells include all dendritic cells other than plasmacytoid dendritic cells. Dendritic cells are described in greater detail in, e.g., Schraml et al. Curr. Opin. Immunol.
- the source cells can be a non-thymic cell, e.g., an epithelial cell or fibroblast cell.
- a source cell e.g., non-thymic cell
- a thymic transformation agent which induces a thymic gene expression profile or a thymic function in the cell(s).
- An epithelial thymic cell e.g., cortical thymic epithelial cell (cTEC) or medullary thymic epithelial cell (mTEC) gene expression profile can be characterized by one or more of the genes as shown in Table 4. Exemplary thymic functions are described in greater detail in the "Measurement of thymus function" section herein.
- a thymic transformation agent includes an agent that induces a thymic gene expression profile and/or thymic function in a cell/population of cells that are not derived from the thymus.
- An example of a thymic transformation agent is a thymic function modulator, e.g., described herein.
- Thymic transformation agents can be in the form of nucleic acid molecules (e.g., mRNAs, DNAs), peptides, antibody molecules, or small molecules.
- a thymic transformation agent is a nucleic acid molecule, e.g., a synthetic mRNA, e.g., that encodes a transcription factor, sucha s FOXNl.
- a thymic transformation agent can include an agent that changes the stromal/non-stromal cellular balance in a thymus.
- a thymic transformation agent changes the medullary/cortical cellular balance in a thymus.
- imaging techniques such as ultrasound, histological analysis, or PET imaging (e.g., FDG avidity via PET).
- a thymic transformation agent shifts the ratio of medullary to cortical thymus (e.g., ratio of medullary TECs to cortical TECs), which can be assessed by imaging or histological analysis of surface markers, such as K5 and/or K8 staining.
- a thymic transformation agent changes the gene expression profile in a sample, e.g., thymus sample, e.g., from a subject, to reflect increased cell function or expansion of epithelial cells.
- a gene expression profile can include expression of AIRE, FEZF2, FOXN1, e.g., of medullary TECs or of cortical TECs.
- a gene expression profile can be determined by gene expression profiling techniques, such as RT-PCR or arrays.
- a thymic transformation agent causes a thymic modification that results in an expansion or contraction of an antigen- specific T cell population.
- Antigen- specific T cell populations can be identified/quantified by using TCR Seq, tetramers, or a type IV
- the source cell(s) is cultured with a thymic transformation agent at least until a marker of thymic function is detected.
- exemplary markers of thymic functions include formation of a plasma cell, development of an antigen- specific T cell, and/or formation of a thymic organoid, and are described in greater detail in the "Measurement of thymus function" section herein.
- the cell(s) is administered to a subject in need thereof after detection of a marker of thymic function.
- a cell culture/cell(s)/preparation thereof can be transplanted into a subject, e.g., as described in Markert et al. Clin. Immunol.
- the cell culture/cell(s)/preparation thereof can be transplanted into the quadriceps muscles of the subject.
- Other methods of delivering/administering the cell culture/cell(s)/preparation thereof are contemplated, e.g., described herein, and also described in Sachs et al. Transpl. Immunol. 21.2(2009): 101- 105.
- a method described herein comprises one or more steps as described herein, where instead of, or in addition to, contacting a source cell with a thymic function modulator, the method comprises mechanical manipulation of the source cell(s).
- the method comprises applying a force or stimulus, e.g., physical/mechanical force (e.g., stress), to the source cell, e.g., to generate/produce a cell having thymic structure/function (e.g., improved thymic structure/function compared to the source cell prior to the application of the force).
- a force or stimulus e.g., physical/mechanical force (e.g., stress)
- the source cell can comprise a single cell or multiple cells, e.g., tissue and/or organ.
- the force comprises a shear force, a bending force, a stretching force, a compression force, and/or magnetic pulse(s).
- the force is applied cyclically.
- the force comprises cyclic strain, which can include repeatable tensile strain and/or cyclic compressive strain.
- Thymic function factors modulate thymic function and can be characterized by one or more properties described herein.
- a thymic function factor can itself be a thymic function modulator.
- a thymic function factor is a positive regulator of thymic function (e.g., increases one or more activity of the thymus). In other embodiments, a thymic function factor is a negative regulator of thymic function (e.g., decreases one or more activity of the thymus). In embodiments, a thymic function factor can be both a positive and a negative regulator of thymic function. Exemplary positive and/or negative regulators of thymic function are listed in Table 1.
- a thymic function factor increases the proliferation or cell count of stromal cells or non-adipocyte cells.
- Proliferation/cell count can be determined by proliferation assays, e.g., Ki67 staining or PCNA staining.
- a thymic function factor changes the stromal/non-stromal cellular balance in the thymus.
- the stromal/non-stromal cellular balance is determined by a method such as ultrasound, histological analysis, or imaging (e.g., PET imaging, e.g., FDG avidity via PET imaging).
- a thymic function factor increases or decreases the stromal/non-stromal cellular balance, e.g., increases or decreases the ratio of thymic epithelial cells to thymocytes; or increases or decreases the ratio of adipocytes to thymocytes.
- a thymic function factor increases the production and/or level of a thymic hormone.
- a thymic hormone is associated with the size of the thymus.
- An exemplary thymic hormone is thymulin.
- the level of a thymic hormone can be determined by an assay, e.g., a rosette inhibition assay, e.g., as described in Consolini et al. Haematologica 77.3(1992):243-47.
- a thymic function factor increases the level of a thymic hormone by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 2-fold, 4-fold, 6-fold, 8-fold, 10-fold, 15-fold, 20-fold, 30-fold, 40-fold, 50- fold, 100-fold, 1000-fold, or more, e.g., relative to a reference level.
- a reference level is the level of the thymic hormone in a sample (e.g., a cell or tissue sample, e.g., from a subject) lacking the thymic function factor or a sample (e.g., a cell or tissue sample, e.g., from a subject) prior to addition/administration of the thymic function factor.
- a sample e.g., a cell or tissue sample, e.g., from a subject
- a sample e.g., a cell or tissue sample, e.g., from a subject
- a thymic function factor modulates a T cell phenotype, e.g., a peripheral T cell phenotype.
- An exemplary peripheral T cell phenotype includes a thymic emigrant profile, e.g., percent of T cells that have unique T cell receptors (TCRs) (e.g., TCR diversity), percent of T cells that are FoxP3 positive, percent of T cells that are regulatory T cells (Tregs), percent of cells that are positive for a CD45RA isoform (e.g., CD45RA), percent of cells that are CD4 positive and CD25 positive, or percent of T cells that are cytotoxic T lymphocytes (CTLs).
- TCRs unique T cell receptors
- Tregs percent of T cells that are regulatory T cells
- CD45RA percent of cells that are positive for a CD45RA isoform
- CTLs cytotoxic T lymphocytes
- thymic emigrant profile can be determined by quantifying and/or comparing the levels of different T cell populations.
- a thymic function factor increases the number of Tregs (or percent of cells that are Tregs), e.g., thereby decreasing autoimmunity.
- a thymic function factor decreases the number of Tregs (or percent of cells that are Tregs), e.g., thereby decreasing the progression or severity of a cancer (e.g., decreasing the number of cancer cells.
- a thymic function factor modulates the polyclonality of a B cell response.
- polyclonality of a B cell responses can be determined by measuring changes in B-cell isotype distribution, polyclonal antibody titers to an antigen, and/or polyclonal antibody titers to one or more thymus -dependent antigens.
- B-cell isotypes can be detected and/or quantified by assays such as flow cytometry, e.g., fluorescence activated cell sorting (FACS).
- Antibody titer can be measured by assays such as ELISAs, cytometric bead array, and other kits/methods.
- ELISAs are plate based assays to quantify soluble proteins, including immunoglobulins (see, e.g., Pathak et al.; 1997; Immunology Methods Manual, vol. 2. 1.
- Cytometric Bead Array is a bead-based immunoassay that allows multiplexed quantitation of soluble and intracellular proteins including immunoglobulin and can be combined with further markers that are used for phenotyping (see, e.g., Morgan et al.; Clin Immunol. 2004).
- CBAs and ELISAs allow evaluation of immunoglobulin isotypes in serum, plasma or cell culture supernatants. Other methods, e.g., commercially available kits, are available in the art to perform individual isotype determination of secreted immunoglobulins.
- B cells can be quantified using FACS, as described in Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol. 2008;20: 149-157. Also, high-throughput DNA sequencing allows determination of the antibody repertoire encoded by B cells in the blood or lymphoid organs and can be applied to detect B-cell malignancies with high sensitivity, to discover antibodies specific for antigens of interest, to guide vaccine development, and to understand autoimmunity (see, e.g., Georgiou et al. 2014. Nature Biotechnology). The detection limit is an estimated 1 in a million (see, e.g., Wu et al. 2014. Clin Cancer Res.).
- a thymic function factor modulates thymocyte flux.
- Thymocyte flux can be determined by measuring the T-Cell Receptor Excision Circles (TRECs) per number of cells, e.g., over a period of time, e.g., over about 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, or more.
- T-Cell Receptor Excision Circles T-Cell Receptor Excision Circles
- thymic function factors are listed in Table 1.
- a thymic function factor is associated with, e.g., results in, one or more effects described in Table 1.
- a thymic function factor comprises a peptide, polypeptide, protein, or nucleic acid molecule (e.g., oligonucleotide, RNA, mRNA (e.g., modified or synthetic mRNA), DNA, or gene or gene fragment).
- nucleic acid molecule e.g., oligonucleotide, RNA, mRNA (e.g., modified or synthetic mRNA), DNA, or gene or gene fragment.
- a thymic function factor comprises a ligand (e.g., secreted ligand, a non- secreted ligand (i.e., membrane-bound)), a transmembrane protein (e.g., receptor, e.g., cell surface receptor or nuclear receptor), or a nucleic acid molecule (e.g., gene, DNA, RNA, or mRNA) encoding same.
- a ligand e.g., secreted ligand, a non-secreted ligand (i.e., membrane-bound)
- a transmembrane protein e.g., receptor, e.g., cell surface receptor or nuclear receptor
- a thymic function factor comprises a hormone, a transcription factor, an enzyme (e.g., proteinase, protease, phosphatase), a chemokine, a cell matrix protein, cytoplasmic protein, or a nucleic acid molecule (e.g., gene, DNA, RNA, or mRNA) encoding same.
- an enzyme e.g., proteinase, protease, phosphatase
- a chemokine e.g., a cell matrix protein, cytoplasmic protein, or a nucleic acid molecule (e.g., gene, DNA, RNA, or mRNA) encoding same.
- a hormone examples include a transcription factor, an enzyme (e.g., proteinase, protease,
- phosphatase a chemokine
- a cell matrix protein a cell matrix protein
- cytoplasmic protein a chemokine
- a thymic function factor comprises a growth factor (e.g., T cell growth factor, thymic epithelial cell (TEC) growth factor, thymocyte growth factor, T cell subset specific growth factor (e.g., Tregs, naive T cells, or memory T cells), a growth factor receptor (e.g., a T cell growth factor receptor, a TEC growth factor receptor, a proliferation factor (e.g., T cell proliferation factor, thymic epithelial cell (TEC) proliferation factor), cell migration factor (e.g., T cell migration factor), T cell activity factor, TEC function factor, and/or a thymus homeostasis factor, or a nucleic acid molecule (e.g., gene, DNA, RNA, or mRNA) encoding same.
- a growth factor e.g., T cell growth factor, thymic epithelial cell (TEC) growth factor, thymocyte growth factor, T cell subset specific growth factor (e
- one or more thymic function factors e.g., one, two, three, four, or five thymic function factors (e.g., a second, third, fourth, fifth or sixth thymic function factor) is administered to the subject.
- the one or more of the thymic function factors are associated with increased or decreased activity level of a thymic function as described herein.
- a T cell growth factor is involved in T cell development and/or maturation, e.g., involved in proliferation of thymocytes, commitment to T-cell lineage, and/or positive and/or negative selection of immune cells.
- Exemplary T cell growth factors include but are not limited to BMP4, Bmprla, CD70, Cldn4, DM, Egrl, Egr2, Egr3, EphB2, Flt3, Flt3L, Foxol, FoxP3, Gata2, Gata3, Gfil, Ghrl (ghrelin), GnRH, Icaml, Id3, Ifnarl, IL-2, IL-6, IL-7, IL-12b (IL12 p40 subunit), IL- 15, IL-18, IL-21, ⁇ , K , Klf3, Lefl, leptin, Lif, Nfat5, Nfatcl, Notch 1, Prolactin, Ragl, Rag2, Runxl, Satbl, SCF (K ), Shh (
- Exemplary TCR variants include a TCR comprising an alpha and a beta chain, a TCR comprising a gamma chain and a delta chain, a TCR comprising a CD3 chain, a TCR comprising a zeta chain, a TCR comprising a complementarity determining region, and a TCR comprising a T cell co-receptor (e.g., CD4 or CD8).
- a TCR includes a TCR that binds to an epitope presented on an MHCI molecule, an epitope presented on an MHCII molecule, or an epitope presented on an MHCIII molecule.
- the T cell growth factor is selected from at least one of Flt3, Flt3L, Foxol, FoxP3, Gfil, Ghrl (ghrelin), GnRH, Icaml, Id3, Ifnarl, IL-2, IL-6, IL-7, IL-12b (IL12 p40 subunit), IL-15, IL-18, IL-21, KM, Klf3, Lefl, leptin, Lif, and SCF (KM).
- the T cell growth factor is selected from at least one of IL-7, IL-21, Delta-like 4 (DLL4), Flt3L, SCF (Kitl), and miR-29a.
- one or more the T cell growth factors e.g., one, two, three, four, or five T cell growth factors (e.g., a second, third, fourth, fifth or sixth T cell growth factor) is administered to the subject.
- the T cell growth factor may also include at least one selected from IL-15, IL-2, IL-12, IL-18, and IFNy. Examples of a T cell growth factor are listed in Table 1.
- a TEC growth factor is involved in TEC development, differentiation, and/or
- TEC growth factors include but are not limited to Atf3, BMP4 (TEC), Cbx4, Cdh5 (VE cadherin), E2F3, E2F4, Foxnl, Fspl, Fstll, Ml, Kl (Klotho), Ltbr, NFkB l, PPARgamma, Pten, RANK, RANKL, Shh (TEC), Sin/Polr3e, Stat3, Tbata, Tbxl, Tgfbr2, Tnfrsfl la /RANK, Tnfrsf 1 lb, Traf6, Wnt3a (TEC), and Wnt4 (TEC). Examples of a TEC growth factor are listed in Table 1.
- the TEC growth factor enhances thymus function by modulating, e.g., increasing, e.g., enhancing, proliferation, survival and/or generation of thymic epithelial cells.
- the TEC growth factor is selected from at least one of FGF21, FGF7 (KGF), FGF8, FGF10, IL-22, Wnt4, Bmp4, RANKL, LTa, CL40L, Foxnl, leptin, IGF-1, GH, (Ghrl) ghrelin, GnRH, and NGF.
- one or more the TEC growth factors e.g., one, two, three, four, or five TEC growth factors (e.g., a second, third, fourth, fifth or sixth TEC growth factor) is administered to the subject.
- a T cell growth factor receptor binds to (e.g., is a receptor for) a T cell growth factor.
- exemplary T cell growth factor receptors include but are not limited to CD 127 (non-soluble IL- 7R), CD27, Crlf2 (TSLP-R), Fzdl, FzdlO, Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7, Fzd8, Fzd9, Ihh, IL-7R alpha, Ptchl, and Ptch2. Examples of a T cell growth factor receptor are listed in Table 1.
- a TEC growth factor receptor binds to (e.g., is a receptor for) a TEC growth factor.
- Exemplary TEC growth factor receptors include but are not limited to Bmpr2, Fgfr2, and bmprla (TEC). Examples of a TEC growth factor receptor are listed in Table 1.
- a T cell migration factor is involved in early thymic progenitor (ETP) homing, thymocyte migration within the thymus, and/or T-cell export.
- ETPs are a population of cells comprising about 0.01% of total thymocytes; they are the more immature T-cell precursors in the thymus and can expand to repopulate thymocyte populations, e.g., after intrathymic transfer.
- ETPs have the following phenotype: lin low CD44 + cKit high CD25 " . Without wishing to be bound by theory, it is believed that one or more factors are involved in Treg egress and migration.
- S 1P1 sphingosine-1 phosphate receptor- 1
- CCMJ corticomedullary junction
- S 1P1 expression in thymocytes is believed to be regulated by KLF2.
- factors believed to be involved in Treg migration include CCL20 (e.g., which binds to CCR6 receptor expressed on Tregs), CCR6, CXCLl-3 (e.g., which binds to CXCR2 receptor expressed on Tregs), CXCR2, IL8 (e.g., which binds to CXCR1 receptor expressed on Tregs), CXCR1, CCL2, CCL4, CCL5, CCL22, CXCL8, and CXCL10.
- T cell migration factors include but are not limited to CC119, Ccl21, CCL25, Ccr7, Ccr9, Cxcll2, Cxcr4, S 1PR1 (S 1P1), Sele (E-selectin, CD62E, ELAM-1, or LECAM2), Sell (CD62L), Selp (P-selectin), CCL20, CCR6, CXCLl-3, CXCR2, IL8, CXCR1, CCL2, CCL4, CCL5, CCL22, CXCL8, and CXCL10.
- one or more the T cell migration factors e.g., one, two, three, four, or five T cell migration factors (e.g., a second, third, fourth, fifth or sixth T cell migration factor) is administered to the subject.
- T cell migration factors are listed in Table 1.
- a T cell activity factor is involved in T cell function.
- An exemplary T cell activity factor includes E2F2.
- one or more the T cell activity factors e.g., one, two, three, four, or five T cell activity factors (e.g., a second, third, fourth, fifth or sixth T cell activity factor) is administered to the subject. Examples of a T cell activity factor are listed in Table 1. Assessment of T cell function is described in greater detail in the "T cell function section" herein.
- a TEC proliferation factor is involved in TEC proliferation, e.g., in an adult thymus.
- TEC proliferation factors include but are not limited to Cyr61, E2F2 (TEC), IGF-1, IL-22, IL-23, and KGF (Fgf7).
- one or more the TEC proliferation factors e.g., one, two, three, four, or five TEC proliferation factors (e.g., a second, third, fourth, fifth or sixth TEC proliferation factor) is administered to the subject. Examples of a TEC proliferation factor are listed in Table 1.
- a thymic function factor is involved in one or more TEC functions.
- TEC function factors include but are not limited to AIRE, beta(5t)/Psmbl l, Fezf2, HLA (e.g., any HLA variant/polymorph, e.g., HLA-A, HLA-B, HLA-B27, HLA-B47, HLA-C, HLA-E, HLA-F, HLA-G, p2-microglobulin, HLA-DM (e.g., HLA-DMA1 and/or HLA-DMB 1), HLA-DO (e.g., HLA-DOA1 and/or HLA-DOB 1), HLA-DP (e.g, HLA-DPA1 and/or HLA-DPB 1), HLA-DQ (e.g., HLA-DQA1 and/or HLA-DQB 1), HLA-DQ2, HLA-DQ8, HLA-DR (e.g., HLA-DR
- an HLA comprises a HLA Class I allele (e.g., HLA-A, -B, -C, -E, -F, or -G allele), a HLA Class I Pseudogene (e.g., HLA-H, -J, -K, -L, -P, -T, -U, -V, -W, -X, or -Y), HLA Class II allele (e.g., HLA-DRA, -DRB, -DQA1, -DQB 1, -DPA1, -DPB 1, -DPB2, -DMA, - DMB, -DOA, -DOB), or HLA Class II DRB allele (e.g., HLA-DRB 1, -DRB2, -DRB 3, -DRB4, - DRB 5, -DRB6, -DRB7, -DRB 8, -DRB 9).
- HLA Class I allele e.
- an HLA Class I allele comprises an HLA Class I allele described at http://hla.alleles.org/alleles/classl.html (accessed as of June 9, 2016), incorporated herein by reference.
- an HLA comprises an HLA Class II allele described at http://hla.alleles.org/alleles/class2.html (accessed as of June 9, 2016), incorporated herein by reference.
- a thymus homeostasis factor is involved in homeostatic maintenance of the thymus.
- Exemplary thymus homeostasis factors include but are not limited to l lb-HSD2, AR, ASC, Axin, Fgf21, IL10, IL2 (stroma), Leptin (TEC), Meisl, and NLRP3.
- one or more the thymus homeostasis factors e.g., one, two, three, four, or five thymus homeostasis factors (e.g., a second, third, fourth, fifth or sixth thymus homeostasis factor) is administered to the subject. Examples of a thymus homeostasis factor are listed in Table 1.
- exemplary thymic function factors include Cd44, gpl30, hGH (GH1 and GH2), Nfkb2, Ptma (thymosin alpha- 1), Smad4, Smad6, and Tmpo (thymopoetin), e.g., as described in Table 1.
- Exemplary thymic function factors include but are not limited to those described in Table 1.
- the thymic function factors listed in Table 1 can include the nucleic acid molecule (DNA or RNA, e.g., mRNA) or polypeptide (e.g., translated protein).
- a thymic function factor comprises a polypeptide/protein or nucleic acid molecule homologous to a thymic function factor described herein, e.g., in Table 1.
- a thymic function factor comprises an amino acid sequence or nucleic acid sequence that is substantially identity to, e.g., having at least 60% (e.g., at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99%, or more, e.g., 100%) identity to the amino acid sequence or nucleic acid sequence of a thymic function factor described herein, e.g., in Table 1.
- NM_001302822 hormone, NM_001302821.
- T-cell proliferation secreted, NM_001134941, increased ETPs, encodes NM_016362, restoration of thymic ghrelin- NM_001134946, architecure, t-cell obestatin NM_001134945, increased thymus growth preproprotei
- IL-15 NR 037840 Pos thymoctye survival factor secreted t-cell
- IL-7Ralpha (CD 127) Pos complex receptor receptor
- RANK NM_001270951 Pos numbers factor receptor positive selection t-cell
- Gfil NM_005263 Pos differentiation factor factor t-cell
- Stat3 NM_139276 Pos and homeostasis factor factor
- Egrl NM_001964 Pos thymocyte survival factor factor factor NM_001 199881, t-cell
- Egr3 NM_004430 Pos functions with Egrl factor factor
- Egr2 NM_001 136177 Pos with Egrl/3 factor factor
- NM_001206488 null show decreased TEC growth transcription
- Gata3 NM_002051 Pos development factor factor
- Lefl NM_001 130713 Pos expression factor factor factor t-cell
- Tcfl NM_000545 Pos T-cell specification factor factor same as TEC growth
- NM_138711 overexpression nuclear NM_015869, copies thymic receptor,
- PPARgam NM_138712 involution, involved TEC growth transcription ma NM_005037 Neg in adipogenesis factor factor
- Nfatcl NM_001278669 Pos SP factor factor
- Nfat5 NM_173215 Pos beta selection to DP factor factor
- Nfkbl NM_001319226 Pos function factor factor
- Nfkb2 NM_001322934 Pos CD8+ T-cell factor t-cell
- NM_181050 promotes thymocyte thymus
- NM_001083111 thymic involution in growth hormone
- hGH (GH1 NM_022556, thymus recovery hormone, and GH2) NM_002059 Pos after insult secreted thymocyte
- IL21 NM_001207006 Pos recovery post GC factor secreted thymocyte survival
- NM_001163558 counteracts growth hormone
- Thyrotrop activates calcium t-cell
- Zfp3611 NM_004926 Pos Notch 1 mRNA factor factor role in beta selection t-cell
- Zfp3612 NM_006887 Pos Notch 1 mRNA factor factor required for T-cell t-cell
- thymosin NM_001099285 expression in human hormone
- Ptma alpha- 1 NM_002823 Pos APCs secreted thymus cellularity
- NM_0003144 architecture, enzyme NM_001304717, decreased thymocyte TEC growth (phosphatas
- Prssl6 NM_005865 Pos antigen presentation function (protease) mTEC
- NM_138551 thymocyte t-cell
- NM_033035 progenitor and T-cell growth ligand
- Tslp NR_045089 Pos proliferation factor secreted thymocyte
- NM_001562 phenotypic change in growth ligand
- NM_000600 causes loss of DP at growth ligand
- IL6 NM_001318095 Pos/Neg higher levels factor secreted required for
- NM_002309 causes loss of DP at growth ligand
- Runxl NM_001122607 Pos thymocyte survival factor factor
- EphB2 NM_004442 Pos TECs factor receptor
- thymocyte survival thymocyte survival
- t-cell ligand t-cell ligand
- Vcaml NM_080682 Pos positive selection factor bound neg regulator of
- Meisl NM_002398 Pos homeostasis homeostasis factor temporarily required
- NM_031200 progenitors
- Flt3 NR_130706 Pos receptor for Flt3L factor receptor receptor for Cxcll2,
- Fgfr2 NM_001320654 Pos receptor receptor receptor t-cell
- Fzdl NM_003505 Pos Wnt receptor factor receptor receptor t-cell
- Ptchl NM_001083603 Pos ligands receptor receptor
- Ptch2 NM_003738 Pos hedgehog signalling growth receptor ligands factor
- CD27 NM_001242 Pos survival receptor receptor thymocyte
- CD70 NM_001252 Pos survival factor bound dendritic cell
- NM_022148 progenitor and T-cell factor
- the expression or level of a thymic function factor can refer to the level of mRNA or protein.
- the level, e.g., mRNA level, of a thymic function factor can be determined by a number of assays, e.g., Northern blots, PCR, RT-PCR, or fluorescence in situ hybridization.
- the level, e.g., protein level, of a thymic function factor can be determined by a number of assays, e.g., Western blot, mass spectrometry (MS), liquid chromatography (LC) (e.g., LC-MS), ELISA, or histological methods (e.g., immunohistochemistry).
- the level of a thymic function factor is determined in a sample, e.g., a sample from a subject.
- the sample can comprise a cell or tissue sample.
- the sample comprises a blood, serum, urine, or tissue (e.g., biopsy) sample.
- the activity of a thymic function factor can include one or more of the effects listed in Table 1, corresponding to each thymic function factor.
- the activity of an enzyme thymic function factor is determined using an assay for catalytic activity of the enzyme.
- the activity of a non-enzyme thymic function factor can be determined by assessing a downstream effect of the factor. For example, if the thymic function factor is in a signaling pathway that leads to the increase or decrease of a particular molecule, e.g., polypeptide, nucleic acid, or metabolite, the activity of the factor can be measured by measuring the level of the particular molecule.
- Thymic function modulators e.g., a particular molecule, e.g., polypeptide, nucleic acid, or metabolite
- Thymic function modulators are used in the methods (e.g., therapeutic methods or ex- vivo culture methods) described herein.
- a thymic function modulator modulates, e.g., increases or decreases, a thymic function (e.g., in vivo or ex vivo).
- a thymic function modulator improves a thymus function, e.g., a thymus function described herein, e.g., one or more of: increases the number of T cells in a subject; increases the number and/or relative ratio of a T cell subset (e.g., Tregs, CD4 positive T cells, and/or CD8 positive T cells) in a subject, improves a T cell function in a subject; and/or increases T cell migration in a subject.
- a thymus function e.g., a thymus function described herein, e.g., one or more of: increases the number of T cells in a subject; increases the number and/or relative ratio of a T cell subset (e.g., Tregs, CD4 positive T cells, and/or CD8 positive T cells) in a subject, improves a T cell function in a subject; and/or increases T cell migration in a subject.
- a T cell subset e
- a thymic function modulator modulates the function of dendritic cells associated with thymus tissue (e.g., modulates antigen presentation of a dendritic cell, modulates the inflammatory properties of a dendritic cell, and/or modulates the cytokines secreted by a dendritic cell).
- a thymic function modulator modulates, e.g., increases or decreases, the level and/or activity of a thymic function factor, e.g., a thymic function factor described herein, e.g., in Table 1.
- a thymic function modulator results in one or more effects listed in Table 1.
- a thymic function modulator modulates one or more thymic function factors, e.g., one or more thymic function factors described herein, e.g., in Table 1.
- a thymic function modulator modulates the level and/or activity of a thymic function factor selected from a T cell growth factor, T cell growth factor receptor, T cell migration factor, T cell activity factor, TEC proliferation factor, TEC growth factor, TEC growth factor receptor, TEC function factor, or thymus homeostasis factor, e.g., as described in Table 1.
- a thymic function modulator modulates the level and/or activity of a thymic function factor selected from a chemokine, cytoplasmic protein, enzyme (e.g., phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, receptor (e.g., cell surface receptor or nuclear receptor), or transcription factor, e.g., as described in Table 1.
- a thymic function factor selected from a chemokine, cytoplasmic protein, enzyme (e.g., phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, receptor (e.g., cell surface receptor or nuclear receptor), or transcription factor, e.g., as described in Table 1.
- one or more thymic function modulators e.g., one, two, three, four, or five thymic function modulators (e.g., a second, third, fourth, fifth or sixth thymic function modulator) is administered to the subject.
- administration of one or more of the thymic function modulators increases or decreases expression of or activity level of a thymic function factor, e.g., a T cell growth factor, a T cell growth factor receptor, a T cell proliferation factor, a T cell migration factor, a T cell activity factor, a TEC proliferation factor, a TEC growth factor, a TEC growth factor receptor, a TEC function factor, or a thymus homeostasis factor.
- a thymic function modulator increases the level and/or activity of a thymic function factor (e.g., a positive regulator of thymic function, e.g., described in Table 1) by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2- fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, increased as compared to a reference expression or activity level of the one or more thymic function factors.
- a thymic function factor e.g., a positive regulator of thymic function, e.g., described in Table 1
- a thymic function factor e.g., a positive regulator of thymic function, e.g., described in Table 1
- a thymic function factor e.g., a positive regulator of thymic function, e.g., described in Table 1
- a thymic function modulator decreases the level and/or activity of a thymic function factor (e.g., a negative regulator of thymic function, e.g., described in Table 1) by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, decreased as compared to a reference expression or activity level of the one or more thymic function factors.
- the reference expression or activity level is the expression or activity level of the one or more thymic function factors prior to administration of the thymic function modulator.
- a thymic function modulator can be itself a thymic function factor described herein, e.g., in Table 1.
- a thymic function modulator comprises a polypeptide/protein or nucleic acid molecule homologous to a thymic function modulator described herein, e.g., in Table 1.
- a thymic function modulator comprises an amino acid sequence or nucleic acid sequence that is substantially identity to, e.g., having at least 60% (e.g., at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99%, or more, e.g., 100%) identity to the amino acid sequence or nucleic acid sequence of a thymic function modulator described herein, e.g., in Table 1.
- a thymic function modulator can comprise a number of different modalities.
- a thymic function modulator comprises a nucleic acid molecule (e.g., DNA molecule or RNA molecule, e.g., mRNA, guide RNA (gRNA), or inhibitory RNA molecule (e.g., siRNA, shRNA, or miRNA), or a hybrid DNA-RNA molecule), a small molecule, a peptide, or a polypeptide (e.g., an antibody molecule, e.g., an antibody or antigen binding fragment thereof).
- the nucleic acid molecule, peptide, polypeptide, or antibody molecule can be modified.
- the modification can be a chemical modification, e.g., conjugation to a marker, e.g., fluorescent marker or a radioactive marker.
- the modification can include conjugation to a molecule that enhances the stability of the thymic function modulator (e.g., stability in vivo and/or in cell/tissue culture).
- a thymic function modulator described herein comprises a thymic function factor polypeptide or functional fragment or derivative thereof.
- a thymic function modulator is a polypeptide listed in Table 1, wherein the primary sequence of the thymic function modulator is provided by reference to accession number. Methods of making a therapeutic polypeptide are routine in the art. See, in general, Smales & James (Eds.), Therapeutic Proteins: Methods and Protocols (Methods in Molecular Biology), Humana Press (2005); and Crommelin, Sindelar & Meibohm (Eds.), Pharmaceutical Biotechnology:
- Mammalian expression vectors may comprise nontranscribed elements such as an origin of replication, a suitable promoter and enhancer, and other 5' or 3' flanking nontranscribed sequences, and 5' or 3' nontranslated sequences such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and termination sequences.
- DNA sequences derived from the SV40 viral genome for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the other genetic elements required for expression of a heterologous DNA sequence.
- Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described in Green & Sambrook, Molecular Cloning: A Laboratory Manual (Fourth Edition), Cold Spring Harbor Laboratory Press (2012).
- mammalian cell culture systems can be employed to express and manufacture recombinant protein.
- mammalian expression systems include CHO cells, COS cells, HeLA and BHK cell lines. Processes of host cell culture for production of protein therapeutics are described in Zhou and Kantardjieff (Eds.), Mammalian Cell Cultures for Biologies
- the thymic function modulator is an antibody or antigen binding fragment thereof.
- a target antigen e.g., a thymic function factor described herein.
- a target antigen e.g., a thymic function factor described herein.
- Zhiqiang An Editor
- Therapeutic Monoclonal Antibodies From Bench to Clinic. 1st Edition. Wiley (2009) and Greenfield (Ed.), Antibodies: A Laboratory Manual. 2d ed.
- the thymic function modulator comprises an mRNA molecule, e.g., a modified mRNA molecule encoding a thymic function factor.
- the mRNA molecule increases the level (e.g., protein and/or mRNA level) and/or activity of a thymic function factor, e.g., a positive regulator of thymus function.
- the mRNA molecule encodes a thymic function factor or a fragment thereof.
- the mRNA molecule encodes a polypeptide having at least 50% (e.g., at least 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, or greater) identity to the amino acid sequence of a thymic function factor listed in Table 1.
- the mRNA molecule has at least 50% (e.g., at least 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, or greater) identity to the nucleic acid sequence of a thymic function factor listed in Table 1.
- the mRNA molecule encodes an amino acid sequence differing by no more than 30 (e.g., no more than 30, 20, 10, 5, 4, 3, 2, or 1) amino acids to the amino acid sequence of a thymic function factor listed in Table 1.
- the mRNA molecule comprises a fragment of a thymic function factor listed in Table 1.
- the fragment comprises 10-20, 20-40, 40-60, 60-80, 80-100, 100-120, 120-140, 140- 160, 160-180, 180-200, 200-250, 250-300, 300-400, 400-500, 500-600, or more amino acids in length.
- the fragment is a functional fragment, e.g., having at least 20%, e.g., at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or greater, of an activity of a full length thymic function factor listed in Table 1.
- the mRNA molecule increases the level and/or activity of or encodes a thymic function factor (or fragment thereof) that is a positive regulator of thymus function.
- the mRNA molecule can be modified, e.g., chemically.
- the mRNA molecule can be chemically synthesized or transcribed in vitro.
- the mRNA molecule can be disposed on a plasmid, e.g., a viral vector, bacterial vector, or eukaryotic expression vector.
- the mRNA molecule can be delivered to cells by transfection, electroporation, or transduction (e.g., adenoviral or lentiviral transduction).
- the modified RNA encoding a thymic function factor of interest described herein has modified nucleosides or nucleotides. Such modifications are known and are described, e.g., in WO 2012/019168. Additional modifications are described, e.g., in
- the modified RNA encoding a polypeptide of interest described herein has one or more terminal modification, e.g., a 5'Cap structure and/or a poly-A tail (e.g., of between 100-200 nucleotides in length).
- the 5' cap structure may be selected from the group consisting of CapO, Capl, ARCA, inosine, Nl-methyl-guanosine, 2'fluoro- guanosine, 7-deaza- guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido- guanosine.
- the modified RNAs also contain a 5 ' UTR comprising at least one Kozak sequence, and a 3 ' UTR.
- modifications are known and are described, e.g., in WO2012135805 and WO2013052523. Additional terminal modifications are described, e.g., in WO2014164253 and WO2016011306.
- WO2012045075 and WO2014093924 are described, e.g., in WO2012045075 and WO2014093924
- Chimeric enzymes for synthesizing capped RNA molecules which may include at least one chemical modification are described in WO2014028429.
- a modified mRNA may be cyclized, or concatemerized, to generate a translation competent molecule to assist interactions between poly-A binding proteins and 5 '-end binding proteins.
- the mechanism of cyclization or concatemerization may occur through at least 3 different routes: 1) chemical, 2) enzymatic, and 3) ribozyme catalyzed.
- the newly formed 5'-/3'- linkage may be intramolecular or intermolecular.
- modifications are described, e.g., in WO2013151736.
- modified RNAs are made using only in vitro transcription (IVT) enzymatic synthesis.
- IVT in vitro transcription
- Methods of making IVT polynucleotides are known in the art and are described in WO2013151666, WO2013151668, WO2013151663, WO2013151669, WO2013151670, WO2013151664, WO2013151665, WO2013151671, WO2013151672, WO2013151667 and WO2013151736.
- S Methods of purification include purifying an RNA transcript comprising a polyA tail by contacting the sample with a surface linked to a plurality of thymidines or derivatives thereof and/or a plurality of uracils or derivatives thereof (polyT/U) under conditions such that the RNA transcript binds to the surface and eluting the purified RNA transcript from the surface (WO2014152031); using ion (e.g., anion) exchange
- Formulations of modified RNAs are known and are described, e.g., in WO2013090648.
- the formulation may be, but is not limited to, nanoparticles, poly(lactic-co-glycolic acid)(PLGA) microspheres, lipidoids, lipoplex, liposome, polymers, carbohydrates (including simple sugars), cationic lipids, fibrin gel, fibrin hydrogel, fibrin glue, fibrin sealant, fibrinogen, thrombin, rapidly eliminated lipid nanoparticles (reLNPs) and combinations thereof.
- RNAs encoding polypeptides in the fields of human disease, antibodies, viruses, and a variety of in vivo settings are known and are disclosed in for example, Table 6 of International Publication Nos. WO2013151666, WO2013151668, WO2013151663,
- the thymic function modulator comprises an inhibitory RNA molecule, e.g., that acts via the RNA interference (RNAi) pathway.
- an inhibitory RNA molecule includes a short interfering RNA, short hairpin RNA, and/or a microRNA.
- a siRNA is a double- stranded RNA molecule that typically has a length of about 19-25 base pairs.
- a shRNA is a RNA molecule comprising a hairpin turn that decreases expression of target genes via RNAi.
- shRNAs can be delivered to cells in the form of plasmids, e.g., viral or bacterial vectors, e.g., by transfection, electroporation, or transduction).
- a microRNA is a non-coding RNA molecule that typically has a length of about 22 nucleotides.
- MiRNAs bind to target sites on mRNA molecules and silence the mRNA, e.g., by causing cleavage of the mRNA, destabilization of the mRNA, or inhibition of translation of the mRNA.
- the inhibitory RNA molecule decreases the level and/or activity of a negative regulator of thymic function. In other embodiments, the inhibitor RNA molecule decreases the level and/or activity of an inhibitor of a positive regulator of thymic function.
- An inhibitory RNA molecule can be modified, e.g., to contain modified nucleotides, e.g., 2'-fluoro, 2'-o-methyl, 2'-deoxy, unlocked nucleic acid, 2' -hydroxy, phosphorothioate, 2'- thiouridine, 4'-thiouridine, 2'-deoxyuridine.
- modified nucleotides e.g., 2'-fluoro, 2'-o-methyl, 2'-deoxy, unlocked nucleic acid, 2' -hydroxy, phosphorothioate, 2'- thiouridine, 4'-thiouridine, 2'-deoxyuridine.
- modified nucleotides e.g., 2'-fluoro, 2'-o-methyl, 2'-deoxy, unlocked nucleic acid, 2' -hydroxy, phosphorothioate, 2'- thiouridine, 4'-thiouridine, 2'-deoxyuridine.
- the inhibitory RNA molecule decreases the level and/or activity of a thymic function factor. In embodiments, the inhibitory RNA molecule inhibits expression of a thymic function factor (e.g., inhibits translation to protein). In other embodiments, the inhibitor RNA molecule increases degradation of a thymic function factor and/or decreases the stability (i.e., half-life) of a thymic function factor.
- the inhibitory RNA molecule can be chemically synthesized or transcribed in vitro.
- inhibitory therapeutic agents based on non-coding RNA such as ribozymes, RNAse P, siRNAs, and miRNAs are also known in the art, for example, as described in Sioud, RNA Therapeutics: Function, Design, and Delivery (Methods in Molecular Biology).
- the thymic function modulator comprises a component of a gene editing system.
- the thymic function modulator introduces an alteration (e.g., insertion, deletion (e.g., knockout), translocation, inversion, single point mutation, or other mutation) in a thymic function factor, e.g., described in Table 1.
- exemplary gene editing systems include the clustered regulatory interspaced short palindromic repeat (CRISPR) system, zinc finger nucleases (ZFNs), Transcription Activator-Like Effector-based Nucleases (TALEN). ZFNs, TALENs, and CRISPR-based methods are described, e.g., in Gaj et al. Trends Biotechnol.
- the thymic function modulator comprises a guide RNA (gRNA) for use in a clustered regulatory interspaced short palindromic repeat (CRISPR) system for gene editing.
- the thymic function modulator comprises a zinc finger nuclease (ZFN), or a mRNA encoding a ZFN, that targets (e.g., cleaves) a nucleic acid sequence (e.g., DNA sequence) encoding a thymic function factor, e.g., a thymic function factor described in Table 1.
- the thymic function modulator comprises a TALEN, or an mRNA encoding a TALEN, that targets (e.g., cleaves) a nucleic acid sequence (e.g., DNA sequence) encoding a thymic function factor, e.g., a thymic function factor described in Table 1.
- targets e.g., cleaves
- a nucleic acid sequence e.g., DNA sequence
- a thymic function factor e.g., a thymic function factor described in Table 1.
- the gRNA can be used in a CRISPR system to engineer an alteration in a gene (e.g., a thymic function factor, e.g., described in Table 1).
- the ZFN and/or TALEN can be used to engineer an alteration in a gene (e.g., a thymic function factor, e.g., described in Table 1).
- Exemplary alterations include insertions, deletions (e.g., knockouts), translocations, inversions, single point mutations, or other mutations.
- the alteration can be introduced in the gene in a cell, e.g., in vitro, ex vivo, or in vivo.
- the alteration increases the level and/or activity of a thymic function factor, e.g., a positive regulator of thymic function, e.g., described in Table 1.
- the alteration decreases the level and/or activity of (e.g., knocks down or knocks out) a thymic function factor, e.g., a negative regulator of thymic function, e.g., described in Table 1.
- the alteration corrects a defect (e.g., a mutation causing a defect), in a thymic function factor, e.g., described in Table 1.
- CRISPR refers to a set of (or system comprising a set of) clustered regularly interspaced short palindromic repeats.
- a CRISPR system refers to a system derived from CRISPR and Cas (a CRISPR-associated protein) or other nuclease that can be used to silence or mutate a gene described herein (e.g., a thymic function factor or thymic function modulator, e.g., described herein).
- the CRISPR system is a naturally occurring system found in bacterial and archeal genomes.
- the CRISPR locus is made up of alternating repeat and spacer sequences.
- the spacers are typically sequences that are foreign to the bacterium (e.g., plasmid or phage sequences).
- the CRISPR system has been modified for use in gene editing (e.g., changing, silencing, and/or enhancing certain genes) in eukaryotes. See, e.g., Wiedenheft et al. (2012) Nature 482: 331-8.
- modification of the system includes introducing into a eukaryotic cell a plasmid containing a specifically-designed CRISPR and one or more appropriate Cas proteins.
- the spacers of the CRISPR are derived from a target gene sequence, e.g., a sequence from a thymic function factor or thymic function modulator, e.g., described herein.
- the CRISPR locus is transcribed into RNA and processed by Cas proteins into small RNAs that comprise a repeat sequence flanked by a spacer.
- the RNAs serve as guides to direct Cas proteins to silence specific DNA/RNA sequences, depending on the spacer sequence. See, e.g., Horvath et al. (2010) Science 327: 167-170; Makarova et al. (2006) Biology Direct 1: 7; Pennisi (2013) Science 341: 833-836.
- the CRISPR system includes the Cas9 protein, a nuclease that cuts on both strands of the DNA. See, e.g., i.d.
- the CRISPR system is used to edit (e.g., to add or delete a base pair) a target gene, e.g., a thymic function factor or thymic function modulator, e.g., described herein.
- a target gene e.g., a thymic function factor or thymic function modulator, e.g., described herein.
- the CRISPR system is used to introduce a premature stop codon, e.g., thereby decreasing the expression of a target gene, e.g., a thymic function factor or thymic function modulator, e.g., described herein.
- the CRISPR system is used to turn off a target gene (e.g., a thymic function factor or thymic function modulator, e.g., described herein) in a reversible manner, e.g., similarly to RNA interference.
- a target gene e.g., a thymic function factor or thymic function modulator, e.g., described herein
- the CRISPR system is used to direct Cas to a promoter of a thymic function factor or thymic function modulator, e.g., described herein, for example, thereby blocking an RNA polymerase sterically.
- a CRISPR system can be generated to edit a thymic function factor or thymic function modulator (e.g., described herein), using technology described in, e.g., U.S. Publication No.20140068797, Cong (2013) Science 339: 819-823, Tsai (2014) Nature
- the CRISPR interference (CRISPRi) technique can be used for transcriptional repression of specific genes, e.g., a gene encoding a thymic function modulator or thymic function factor described herein.
- an engineered Cas9 protein e.g., nuclease-null dCas9, or dCas9 fusion protein, e.g., dCas9-KRAB or dCas9-SID4X fusion
- sgRNA sequence specific guide RNA
- the Cas9-gRNA complex can block RNA polymerase, thereby interfering with transcription elongation.
- the complex can also block transcription initiation by interfering with transcription factor binding.
- the CRISPRi method is specific with minimal off-target effects and is multiplexable, e.g., can simultaneously repress more than one gene (e.g., using multiple gRNAs). Also, the CRISPRi method permits reversible gene repression.
- CRISPR-mediated gene activation can be used for transcriptional activation, e.g., of one or more genes described herein, e.g., genes encoding a thymic function modulator or thymic function factor described herein.
- dCas9 fusion proteins recruit transcriptional activators.
- dCas9 can be used to polypeptides (e.g., activation domains) such as VP64 or the p65 activation domain (p65D) and used with sgRNA (e.g., a single sgRNA or multiple sgRNAs), to activate a gene or genes, e.g., endogenous gene(s).
- RNA aptamers can be incorporated into a sgRNA to recruit proteins (e.g., activation domains) such as VP64.
- proteins e.g., activation domains
- VP64 proteins
- the synergistic activation mediator (SAM) system can be used for transcriptional activation.
- SAM synergistic activation mediator
- MS2 aptamers are added to the sgRNA.
- MS2 recruits the MS2 coat protein (MCP) fused to p65AD and heat shock factor 1 (HSF1).
- MCP MS2 coat protein
- HSF1 heat shock factor 1
- dCas9-mediated epigenetic modifications and simultaneous activation and repression using CRISPR systems can be used to modulate a thymic function modulator or thymic function factor described herein.
- the thymic function modulator comprises an epigenetic modifying agent.
- An epigenetic modifying agent is an agent that modifies chromatin structure, e.g., directly and/or indirectly, and in some cases affects gene expression and function.
- an epigenetic modifying agent modifies an epigenetic status of a cell (e.g., phenotype or gene expression in the cell that is caused by mechanisms other than alterations in DNA sequence).
- an epigenetic status of a cell includes DNA methylation, histone modification(s) and RNA-associated silencing.
- epigenetic alterations in the genome can contribute to certain diseases, e.g., cancer initiation and progression.
- abnormal DNA methylation and histone hypoacetylation in promoter regions of important genes can lead to gene silencing.
- an epigenetic modifying agent involves sequence-specific targeting of an epigenetic enzyme (e.g., an enzyme that generates or removes epigenetic marks, e.g., acetylation and/or methylation, e.g., histone modifying enzyme).
- an epigenetic modifying agent comprises a DNA-sequence-specific targeting system in which an epigenetic enzyme is linked (e.g., fused) to a DNA binding domain.
- an epigenetic modifying agent modulates (e.g., downregulates or upregulates) gene expression, e.g., expression of a thymus function factor or thymus function modulator described herein.
- Exemplary epigenetic enzymes include DNA methyltransferases, DNA methylases, histone
- methyltransferases histone deacetylase (e.g., HDAC1, HDAC2, HDAC3), sirtuin 1, 2, 3, 4, 5, 6, or 7, lysine-specific histone demethylase 1 (LSDl), histone-lysine-N-methyltransferase (Setdbl), Vietnamese histone-lysine N-methyltransferase 2 (G9a), histone-lysine N-methyltransferase (SUV39H1), enhancer of zeste homolog 2 (EZH2), viral lysine methyltransferase (vSET), histone methyltransferase (SET2), and protein-lysine N-methyltransferase (SMYD2).
- HDAC1, HDAC2, HDAC3 sirtuin 1, 2, 3, 4, 5, 6, or 7, lysine-specific histone demethylase 1
- LSDl histone-lysine-N-methyltransferase
- G9a histone-lysine
- an epigenetic modifying agent is a small molecule. Exemplary small molecule epigenetic modifying agents are described, e.g., in Lu et al. J. Biomolecular Screening 17.5(2012):555-71, e.g., at Table 1 or 2, incorporated herein by reference.
- an epigenetic modifying agent comprises vorinostat, romidepsin.
- an epigenetic modifying agent comprises an inhibitor of class I, II, III, and/or IV histone deacetylase (HDAC).
- HDAC histone deacetylase
- an epigenetic modifying agent comprises an activator of SirTI.
- an epigenetic modifying agent comprises Garcinol, Lys-CoA, C646, (+)-JQI, I- BET, BICI, MS 120, DZNep, UNC0321, EPZ004777, AZ505, AMI-I, pyrazole amide 7b, benzo[d] imidazole 17b, acylated dapsone derivative (e.e.g, PRMTI), methylstat, 4,4'-dicarboxy- 2,2'-bipyridine, SID 85736331, hydroxamate analog 8, tanylcypromie, bisguanidine and biguanide polyamine analogs, UNC669, Vidaza, or decitabine.
- an epigenetic modifying agent comprises a construct described in Koferle et al. Genome Medicine 7.59(2015): 1-3 (e.g., at Table 1), incorporated herein by reference.
- an epigenetic modifying agent inhibits DNA methylation, e.g., is an inhibitor of DNA methyltransferase (e.g., is 5-azacitidine and/or decitabine).
- an epigenetic modifying agent modifies histone modification, e.g., histone acetylation, histone methylation, histone sumoylation, and/or histone phosphorylation.
- the epigenetic modifying agent is an inhibitor of a histone deacetylase (e.g., is vorinostat and/or trichostatin A).
- the epigenetic modifier comprises sodium phenyl butyrate (SDB), lipoic acid (LA), quercetin, valproic acid, hydralazine, bactrim, green tea extract (e.g., epigallocatechin gallate (EGCG)), curcumin, sulforphane and/or allicin/diallyl disulfide.
- SDB sodium phenyl butyrate
- LA lipoic acid
- quercetin valproic acid
- hydralazine hydralazine
- bactrim green tea extract
- green tea extract e.g., epigallocatechin gallate (EGCG)
- curcumin e.g., curcumin
- sulforphane and/or allicin/diallyl disulfide e.g., curcumin
- an epigenetic modifying agent modifies, e.g., increases or decreases, the expression level of a thymic function factor (e.g.
- the thymic function modulator comprises an aptamer.
- An aptamer can be made up of nucleic acids (e.g., DNA, RNA, modified DNA, modified RNA, or combinations thereof) and/or peptides. Aptamers form three-dimensional structures that bind specifically to a target molecule, inhibiting or activating the target molecule.
- an aptamer can be generated using systematic evolution of ligands using exponential enrichment (SELEX).
- the aptamer binds to a thymic function factor, e.g., described in Table 1.
- the aptamer decreases the activity of a thymic function factor, e.g., a negative regulator of thymic function, e.g., described in Table 1.
- the aptamer increases the activity and/or stability of a thymic function factor, e.g., a positive regulator of thymic function, e.g., described in Table 1.
- the thymic function modulator comprises an antibody molecule or an mRNA encoding an antibody molecule.
- the antibody molecule binds to a thymic function factor, e.g., described in Table 1.
- the antibody molecule decreases the activity of a thymic function factor, e.g., a negative regulator of thymic function, e.g., described in Table 1.
- the antibody molecule increases the activity and/or stability of a thymic function factor, e.g., a positive regulator of thymic function, e.g., described in Table 1.
- the thymic function modulator comprises a peptide or polypeptide, e.g., a thymic function factor or fragment thereof (e.g., functional fragment thereof) described in Table 1.
- the peptide or polypeptide comprises an amino acid sequence having at least 50% (e.g., at least 50%, 60%, 70%, 80%, 90%, 95%, or more) identity to an amino acid sequence of a thymic function factor described in Table 1, e.g., a positive regulator of thymic function described in Table 1.
- a peptide has a molecular weight between about 700 to about 5000 Daltons.
- a polypeptide has a molecular weight between about 5000 and about 500,000 Daltons, e.g., between about 5000 and about 150,000 Daltons.
- Peptides and polypeptides can be naturally occurring, recombinant or chemically synthesized.
- the thymic function modulator comprises a small molecule.
- the small molecule binds to a thymic function factor, e.g., described in Table 1.
- the small molecule inhibits the activity of a thymic function factor, e.g., a negative regulator of thymic function, e.g., described in Table 1.
- the small molecule increases the activity of a thymic function factor, e.g., a positive regulator of thymic function, e.g., described in Table 1.
- a small molecule has a molecular weight of between about 50 and about 1000 Daltons, e.g., between about 100 Daltons and about 700 Daltons. Measurement of thymus function
- Methods described herein may include the assessment of certain thymic activities, structure, functions or characteristics.
- methods described herein can modulate (e.g., increase or decrease, as desired) T cell exhaustion, TILs, T-cell diversity, T cell clonality, thymocytes, thymic epithelial cells, thymic stromal cells, and thymus size.
- subjects being treated may be assessed for one or more such thymic activities, functions or parameter before, during and/or after treatment.
- a cell culture/cell(s)/preparation thereof produced using a method described herein can be assessed for thymus function ex vivo using one or more of the methods described herein, e.g., assessed prior to administration into a subject.
- patients are assessed before treatment, e.g., to establish a baseline level of a particular thymic parameter.
- a patient may be selected for treatment based on a pre-treatment assessment described herein.
- a patient is assessed after a first administration of the therapy, e.g., one or more times (e.g., 2, 3, 4, 5, 7, 10, 15 or more times) during the period encompassing the treatment regimen.
- a patient may be monitored for disease treatment or progression based on assessments during the period encompassing the treatment regimen, e.g., where an increase in a thymic function parameter is intended by treatment, such assessments may be used to confirm the effect of treatment, or to determine whether to stop or continue treatment.
- a patient is assessed after the period encompassing a treatment regimen is complete.
- the results of such assessments may be used, e.g., to determine if the patient should undergo a different treatment, continue with another round of the same treatment regimen, or another action determined by the patient' s health care provider.
- Thymus function (e.g., extent of thymic involution, thymic damage, thymic regeneration, or decrease/reverse in thymic involution or damage) can be determined a number of methods.
- an increase in thymus tissue size/mass after treatment in a subject is indicative of a decrease/reverse in thymic involution.
- Thymus size can be assessed by direct visualization in vivo, ex vivo, or intraoperatively, as well as through a wide variety of histological processing techniques known to the art, including but not limited to hematoxylin and eosin staining. Thymus size can also be assessed using biomedical imaging techniques such as ultrasound, magnetic resonance imaging (MRI or MR imaging), computed tomography (CT), and position emission tomography (PET) (PMID: 21700977). Ultrasound can be used to measure the size and/or shape of the thymus.
- MRI or MR imaging magnetic resonance imaging
- CT computed tomography
- PET position emission tomography
- ultrasound can be used to determine the size and/or shape of each of the two lobes of the thymus.
- Ultrasound permits the imaging of individual parts of the thymus, e.g., medulla, cortex, interlobular septum, and blood vessels. See, e.g., Han et al. Pediatr. Radiol. 31(2001):474-79; and Nasseri et al. RadioGraphics 30(2010):413-28.
- the size of the thymus can be expressed, e.g., in terms of volume and/or a Thymus index, e.g., as described in Hasselbalch et al. Eur. Radiol. 6.5(1996):700-03; and Varga et al. Surg. Radiol. Anat. 33(2011):689-95.
- 18F-FDG PET imaging is an important tool for the visualization and staging of human cancer.
- the thymus's extensive cellularity and metabolic activity results in physiologic uptake of FDG, although this disappears during adolescence as the thymus involutes.
- transient thymic hyperplasia has been sporadically observed following chemotherapy, particularly for testicular carcinoma or malignant lymphoma; additionally, a retrospective study showed that in a subset of adult patients who experience chemotherapy-induced thymic hyperplasia, the hyperplasia is detectible via increased FDG uptake, rendering thymus FDG uptake an imaging biomarker for enhanced thymic cellularity (PMID 11337547).
- thymus size is increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to prior to treatment.
- anterior mediastinal mass is a marker of thymic function (e.g., extent of thymic involution or extent of decrease/reverse in thymic involution).
- a larger, longer, thicker, denser, and/or more opaque anterior mediastinal mass is indicative of a decrease/reverse in thymic involution.
- methods described herein include in some embodiments measuring the size, (e.g., length, width, and/or thickness), opacity, and/or density of the anterior mediastinal shadow in a subject, e.g., before, during, and/or after treatment with a therapy, e.g., a cell culture, cell(s), or preparation thereof, e.g., described herein.
- Anterior mediastinal shadow can be measured by imaging techniques such as ultrasound, X-ray, CT scan, MRI, or PET (e.g., FDG avidity via PET).
- a treatment e.g., described herein (e.g., cell culture, cell(s), or preparation thereof, and/or second therapeutic agent or procedure, as described herein), increases the size (e.g., length, width, and/or thickness), opacity, and/or density of the anterior mediastinal shadow in a subject, compared to a reference value.
- the treatment increases the size, opacity, and/or density of the anterior mediastinal shadow by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60-fold, 80- fold, 100-fold, or more, compared to a reference value.
- an increase e.g., of at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold, or more
- an improvement in thymic function e.g., a decrease or reverse in thymic involution.
- the reference value is the size (e.g., length, width, and/or thickness), opacity, and/or density of the anterior mediastinal shadow in the subject prior to administration with a treatment, e.g., described herein.
- thymic involution Another marker of thymic function, e.g., thymic involution, is the level of stromal cells in the thymus.
- Stromal cells in the thymus include dendritic cells and epithelial cells of the thymic medulla and cortex. Stromal cells are involved in the selection of a self-tolerant and functional T cell repertoire.
- Thymic stromal cells are the non-thymocyte cells within the thymus that mediate the thymus's system for 'training' T lineage progenitor T cells as developing thymocytes for proper binding of a T cell receptor recognizing 'self in the context of a peptide; this compartment includes fibroblasts, epithelium, endothelium, and dendritic cells (Gray et al., J Immun., 2007). The main stromal compartments responsible for interacting with developing thymocytes are lined with TECs. Among other cell types, thymic stromal cells also comprise fibroblasts;
- fibroblasts are also known to play a role in guiding thymocyte development.
- Thymic stromal cells are heterogeneous and can be assessed by determining the relative or absolute quantity of the subsets comprising thymic stromal cells (e.g., fibroblasts, TECs, endothelium).
- the stromal cell subset comprising thymic fibroblasts can be assessed through the use of the monoclonal antibody MTS-15 as known to the art (Gray et al., J. Immun., 2007).
- thymic stromal cells e.g., one or more or all of: fibroblasts, TECs, endothelium
- thymic stromal cells are increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to prior to treatment.
- a treatment increases the level of stromal cells (e.g., dendritic cells, medulla epithelial cells, and/or cortex epithelial cells) in the thymus of a subject, e.g., by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value.
- stromal cells e.g., dendritic cells, medulla epithelial cells, and/or cortex epithelial cells
- a treatment increases the percentage of stromal cells (e.g., dendritic cells, medulla epithelial cells, and/or cortex epithelial cells) in a population of cells in a thymic sample, e.g., by at least 1.25- fold, 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value.
- stromal cells e.g., dendritic cells, medulla epithelial cells, and/or cortex epithelial cells
- an increase (by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40- fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value) in the level of stromal cells in the thymus in a subject after administration of a treatment, e.g., described herein, is indicative of an improvement in thymic function, e.g., a decrease or reverse in thymic involution.
- an increase by at least 1.25-fold, 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5- fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value
- stromal cells e.g., dendritic cells, medulla epithelial cells, and/or cortex epithelial cells
- an improvement in thymic function e.g., a decrease or reverse in thymic involution.
- the reference value is the level of the stromal cells (e.g., dendritic cells, medulla epithelial cells, and/or cortex epithelial cells) in the subject prior to administration with a treatment, e.g., described herein.
- the reference value is the percentage of stromal cells (e.g., dendritic cells, medulla epithelial cells, and/or cortex epithelial cells) in a population of cells in a thymic sample from the subject prior to administration with a treatment, e.g., described herein.
- the level of stromal cells can be determined by identifying/quantifying one or more markers of stromal cells (e.g, dendritic cells, medulla epithelial cells, and/or cortex epithelial cells).
- the level of stromal cells can be determined by using flow cytometry, e.g., FACS.
- the level of stromal cells can be determined (e.g., using FACS) by using one or more of the cell surface markers shown in Table 2.
- the level of stromal cells is determined in a sample from the subject, e.g., a blood or tissue sample from the subject.
- Table 2 Exemplary FACS/surface markers for thymic stromal cells
- thymic involution Another marker of thymic function, e.g., thymic involution, is the level of adipocytes in the thymus. As a thymus ages or involutes, thymic tissue degenerates into adipose tissue.
- a decrease or reverse in thymic involution is characterized, in part, by a decrease in the level and/or size of adipocytes in the thymus.
- a treatment decreases the level and/or size of adipocytes in the thymus of a subject, e.g., by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20- fold, 40-fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value.
- a decrease (by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60- fold, 80-fold, 100-fold, or more, compared to a reference value) in the level and/or size of adipocytes in the thymus in a subject after administration of a treatment, e.g., described herein, is indicative of an improvement in thymic function, e.g., a decrease or reverse in thymic involution.
- the reference value is the level and/or size of adipocytes in a thymic samples from the subject prior to administration with a treatment, e.g., described herein.
- the size of adipocytes can be the average size of adipocytes, e.g., in a sample containing a population of adipocytes, or the size of an individual adipocyte.
- the level of adipocytes can be determined by identifying/quantifying one or more markers of adipocytes.
- the level and/or size of adipocytes can be determined by using flow cytometry, e.g., FACS.
- the level and/or size of adipocytes can be determined using histological methods, e.g., in situ hybridization or immunohistochemistry.
- the level of adipocytes can be determined by using PPARy staining (e.g., to identify adipogenic fibroblasts), LipidTOX Green (Invitrogen), Oil Red O staining, and/or magnetic resonance imaging (MRI).
- the level of adipocytes is determined in a sample from the subject, e.g., a blood or tissue sample (e.g., biopsy, e.g., thymus biopsy) from the subject.
- Thymocytes are T-cells and T-cell progenitors found in the thymus. In the thymus, under the influence of the thymic stromal microenvironment, immature thymocytes acquire various cell surface molecules useful in their future role as mature T cells. Thymocytes can be assessed by multiple methods as described in the art. For example, thymocytes can be assessed by assaying for cell surface expression of developmentally regulated thymocyte markers, using labeled antibodies that specifically bind to these markers.
- CD4-CD8- double-negative (DN) thymocytes give rise to CD4+CD8+ double-positive (DP) thymocytes, which give rise to mature CD4+CD8- single-positive (SP) and CD4-CD8+ SP T cells.
- the DN population can be further subdivided by the expression of CD44 and CD25: CD44+CD25- (DN1) cells differentiate into CD44+CD25+ (DN2) cells, which give rise to CD44-CD25+ (DN3) cells, which finally become the most mature CD44-CD25- (DN4) DN population.
- the DN4 cells may pass through an intermediate population expressing either coreceptor alone before becoming DP cells. This intermediate population, most commonly expressing CD8, is known as immature single positive (ISP) cells. Progression beyond the DN3 stage is dependent on successful rearrangement of a TCRP-chain gene and pre-TCR signaling, whereas
- telomere differentiation from DP to mature SP cell is dependent on the expression and positive selection of an apTCR (Von Boehmer et al., Immunol. Rev. 191: 62, 2003; Ceredig and Rolink, Nat. Rev. Immunol. 2: 888, 2002). Additionally, the cellularity of the thymus (including thymocytes) can be assessed using clinical imaging modalities such as MRI, CT, or PET, as described in the art (Brink et al., J. Nuc. Med., 2001; Ackman and Wu, Am. J. Roent, 2011).
- thymocytes e.g., one or more of: CD4+CD8+ DP thymocytes; CD4+CD8- SP thymocytes; CD4-CD8+ SP T cells; CD44+CD25- DN1 cells; CD44+CD25+ DN2 cells; to CD44-CD25+ DN3 cells; CD44-CD25- DN4
- thymocytes are increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to prior to treatment.
- Thymic epithelial cells or TECs are epithelial cells located in the thymus, including cortical thymic epithelial cells (cTECs) and medullary TECs (mTECs). They comprise the stromal compartment of the thymus responsible for guiding developing thymocytes through various developmental stages and to maturity. Thymocytes can be assessed by multiple methods as described in the art.
- TECs can be assessed by assaying for cell surface expression of developmentally regulated TEC markers using labeled antibodies that specifically bind these markers; such cell surface markers include Keratin 8 (K8), K5, EpCAM, MHC class I, MHC class II, CD45, CD80, CD86, CD90, CDl lc, CCL25, RANK, RANKL and CXCL12 (Gray et al., Immun. Meth., 2008).
- Other markers of TECs are intracellular or secreted and can be assessed using intracellular staining or other methods known to the art.
- Such markers include AIRE, FezF2, FoxNl, Hoxa3, proteasome subunit ⁇ 5 ⁇ , proteasome subunit ⁇ 5 ⁇ , BMP4, retinoic acid, Wnt, Shh, FGF, and SCF.
- a particular marker can be useful in assessing the identity of a cell as a TEC, for example, CD45.
- the cellularity of the thymus can be assessed using clinical imaging modalities such as MRI, CT, or PET, as described in the art (Brink et al., J. Nuc. Med., 2001; Ackman and Wu, Am. J. Roent., 2011).
- thymic epithelial cells are increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to prior to treatment.
- T cell output A measure of thymic activity is T cell output.
- T cell maturation takes place in the thymus.
- Hematopoietic progenitor cells e.g., a CD34 positive hematopoietic stem cell
- enter the thymus where they proliferate to generate a large population of immature thymocytes.
- Immature thymocytes make distinct T cell receptor via gene rearrangement. Some T cell receptors are functional (e.g., recognize specific cell surface molecules, e.g., foreign antigens) and some T cell receptors are autoreactive (e.g., recognize self-peptides).
- T cell maturation in the medulla of the thymus immature thymocytes undergo positive selection and negative selection based on their T cell receptor specificity. These newly generated T cells are exported into the periphery and circulate through the lymphoid tissues and blood.
- the recently exported T cells are CD4+ and CD8+.
- recently exported T cells are referred to as recent thymic emigrants and typically have undergone no more than a few cellular divisions after leaving the thymus. It is believed that the number of T cells exported into the periphery, i.e., T cell output, e.g., recent thymic emigrants, decreases during the process of thymic involution.
- T cell output e.g., over a period of time (e.g., T cell output per day, per hour, or per 12 hours) can be determined, e.g., by measuring one or more markers of recent thymic emigrants.
- markers of recent thymic emigrants include chTl+, CD45RA, and CD31 (PECAM-1),
- a RTE has the following expression pattern: CD3 + CD62L + CD45RA + CD31 + CD44 _/1 °.
- a RTE can be distinguished from an older non- RTE naive CD4+ T cell, e.g., using TPK7 as a marker.
- a RTE can be distinguished from a mature naive T cell, e.g., by using Rag2 as a marker. See, e.g., Houston Jr. et al. J. Immunol. 181(2008):5213- 17.
- Another measure of T cell output e.g., recent thymic emigrants, is the concentration of T cell receptor excision circles (TRECs). TRECs are extrachromosomal nonreplicative DNA byproducts generated during T-cell receptor (TCR) rearrangement.
- TRECs are expressed only in thymus -originated T cells, each of which is believed to contain a single TREC.
- TRECs are exported into the periphery from the thymus, and it is believed that TREC levels in the periphery are an indicator of the number of recent thymic emigrants, which is a measure of T cell output and/or T-cell recovery (e.g., after hematopoietic cell transplantation).
- TREC concentration can be measured using PCR, real-time PCR, quantitative-competitive PCR, or PCR-ELISA. T cell output and measurement of recent thymic emigrant and/or TREC concentration is described, e.g., in Ye et al. J. Immunol. 168(2002):4968-79 or in http://www.mayomedicallaboratories.com/test- catalog/Clinical+and+Interpretive/87959 (accessed as of June 9, 2016).
- a treatment e.g., described herein (e.g., a cell culture, cell(s), or preparation thereof and/or a second therapeutic agent or procedure, as described herein), increases the T cell output (e.g., number of recent thymic emigrants, e.g., concentration of TRECs) in a subject, e.g., by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60- fold, 80-fold, 100-fold, or more, compared to a reference value.
- T cell output e.g., number of recent thymic emigrants, e.g., concentration of TRECs
- an increase by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3- fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value) in the T cell output (e.g., number of recent thymic emigrants, e.g., concentration of TRECs) in a subject after administration of a treatment, e.g., described herein, is indicative of an improvement in thymic function, e.g., a decrease or reverse in thymic involution.
- the reference value is the T cell output (e.g., number of recent thymic emigrants, e.g., concentration of TRECs) in a sample from the subject prior to
- T cell output e.g., markers of recent thymic emigrants, e.g., concentration of TRECs
- markers of recent thymic emigrants e.g., concentration of TRECs
- concentration of TRECs can be determined in a sample from a subject, e.g., a blood (peripheral blood) or tissue sample.
- Additional indicators of thymic function include T cell diversity, TCR repertoire diversity, T cell clonality, and/or T cell diversity.
- a treatment increases the T cell diversity, TCR repertoire diversity, and/or T cell clonality in a subject, e.g., by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10- fold, 15-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value.
- an increase (by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40- fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value) in the T cell diversity, TCR repertoire diversity, and/or T cell clonality in a subject after administration of a treatment, e.g., described herein, is indicative of an improvement in thymic function, e.g., a decrease or reverse in thymic involution.
- the reference value is the T cell diversity, TCR repertoire diversity, and/or T cell clonality in a sample from the subject prior to administration with a treatment, e.g., described herein.
- T cell exhaustion also referred to as T cell dysfunction
- T cell dysfunction refers to dysfunctional state of T cells indicated by reduced or absent production of effector cytokines IFNg, TNFa, IL-2, effector molecules perforin, granzyme A, B, or K, reduced ability of cells to proliferate, and increased expression of co-inhibitory receptors PD-1, LAG-3, TEVI-3, CTLA-4, CD160, 2B4 (CD244), BTLA, or TIGIT as described in the art (PMID: 26205583, PMID:21739672).
- T cell exhaustion can be assessed by the following methods: T cells are stained for the expression of above mentioned surface receptors, or reactivated ex vivo with cognate peptide, PMA + Ionomycin, or anti-CD3, to assess their ability to produce cytokines and other effector molecules, as well as their ability to proliferate as measured by the increase of Ki-67 expression, incorporation of BrdU, or dilution of a cell dye such as CSFE or CellTrace Violet.
- a cell dye such as CSFE or CellTrace Violet.
- T cell exhaustion is increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to a reference level, e.g., the extent of T cell exhaustion prior to treatment.
- a reference level e.g., the extent of T cell exhaustion prior to treatment.
- composition or method described herein stimulates a robust memory T cell response. This memory T cell response will aid in the clearance of pathogens or tumor cells and will prevent the occurrence of relapse.
- antigen-specific CD 8 T cells will be activated by antigen-presenting cells and will differentiate into effector T cells. Effector CD8 T cells proliferate rapidly, produce pro-inflammatory cytokines, and kill infected target cells or tumor cells using cytotoxic molecules such as granzymes and perforin.
- the number of antigen- specific T cells responding to a pathogen peaks at day 8 after the initial infection and then the contraction phase of the T cell response begins. During contraction, the majority of T cells die and 5-10% persist as memory cells (PMID: 23080391). Before the contraction phase begins, T cells have already entered a molecular program of cellular death during the contraction phase or persist as memory cells.
- SLECs short-lived effector cells
- MPECs memory- precursor effector cells
- memory T cells are increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to a reference level, e.g., the level of memory T cells prior to treatment.
- MPECs comprise between 1-20%, between 2-20%, between 5-20%, between 2-15%, between 5-15%, between 7- 20%, between 7-15%, between 10-20% of T cells in a treated subject.
- TILs Tumor infiltrating lymphocytes
- Tumor infiltrating lymphocytes are populations of immune cells that are associated with tumor tissue.
- TIL can be made up of lymphocytes such as CD4 T cells, CD8 T cells and NK cells, and also myeloid cells such as macrophages, dendritic cells, and myeloid-derived suppressor cells (MDSCs). These populations of cells can be enriched from single-cell suspensions of tumor tissue using density gradient centrifugation. The presence of TIL in tumors is associated with better prognosis, particularly for CD8 T cells.
- TILS can be assessed, identified, and/or phenotyped by direct antibody labeling and flow cytometric analysis.
- CD45 is often used to identify hematopoietic cells from the tumor, which can then be phenotyped for more parameters such as CD3, CD4, CD8, CDl lb, CDl lc, NK1.1.
- Better pheno type and function of CD8 T cells in tumors is associated with good responses to immunomodulatory antibody therapy (PD-1 and CTLA-4 pathways) and can be assessed using flow cytometry markers that have been described previously (PMID: 25754329; PMID: 23197535).
- TILs are increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to prior to treatment.
- T cell diversity refers to the range of phenotypically, genetically, epigenetically, biochemically, and/or functionally distinct T cell populations present within a given sample or subject. T cell diversity can be assessed through a wide variety of methods known to the art. For example, T cell diversity can be assessed through qualitative and/or quantitative comparison of T cell receptor repertoire, as described herein. Importantly, T cell diversity can also be assessed by methods known to the art that do not involve and that are independent of TCR analysis.
- high-resolution mass spectrometry can be used to map the proteome from cytotoxic T lymphocytes and use this information to identify different functional subgroups that vary in population size and cytotoxic efficacy (PMID: 26551880)
- T cell diversity can also be assessed through quantitative or qualitative assessment of such metabolic pathways and properties through a variety of methods known to the art (PMID 23746840, PMID 26261266).
- the diversity of cells can also be assessed from blood samples or other tissues such as biopsied tumor, using flow cytometry or mass cytometry (CyTOF), by staining cell surface markers.
- CD4 T cells can be divided into naive (CD4+CCR7+CD45RA+CD45RO-), TH1 (CD4+CXCR3+CCR6-CD 161 -) , TH17 (CD4+CCR6+CD 161 +CXCR3 -) , TH2
- CD4+CRTH2+CXCR3 - Treg (CD4+CD1271oCD25+), memory (CD4+CD45RA-CD45RO+), TCM (CD4+CCR7+CD45RA-CD45RO+), TEM (CD4+CCR7-CD45RA-CD45RO+), TEMRA (CD4+CCR7-CD45RA+CD45RO-), Trl: (CD49b and Lag3 co-expression), Tfh (CXCR5, PD-1, BCL6, FoxP3-), and Tfr (CXCR5, PD-1, BCL6, FoxP3+), and CD8 T cells can be similarly divided into naive (CD8+CCR7+CD45RA+CD45RO-), TCM (CD8+CCR7+CD45RA- CD45RO+), TEM (CD8+CCR7-CD45RA-CD45RO+), TEMRA (CD8+CD45RA+CCR7- CD45RO-), Tel (IFNg expression following
- T cell diversity is increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to a reference level, e.g., the T cell diversity prior to treatment.
- TCR repertoire diversity refers to the number of different T cell receptors (TCR) in a population of T cells; sources of diversity within TCR repertoire include unique alpha and beta TCR subunits, genetic differences stemming from V-J (TCR alpha) and V-D-J (TCR beta) recombination, as well as different terminal deoxynucleotidyl transferase (TdT) - introduced nucleotides at DNA junctions, resulting in sequence variation.
- TCR alpha V-J
- TCR beta V-D-J
- TdT terminal deoxynucleotidyl transferase
- TCR repertoire diversity can additionally refer to the number of different clonal populations of T-cells that harbor distinct TCRs within a sample.
- An increase in TCR repertoire diversity is an indicator of either the presence of or an increased potential for a robust antigen- specific T cell response to a pathogen or tumor, as increased diversity suggests that more T cells are capable of responding to the pathogen or tumor, which is beneficial for ensuring effective control of the pathogen or tumor.
- TCR repertoire diversity can be assessed by methods known to art including RNA- Sequencing, DNA- sequencing, TCR-targeted sequencing, and TCR probe-based PCR.
- TCR repertoire profiling can measure the distribution of individual T cell clones in a population. This is done by amplifying the CDR3 region of the TCR alpha and TCR beta chains from T cell genomic DNA and next-generation sequencing the region.
- T cell repertoire diversity is increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to a reference level, e.g., the T cell repertoire diversity prior to treatment.
- T cell clonality refers to the absolute or relative size of a clonal T cell population or of several clonal T cell populations, including peripheral blood mononuclear cells, TILs, or other tissue-derived immune cells, or the magnitude of a T cell expansion giving rise to said clonal population.
- TILs peripheral blood mononuclear cells
- TILs tissue-derived immune cells
- T cell expansion giving rise to said clonal population.
- a T cell that is specific for said antigen will undergo a series of receptor-mediated reactions, resulting in the division of the cell into daughter cells and establishing a clonal population of T cells expressing the same TCR.
- an increase TCR clonality is a good indicator of a robust antigen-specific T cell response to a pathogen or tumor.
- T cell clonality can be used to refer to the absolute or relative size of a specific T cell clonal population, or it can be used to refer to multiple clonal T cell populations simultaneously. Increases in T cell clonality can also suggest that T cells are expanding vigorously after antigen recognition, indicating that they are not functionally suppressed (e.g., exhausted). Accordingly, in some embodiments, an increase in T cell clonality (e.g., of disease-specific T cells, e.g., cancer- specific T cells) can be desirable.
- a subject can achieve a state of T cell clonality in which clonal populations of T cells specific to a particular target or set of targets (e.g., cytomegalovirus or Epstein-Barr Virus) represent a disproportionately large portion of the total T-cell pool.
- targets e.g., cytomegalovirus or Epstein-Barr Virus
- a decrease in T cell clonality may be desirable.
- T cell clonality can be assessed by performing T cell spectratyping on a population of T cells, performing tetramer staining on a population of T cells, sequencing at least one TCR subunit from a population of cells, staining a population of T cells with an anti-TCR antibody, performing flow cytometry, or a combination thereof.
- TCR sequence can be assessed by methods known to art including RNA-Sequencing, DNA-sequencing, TCR-targeted sequencing, and TCR probe-based PCR (US 20100035764 Al, PMID: 26404496, PMID: 2343517, PMID: 24329790).
- TCR-Immunosequencing is a platform technology that allows the enumeration, specification and quantification of each and every T-cell in any biologic sample of interest. It is based on bias-controlled multiplex PCR and high throughput sequencing and is highly accurate, standardized, and sensitive. See, e.g., Kirsch. J. Immunother Cancer. 3.29(2015); or Carlson et al. Nat. Commun. 4(2013):2680, both incorporated herein by reference. Without wishing to be bound by theory, it is believed that the average clonal size of a naive cell is about 100-200 cells.
- Qi et al. have described that there is an increase in T-cell clonality in the naive repertoire of the elderly; the contribution of clonally expanded T cells to the observed repertoire increased by a factor of >100 for naive CD8 and of >10 for naive CD4 T cells compared with young adults. See Qi et al. Proc. Natl. Acad. Sci. USA. 111.36(20140: 13139-44.
- T cell clonality is increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to a reference level, e.g., the clonality prior to treatment.
- the T cell clonality is increased or decreased, e.g., as determined by TCR-immunosequencing, by 1.5-fold to 1000-fold, e.g., 1.5- fold to 10-fold, 10-fold to 20-fold, 20-fold to 50-fold, 50-fold to 100-fold, 100-fold to 250-fold, 250-fold to 500-fold, or 500-fold to 1000-fold, compared to a reference level, e.g., the clonality prior to treatment.
- a reference level e.g., the clonality prior to treatment.
- markers of thymic structure/function include the formation of a plasma cell, development of an antigen- specific T cell, and/or formation of a thymic organoid.
- Another marker of thymic structure/function comprises the formation of, or modulation (e.g., increase or decrease) in quantity, size, function, and/or distribution of, Hassall's corpuscles in the cell(s)/tissue(s)/organoid(s), compared to before the culture step(s).
- a plasma cell e.g., polyclonal plasma cell
- the formation of a plasma cell can be determined by detection (e.g., using flow cytometry, e.g., FACS, and/or immunohistochemistry) of one or more surface markers, e.g., CD138, CD38, CD45, CD19, and/or the presence of kappa and/or lambda cytoplasmic immunoglobulin light chains in the cells.
- high expression of CD38 and CD138 in conjunction with scatter properties of cells, e.g., in flow cytometric methods or immunohistochemical methods, can indicate presence of polyclonal plasma cells.
- CD45 and CD 19 are expressed on normal plasma cells; abnormal plasma cells lack CD19 and variably express CD45. Clonality can be confirmed based on the presence of either kappa or lambda cytoplasmic immunoglobulin light chains (or both) in the cells.
- plasma cells e.g., polyclonal plasma cells
- morphological analysis e.g., in smear slides (e.g., stained with Giemsa).
- mature plasma cells can be detected via their eccentric nuclei and basophilic cytoplasm with perinuclear halos.
- morphological analysis is combined with cellular marker staining (e.g., CD138 or other cellular marker(s)).
- Antigen-specific T cells can be identified and/or quantified.
- cells e.g., T cells
- ICS intracellular cytokine staining
- ELISpot enzyme-linked immunospot
- CFSE carboxyfluorescein succinimidyl ester
- TCR sequencing e.g., TCR sequencing
- mass spectrometry based methods e.g., CyTOF
- tetramer staining e.g., detection of peptide- MHC multimers.
- pre-enrichment e.g., magnetic pre-enrichment
- pre-enrichment can be used to pre-enrich rare antigen-specific T cells, e.g., in order to achieve a higher signal-to-noise ratio, increased sensitivity, and/or improved detection of antigen-specific T cells, e.g., within the naive and/or Treg compartment.
- ICS detects antigen-induced secretion of cytokines by blocking cytokine secretion by cells (e.g., trapping in Golgi/endoplasmic reticulum).
- ICS may provide more flexibility than ELISpot and can be performed on cryopreserved cells as well as fresh samples.
- ICS can be combined with MHC multimer staining and flow cytometry. ICS works well with Thl cells. ICS can detect a limited number of cytokines and does not permit analysis of live cells. ICS typically provides supporting evidence of antigen specificity (e.g., in combination with another method, e.g., described herein). ELISpot detects antigen-induced secretion of cytokines using an enzyme linked immunosorbent assay (ELISA) based method. ELISpot is highly reproducible and sensitive and is suited for high-throughput analysis. ELISpot detects secreted cytokines at a single cell level, measures one or two parameters at a time, and requires cell purification to identify the source of the cytokine.
- ELISA enzyme linked immunosorbent assay
- CFSE based methods utilize the dye, 5,6- carboxyfluorescein diacetate succinimidyl ester, which is distributed evenly between daughter cells (of proliferating activated T-cells).
- Flow cytometry can identify antigen- specific T cells through antibodies specific for surface and/or cytoplasmic markers. Flow cytometry can be used to detect rare T cell populations and provides a quantitative analysis of lymphocytes expressing a specific TCR. For example, CD 154 (CD40L) is expressed after 5-7 hours of TCR stimulation by all naive and memory CD4 T-cells. Similarly, CD137 is expressed by Treg cells after 5-7 hours of antigen stimulation.
- Flow cytometry can detect these markers.
- TCR-seq methods TCR clones are sequenced; this provides comprehensive information about antigen-activated T cells.
- CyTOF is a mass spectrometry based approach that identifies antigen specificity; it allows analysis of over 40 parameters at a single cell level with moderate throughput.
- Detection of peptide-MHC multimers permits direct identification of T cells according to TCR binding, independently of functional status of T cells or antigen presenting cells (APCs).
- APCs antigen presenting cells
- up to 100 different multimers can be combined in cytometric analysis using barcoding.
- the peptide-MHC multimer method requires knowledge of antigens and epitopes, and works for pathogens with low antigen complexity and peptides.
- differences in TCR specificities among individuals or within an individual, e.g., at different stages of disease can be detected using the peptide-MHC multimer method.
- Thymic organoids can be detected by the detection of one or more thymus cell markers, e.g., as described in Table 2 or Table 4, or the detection of a thymus structure, e.g., cortex and/or medulla.
- Hassall's corpuscles are histologically distinct groups of epithelial cells present in the thymic medulla that are known to engage dendritic cells and facilitate production of CD4+ CD25+ FoxP3+ regulatory T cells (i.e., natural or thymic Tregs, nTregs.) See, e.g., Watanabe et al. Nature. 436(2005): 1181-85; or Skogberg et al. J. Immunol. 193(2014):2187-95, both incorporated herein by reference.
- CD4+ CD25+ FoxP3+ regulatory T cells i.e., natural or thymic Tregs, nTregs.
- Hassall's corpuscles can change the rate of generation of nTregs, their molecular properties, and their population in the bloodstream.
- a change in Hassall's corpuscles e.g., in an ex vivo culture or in a subject treated with a therapy described herein
- a change in Hassall's corpuscles can be detected, e.g., by detecting a change in the number of sjTREC+, FoxP3+, and/or nTreg cells in the bloodstream of the subject.
- a change in Hassall's corpuscles can be detected, e.g., by detecting a serum biomarker such as a secreted thymus exosome with distinct molecular properties.
- a method can comprise contacting a source cell with a combination of thymic function modulators, e.g., thymic function modulators described herein.
- Combinations can include two or more, e.g., two, three, four, five, six, seven, eight, nine, ten or more thymic function modulators, e.g., thymic function factors described in Table 1 or modulators thereof.
- combinations can include one or more of the following and/or modulators thereof:
- a chemokine listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional chemokine listed in Table 1 ;
- enzyme phosphatase, protease, or proteinase
- hormone e.g., secreted hormone
- ligand e.g., membrane bound or secreted ligand
- matrix protein e.g., transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional chemokine listed in Table 1 ;
- an enzyme phosphatase, protease, or proteinase listed in Table 1 with a chemokine, cytoplasmic protein, hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional enzyme listed in Table 1 ;
- a hormone e.g., secreted hormone listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional hormone (e.g., secreted hormone) listed in Table 1;
- a hormone e.g., secreted hormone listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional hormone (e.g., secreted hormone) listed in Table 1;
- cytoplasmic protein cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional ligand (e.g., membrane bound or secreted ligand) listed in Table 1 ;
- enzyme phosphatase, protease, or proteinase
- hormone e.g., secreted hormone
- matrix protein e.g., transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional ligand (e.g., membrane bound or secreted ligand) listed in Table 1 ;
- a matrix protein listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional matrix protein listed in Table 1 ;
- phosphatase, protease, or proteinase phosphatase, protease, or proteinase
- hormone e.g., secreted hormone
- ligand e.g., membrane bound or secreted ligand
- matrix protein e.g., receptor or nuclear receptor
- receptor e.g., cell surface receptor or nuclear receptor
- a receptor e.g., cell surface receptor or nuclear receptor listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, or additional receptor (e.g., cell surface receptor or nuclear receptor) listed in Table 1.
- a receptor e.g., cell surface receptor or nuclear receptor listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, or additional receptor (e.g., cell surface receptor or nuclear receptor) listed in Table 1.
- combinations can include one or more of the following and/or modulators thereof: (i) a T-cell activity factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, or additional T-cell activity factor listed in Table 1 ;
- T-cell growth factor listed in Table 1 with a T-cell activity factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, or additional T-cell growth factor listed in Table 1 ;
- T-cell growth factor receptor listed in Table 1 with a T-cell growth factor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional T-cell growth factor receptor listed in Table 1 ;
- T-cell migration factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional T-cell migration factor listed in Table 1 ;
- a TEC function factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, T-cell migration factor, or additional TEC function factor listed in Table 1 ;
- T-cell migration factor T-cell migration factor
- TEC function factor TEC growth factor receptor
- TEC growth factor receptor TEC proliferation factor
- thymus homeostasis factor T-cell activity factor, or additional TEC growth factor listed in Table 1 ;
- a TEC growth factor receptor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional TEC growth factor receptor listed in Table 1 ;
- a TEC proliferation factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, thymus homeostasis factor, T-cell activity factor, or additional TEC proliferation factor listed in Table 1 ; or
- T-cell migration factor T-cell migration factor
- TEC function factor TEC growth factor
- TEC growth factor TEC growth factor receptor
- TEC proliferation factor T-cell activity factor, or additional thymus homeostasis factor listed in Table 1.
- Methods described herein can include administration of a cell culture, cell(s), or preparation thereof in combination with a second therapeutic agent or procedure.
- the second therapeutic agent comprises one or more (e.g., any combination of) thymic function modulators, e.g., thymic function factors described in Table 1 or modulators thereof.
- Combinations can include two or more, e.g., two, three, four, five, six, seven, eight, nine, ten or more thymic function modulators.
- combinations can include any one or more of the following or modulators thereof:
- chemokine listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional chemokine listed in Table 1 ;
- enzyme phosphatase, protease, or proteinase
- hormone e.g., secreted hormone
- ligand e.g., membrane bound or secreted ligand
- matrix protein e.g., transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional chemokine listed in Table 1 ;
- cytoplasmic protein listed in Table 1 with a chemokine, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional cytoplasmic protein listed in Table l ;
- xi an enzyme (phosphatase, protease, or proteinase) listed in Table 1 with a chemokine, cytoplasmic protein, hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional enzyme listed in Table 1 ;
- a hormone e.g., secreted hormone listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional hormone (e.g., secreted hormone) listed in Table 1;
- a hormone e.g., secreted hormone listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional hormone (e.g., secreted hormone) listed in Table 1;
- cytoplasmic protein cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional ligand (e.g., membrane bound or secreted ligand) listed in Table 1 ;
- enzyme phosphatase, protease, or proteinase
- hormone e.g., secreted hormone
- matrix protein e.g., transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional ligand (e.g., membrane bound or secreted ligand) listed in Table 1 ;
- a matrix protein listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional matrix protein listed in Table 1 ;
- phosphatase, protease, or proteinase phosphatase, protease, or proteinase
- hormone e.g., secreted hormone
- ligand e.g., membrane bound or secreted ligand
- matrix protein e.g., receptor or nuclear receptor
- receptor e.g., cell surface receptor or nuclear receptor
- a receptor e.g., cell surface receptor or nuclear receptor listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, or additional receptor (e.g., cell surface receptor or nuclear receptor) listed in Table 1.
- a receptor e.g., cell surface receptor or nuclear receptor listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, or additional receptor (e.g., cell surface receptor or nuclear receptor) listed in Table 1.
- combinations can include any one or more of the following or modulators thereof:
- T-cell activity factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, or additional T-cell activity factor listed in Table 1 ;
- T-cell growth factor listed in Table 1 with a T-cell activity factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, or additional T-cell growth factor listed in Table 1 ;
- T-cell growth factor receptor listed in Table 1 with a T-cell growth factor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional T-cell growth factor receptor listed in Table 1 ;
- T-cell migration factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional T-cell migration factor listed in Table 1 ;
- TEC function factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, T-cell migration factor, or additional TEC function factor listed in Table 1 ;
- T-cell migration factor T-cell migration factor
- TEC function factor TEC growth factor receptor
- TEC growth factor receptor TEC proliferation factor
- thymus homeostasis factor T-cell activity factor, or additional TEC growth factor listed in Table 1 ;
- TEC growth factor receptor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional TEC growth factor receptor listed in Table 1 ;
- a TEC proliferation factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, thymus homeostasis factor, T-cell activity factor, or additional TEC proliferation factor listed in Table 1 ; or
- methods described herein can comprise use of (e.g., administration of, or use of in an ex vivo method) one or more thymic function modulators, e.g., described herein, with one or more other therapy/agent.
- methods can include use of a one or more of: a thymus homeostasis factor, a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, T-cell activity factor listed in Table 1, or a modulator thereof, optionally in combination with one or more other therapy/agent.
- a thymus homeostasis factor a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, T-cell activity factor listed in Table 1, or a modulator thereof, optionally in combination with one or more other therapy/agent.
- the combination of thymic function modulators and/or other therapies/agents can be formulated together or separately.
- methods described herein can include use of (e.g., administration of, or use of in an ex vivo method) more than one thymic function modulator, e.g., thymic function modulator described herein. Methods described herein can also include use of a thymic function modulator (e.g., described herein) in combination with a different therapy or agent.
- therapies or agents suitable for use in combination with a thymic function modulator described herein include but are not limited to a surgery, radiation, antimicrobial, or chemotherapy.
- antimicrobials include antibacterial, antiviral, antifungal, antimycobacterial, antihelmintic and/or antiprotozoan pharmaceutical compositions.
- antimicrobial compositions include Penicillins, Macrolides, Ketolides, Cephalosporins, and/or Streptomycin.
- an antimicrobial drug is selected from the group consisting of penicillin, amoxicillin, oxacillin, dicloxoacilline, clavulinic acid with a penicillin, bicillin, ticarcillin, piperacillin, taxobactam, cephalexin, cefazolin, cephaclor, ceftibuten, cefuroxime, cefprozil, cefotaxime, ceftazidime, cefepime, cifdinir, ceftriaxone, cefditoren, cefpodoxime, aztreonam, ertapenem, cefoxitin, meropenem, imipenem, erythromycin, clarithromycin, azithromycin, telithromycin, clindamycin, daptomycin, cycloserine, quinupristin, dalfopristin, streptomycin, vancomycin, linezolid and combinations thereof.
- an antimicrobial composition comprises penicillin, amoxicillin, oxacillin, dicloxoacilline, clavulinic acid with a penicillin, bicillin, ticarcillin, piperacillin, taxobactam, cephalexin, cefazolin, cephaclor, ceftibuten, cefuroxime, cefprozil, cefotaxime, ceftazidime, cefepime, cifdinir, ceftriaxone, cefditoren, cefpodoxime, aztreonam, ertapenem, cefoxitin, meropenem, imipenem, erythromycin, clarithromycin, azithromycin, telithromycin, clindamycin, daptomycin, cycloserine, quinupristin, dalfopristin, streptomycin, vancomycin, linezolid, albendazole and mebendazole.
- exemplary antimicrobial compositions are described in Table 3.
- Penicillins e.g., benzylpenicillin, amoxicillin, ticarcillin,
- Cephalosporins e.g., cefpodoxime, cefuroxime, cefazolin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Ex vivo cultures of cells having thymic function and methods of use and methods of making are disclosed.
Description
METHODS AND COMPOSITIONS FOR THYMIC TRANSPLANTATION
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application No. 62/361,070, filed on July 12, 2016, the contents of which is hereby incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
The thymus is a specialized primary lymphoid organ of the immune system, responsible for the development, selection and maturation of T cells. The thymus provides an inductive environment for development of T cells from hematopoietic progenitor cells. In addition, thymic stromal cells allow for the selection of a functional and self-tolerant T cell repertoire. The thymus is largest and most active during the neonatal and pre-adolescent periods. By the early teens, the thymus begins to atrophy and thymic stroma is mostly replaced by adipose tissue.
SUMMARY OF THE INVENTION
The invention features methods for producing (e.g., making/providing) a cell (e.g., a cell or population of cells, e.g., tissue or organoid) having a thymic function. Also featured are methods of evaluating the cell having thymic function. Also featured are methods of
transplanting an ex vivo-manipulated cell(s) (e.g., having a thymic function) into a subject. Also featured herein are methods of treating a subject who has a heterologous thymic capability, e.g., who has, will have, or has had a thymic implant or thymus cell implant. The invention also features methods for modulating (e.g., in vivo or ex-vivo) thymic function, e.g., for decreasing or reversing thymic involution, improving thymic function, treating thymic damage, or treating conditions or diseases related to thymic function, in a subject (e.g., a human or an agricultural animal). The invention also features methods for treating physiological senescence and age associated diseases in a subject.
Ex Vivo Methods of Producing Thymic Culture/Cell with Thymic Function
In an aspect, the invention features methods of providing (e.g., making/providing) a thymic culture. The method includes: contacting a source cell (e.g., a population of cells, e.g., cells isolated from a thymus tissue or T cells of a subject, e.g., a cell described herein) with one
or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more) thymic function modulator described herein; and culturing the cell (e.g., a population of cells) under conditions sufficient to produce a cell (e.g., population of cells) with thymic function (e.g., cells having one or more marker of thymus function described herein). In embodiments, the cultured cell has at least one (at least 2, 3, 4, 5, 6, 7) increased marker of thymus function relative to the source cell (e.g., increased by at least 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 80%, 90%, 100% or more).
In another aspect, the invention features methods of producing (e.g., making/providing) a cell having a thymic function. The method includes:
(a) providing a source cell from a subject;
(b) forming an ex vivo reaction mixture comprising the source cell and one or more
thymic function modulator (e.g., a thymic function modulator described herein), thereby producing the cell having the thymic function.
In embodiments, the method further comprises expanding, selecting, and/or purifying the cell having the thymic function from (b).
In embodiments, the method comprises purifying the cell (e.g., population of cells) having the thymic function, e.g., from the thymic function modulator. In embodiments, the method comprises selecting the cell (e.g., population of cells) having the thymic function.
In embodiments, the purification or selection step comprises using a fluorescently labeled molecule (e.g., antibody or fragment thereof and/or a dye) that binds to one or more cell surface markers for thymic function. In embodiments, the purification or selection step comprises using fluorescence activated cell sorting (FACS). In other embodiments, the purification or selection step comprises using a bead (e.g., magnetic bead) coated with an antibody (or fragment thereof) that binds to one or more cell surface markers for thymic function.
In embodiments, the method comprises expanding the cell (e.g., population of cells) having the thymic function. In embodiments, the expansion comprising increasing the number of the cells by at least about 2-fold, e.g., at least about 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 50-, 100-, 1000-, 104-, 105-fold, or more.
In embodiments, the method further comprises producing a preparation, e.g.,
pharmaceutical preparation, comprising the cell having the thymic function. In embodiments, the thymic function modulator is present in the preparation at a concentration of less than 15%
by weight, e.g., less than 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, 0.01%, or less. In embodiments, the thymic function modulator is present at no less than 0.005% (by weight) in the preparation. In embodiments, the preparation comprises 106-1010 cells, e.g., 107-1010 cells, 108-1010 cells, 109-1010 cells, 106-107 cells, 106-108 cells, 106-109 cells,
10 7-109 cells, 107 -108 cells, or 108 -109 cells. In embodiments, the preparation comprises a tissue or an organoid.
In embodiments, ex-vivo reaction mixture is prepared according to Good Manufacturing Practice (GMP). In embodiments, one or more of the expansion, selection, and/or purification of the cell(s) is according to Good Manufacturing Practice (GMP).
In embodiments, the method further comprises evaluating one or more thymic functions (e.g., thymic functions described herein) of the cell preparation. In embodiments, the cell(s) having the thymic function has one or more markers of thymic function described herein. In embodiments, the cell(s) having the thymic function has at least one (at least 2, 3, 4, 5, 6, 7) increased marker of thymus function relative to the source cell (e.g., increased by at least 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 80%, 90%, 100% or more).
In embodiments, the method further comprises administering the cell or preparation to a subject in need thereof. In embodiments, the subject is the same subject from which the source cell is derived. In embodiments, the subject is a different subject from the subject from which the source cell is derived.
In embodiments, the method further comprises sending the produced cell(s) or preparation to a health care provider or hospital. In embodiments, the method comprises receiving the source cell from a health care provider or hospital.
Mechanical manipulation
In certain aspects, the method comprises one or more steps as described herein, where instead of, or in addition to, contacting a source cell with a thymic function modulator, the method comprises applying a force, e.g., physical/mechanical force (e.g., stress or strain), to the source cell, e.g., to generate/produce a cell having thymic structure/function (e.g., improved thymic structure/function compared to the source cell prior to the application of the force). In embodiments, the source cell can comprise a single cell or multiple cells, e.g., tissue and/or
organ. In embodiments, the force comprises a shear force and/or a stretching force. Additional embodiments are described herein.
Alternative or additional factors for ex vivo methods
In certain aspects, the method comprises one or more steps as described herein, where instead of, or in addition to, contacting a source cell with a thymic function modulator, the method comprises contacting the source cell with a sample from a subject, e.g., a subject younger than 50 years of age (e.g., younger than 50, 40, 30, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or younger). In embodiments, the source cell and the sample are derived from the same subject. In other embodiments, the source cell and the sample are derived from different subjects. In embodiments, the sample comprises blood, plasma, and/or one or more factors derived from the blood or plasma of the subject.
Ex vivo reaction mixture
In another aspect, the invention features an ex vivo reaction mixture comprising a source cell and a thymic function modulator, wherein the source cell is derived from a sample from a subject.
In embodiments, the sample comprises a cell/tissue sample (e.g., biopsy, blood, or lymph sample) from the subject. In embodiments, the sample comprises/is a biopsy from a thymus and/or surrounding tissue(s).
In embodiments, the subject is a subject described herein.
Composition (e.g., pharmaceutical composition)
In another aspect, the invention features a composition (e.g., pharmaceutical
preparation, e.g., purified preparation) comprising a cell(s) having thymic function described herein, e.g., produced by a method described herein.
In embodiments, the composition comprises a thymic function modulator, e.g., present at a concentration of at least 0.001% by weight (e.g., at least 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, or more). In embodiments, the composition comprises a trace amount of a thymic function modulator, e.g., wherein the thymic function
modulator is present at a concentration of less than 1% by weight, e.g., less than 0.5%, 0.1%, 0.05%, 0.01%, or less.
Methods of treatment/use
In another aspect, the invention features a method of:
(i) improving thymus function (e.g., decreasing, reversing, or preventing thymic involution, treating a thymic injury, treating a thymus related disease or condition (e.g., aging-related disease or condition), or replacing/augmenting thymic function);
(ii) modulating, e.g., treating, physiological senescence, e.g., aging associated
senescence or non-aging associated senescence (e.g., reversing, reducing the rate of, or delaying physiological senescence);
(iii) enhancing, e.g., increasing, an immune response;
(iv) decreasing an immune response;
(v) treating an infectious disease;
(vi) preventing a transplant rejection; and/or
(vii) treating an autoimmune disease
in a subject in need thereof. The method includes administering to the subject a thymic culture described herein or a cell or preparation thereof having thymic function as described herein, thereby performing one or more of (i)-(vii) in the subject.
In embodiments, the method comprises administering a cell (e.g., population of cells) having thymic function or preparation thereof described herein to the subject. In embodiments, the cell (e.g., population of cells) having thymic function or preparation thereof is produced using a method described herein.
In embodiments, the method includes:
a) providing a source cell from a subject (e.g., a population of cells, e.g., cells isolated from a thymus tissue or T cells of the subject, e.g., a cell described herein),
b) contacting the source cell with one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more) thymic function modulator described herein;
c) culturing the cell (e.g., a population of cells) under conditions sufficient to produce a cell (e.g., population of cells) with thymic function, e.g., an improved thymic function
described herein (e.g., cells having one or more marker of thymus function described herein); and
d) administering the cell (e.g., population of cells), having improved thymic function to a subject in need thereof (e.g., who may be the same or a different subject than the subject from which the source cell is provided in (a)).
In embodiments, the cultured cell, the cell(s) having thymic function, or preparation thereof, has at least one (at least 2, 3, 4, 5, 6, 7) increased marker of thymus function described herein relative to the source cell (e.g., increased by at least 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 80%, 90%, 100% or more).
In some embodiments, the cell is from the same subject that is receiving the treatment for any of (i)-(vii), e.g., the cell is an autologous cell. In one embodiment, the method further incudes obtaining the cell (e.g., population of cells) from the same subject.
In other embodiments, the cell is from a different subject, e.g., the cell is an allogeneic cell. In one embodiment, the method further incudes obtaining the cell (e.g., population of cells) from a different subject.
The following embodiments pertain to any method or composition described herein.
Source cell
In some embodiments, the source cell is a thymic cell. In one embodiment, the thymic cell is a cortical thymic epithelial cell, a medullar thymic epithelial cell, a thymic stromal cell, or a dendritic cell (e.g., conventional dendritic cell (also called myeloid dendritic cell) or a plasmacytoid dendritic cell). In embodiments, the source cell is a population of cells, a tissue, and/or an organ/organoid. In embodiments, the source cell is a thymus tissue, thymus organ, or part of a thymus organ.
In some embodiments, the source cell is not a thymic cell. In one embodiment, the cell is an epithelial cell or a fibroblast cell. In such embodiments, the epithelial cell or fibroblast cell is contacted with a thymic transformation agent that induces a thymic gene expression profile or a thymic function. E.g., a thymic gene expression profile comprises the expression of two or more of the genes described in Table 2 or Table 4. E.g., a thymic function comprises extent of thymic involution, thymic damage, thymic regeneration, decrease/reverse in thymic involution or
damage, increased or decreased T cell exhaustion, memory T cell response, tumor infiltrating lymphocyte activity, increased or decreased T cell diversity, increased or decreased T cell repertoire diversity, and/or increased or decreased T cell clonality.
Thymic transformation agent
In some embodiments, a thymic transformation agent comprises a nucleic acid molecule, a peptide, an antibody molecule (e.g., an antibody or antigen binding fragment thereof), or a small molecule that induces a thymic gene expression profile or other marker of thymic function in a cell or a population of cells, wherein the cell is not derived from the thymus. In one embodiment, a thymic transformation agent is a thymic function modulator. In one embodiment a thymic transformation agent is a nucleic acid molecule, e.g., a synthetic mRNA, encoding a transcription factor, e.g., FOXN1.
In some embodiments, the thymic transformation agent can be characterized by one or more, e.g., one, two, three, four, or all, of the following:
1) changes the stromal/non- stromal cellular/tissue balance in a thymus (e.g., as assessed by ultrasound, histological analysis, or FDG avidity via PET imaging);
2) changes the medullary/cortical cellular/tissue balance in a thymus (e.g., as assessed by ultrasound, histological analysis, or FDG avidity via PET imaging);
3) shifts the ratio of medullary to cortical thymus (e.g., ratio of medullary TECs to
cortical TECs, e.g., as assessed by imaging or histological analysis of surface markers, e.g., K5 and/or K8 staining);
4) changes in gene expression profiles that indicate enhanced cell function or expansion of epithelial cells (e.g., expression of AIRE, FEZF2, FOXN1 of medullary TECs; e.g., as assayed by gene expression profiling techniques such as arrays, RT-PCR); and/or
5) assessing expansion or contraction of an antigen specific T cell population as a result of specific thymic modifications (e.g., as assessed by TCR Seq or tetramers, type IV hypersensitivity test.
In embodiments, a thymic transformation agent can be identified by the assays as described herein.
Evaluating thymic function (e.g., thymic involution)
In some embodiments, the method further includes assessing one or more markers of thymic structure/function (e.g., one or markers of thymus involution).
In embodiments, the one or more markers are assessed in the cell, or population of cells, after culturing the cell(s) and prior to administering the cell(s), culture, or preparation thereof to a subject. In such embodiments, the marker of thymic structure/function comprises the formation of a plasma cell, development of an antigen- specific T cell, and/or formation of a thymic organoid. In other embodiments, the marker of thymic structure/function comprises the formation of, or modulation (e.g., increase or decrease) in quantity, size, function, and/or distribution of, Hassall' s corpuscles in the cell(s)/tissue(s)/organoid(s), compared to before the culture step(s). In embodiments, a change in Hassall' s corpuscles can be detected histologically and/or through a thymus exosome profile, e.g., as described in Skogberg et al. J. Immunol.
193(2014):2187-95, incorporated herein by reference.
In some embodiments, the one or more markers of thymic structure or function are assessed after administering the cell(s), culture, or preparation thereof to a subject. In some embodiments, the methods include identifying the presence of a thymus tissue after treatment in subjects where no thymus or thymus tissue was detectable prior to treatment.
In some embodiments, the method includes measuring the size (e.g., length, width, and/or thickness), opacity, and/or density of the anterior mediastinal shadow, e.g., to assess a decrease or a reverse in thymic involution. In one embodiment, measuring the size of the anterior mediastinal shadow includes measuring the length, measuring the width, and/or measuring the thickness of the anterior mediastinal shadow. In one embodiment, the size, opacity, and/or density of the anterior mediastinal shadow determined from an imaging technique. Examples of imaging techniques include ultrasound, X-ray, CAT scan, MRI, or PET (e.g., FDG avidity via PET). In one embodiment, a decrease or reverse in thymic involution is characterized by an increase, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or more, in size (e.g., length and/or width) of the anterior mediastinal shadow, as compared to a reference size of the anterior mediastinal shadow. In one embodiment, a decrease or reverse in thymic involution is characterized by an increase, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or more increase, in the density of the anterior mediastinal shadow, as compared
to a reference density of the anterior mediastinal shadow. In one embodiment, a decrease or reverse in thymic involution is characterized by an increase, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or more increase, in the opacity of the anterior mediastinal shadow, as compared to a reference opacity of the anterior mediastinal shadow. In such embodiments, the reference size, density, and/or opacity of the anterior mediastinal shadow is the size, density, and/or opacity of the anterior mediastinal shadow in the subject prior to administration of the thymic function modulator.
In some embodiments, the method includes assessing one or more markers of thymic structure/function (e.g., thymic involution). In one embodiment, the marker of thymic structure/function (e.g., thymic involution)is selected from: the level of stromal cells; the level of non-stromal cells; the level of adipocytes; the level of non-adipocytes; T cell diversity; TCR repertoire diversity; T cell clonality; or T cell diversity and T cell clonality. In one embodiment, an improvement in thymic structure/function (e.g., a decrease or a reverse in thymic involution) is characterized by a decrease in the level or number of adipocytes, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more decrease, e.g., as compared to prior to treatment. In one embodiment, a an improvement in thymic structure/function (e.g., a decrease or a reverse in thymic involution) is characterized by a increase in the level or number of non- adipocytes, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more decrease, e.g., as compared to prior to treatment. In one embodiment, an improvement in thymic structure/function (e.g., a decrease or a reverse in thymic involution) is characterized by an increase in T cell diversity, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more increase in T cell diversity, e.g., as compared to prior to treatment. In one embodiment, an improvement in thymic structure/function (e.g., a decrease or a reverse in thymic involution) is characterized by an increase in TCR repertoire diversity, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more increase in TCR repertoire diversity, e.g., as compared to prior to treatment. In one embodiment, an improvement in thymic structure/function (e.g., a decrease or a reverse in thymic involution) is characterized by a decrease in T cell clonality, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more decrease in T cell clonality, e.g., as compared to prior to treatment. In one embodiment, an improvement in thymic structure/function (e.g., a decrease or a reverse in thymic involution) is characterized by an increase in T cell clonality, e.g., a 1%, 5%, 10%, 20%,
30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more increase in T cell clonality, e.g., as compared to prior to treatment. In one embodiment, an improvement in thymic structure/function (e.g., a decrease or a reverse in thymic involution) is characterized by an increase in T cell or TCR repertoire diversity, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more increase in T cell or TCR repertoire diversity, and a decrease or increase in T cell clonality, e.g., a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or more decrease or increase in T cell clonality, e.g., as compared to prior to treatment.
Combination therapies
In embodiments, the method further comprises administering a second therapeutic agent or procedure. In embodiments, the second therapeutic agent or procedure is chosen from one or more of thymic function modulator, chemo therapeutic, antimicrobial, a cell based therapy, a cell or organ transplant (e.g., stem cell transplant), a radiation procedure, a surgical procedure, an immunomodulatory agent (e.g., an inhibitor of an inhibitory molecule, immune checkpoint inhibitor), a vaccine, or an immunotherapy (e.g., cellular immunotherapy).
In embodiments, the second therapeutic agent is one or more thymic function modulator, e.g., thymic function modulator described herein.
In embodiments, the thymic function modulator is an agent that modulates, e.g., increases or decreases, thymic function. In embodiments, the thymic function modulator can decrease or reverse thymic involution (e.g., decreasing the rate of thymic involution) in a subject.
Dosing/Administration
In some embodiments, the cell culture, cell(s), or preparation thereof is administered to the subject when one or more of the following is observed: one or more markers of thymic structure/function (e.g., an increase in one or more markers of thymic structure/function relative to the source cell); formation of a plasma cell; development of an antigen-specific T cell; and/or formation of a thymic organoid.
In embodiments, the cell culture, cell(s), or preparation thereof is administered in a single dose. In embodiments, the cell culture, cell(s), or preparation thereof is administered in multiple doses (e.g., two or more, three or more, four or more, or five or more doses). In embodiments,
the time interval between each dose is at least 1 week, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8 weeks, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months, or more.
In embodiments, the cell culture, cell(s), or preparation thereof is administered subcutaneously, intravenously, intramuscularly, intrasternally, intraperitoneally, into a thymus, e.g., via infusion, implantation, or injection. In embodiments, the cell culture, cell(s), or preparation thereof is administered through a device, e.g., implantable device. In embodiments, the cell culture, cell(s), or preparation thereof is administered using an infusion technique, e.g., as described in Rosenberg et ah, New Eng. J. of Med. 319: 1676, 1988.
In embodiments, the cell culture/cells(s)/preparation thereof is administered at a dose of about 104 to 1010 cells/kg body weight, e.g., 104 to 108 cells/kg body weight, e.g., 105 to 106 cells/kg body weight, including all integer values within those ranges. In embodiments, the cell culture/cells(s)/preparation thereof is administered multiple times at these doses.
In embodiments, the cell culture/cell(s)/preparation is administered in combination with the second therapeutic agent (e.g., thymic function modulator) or procedure (e.g., transplant, e.g., cell transplant or thymus transplant). In embodiments, the cell culture/cell(s)/preparation and the second therapeutic agent are administered concurrently or sequentially, in the same or in separate compositions. In embodiments, the cell culture/cell(s)/preparation is administered concurrently or sequentially with the second procedure. In embodiments, the cell culture/cell(s)/preparation is administered prior to (e.g., at least 2 hours after, e.g., at least 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, 4 weeks, 1 month, 2 months, or more before) administration of the second therapeutic agent or procedure. In embodiments, the cell culture/cell(s)/preparation is administered after (e.g., at least 2 hours after, e.g., at least 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, 4 weeks, 1 month, 2 months, or more after) administration of the second therapeutic agent or procedure. In embodiments, the cell
culture/cell(s)/preparation and the second therapeutic agent or procedure are administered concurrently, e.g., within 2 days (e.g., within 2 days, 1.5 day, 1 day, 24 hours, 12 hours, 6 hours, 4 hours, 2 hours, 1 hour, or less) of each other.
In some embodiments, the second therapeutic agent (e.g., thymic function modulator) is administered in a single dose. In some embodiments, the second therapeutic agent (e.g., thymic function modulator) is administered in multiple, e.g., two or more, doses. In one embodiment,
the second therapeutic agent (e.g., thymic function modulator) is administered once a day, once every two days, once every 5 days, once a week, once every other week, or once a month. In one embodiment, multiple doses of the second therapeutic agent (e.g., thymic function modulator) are administered over a period of 1 month, 2 months, 3 months, 4 months, 6 months, or more. In another embodiment, multiple doses of the second therapeutic agent (e.g., thymic function modulator) are administered over a period of 4 weeks, 3 weeks, 2 weeks, 1 week, 6 days, 5 days, 4 days, 3 days or less.
In embodiments, the second therapeutic agent comprises more than one agent (e.g., a first agent, a second agent, or more agents). In some embodiments, a first treatment regimen comprising one or more doses of a first thymic function modulator and a second treatment regimen comprising one or more doses of a second thymic function modulator are administered simultaneously or sequentially to the subject. In one embodiment, the first treatment regimen and the second treatment regimen are administered simultaneously. In one embodiment, the first treatment regimen and the second treatment regimen are overlapping. In one embodiment, the first treatment regimen is initiated prior to, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, the initiation of the second treatment regimen. In one embodiment, the second treatment regimen is initiated prior, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, to the initiation of the first treatment regimen. In one embodiment, the first treatment regimen is completed prior to, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, initiation of the second treatment regimen. In one embodiment, the second treatment regimen is completed prior to, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, the initiation of the first treatment regimen.
In some embodiments, a first treatment regimen comprising one or more doses of a first thymic function modulator and one or more additional treatment regimens, e.g., a second, third, fourth, or fifth treatment regimen, wherein each additional treatment regimen comprises one or more doses of an additional thymic function modulator, e.g., second, third, fourth, or fifth thymic function modulator, are administered simultaneously or sequentially to the subject. In one embodiment, the first treatment regimen and the one or more, e.g., second, third, fourth, or fifth, treatment regimens are administered simultaneously. In one embodiment, the first treatment regimen and the one or more, e.g., second, third, fourth, or fifth, treatment regimens are
overlapping. In one embodiment, the one (e.g., the first) treatment regimen is initiated prior to, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, the initiation of another (e.g., the second, third, fourth, and/or fifth) treatment regimen. In one embodiment, the one (e.g., the first) treatment regimen is completed prior to, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, the initiation of another (e.g., the second, third, fourth, and/or fifth) treatment regimen.
In any such treatment regimens, the cell culture/cell(s)/preparation can be administered before the initial dose of the thymic function modulator, after the initial dose but before the last dose of the thymic function modulator, or after the last dose of the thymic function modulator.
In some embodiments, the method further includes monitoring the subject for one or more of the following: anterior mediastinal shadow size (e.g., length, width, and/or thickness); anterior mediastinal shadow density; anterior mediastinal shadow opacity; level of adipocytes and/or non-adipocytes; level of stromal and/or non-stromal cells; T cell clonality; T cell diversity or TCR repertoire diversity; or T cell clonality and T cell diversity or TCR repertoire diversity.
In some embodiments, doses of the cell culture/cell(s)/preparation are administered until one or more of the following occurs in the subject: an increase in a parameter associated with anterior mediastinal shadow (e.g., size, density, and/or opacity); an increase in the level of non- adipocyte cells and/or a decrease in adipocyte cells; an increase in the level of stromal cells and/or a decrease in the level of non-stromal cells; a decrease in T cell clonality; an increase in T cell diversity or TCR repertoire diversity; or a decrease in T cell clonality and an increase in T cell diversity or TCR repertoire diversity.
In embodiments, five or fewer (e.g., five, four, three, two, or one) doses of the cell culture/cell(s)/preparation are administered, and doses of the second therapeutic agent (e.g., thymic function modulator) are administered until one or more of the following occurs in the subject: an increase in a parameter associated with anterior mediastinal shadow (e.g., size, density, and/or opacity); an increase in the level of non-adipocyte cells and/or a decrease in adipocyte cells; an increase in the level of stromal cells and/or a decrease in the level of non- stromal cells; a decrease in T cell clonality; an increase in T cell diversity or TCR repertoire diversity; or a decrease in T cell clonality and an increase in T cell diversity or TCR repertoire diversity.
In some embodiments, the second therapeutic agent (e.g., thymic function modulator) is administered intravenously. In embodiments, the second therapeutic agent (e.g., thymic function modulator) is administered orally. In some embodiments, the second therapeutic agent (e.g., thymic function modulator) is administered intrathymically. In embodiments where more than one thymic function modulator is administered, one thymic function modulator is administered intravenously and another thymic function modulator is administered intrathymically.
In some embodiments, the second therapeutic agent (e.g., thymic function modulator) is administered in combination with an additional (e.g., a third, fourth, fifth, etc.) therapeutic agent. In one embodiment, the additional therapeutic agent is selected from: an immunomodulatory agent, an antimicrobial, or a chemotherapy. In embodiments, the second therapeutic agent (e.g., thymic function modulator) is administered in combination with an additional treatment, e.g., a radiation or surgery.
Thymic Function Factors
In some embodiments of any of the methods described herein, the thymic function modulator increases or decreases the expression or activity of a thymic function factor described herein.
In some embodiments of any of the methods described herein, the thymic function factor can be characterized by one or more, e.g., one, two, three, four, five, or all, of the following:
1) increases the proliferation or cell count of stromal cells or non-adipocyte cells (e.g., as assessed by proliferation assays, e.g., Ki67 staining), e.g., by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, or more.
2) changes the stromal/non- stromal cellular balance in the thymus (e.g., as assessed by ultrasound, histological analysis, or FDG avidity via PET imaging), e.g., an increase or decrease in the ratio of stromal to non-stromal cells, e.g., an increase of decrease in the ratio of thymic epithelial cells to thymocytes, or an increase or decrease in the ratio of adipocytes to thymocytes;
3) increases thymic hormonal production and/or levels; wherein the thymic hormone is associated with thymic size, e.g., thymulin (e.g., as assessed by rosette inhibition assay, e.g., as described in Consolini et al.), e.g., by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, or more.
4) changes in peripheral T cell phenotype, e.g., measuring changes in thymic emigrant profile (e.g., as assessed by comparing levels of different T cell populations, e.g., comparing percentages of T cells and clonal populations of T cells with unique TCRs that are FoxP3 positive, e.g., Tregs)
5) polyclonality of B-cell response or emergence of a particular antibody (e.g., as
assessed by changes in B-cell isotype distribution or polyclonal antibody titers to an antigen of interest, or particular set of thymus-dependent antigens); and/or
6) changes in thymocyte flux (e.g., as assessed by determining TRECs per number of cells, e.g., over time).
In some embodiments of any of the methods described herein, the thymic function factor comprises a T cell growth factor, a T cell growth factor receptor, a T cell proliferation factor, a T cell migration factor, a T cell activity factor, a thymic epithelial cell (TEC) proliferation factor, a thymic epithelial cell (TEC) growth factor, a thymic epithelial cell (TEC) growth factor receptor, a thymic epithelial cell (TEC) function factor, or a thymus homeostasis factor. In some embodiments, the thymic function modulator increases or decreases the expression or activity of one or more thymic function factors described herein, e.g., listed in Table 1.
In one embodiment, the T cell growth factor is selected from BMP4, Bmprla, CD70, Cldn4, DM, Egrl, Egr2, Egr3, EphB2, Flt3, Flt3L, Foxol, FoxP3, Gata2, Gata3, Gfil, Ghrl (ghrelin), GnRH, Icaml, Id3, Ifnarl, IL-2, IL-6, IL-7, IL-12b (IL12 p40 subunit), IL- 15, IL-18, IL-21, IFNy, K , Klf3, Lefl, leptin, Lif, Nfat5, Nfatcl, Notch 1, Prolactin, Ragl, Rag2, Runxl, Satbl, SCF (K ), Shh (T-cell), Tcfl, TCR (e.g., a TCR comprising an alpha and a beta chain, a TCR comprising a gamma chain and a delta chain, a TCR comprising a CD3 chain, a TCR comprising a zeta chain, a TCR comprising a complementarity determining region, a TCR comprising a T cell co-receptor (e.g., CD4 or CD8), a TCR that binds to an epitope presented on an MHCI molecule, a TCR that binds to an epitope presented on an MHCII molecule, or a TCR that binds to an epitope presented on an MHCIII molecule), Tshb (thyrotropin beta chain), Tslp, Vcaml, Wnt3a, Wnt4, Zfp3611, or Zfp3612.
In one embodiment, the T cell growth factor receptor is selected from CD 127 (non- soluble IL-7R), CD27, Crlf2 (TSLP-R), Fzdl, FzdlO, Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7, Fzd8, Fzd9, Ihh, Ptchl, and Ptch2, or IL-7R alpha. In one embodiment, the T cell growth factor is selected from at least one of Flt3, Flt3L, Foxol, FoxP3, Gfil, Ghrl (ghrelin), GnRH, Icaml, Id3,
Ifnarl, IL-2, IL-6, IL-7, IL-12b (IL12 p40 subunit), IL-15, IL-18, IL-21, Kitl, Klf3, Lefl, leptin, Lif, and SCF (Kitl). In one embodiment, the T cell growth factor is selected from at least one of IL-7, IL-21, Delta-like 4 (DLL4), Flt3L, SCF (Kitl), and miR-29a. In one embodiment, the T cell growth factor may also include at least one selected from IL-15, IL-2, IL-12, IL-18, and IFNy.
In one embodiment, the T cell migration factor is selected from CC119, Ccl21, CCL25, Ccr7, Ccr9, Cxcll2, Cxcr4, S 1PR1 (S 1P1), Sele (E-selectin, CD62E, ELAM-1, or LECAM2), Sell (CD62L), Selp (P-selectin), CCL20, CCR6, CXCLl-3, CXCR2, IL8, CXCR1, CCL2, CCL4, CCL5, CCL22, CXCL8, or CXCL10.
In one embodiment, the T cell activity factor is E2F2.
In one embodiment, the TEC proliferation factor is selected from Cyr61, E2F2 (TEC), IGF-1, IL-22, IL-23, or KGF (Fgf7).
In one embodiment, the TEC growth factor is selected from Atf3, BMP4 (TEC), Cbx4, Cdh5 (VE cadherin), E2F3, E2F4, Foxnl, Fspl, Fstll, Isll, Kl (Klotho), Ltbr, NFkB l,
PPARgamma, Pten, RANK, RANKL, Shh (TEC), Sin/Polr3e, Stat3, Tbata, Tbxl, Tgfbr2, Tnfrsfl la /RANK, Tnfrsf 1 lb, Traf6, Wnt3a (TEC), or Wnt4 (TEC). In one embodiment, the TEC growth factor enhances thymus function by modulating, e.g., increasing, e.g., enhancing, proliferation, survival and/or generation of thymic epithelial cells. In one embodiment, the TEC growth factor is selected from at least one of FGF21, FGF7 (KGF), FGF8, FGF10, IL-22, Wnt4, Bmp4, RANKL, LTa, CL40L, Foxnl, leptin, IGF-1, GH, (Ghrl) ghrelin, GnRH, and NGF.
In one embodiment, the TEC growth factor receptor is selected from Bmpr2, Fgfr2, or bmprla (TEC).
In one embodiment, the thymic function factor is selected from AIRE, beta(5t)/Psmbl 1, Fezf2, HLA (e.g., an HLA molecule described herein, e.g., HLA-A, HLA-B, HLA-B27, HLA- B47, HLA-C, HLA-E, HLA-F, HLA-G, p2-microglobulin, HLA-DM (e.g., HLA-DMA1 and/or HLA-DMB 1), HLA-DO (e.g., HLA-DOA1 and/or HLA-DOB 1), HLA-DP (e.g., HLA-DPA1 and/or HLA-DPB l), HLA-DQ (e.g., HLA-DQAl and/or HLA-DQB l), HLA-DQ2, HLA-DQ8, HLA-DR (e.g., HLA-DRA, HLA-DRB 1, HLA-DRB3, HLA-DRB4, and/or HLA-DRB5), HLA- DR2, HLA-DR3, HLA-DR4, and/or an HLA encoding a component of the complement system), a Major Histocompatibility Complex (MHC) molecule (e.g., Class I MHC molecule (MHC I), e.g., comprising one or more polypeptides encoded by a HLA-A, HLA-B, HLA-C, HLA-G,
and/or HLA-E gene; Class II MHC molecule (MHC II), e.g., comprising one or more polypeptides encoded by a HLA-DP, HLA-DQ, and/or HLA-DR gene; or Class III MHC molecule (MHC III), e.g., comprising a polypeptide involved in inflammation, e.g., a component of the complement system (e.g., C2, C4, or factor B), tumor necrosis factor (TNF)-a,
lymphotoxin-a, lymphotoxin-β, or a heat shock protein), or Prssl6.
In one embodiment, the thymus homeostasis factor is selected from 1 lb-HSD2, AR, ASC, Axin, Fgf21, IL10, IL2 (stroma), Leptin (TEC), Meisl, or NLRP3.
In embodiments, the thymic function factor comprises Cd44, gpl30, hGH (GH1 and GH2), Nfkb2, Ptma (thymosin alpha- 1), Smad4, Smad6, or Tmpo (thymopeotin).
In embodiments, the thymic function factor comprises a chemokine (e.g., secreted chemokine), cytoplasmic protein, enzyme (e.g., phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound ligand, non-secreted ligand, or secreted ligand), matrix protein, transcription factor, or receptor (e.g., cell surface receptor or nuclear receptor).
In embodiments, the chemokine is selected from Ccl21, CCL25, or Cxcll2. In embodiments, the secreted chemokine is Cxcll2.
In embodiments, the cytoplasmic protein is selected from ASC, Axin, or Fspl.
In embodiments, the enzyme is selected from Cbx4, Kl (Klotho), Ragl, Rag2, Sin/Polr3e, Tmpo (thymopoetin), Traf6, Pten, Prssl6, or beta(5t)/Psmbl l. In embodiments, the enzyme comprises a phosphatase, e.g., Pten. In embodiments, the enzyme comprises a protease, e.g., Prssl6. In embodiments, the enzyme comprises a proteinase, e.g., beta(5t)/Psmbl l.
In embodiments, the hormone, e.g., secreted hormone, is selected from GnRH, hGH (GH1 and GH2), leptin, leptin (TEC), prolactin, Ptma (thymosin alpha-1), Tshb (thyrotropin (beta chain)), or Ghrl (ghrelin). In embodiments, the secreted hormone encodes a preprotein, e.g., a ghrelin-obestatin preprotein.
In embodiments, the ligand is a secreted ligand. In embodiments, the ligand, e.g., secreted ligand, is selected from SCF (Kitl), BMP4, BMP4 (TEC), Ccll9, Cyr61, D114, Fstll, Fgf21, IGF-1, Ihh, IL10, IL-12b (IL12 p40 subunit), IL-15, IL18, IL2, IL2 (stroma), IL21, IL-22, IL23, IL6, IL-7, KGF (Fgf7), Lif, Shh (T-cell), Shh (TEC), Tslp, Wnt3a, Wnt3a (TEC), Wnt4, Wn4 (TEC), Kitl, or Flt3L. In embodiments, the ligand is a non-secreted ligand, e.g., membrane bound ligand. In embodiments, the ligand, e.g., non-secreted ligand, e.g., membrane bound
ligand, is selected from 1 lb-HSD2, CD70, Icaml, RANKL, Tbata, Vcaml, SCF (Kitl), K , or Flt3L.
In embodiments, the matrix protein is Satbl.
In embodiments, the receptor is selected from TCR (e.g., a TCR comprising an alpha and a beta chain, a TCR comprising a gamma chain and a delta chain, a TCR comprising a CD3 chain, a TCR comprising a zeta chain, a TCR comprising a complementarity determining region, and a TCR comprising a T cell co-receptor (e.g., CD4 or CD8)), AR, Bmprla, Bmprla (TEC), Bmpr2, Ccr7, Ccr9, CD127 (non-soluble IL-7R), CD27, Cd44, Cdh5 (VE cadherin), Cldn4, Crlf2 (TSLP-R), Cxcr4, EphB2, Fgfr2, Flt3, Fzdl, FzdlO, Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7, Fzd8, Fzd9, gpl30, HLA (e.g., HLA-A, HLA-B, HLA-B27, HLA-B47, HLA-C, HLA-E, HLA- F, HLA-G, p2-microglobulin, HLA-DM (e.g., HLA-DMA1 and/or HLA-DMB 1), HLA-DO (e.g., HLA-DO A 1 and/or HLA-DOB 1), HLA-DP (e.g, HLA-DPA1 and/or HLA-DPB 1), HLA- DQ (e.g., HLA-DQA1 and/or HLA-DQB 1), HLA-DQ2, HLA-DQ8, HLA-DR (e.g., HLA- DRA, HLA-DRB 1, HLA-DRB3, HLA-DRB4, and/or HLA-DRB5), HLA-DR2, HLA-DR3, HLA-DR4, and/or an HLA encoding a component of the complement system), Ifnarl,
IL7Ralpha, Ltbr, Major Histocompatibility Complexes (e.g., Class I MHC molecule (MHC I), e.g., comprising one or more polypeptides encoded by a HLA-A, HLA-B, HLA-C, HLA-G, and/or HLA-E gene; Class II MHC molecule (MHC II), e.g., comprising one or more
polypeptides encoded by a HLA-DP, HLA-DQ, and/or HLA-DR gene; or Class III MHC molecule (MHC III), e.g., comprising a polypeptide involved in inflammation, e.g., a component of the complement system (e.g., C2, C4, or factor B), tumor necrosis factor (TNF)-a,
lymphotoxin-a, lymphotoxin-β, or a heat shock protein), NLRP3, Notchl, Ptchl, Ptch2, RANK, S 1PR1 (S 1P1), Sele (E-selectin, CD62E, ELAM-1, or LECAM2), Sell (CD62L), Selp (P- selectin), Tgfbr2, Tnfrsfl la/RANK, Tnfrsf 1 lb, or PPARgamma. In embodiments, the receptor is a nuclear receptor, e.g PPARgamma. In embodiments, a TCR includes a TCR that binds to an epitope presented on an MHCI molecule, an epitope presented on an MHCII molecule, or an epitope presented on an MHCIII molecule).
In embodiments, the transcription factor is PPARgamma, AIRE, Atf3, E2F2, E2F2 (TEC), E2F3, E2F4, Egrl, Egr2, Egr3, Fezf2, Foxnl, Foxol, FoxP3, Gata2, Gata3, Gfil, Id3, l, Klf3, Lefl, Meisl, Nfat5, Nfatcl, NFkB l, Runxl, Smad4, Smad6, Stat3, Tbxl, Tcfl, Zfp3611, Zfp3612, or Nfkb2.
In embodiments, the thymic function factor is a positive regulator of a thymic function, e.g., the thymic function factor is selected from Shh (T-cell), E2F2, CD70, Cldn4, DM, Egrl, Egr2, Egr3, EphB2, Flt3, Flt3L, Foxol, FoxP3, Gata3, Gfil, Ghrl (ghrelin), GnRH, Icaml, Id3, Ifnarl, IL-12b (IL12 p40 subunit), IL-15, IL18, IL2, IL21, IL-7, K , Lefl, leptin, Nfat5, Nfatcl, Notchl, prolactin, Ragl, Rag2, Runxl, Satbl, SCF (KM), Tcfl, Tshb (thyrotropin beta chain), Tslp, Vcaml, Wnt3a, Wnt4, Zfp3611, Zfp3612, CD127 (non-soluble IL-7R), CD27, Crlf2 (TSLP- R), Fzdl, FzdlO, Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7, Fzd8, Fzd9, IL-7Ralpha, Ptchl, Ptch2, Ccll9, Ccl21, CCL25, Ccr7, Ccr9, Cxcll2, Cxcr4, S 1PR1 (S 1P1), Sele (E-selectin, CD62E, ELAM-1, or LECAM2), Sell (CD62L), Selp (P-selectin), AIRE, beta(5t)/Psmbl l, Fezf2, Prssl6, BMP4 (TEC), Cbx4, Cdh5 (VE cadherin), E2F3, Foxnl, Fspl, Kl (Klotho), Ltbr, NFkB l, Pten, RANK, RANKL, Shh (TEC), Sin/Polr3e, Stat3, Tnfrsfl la/RANK, Traf6, Wnt3a (TEC), Wnt4 (TEC), Bmpr2, Fgfr2, Bmprla (TEC), Cyr61, E2F2 (TEC), IGF-1, IL-22, IL-23, KGF (Fgf7), l lb-HSD2, Fgf21, IL10, IL2 (stroma), leptin (TEC), Meisl, Cd44, hGH (GHl and GH2), Nfkb2, BMP4, Klf3, Isll, Ptma (thymosin alpha- 1), Smad4, IL6, or Ihh.
In embodiments, the positive regulator of thymic function comprises a T-cell growth factor, e.g., BMP4, Klf3, Shh (T-cell), IL6, CD70, Cldn4, D114, Egrl, Egr2, Egr3, EphB2, Flt3, Flt3L, Foxol, FoxP3, Gata3, Gfil, Ghrl (ghrelin), GnRH, Icaml, Id3, Ifnarl, IL-12b (IL12 p40 subunit), IL-15, IL18, IL2, IL21, IL-7, KM, Lefl, leptin, Nfat5, Nfatcl, Notchl, prolactin, Ragl, Rag2, Runxl, Satbl, SCF (KM), Tcfl, Tshb (thyrotropin beta chain), Tslp, Vcaml, Wnt3a, Wnt4, Zfp3611, or Zfp3612. In embodiments, the positive regulator of thymic function comprises a T-cell activity factor, e.g., E2F2. In embodiments, the positive regulator of thymic function comprises a T-cell growth factor receptor, e.g., Ihh, CD 127 (non-soluble IL-7R), CD27, Crlf2 (TSLP-R), Fzdl, FzdlO, Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7, Fzd8, Fzd9, Ptchl, Ptch2, or IL-7Ralpha. In embodiments, the positive regulator of thymic function comprises a T-cell migration factor, e.g., Ccll9, Ccl21, CCL25, Ccr7, Ccr9, Cxcll2, Cxcr4, S 1PR1 (S 1P1), Sele (E- selectin, CD62E, ELAM-1, or LECAM2), Sell (CD62L), or Selp (P-selectin). In embodiments, the positive regulator of thymic function comprises a TEC function factor, e.g., AIRE, beta(5t)/Psmbl 1, Fezf2, or Prssl6. In embodiments, the positive regulator of thymic function comprises a TEC growth factor, e.g., Isll, BMP4 (TEC), Cbx4, Cdh5 (VE cadherin), E2F3, Foxnl, Fspl, Kl (Klotho), Ltbr, NFkB l, Pten, RANK, RANKL, Shh (TEC), Sin/Polr3e, Stat3, Tnfrsfl la/RANK, Traf6, Wnt3a (TEC), or Wnt4 (TEC). In embodiments, the positive regulator
of thymic function comprises a TEC growth factor receptor, e.g., Bmpr2, Fgfr2, or Bmprla (TEC). In embodiments, the positive regulator of thymic function comprises a TEC proliferation factor, e.g., Cyr61, E2F2 (TEC), IGF-1, IL-22, IL-23, or KGF (Fgf7). In embodiments, the positive regulator of thymic function comprises a thymus homeostasis factor, e.g., l lb-HSD2, Fgf21, IL10, IL2 (stroma), Leptin (TEC), or Meisl.
In other embodiments, the thymic function factor is a negative regulator of a thymic function, e.g., the thymic function factor is selected from Shh, Bmprla, Gata2, Lif, Atf3, E2F4, PPARgamma, Tbata, Tbxl, Tgfbr2, AR, ASC, Axin, NLRP3, gpl30, Tnfrsfl lb, E2F2, BMP4, Ihh, or IL6.
In embodiments, the negative regulator of thymic function comprises a T-cell growth factor, e.g., BMP4, Shh (T-cell), Bmprla, Gata2, IL6, or Lif. In embodiments, the negative regulator of thymic function comprises a TEC growth factor, e.g., Atf3, E2F4, PPARgamma, Tbata, Tbxl, Tgfbr2, or Tnfrsf 1 lb. In embodiments, the negative regulator of thymic function comprises a thymus homeostasis factor, e.g., AR, ASC, Axin, or NLRP3. In embodiments, the negative regulator of thymic function comprises a T-cell activity factor, e.g., E2F2.
In embodiments, the thymic function factor is a positive and/or negative regulator of a thymic function, e.g., the thymic function factor is selected from BMP4, IL6, Ihh, E2F2, or Shh (T-cell).
In embodiments, the thymic function factor is selected from TCR (e.g., a TCR comprising an alpha and a beta chain, a TCR comprising a gamma chain and a delta chain, a TCR comprising a CD3 chain, a TCR comprising a zeta chain, a TCR comprising a
complementarity determining region, or a TCR comprising a T cell co-receptor (e.g., CD4 or CD8)), BMP4, BMP4 (TEC), Bmprla (TEC), Bmpr2, Ccl21, CCL25, CD127 (non-soluble IL- 7R), Cxcll2, D114, E2F2 (TEC), E2F3, Fgf21, Flt3L, Foxnl, Ghrl (ghrelin), GnRH, hGH (GH1 and GH2), IL10, IL21, IL-22, IL-23, IL-7, IL-7Ralpha, KGF (Fgf7), Kitl, leptin, leptin (TEC), prolactin, Ptma (thymosin alpha- 1), or SCF (Kitl). In embodiments, a TCR includes a TCR that binds to an epitope presented on an MHCI molecule, an epitope presented on an MHCII molecule, or an epitope presented on an MHCIII molecule
Thymic Function Modulators
In some embodiments of any of the methods described herein, an agent that modulates, e.g., increases or decreases, thymic function is also referred to as a thymic function modulator. In some embodiments, the thymic function modulator increases or decreases the expression or activity of one or more thymic function factors described herein. In some embodiments, the thymic function modulator is itself a thymic function factor (or fragment thereof), e.g., a thymic function factor described herein, e.g., in Table 1.
In some embodiments of any of the methods described herein, the thymic function modulator comprises a nucleic acid molecule (e.g., DNA, mRNA or an inhibitory RNA), a peptide, an antibody molecule (e.g., an antibody or antigen binding fragment thereof), or a small molecule.
In some embodiments of any of the methods described herein, the thymic function modulator increases the expression or activity of one or more thymic function factors described herein, e.g., listed in Table 1. In one embodiment, the increase in expression or activity of the one or more thymic function factors is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, increased as compared to a reference expression or activity level of the one or more thymic function factors. In one embodiment, the reference expression or activity level is the expression or activity level of the one or more thymic function factors prior to administration of the thymic function modulator.
In some embodiments of any of the methods described herein, the thymic function modulator decreases the expression or activity of one or more thymic function factors described herein, e.g., listed Table 1. In one embodiment, the decrease in expression or activity of one or more thymic function factors is at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, decreased as compared to a reference expression or activity level of the one or more thymic function factors. In one embodiment, the reference expression or activity level is the expression or activity level of the one or more thymic function factors prior to administration of the thymic function modulator.
In one embodiment of any of the methods described herein, the thymic function modulator comprises a nucleic acid molecule. In one embodiment, the thymic function
modulator comprises a DNA molecule or a RNA molecule. In one embodiment, the thymic function modulator comprises a RNA molecule, e.g., an inhibitory RNA or an RNA therapeutic that encodes a protein. In one embodiment, the thymic function modulator comprises an inhibitory or agonistic antibody.
In one embodiment of any of the methods described herein, the thymic function modulator comprises an mRNA molecule (e.g., an RNA therapeutic) that encodes one or more of the thymic function factors described herein, e.g., listed in Table 1, or a functional fragment thereof. In one embodiment, the mRNA molecule encodes an amino acid sequence having 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to an amino acid sequence listed in Table 1, or a functional fragment thereof. In one embodiment, the mRNA molecule encodes an amino acid sequence that differs by no more than 20, 10, 5, 4, 3, 2, or 1 amino acids to an amino acid sequence listed in Table 1. In one embodiment, the mRNA molecule encodes an amino acid sequence comprising an amino acid sequence listed in Table 1, or a functional fragment thereof.
In one embodiment of any of the methods described herein, the thymic function modulator comprises an inhibitory RNA, e.g., an interfering RNA (RNAi) molecule. In one embodiment, the RNAi molecule is selected from a siRNA, a short hairpin RNA, or a microRNA. In one embodiment, the interfering RNA molecule decreases or inhibits expression of one or more of the thymic function factors listed in Table 1.
In one embodiment of any of the methods described herein, the thymic function modulator comprises an mRNA molecule that encodes an antibody molecule (e.g., an antibody or an antigen binding fragment thereof) that targets (e.g., specifically binds to) one or more of the thymic function factors described herein, e.g., listed in Table 1.
In one embodiment of any of the methods described herein, the thymic function modulator comprises a guide RNA sequence that enables CRISPR-mediated gene editing of one or more of the thymic function factors described herein, e.g., listed in Table 1.
In one embodiment of any of the methods described herein, the thymic function modulator comprises an mRNA molecule that encodes a zinc finger nuclease (ZFN) that targets (e.g., cleaves) the sequence encoding one or more thymic function factors described herein, e.g., listed in Table 1.
In one embodiments of any of the methods described herein, the thymic function modulator comprises an epigenetic modifying agent, e.g., an epigenetic modifying agent described herein.
In some embodiments of any of the methods described herein, one or more additional thymic function modulators, e.g., one, two, three, four, or five additional thymic function modulators (e.g., a second, third, fourth, fifth or sixth thymic function modulator) is administered to the subject. In one embodiment, the one or more of the thymic function modulators increase or decrease the expression or activity level of the same type of thymic function factor, e.g., a T cell growth factor, a T cell growth factor receptor, a T cell proliferation factor, a T cell migration factor, a T cell activity factor, a TEC proliferation factor, a TEC growth factor, a TEC growth factor receptor, a TEC function factor, or a thymus homeostasis factor. By way of example, in an embodiment, two thymic function modulators are administered, and both thymic function modulators increase or decrease the expression or activity level of a T cell growth factor. In other embodiments where two or more thymic functional modulators are administered, two or more of the thymic function modulators increase or decrease the expression or activity level of different types of thymic function factors, e.g., a T cell growth factor, a T cell growth factor receptor, a T cell proliferation factor, a T cell migration factor, a T cell activity factor, a TEC proliferation factor, a TEC growth factor, a TEC growth factor receptor, a TEC function factor, or a thymus homeostasis factor. By way of another example, in another embodiment, two thymic function modulators are administered, and one thymic function modulator increases or decreases the expression or activity level of a T cell growth factor while the other thymic function modulator increases or decreases the expression or activity level of a TEC proliferation factor. In any of the aforementioned embodiments, the one or more thymic function modulators increase or decrease the expression or activity level of a thymic function factor described herein, e.g., listed in Table 1.
In some embodiments of any of the methods described herein, administering two or more thymic function modulators results in a synergistic effect. In one embodiment, a synergistic effect is observed when the effect of the two or more thymic function modulators is greater than the additive effect observed of each of the thymic function modulators.
In some embodiments, the method includes administering a first and a second thymic function modulator. In one embodiment, the first and second thymic function modulators are
formulated in separate dosage forms. In another embodiment, the first and second thymic function modulators are formulated in the same dosage form. In one embodiment, the first and second thymic function modulators are coupled by a covalent bond, a non-covalent bond, or a chemical linkage. In one embodiment, the first and second thymic modulators are separated by a linker.
In some embodiments, the first and second thymic function modulators are each mRNA molecules (e.g., encoding a thymic function factor or functional fragment thereof). In one embodiment, the first and second thymic function modulators are coupled by a phosphodiester bond. In one embodiment, the first and second thymic function modulators are translated into a single polypeptide (e.g., a chimeric polypeptide or a polypeptide that can be cleaved into two polypeptides). In one embodiment, the first and second thymic function modulators are separated by a peptide cleavage site. In one embodiment, the first thymic function modulator is translated into a first polypeptide and the second thymic function modulator is translated into a second polypeptide.
In some embodiments, the first and second thymic function modulators are each interfering RNA molecules (e.g., a siRNA, a shRNA, or a miRNA). In one embodiment, the first and second thymic function modulators are each siRNAs, and wherein the first and second thymic function modulators are coupled by a linker, e.g., a peptide linkage or a chemical linkage, e.g., as described herein.
In some embodiments, the method includes administering more than one (e.g., two, three, four, five, or more) thymic function modulator. In one embodiment, the more than one (e.g., two, three, four, five, or more) thymic function modulators are formulated in separate dosage forms. In another embodiment, the more than one (e.g., two, three, four, five, or more) thymic function modulators are formulated in the same dosage form. In one embodiment, the more than one (e.g., two, three, four, five, or more) thymic function modulators are coupled to each other by a covalent bond, a non-covalent bond, or a chemical linkage. In one embodiment, the more than one (e.g., two, three, four, five, or more) thymic modulators are separated from each other by a linker.
In some embodiments, the more than one (e.g., two, three, four, five, or more) thymic function modulators are each mRNA molecules (e.g., encoding a thymic function factor or functional fragment thereof). In one embodiment, the more than one (e.g., two, three, four, five,
or more) thymic function modulators are coupled to each other by a phosphodiester bond. In one embodiment, the more than one (e.g., two, three, four, five, or more) thymic function modulators are translated into a single polypeptide (e.g., a chimeric polypeptide or a polypeptide that can be cleaved into multiple polypeptides). In one embodiment, the more than one (e.g., two, three, four, five, or more) thymic function modulators are separated from each other by a peptide cleavage site. In one embodiment, each thymic function modulator is translated into a polypeptide.
In some embodiments, the more than one (e.g., two, three, four, five, or more) thymic function modulators are each interfering RNA molecules (e.g., a siRNA, a shRNA, or a miRNA). In one embodiment, the more than one (e.g., two, three, four, five, or more) thymic function modulators are each siRNAs, and each of the thymic function modulators are coupled by a linker, e.g., a peptide linkage or a chemical linkage, e.g., as described herein.
Physiological senescence
In accordance with any method or composition described herein, e.g., in embodiments of methods of modulating physiological senescence, the physiological senescence is associated with one or more of muscle atrophy/degeneration; decrease in bone health (e.g., bone strength and/or density); immunosenescence (e.g., decrease in immune responsiveness); cardiac disease; uncontrolled cell growth (e.g., tumorigenesis).
In some embodiments, a subject experiencing physiological senescence has a disease or condition associated with muscle atrophy/degeneration; decrease in bone health (e.g., bone strength and/or density); immunosenescence (e.g., decrease in immune responsiveness); cardiac disease; uncontrolled cell growth (e.g., tumorigenesis). In one embodiment, the subject has a muscular degenerative disorder (e.g., a myopathy, muscle wasting, or sarcopenia); amyotrophic lateral sclerosis (ALS); osteoporosis and related diseases; a cardiac disease (e.g., myocardial infarction, atherosclerosis); a cancer (e.g., a solid cancer, such as uterine cancer, colon cancer, ovarian cancer, rectal cancer, skin cancer, stomach cancer, lung cancer, non-small cell carcinoma of the lung, breast cancer, cancer of the small intestine, testicular cancer, cancer of the anal region, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, rectal cancer, renal-cell carcinoma, liver cancer, cancer of the esophagus, melanoma, cutaneous or intraocular malignant melanoma, uterine cancer, brain cancer, brain stem glioma,
pituitary adenoma, Kaposi's sarcoma, cancer of the adrenal gland, bone cancer, pancreatic cancer, cancer of the head or neck, epidermoid cancer, carcinoma of the endometrium, carcinoma of the vagina, cervical cancer, sarcoma, uterine cancer, stomach cancer, esophageal cancer, colorectal cancer, liver cancer, prostate cancer, carcinoma of the cervix squamous cell cancer, carcinoma of the fallopian tubes, sarcoma of soft tissue, cancer of the urethra, carcinoma of the vulva, cancer of the kidney or ureter, carcinoma of the renal pelvis, spinal axis tumor, cancer of the penis, cancer of the bladder, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, metastatic lesions of said cancers, and/or combinations thereof; or a hematological cancer, e.g., a leukemia or lymphoma, e.g., a hematological cancer such as acute lymphoid leukemia (ALL); one or more chronic leukemias, e.g., chronic myelogenous leukemia (CML), Chronic Lymphoid Leukemia (CLL), B cell prolymphocytic leukemia; B-cell acute Lymphoid Leukemia ("BALL"); T-cell acute Lymphoid Leukemia ("TALL"); blastic plasmacytoid dendritic cell neoplasm; Follicular lymphoma; diffuse large B cell lymphoma; non-Hodgkin lymphoma; Hodgkin lymphoma; Burkitt's lymphoma; malignant lymphoproliferative conditions; Hairy cell leukemia; small cell- or large cell-follicular lymphoma; mantle cell lymphoma; MALT lymphoma; marginal zone lymphoma; multiple myeloma; myelodysplasia; myelodysplastic syndrome; Waldenstrom macroglobulinemia;
plasmablastic lymphoma; and plasmacytoid dendritic cell neoplasm); or a metabolic disease (e.g., diabetes, e.g., type I diabetes, or obesity).
In some embodiments, the method further includes monitoring the muscle function, bone health, cardiac health, and/or immune responsiveness of the subject.
Thymic Injury
In accordance with any method or composition described herein, e.g., in embodiments of methods of treating thymic injury, the injury is induced by a disease, a drug treatment, irradiation, or other environmental factor. In one embodiment, the injury is induced by drug is a cytoreductive or chemotherapeutic drug.
In embodiments, the injury is an acute injury. In other embodiments, the injury is a chronic injury.
Enhancing/decreasing immune response
In accordance with any method or composition described herein, e.g., in embodiments of methods of enhancing (e.g., increasing) or decreasing an immune response, the immune response comprises an anti-cancer immune response, a vaccine response, or an immune response to an infection (e.g., chronic infection).
In some embodiments, the cancer is selected from a hematological cancer or a solid cancer such as lung cancer, non-small cell lung cancer (NSCLC), skin cancer, melanoma, cervical cancer, uterine cancer, ovarian cancer, breast cancer, pancreatic cancer, stomach cancer, esophageal cancer, colorectal cancer, liver cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, sarcoma, lymphoma, and brain cancer. In embodiments, the method comprises administering the thymic function modulator in combination with an immunotherapy, e.g., cancer immunotherapy, e.g., cancer immunotherapy described herein.
In embodiments, the infection is a chronic infection or an acute infection. In
embodiments, the infection is a bacterial or viral infection.
Infectious disease
In accordance with any method or composition described herein, e.g., in embodiments of methods of treating an infectious disease, the infectious disease is a bacterial infection. In some embodiments, the infectious disease is a viral infection. In one embodiment, the infection is a chronic infection or an acute infection. In one embodiment, the infection is a parasitic infection.
Autoimmune disease
In accordance with any method or composition described herein, e.g., in embodiments of methods of treating an autoimmune disease, the method comprises inducing negative selection in the subject, e.g., inducing clonal deletion and/or inducing Treg generation in the subject. In embodiments, the method prevents rejection of a transplant in the subject.
In embodiments, the autoimmune disease is rheumatoid arthritis, j venile oligoarthritis, collagen-induced arthritis, adjuvant-induced arthritis, Sjogren's syndrome, multiple sclerosis, experimental autoimmune encephalomyelitis, inflammatory bowel disease (for example, Crohn's disease, ulcerative colitis), autoimmune gastric atrophy, pemphigus vulgaris, psoriasis, vitiligo, type 1 diabetes, non-obese diabetes, myasthenia gravis, Grave's disease, Hashimoto's thyroiditis,
sclerosing cholangitis, sclerosing sialadenitis, systemic lupus erythematosis, autoimmune thrombocytopenia purpura, Goodpasture's syndrome, Addison's disease, systemic sclerosis, polymyositis, dermatomyositis, autoimmune hemolytic anemia, or pernicious anemia.
In embodiments, the transplant comprises a cell or organ transplant. In embodiments, the cell comprises a stem cell, e.g., hematopoietic stem cell and/or mesenchymal stem cell. In embodiments, the organ comprises a lung, heart, eye, liver, or kidney.
Thymic Involution
In accordance with any method or composition described herein, e.g., in embodiments of methods of reducing, reversing, or preventing thymic involution, the thymic involution is caused by aging, a drug or treatment, and/or a disease.
In embodiments, the drug or treatment comprises a chemotherapy, radiation, or immunotherapy.
In embodiments, the disease comprises a cancer or an infection, e.g., chronic or acute infection.
In embodiments, the cancer is selected from a hematological cancer or a solid cancer, e.g., a hematological or solid cancer described herein, e.g., lung cancer, non-small cell lung cancer (NSCLC), skin cancer, melanoma, cervical cancer, uterine cancer, ovarian cancer, breast cancer, pancreatic cancer, stomach cancer, esophageal cancer, colorectal cancer, liver cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, sarcoma, lymphoma, or brain cancer.
In embodiments, the infection is a bacterial infection or a viral infection. Subjects
In some embodiments of any of the methods described herein, the subject (e.g., subject from which the source cell is derived and/or subject to be administered a therapy described herein, e.g., a cell culture/cell(s)/preparation described herein and/or other therapy described herein) has or is experiencing physiological senescence. In one embodiment, physiological senescence comprises muscle atrophy/degeneration, inadequate bone strength/density, immunosenescence (age-related decrease in immune responsiveness or menopause), or cardiac disease.
In some embodiments of any of the methods described herein, the subject has a disease or condition associated with muscle atrophy/degeneration, inadequate bone strength/density, immunosenescence (age-related decrease in immune responsiveness or menopause), or cardiac disease.
In some embodiments of any of the methods described herein, the subject has an acute thymic injury.
In some embodiments of any of the methods described herein, the subject has drug or radiation induced thymic damage.
In some embodiments of any of the methods described herein, the subject is an adult subject, e.g., a geriatric subject, e.g., a subject older than 60, 65, 70, 75, 80, 85, 90.
In some embodiments of any of the methods described herein, the subject is a juvenile subject, e.g., less than 18 years old.
In some embodiments of any of the methods described herein, the subject does not have a detectable thymus before treatment.
In some embodiments of any of the methods described herein, the subject has an implanted thymus tissue, e.g., has an implanted thymus.
In some embodiments of any of the methods described herein, the subject has had a thymic transplant.
In some embodiments of any of the methods described herein, the subject has undergone, is undergoing, or will undergo a cell (e.g., stem cell, e.g., hematopoietic stem cell) transplant.
DETAILED DESCRIPTION OF THE INVENTION
The disclosure relates to methods of generating and/or enhancing thymic function in cells ex vivo as well as treatment comprising use of such ex vivo thymic cultures. The disclosure also relates to compositions comprising cells (e.g., tissues) having thymic function, e.g., cells that were generated using an ex vivo method, and methods of use. Without wishing to be bound by theory, it is believed that thymic function modulators improve one or more functions of the thymus and can, e.g., lead to rejuvenation of thymus activity. Accordingly, thymic function modulators and/or cells generated using thymic function modulators are useful for treating diseases and conditions associated with a loss or reduction of thymic activity. A reduction in thymic activity can occur, e.g., due to age (e.g., thymic involution) or stresses (e.g., trauma, drug
effects, and diseases). Such diseases and conditions can be related to or include: physiological senescence, autoimmunity, cardiac disease, cancer, infectious disease, muscle
atrophy/degeneration, decrease in bone health, immunosenescence, thymic injury, and other diseases/conditions described herein. For example, featured herein are therapeutic methods for decreasing or reversing thymic involution. Also featured herein are methods of enhancing the function/lifetime of a thymus transplant. Further embodiments are described in greater detail herein.
Definitions:
As used herein, a "thymic function modulator" is an agent that modulates, e.g., increases or decreases, thymic function. Determination of thymic function is described herein, e.g., in the "Measurement of thymus function" section. Thymic function modulators are described in greater detail herein, e.g., in the "Thymic function modulators" section.
As used herein, a "thymic function factor" is a molecule, e.g., protein, peptide, polypeptide, or nucleic acid molecule (e.g., oligonucleotide, e.g., DNA, RNA, or mRNA, or gene), that is associated with thymic function. In embodiments, expression, e.g., high
expression, of a thymic function factor is associated with increased or decreased thymic function. In embodiments, lack of or low expression of a thymic function factor is associated with increased or decreased thymic function. Thymic function factors are described in greater detail herein, e.g., in the "Thymic function factors" section.
As used herein, an "antibody molecule" is a protein that includes at least one
immunoglobulin variable domain or immunoglobulin variable domain sequence. For example, an antibody molecule can include a heavy (H) chain variable region (abbreviated herein as VH), and a light (L) chain variable region: (abbreviated herein as VL). In another example, an antibody includes two heavy (H) chain variable regions and two light (L) chain variable regions. The term "antibody molecule" encompasses antigen-binding fragments of antibodies (e.g., single chain antibodies, Fab and sFab fragments, F(ab') 2, Fd fragments, Fv fragments, scFv, and domain antibodies (dAb) fragments as well as complete antibodies. An antibody can have the structural features of IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof). In some embodiments, antibodies are recombinant human or humanized antibodies.
As used herein, a "combination therapy" or "administered in combination" means that two (or more) different agents or treatments are administered to a subject as part of a defined treatment regimen for a particular disease or condition. The treatment regimen defines the doses and periodicity of administration of each agent such that the effects of the separate agents on the subject overlap. In some embodiments, the delivery of the two or more agents is simultaneous or concurrent and the agents may be co-formulated. In other embodiments, the two or more agents are not co-formulated and are administered in a sequential manner as part of a prescribed regimen. In some embodiments, administration of two or more agents or treatments in combination is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one agent or treatment delivered alone or in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive (e.g., synergistic). Sequential or substantially simultaneous
administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination may be administered by intravenous injection while a second therapeutic agent of the combination may be
administered orally.
As used herein, the term "pharmaceutical composition" refers to a medicinal or pharmaceutical formulation that contains one or more active ingredient as well as one or more excipients and diluents to enable the active ingredient(s) suitable for the method of
administration. The pharmaceutical composition of the present invention includes
pharmaceutically acceptable components that are compatible with the agents described herein. The pharmaceutical composition is typically in aqueous form for intravenous or subcutaneous administration. In embodiments, a pharmaceutical composition or pharmaceutical preparation is a composition or preparation produced under good manufacturing practices (GMP) conditions, having pharmacological activity or other direct effect in the mitigation, treatment, or prevention of disease, and/or a finished dosage form or formulation thereof and is for human use.
As used herein, the terms "increasing" and "decreasing" refer to modulating resulting in, respectively, greater or lesser amounts, function or activity of a metric relative to a reference. For example, subsequent to administration of a thymic function modulator, the amount of a
marker of thymic function may be increased or decreased in a subject by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% or more relative to the amount of the marker prior to administration. Generally, the metric is measured subsequent to administration at a time that the administration has had the recited effect, e.g., at least one week, one month, 3 months, 6 months, after a treatment regimen (e.g., a therapy described herein) has begun.
"Treatment" and "treating," as used herein, refer to the medical management of a subject with the intent to improve, ameliorate, stabilize, prevent or cure a disease, pathological condition, or disorder. This term includes active treatment (treatment directed to improve the disease, pathological condition, or disorder), causal treatment (treatment directed to the cause of the associated disease, pathological condition, or disorder), palliative treatment (treatment designed for the relief of symptoms), preventative treatment (treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder); and supportive treatment (treatment employed to supplement another therapy).
The term "synergy" or "synergistic" means a more than additive effect of a combination of two or more agents (e.g., a combination therapy described herein) compared to their individual effects. In certain embodiments, synergistic activity is present when a first agent produces a detectable level of an output X, a second agent produces a detectable level of the output X, and the first and second agents together produce a more-than-additive level of the output X.
The term "heterologous thymic capability," as used herein, refers to the ability to carry out one or more thymic functions, e.g., the presence of a cell or tissue that has a thymic function, e.g., a thymic cell or tissue. In embodiments, the thymic cell or tissue comprises a thymocyte, epithelial thymic cell (e.g., of the cortex or medulla), stromal cell and/or a dendritic cell (e.g., a conventional dendritic cell or a plasmacytoid dendritic cell). In embodiments, the thymic cell or tissue can be autologous or allogeneic. In embodiments, the thymic cell or tissue can be suitable for implantation. In embodiments, the thymic cell or tissue has been implanted in a subject. In embodiments, the thymic cell or tissue is cultured ex vivo prior to implantation into a subject, e.g., using a method described herein, e.g., in the "Ex Vivo Manipulation Methods" section herein. In embodiments, the thymic cell or tissue is evaluated by assessing certain thymic
activities, functions, markers or characteristics, e.g., using a method described herein, e.g., in the "Measurement of thymus function" section herein.
As used herein the term "peptide linker" refers to an amino acid sequence (e.g., synthetic amino acid sequence) that connects or links two polypeptide sequences, e.g., that links two polypeptide domains. As used herein the term "synthetic" refers to amino acid sequences that are not naturally occurring. In embodiments, peptide linkers connect two amino acid sequences via peptide bonds, e.g., in a linear sequence. In one embodiment, a peptide linker connects a biologically active moiety to a second moiety in a linear sequence. In another embodiment, a peptide linker connects two biologically active moieties.
As used herein, the terms "linked," "fused", or "fusion", are used interchangeably. These terms refer to the joining together of two more elements or components, by whatever means including chemical conjugation or recombinant means. Any method of chemical conjugation (e.g., using heterobifunctional crosslinking agents) can be used. For example, two or more molecules, e.g., nucleic acid molecules (e.g., mRNAs or inhibitory nucleic acid molecules), small molecules, and/or peptides/polypeptides can be linked, e.g., using a linker, e.g., chemical linker or peptide linker. As used herein, the term "genetically fused," "genetically linked" or "genetic fusion" refers to the co-linear, covalent linkage or attachment of two or more proteins, polypeptides, or fragments thereof via their individual peptide backbones, e.g., through genetic expression of a single polynucleotide molecule encoding those proteins, polypeptides, or fragments. Such genetic fusion results in the expression of a single contiguous genetic sequence. Exemplary genetic fusions are in frame, i.e., two or more open reading frames (ORFs) are fused to form a continuous longer O F, in a manner that maintains the correct reading frame of the original ORFs. Thus, the resulting recombinant fusion protein is a single polypeptide containing two or more protein segments that correspond to polypeptides encoded by the original ORFs (which segments are not normally so joined in nature). In this case, in some embodiments, the single polypeptide is cleaved during processing to yield dimeric molecules comprising two polypeptide chains.
Percent identity in the context of two or more polypeptide sequences or nucleic acids, refers to two or more sequences that are the same. Two sequences are "substantially identical" if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (e.g., at least 60% identity, e.g., at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%,
78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity, e.g., over a specified region, or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using a sequence comparison algorithms or by manual alignment and visual inspection. In some cases, the identity (or substantial identity) exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length.
For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman, (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Brent et al., (2003) Current Protocols in Molecular Biology).
Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402; and Altschul et al., (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller, (1988) Comput. Appl. Biosci. 4: 11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap
length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (1970) J. Mol. Biol.
48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
Ex vivo manipulation methods
Provided herein are methods of generating and/or improving thymic function ex vivo, e.g., in a cell, organ, or organoid culture. For example, provided herein are methods of decreasing or reversing thymic involution comprising culturing a cell under conditions that improve thymic function, e.g, and subsequently administering the cultured cell to a subject in need thereof.
In embodiments, a source cell (e.g., population of cells, e.g., cells isolated from a thymus tissue, or T cells) is contacted with a thymic function modulator, e.g., described herein. In embodiments, the source cell(s) is cultured under conditions sufficient to produce a cell(s) with improved thymic function. The cell(s) having improved thymic function can be administered to a subject, e.g., alone or in combination with a thymic function modulator or other therapy/agent described herein.
The cell(s) can be administered at a dosage or dosage frequency described herein, e.g., 104 to 109 cells/kg body weight, e.g., 105 to 106 cells/kg body weight, including all integer values within those ranges. The cell(s) can also be administered multiple times at these dosages. The cells can be administered by using infusion techniques that are known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319: 1676, 1988).
The cells can be autologous or allogeneic. The source cells can be thymic cells, e.g., epithelial thymic cells (e.g., of the cortex or medulla), stromal cells, and/or dendritic cells (e.g., conventional dendritic cells or plasmacytoid dendritic cells). Conventional dendritic cells (also called myeloid dendritic cells) include all dendritic cells other than plasmacytoid dendritic cells. Dendritic cells are described in greater detail in, e.g., Schraml et al. Curr. Opin. Immunol.
32(2015): 13-20, incorporated herein by reference.
In other examples, the source cells can be a non-thymic cell, e.g., an epithelial cell or fibroblast cell. In some cases, a source cell, e.g., non-thymic cell, is contacted with a thymic
transformation agent, which induces a thymic gene expression profile or a thymic function in the cell(s). An epithelial thymic cell (e.g., cortical thymic epithelial cell (cTEC) or medullary thymic epithelial cell (mTEC)) gene expression profile can be characterized by one or more of the genes as shown in Table 4. Exemplary thymic functions are described in greater detail in the "Measurement of thymus function" section herein.
Table 4 - Genes characteristic of the thymic epithelium
In embodiments, a thymic transformation agent includes an agent that induces a thymic gene expression profile and/or thymic function in a cell/population of cells that are not derived from the thymus. An example of a thymic transformation agent is a thymic function modulator, e.g., described herein. Thymic transformation agents can be in the form of nucleic acid molecules (e.g., mRNAs, DNAs), peptides, antibody molecules, or small molecules. In one embodiment, a thymic transformation agent is a nucleic acid molecule, e.g., a synthetic mRNA, e.g., that encodes a transcription factor, sucha s FOXNl.
A thymic transformation agent can include an agent that changes the stromal/non-stromal cellular balance in a thymus. In other embodiments, a thymic transformation agent changes the medullary/cortical cellular balance in a thymus. For example, such changes in cellular or tissue balance can be assessed by imaging techniques, such as ultrasound, histological analysis, or PET imaging (e.g., FDG avidity via PET). In embodiments, a thymic transformation agent shifts the ratio of medullary to cortical thymus (e.g., ratio of medullary TECs to cortical TECs), which can be assessed by imaging or histological analysis of surface markers, such as K5 and/or K8 staining. In embodiments, a thymic transformation agent changes the gene expression profile in a sample, e.g., thymus sample, e.g., from a subject, to reflect increased cell function or expansion of epithelial cells. For example, such a gene expression profile can include expression of AIRE,
FEZF2, FOXN1, e.g., of medullary TECs or of cortical TECs. A gene expression profile can be determined by gene expression profiling techniques, such as RT-PCR or arrays. In
embodiments, a thymic transformation agent causes a thymic modification that results in an expansion or contraction of an antigen- specific T cell population. Antigen- specific T cell populations can be identified/quantified by using TCR Seq, tetramers, or a type IV
hypersensitivity test.
In embodiments, the source cell(s) is cultured with a thymic transformation agent at least until a marker of thymic function is detected. Exemplary markers of thymic functions include formation of a plasma cell, development of an antigen- specific T cell, and/or formation of a thymic organoid, and are described in greater detail in the "Measurement of thymus function" section herein. In embodiments, the cell(s) is administered to a subject in need thereof after detection of a marker of thymic function.
In accordance with any method described herein, a cell culture/cell(s)/preparation thereof can be transplanted into a subject, e.g., as described in Markert et al. Clin. Immunol.
135.2(2010):236-46. For example, the cell culture/cell(s)/preparation thereof can be transplanted into the quadriceps muscles of the subject. Other methods of delivering/administering the cell culture/cell(s)/preparation thereof are contemplated, e.g., described herein, and also described in Sachs et al. Transpl. Immunol. 21.2(2009): 101- 105.
Mechanical manipulation
Without wishing to be bound by theory, it is believed that mechanical manipulation of tissues, organs, and/or cells may enable spontaneous regeneration of the cells/tissue/organs, e.g., through remodeling event(s). See, e.g., Palomares et al. J. Orthop. Res. 27.9(2009): 1123-32; or Kang et al. Exp. Mol. Med. 43(2011):367-73, incorporated herein by reference. Accordingly, in certain aspects, a method described herein (e.g., ex vivo method) comprises one or more steps as described herein, where instead of, or in addition to, contacting a source cell with a thymic function modulator, the method comprises mechanical manipulation of the source cell(s). For example, the method comprises applying a force or stimulus, e.g., physical/mechanical force (e.g., stress), to the source cell, e.g., to generate/produce a cell having thymic structure/function (e.g., improved thymic structure/function compared to the source cell prior to the application of the force). In embodiments, the source cell can comprise a single cell or multiple cells, e.g.,
tissue and/or organ. In embodiments, the force comprises a shear force, a bending force, a stretching force, a compression force, and/or magnetic pulse(s). In embodiments, the force is applied cyclically. In embodiments, the force comprises cyclic strain, which can include repeatable tensile strain and/or cyclic compressive strain.
Thymic function factors
Functional characteristics of thymic function factors
Thymic function factors modulate thymic function and can be characterized by one or more properties described herein. A thymic function factor can itself be a thymic function modulator.
In embodiments, a thymic function factor is a positive regulator of thymic function (e.g., increases one or more activity of the thymus). In other embodiments, a thymic function factor is a negative regulator of thymic function (e.g., decreases one or more activity of the thymus). In embodiments, a thymic function factor can be both a positive and a negative regulator of thymic function. Exemplary positive and/or negative regulators of thymic function are listed in Table 1.
In embodiments, a thymic function factor increases the proliferation or cell count of stromal cells or non-adipocyte cells. Proliferation/cell count can be determined by proliferation assays, e.g., Ki67 staining or PCNA staining.
In embodiments, a thymic function factor changes the stromal/non-stromal cellular balance in the thymus. In embodiments, the stromal/non-stromal cellular balance is determined by a method such as ultrasound, histological analysis, or imaging (e.g., PET imaging, e.g., FDG avidity via PET imaging). In embodiments, a thymic function factor increases or decreases the stromal/non-stromal cellular balance, e.g., increases or decreases the ratio of thymic epithelial cells to thymocytes; or increases or decreases the ratio of adipocytes to thymocytes.
In embodiments, a thymic function factor increases the production and/or level of a thymic hormone. In embodiments, a thymic hormone is associated with the size of the thymus. An exemplary thymic hormone is thymulin. The level of a thymic hormone can be determined by an assay, e.g., a rosette inhibition assay, e.g., as described in Consolini et al. Haematologica 77.3(1992):243-47. In embodiments, a thymic function factor increases the level of a thymic hormone by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 2-fold, 4-fold, 6-fold, 8-fold, 10-fold, 15-fold, 20-fold, 30-fold, 40-fold, 50-
fold, 100-fold, 1000-fold, or more, e.g., relative to a reference level. In embodiments, a reference level is the level of the thymic hormone in a sample (e.g., a cell or tissue sample, e.g., from a subject) lacking the thymic function factor or a sample (e.g., a cell or tissue sample, e.g., from a subject) prior to addition/administration of the thymic function factor.
In embodiments, a thymic function factor modulates a T cell phenotype, e.g., a peripheral T cell phenotype. An exemplary peripheral T cell phenotype includes a thymic emigrant profile, e.g., percent of T cells that have unique T cell receptors (TCRs) (e.g., TCR diversity), percent of T cells that are FoxP3 positive, percent of T cells that are regulatory T cells (Tregs), percent of cells that are positive for a CD45RA isoform (e.g., CD45RA), percent of cells that are CD4 positive and CD25 positive, or percent of T cells that are cytotoxic T lymphocytes (CTLs). In embodiments, thymic emigrant profile can be determined by quantifying and/or comparing the levels of different T cell populations. In embodiments, a thymic function factor increases the number of Tregs (or percent of cells that are Tregs), e.g., thereby decreasing autoimmunity. In embodiments, a thymic function factor decreases the number of Tregs (or percent of cells that are Tregs), e.g., thereby decreasing the progression or severity of a cancer (e.g., decreasing the number of cancer cells.
In embodiments, a thymic function factor modulates the polyclonality of a B cell response. In embodiments, polyclonality of a B cell responses can be determined by measuring changes in B-cell isotype distribution, polyclonal antibody titers to an antigen, and/or polyclonal antibody titers to one or more thymus -dependent antigens. B-cell isotypes can be detected and/or quantified by assays such as flow cytometry, e.g., fluorescence activated cell sorting (FACS). Antibody titer can be measured by assays such as ELISAs, cytometric bead array, and other kits/methods. ELISAs are plate based assays to quantify soluble proteins, including immunoglobulins (see, e.g., Pathak et al.; 1997; Immunology Methods Manual, vol. 2. 1.
Lefkovitz, ed. Academic Press, Inc., San Diego, p. 1056-1075). Cytometric Bead Array (CBA) is a bead-based immunoassay that allows multiplexed quantitation of soluble and intracellular proteins including immunoglobulin and can be combined with further markers that are used for phenotyping (see, e.g., Morgan et al.; Clin Immunol. 2004). CBAs and ELISAs allow evaluation of immunoglobulin isotypes in serum, plasma or cell culture supernatants. Other methods, e.g., commercially available kits, are available in the art to perform individual isotype determination of secreted immunoglobulins. Populations of B cells can be quantified using FACS, as described
in Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol. 2008;20: 149-157. Also, high-throughput DNA sequencing allows determination of the antibody repertoire encoded by B cells in the blood or lymphoid organs and can be applied to detect B-cell malignancies with high sensitivity, to discover antibodies specific for antigens of interest, to guide vaccine development, and to understand autoimmunity (see, e.g., Georgiou et al. 2014. Nature Biotechnology). The detection limit is an estimated 1 in a million (see, e.g., Wu et al. 2014. Clin Cancer Res.).
In embodiments, a thymic function factor modulates thymocyte flux. Thymocyte flux can be determined by measuring the T-Cell Receptor Excision Circles (TRECs) per number of cells, e.g., over a period of time, e.g., over about 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, or more.
Exemplary thymic function factors are listed in Table 1. In embodiments, a thymic function factor is associated with, e.g., results in, one or more effects described in Table 1.
Structural characteristics of thymic function factors
In embodiments, a thymic function factor comprises a peptide, polypeptide, protein, or nucleic acid molecule (e.g., oligonucleotide, RNA, mRNA (e.g., modified or synthetic mRNA), DNA, or gene or gene fragment).
In embodiments, a thymic function factor comprises a ligand (e.g., secreted ligand, a non- secreted ligand (i.e., membrane-bound)), a transmembrane protein (e.g., receptor, e.g., cell surface receptor or nuclear receptor), or a nucleic acid molecule (e.g., gene, DNA, RNA, or mRNA) encoding same. Examples of a ligand (e.g., secreted ligand, a non-secreted ligand (i.e., membrane-bound)), a transmembrane protein (e.g., receptor, e.g., cell surface receptor or nuclear receptor), are shown in Table 1.
In embodiments, a thymic function factor comprises a hormone, a transcription factor, an enzyme (e.g., proteinase, protease, phosphatase), a chemokine, a cell matrix protein, cytoplasmic protein, or a nucleic acid molecule (e.g., gene, DNA, RNA, or mRNA) encoding same.
Examples of a hormone, a transcription factor, an enzyme (e.g., proteinase, protease,
phosphatase), a chemokine, a cell matrix protein, cytoplasmic protein are listed in Table 1.
In embodiments, a thymic function factor comprises a growth factor (e.g., T cell growth factor, thymic epithelial cell (TEC) growth factor, thymocyte growth factor, T cell subset specific growth factor (e.g., Tregs, naive T cells, or memory T cells), a growth factor receptor
(e.g., a T cell growth factor receptor, a TEC growth factor receptor, a proliferation factor (e.g., T cell proliferation factor, thymic epithelial cell (TEC) proliferation factor), cell migration factor (e.g., T cell migration factor), T cell activity factor, TEC function factor, and/or a thymus homeostasis factor, or a nucleic acid molecule (e.g., gene, DNA, RNA, or mRNA) encoding same.
In some embodiments, one or more thymic function factors, e.g., one, two, three, four, or five thymic function factors (e.g., a second, third, fourth, fifth or sixth thymic function factor) is administered to the subject. In one embodiment, the one or more of the thymic function factors are associated with increased or decreased activity level of a thymic function as described herein.
A T cell growth factor is involved in T cell development and/or maturation, e.g., involved in proliferation of thymocytes, commitment to T-cell lineage, and/or positive and/or negative selection of immune cells. Exemplary T cell growth factors include but are not limited to BMP4, Bmprla, CD70, Cldn4, DM, Egrl, Egr2, Egr3, EphB2, Flt3, Flt3L, Foxol, FoxP3, Gata2, Gata3, Gfil, Ghrl (ghrelin), GnRH, Icaml, Id3, Ifnarl, IL-2, IL-6, IL-7, IL-12b (IL12 p40 subunit), IL- 15, IL-18, IL-21, ΙΡΝγ, K , Klf3, Lefl, leptin, Lif, Nfat5, Nfatcl, Notch 1, Prolactin, Ragl, Rag2, Runxl, Satbl, SCF (K ), Shh (T-cell), Tcfl, TCR (any TCR variant), Tshb (thyrotropin beta chain), Tslp, Vcaml, Wnt3a, Wnt4, Zfp3611, and Zfp3612. Exemplary TCR variants include a TCR comprising an alpha and a beta chain, a TCR comprising a gamma chain and a delta chain, a TCR comprising a CD3 chain, a TCR comprising a zeta chain, a TCR comprising a complementarity determining region, and a TCR comprising a T cell co-receptor (e.g., CD4 or CD8). In embodiments, a TCR includes a TCR that binds to an epitope presented on an MHCI molecule, an epitope presented on an MHCII molecule, or an epitope presented on an MHCIII molecule.
In some embodiments, the T cell growth factor is selected from at least one of Flt3, Flt3L, Foxol, FoxP3, Gfil, Ghrl (ghrelin), GnRH, Icaml, Id3, Ifnarl, IL-2, IL-6, IL-7, IL-12b (IL12 p40 subunit), IL-15, IL-18, IL-21, KM, Klf3, Lefl, leptin, Lif, and SCF (KM). In some embodiments, the T cell growth factor is selected from at least one of IL-7, IL-21, Delta-like 4 (DLL4), Flt3L, SCF (Kitl), and miR-29a. In some embodiments, one or more the T cell growth factors, e.g., one, two, three, four, or five T cell growth factors (e.g., a second, third, fourth, fifth or sixth T cell growth factor) is administered to the subject. In some embodiments, the T cell
growth factor may also include at least one selected from IL-15, IL-2, IL-12, IL-18, and IFNy. Examples of a T cell growth factor are listed in Table 1.
A TEC growth factor is involved in TEC development, differentiation, and/or
proliferation. Exemplary TEC growth factors include but are not limited to Atf3, BMP4 (TEC), Cbx4, Cdh5 (VE cadherin), E2F3, E2F4, Foxnl, Fspl, Fstll, Ml, Kl (Klotho), Ltbr, NFkB l, PPARgamma, Pten, RANK, RANKL, Shh (TEC), Sin/Polr3e, Stat3, Tbata, Tbxl, Tgfbr2, Tnfrsfl la /RANK, Tnfrsf 1 lb, Traf6, Wnt3a (TEC), and Wnt4 (TEC). Examples of a TEC growth factor are listed in Table 1. In some embodiments, the TEC growth factor enhances thymus function by modulating, e.g., increasing, e.g., enhancing, proliferation, survival and/or generation of thymic epithelial cells. In some embodiments, the TEC growth factor is selected from at least one of FGF21, FGF7 (KGF), FGF8, FGF10, IL-22, Wnt4, Bmp4, RANKL, LTa, CL40L, Foxnl, leptin, IGF-1, GH, (Ghrl) ghrelin, GnRH, and NGF. In some embodiments, one or more the TEC growth factors, e.g., one, two, three, four, or five TEC growth factors (e.g., a second, third, fourth, fifth or sixth TEC growth factor) is administered to the subject.
A T cell growth factor receptor binds to (e.g., is a receptor for) a T cell growth factor. Exemplary T cell growth factor receptors include but are not limited to CD 127 (non-soluble IL- 7R), CD27, Crlf2 (TSLP-R), Fzdl, FzdlO, Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7, Fzd8, Fzd9, Ihh, IL-7R alpha, Ptchl, and Ptch2. Examples of a T cell growth factor receptor are listed in Table 1.
A TEC growth factor receptor binds to (e.g., is a receptor for) a TEC growth factor. Exemplary TEC growth factor receptors include but are not limited to Bmpr2, Fgfr2, and bmprla (TEC). Examples of a TEC growth factor receptor are listed in Table 1.
A T cell migration factor is involved in early thymic progenitor (ETP) homing, thymocyte migration within the thymus, and/or T-cell export. ETPs are a population of cells comprising about 0.01% of total thymocytes; they are the more immature T-cell precursors in the thymus and can expand to repopulate thymocyte populations, e.g., after intrathymic transfer. In embodiments, ETPs have the following phenotype: linlowCD44+cKithighCD25". Without wishing to be bound by theory, it is believed that one or more factors are involved in Treg egress and migration. For example, one factor that may be required for Treg thymic egress is sphingosine-1 phosphate receptor- 1 (S 1P1). It is believed that mature thymocytes follow a S 1P1 gradient, secreted at least in part by the pericytes surrounding the blood vessels at the thymic
corticomedullary junction (CMJ). S 1P1 expression in thymocytes is believed to be regulated by
KLF2. In some examples, factors believed to be involved in Treg migration (e.g., into tissues and/or tumors) include CCL20 (e.g., which binds to CCR6 receptor expressed on Tregs), CCR6, CXCLl-3 (e.g., which binds to CXCR2 receptor expressed on Tregs), CXCR2, IL8 (e.g., which binds to CXCR1 receptor expressed on Tregs), CXCR1, CCL2, CCL4, CCL5, CCL22, CXCL8, and CXCL10. Exemplary T cell migration factors include but are not limited to CC119, Ccl21, CCL25, Ccr7, Ccr9, Cxcll2, Cxcr4, S 1PR1 (S 1P1), Sele (E-selectin, CD62E, ELAM-1, or LECAM2), Sell (CD62L), Selp (P-selectin), CCL20, CCR6, CXCLl-3, CXCR2, IL8, CXCR1, CCL2, CCL4, CCL5, CCL22, CXCL8, and CXCL10. In some embodiments, one or more the T cell migration factors, e.g., one, two, three, four, or five T cell migration factors (e.g., a second, third, fourth, fifth or sixth T cell migration factor) is administered to the subject. Examples of a T cell migration factor are listed in Table 1.
A T cell activity factor is involved in T cell function. An exemplary T cell activity factor includes E2F2. In some embodiments, one or more the T cell activity factors, e.g., one, two, three, four, or five T cell activity factors (e.g., a second, third, fourth, fifth or sixth T cell activity factor) is administered to the subject. Examples of a T cell activity factor are listed in Table 1. Assessment of T cell function is described in greater detail in the "T cell function section" herein.
A TEC proliferation factor is involved in TEC proliferation, e.g., in an adult thymus. Exemplary TEC proliferation factors include but are not limited to Cyr61, E2F2 (TEC), IGF-1, IL-22, IL-23, and KGF (Fgf7). In some embodiments, one or more the TEC proliferation factors, e.g., one, two, three, four, or five TEC proliferation factors (e.g., a second, third, fourth, fifth or sixth TEC proliferation factor) is administered to the subject. Examples of a TEC proliferation factor are listed in Table 1.
A thymic function factor is involved in one or more TEC functions. Exemplary TEC function factors include but are not limited to AIRE, beta(5t)/Psmbl l, Fezf2, HLA (e.g., any HLA variant/polymorph, e.g., HLA-A, HLA-B, HLA-B27, HLA-B47, HLA-C, HLA-E, HLA-F, HLA-G, p2-microglobulin, HLA-DM (e.g., HLA-DMA1 and/or HLA-DMB 1), HLA-DO (e.g., HLA-DOA1 and/or HLA-DOB 1), HLA-DP (e.g, HLA-DPA1 and/or HLA-DPB 1), HLA-DQ (e.g., HLA-DQA1 and/or HLA-DQB 1), HLA-DQ2, HLA-DQ8, HLA-DR (e.g., HLA-DRA, HLA-DRB l, HLA-DRB3, HLA-DRB4, and/or HLA-DRB5), HLA-DR2, HLA-DR3, HLA-DR4, and/or an HLA encoding a component of the complement system), a Major Histocompatibility
Complex (MHC) molecule (e.g., Class I MHC molecule (MHC I), e.g., comprising one or more polypeptides encoded by a HLA-A, HLA-B, HLA-C, HLA-G, and/or HLA-E gene; Class II MHC molecule (MHC II), e.g., comprising one or more polypeptides encoded by a HLA-DP, HLA-DQ, and/or HLA-DR gene; or Class III MHC molecule (MHC III), e.g., comprising a polypeptide involved in inflammation, e.g., a component of the complement system (e.g., C2, C4, or factor B), tumor necrosis factor (TNF)-a, lymphotoxin-a, lymphotoxin-β, or a heat shock protein), and Prssl6. Examples of a TEC function factor are listed in Table 1.
In embodiments, an HLA comprises a HLA Class I allele (e.g., HLA-A, -B, -C, -E, -F, or -G allele), a HLA Class I Pseudogene (e.g., HLA-H, -J, -K, -L, -P, -T, -U, -V, -W, -X, or -Y), HLA Class II allele (e.g., HLA-DRA, -DRB, -DQA1, -DQB 1, -DPA1, -DPB 1, -DPB2, -DMA, - DMB, -DOA, -DOB), or HLA Class II DRB allele (e.g., HLA-DRB 1, -DRB2, -DRB 3, -DRB4, - DRB 5, -DRB6, -DRB7, -DRB 8, -DRB 9). In embodiments, an HLA Class I allele comprises an HLA Class I allele described at http://hla.alleles.org/alleles/classl.html (accessed as of June 9, 2016), incorporated herein by reference. In embodiments, an HLA comprises an HLA Class II allele described at http://hla.alleles.org/alleles/class2.html (accessed as of June 9, 2016), incorporated herein by reference.
A thymus homeostasis factor is involved in homeostatic maintenance of the thymus. Exemplary thymus homeostasis factors include but are not limited to l lb-HSD2, AR, ASC, Axin, Fgf21, IL10, IL2 (stroma), Leptin (TEC), Meisl, and NLRP3. In some embodiments, one or more the thymus homeostasis factors, e.g., one, two, three, four, or five thymus homeostasis factors (e.g., a second, third, fourth, fifth or sixth thymus homeostasis factor) is administered to the subject. Examples of a thymus homeostasis factor are listed in Table 1.
Additional exemplary thymic function factors include Cd44, gpl30, hGH (GH1 and GH2), Nfkb2, Ptma (thymosin alpha- 1), Smad4, Smad6, and Tmpo (thymopoetin), e.g., as described in Table 1.
Exemplary thymic function factors include but are not limited to those described in Table 1. The thymic function factors listed in Table 1 can include the nucleic acid molecule (DNA or RNA, e.g., mRNA) or polypeptide (e.g., translated protein). In embodiments, a thymic function factor comprises a polypeptide/protein or nucleic acid molecule homologous to a thymic function factor described herein, e.g., in Table 1. In embodiments, a thymic function factor comprises an amino acid sequence or nucleic acid sequence that is substantially identity to, e.g., having at least
60% (e.g., at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99%, or more, e.g., 100%) identity to the amino acid sequence or nucleic acid sequence of a thymic function factor described herein, e.g., in Table 1.
Table 1 : Amino acid sequences or nucleic acid sequences of thymic function factors
NM_001302825,
NM_001302824,
NM_001302823,
NM_001302822, hormone, NM_001302821. T-cell proliferation, secreted, NM_001134941, increased ETPs, encodes NM_016362, restoration of thymic ghrelin- NM_001134946, architecure, t-cell obestatin NM_001134945, increased thymus growth preproprotei
Ghrl Ghrelin NM 001134944 Pos factor n
NM_172175, t-cell
NM_000585, growth ligand,
IL-15 NR 037840 Pos thymoctye survival factor secreted t-cell
component of IL7R growth
same as IL7R and TSLP receptor factor
IL-7Ralpha (CD 127) Pos complex receptor receptor
proliferation of
TECs, activaiton of TEC ligand,
Cyr61 NM_001554 Pos AKT signalling proliferation secreted involved in
premature ageing
increased IL7 TEC growth
Kl (Klotho) NM_004795 Pos expression factor enzyme
ligand, secreted and t-cell non-
NM_000899, ETP survival and growth secreted
Kit! NM_003994 Pos proliferation factor forms t-cell
T-cell lineage growth ligand,
D114 NM 019074 Pos commitment factor secreted master regulator of TEC growth transcription
Foxnl NM 003593 Pos TECs factor factor expansion of ETPs t-cell
and immature growth ligand,
Wnt4 NM 030761 Pos thymocyte factor secreted
TEC proliferation,
Wnt4 potential Foxnl TEC growth ligand, (TEC) NM 030761 Pos regulation factor secreted
NM_001270987, mTEC development TEC growth
Ltbr NM_002342 Pos and function factor receptor
NM_001277990,
NM_000609,
NM_001 178134,
NM_199168, t-cell chemokine,
Cxcll2 NM 001033886 Pos chemokine migration secreted decoy receptor for
RANKL, mTEC TEC growth
Tnfrsf 1 lb NM 002546 Neg homeostasis factor receptor
NM_001278268,
NM_003839,
NM_001270950,
Tnfrsfl la/ NM_001270949, increase in mTEC TEC growth
RANK NM_001270951 Pos numbers factor receptor positive selection t-cell
(TCR costimulatory growth
Cldn4 NM_001305 Pos activity) factor receptor survival and
proliferation of early
NM_001127216, thymocyte, control t-cell
NM_001127215, of Treg growth transcription
Gfil NM_005263 Pos differentiation factor factor t-cell
deletion of growth
If nai l NM_000629 Pos autoreactive T cells factor receptor
E2F2 TEC transcription (TEC) NM_004091 Pos TEC proliferation proliferation factor neg regulator of
peripheral T-cell
proliferation and t-cell transcription
E2F2 NM_004091 Neg/Pos autoimmunity activity factor
TEC growth transcription
E2F4 NM_001950 Neg repressor of Foxnl factor factor
NM_001949, activator of Foxnl TEC growth transcription
E2F3 NM_001243076 Pos expression factor factor
NM_213662,
NM_003150, mTEC development TEC growth transcription
Stat3 NM_139276 Pos and homeostasis factor factor
VE TEC growth
Cdh5 cadherin NM_001795 Pos factor receptor
TEC growth
Bmprla BMP4/2 receptor, factor recept
(TEC) NM_004329 Pos thymus size or receptor thymocyte
homeostasis (neg t-cell
regulation of growth
Bmprl a NM_004329 Neg proliferation) factor receptor possible role in TEC TEC growth transcription
Ml NM_002202 Pos differentiation factor factor
TEC growth
factor
Bmpr2 NM_001204 Pos BMP receptor receptor receptor block in HSC
NM_001145662, differentiation t-cell
NM_001145661, towards lymphoid growth transcription
Gata2 NMJB2638 Neg lineage factor factor
Bmp4 antagonists,
proinflamatory TEC growth
Fstll NM_007085 molecule factor secreted progression through
beta selection, t-cell
positive selection, growth transcription
Egrl NM_001964 Pos thymocyte survival factor factor
NM_001 199881, t-cell
NM_001 199880, overlapping growth transcription
Egr3 NM_004430 Pos functions with Egrl factor factor
NM_001321037,
NM_001 136178, DP to SP and NKT
NM_000399, cell, some t-cell
NM_001 136179, overlapping function growth transcription
Egr2 NM_001 136177 Pos with Egrl/3 factor factor
NM_001030287,
NM_001674,
NM_001040619,
NM_001206484,
NM_001206488, null show decreased TEC growth transcription
Atf3 NM_001206486 Neg involution phenotype factor factor t-cell
growth transcription
K1G NM_016531 Pos positive selection factor factor
T-cell lineage t-cell
NM_001002295, commitment and growth transcription
Gata3 NM_002051 Pos development factor factor
NM_001 195470,
NM_001131010,
NM_002971,
NM_001322876,
NM_001322875,
NM_001322874, positive selection,
NM_001322873, Treg numbers and t-cell
NM_001322872, function, negative growth matrix
Satbl NM_001322871 Pos selection factor protein
NM_016269,
NM_001 1661 19, NKT development, t-cell
NM_001 130714, TCRalpha growth transcription
Lefl NM_001 130713 Pos expression factor factor t-cell
NM_001306179, growth transcription
Tcfl NM_000545 Pos T-cell specification factor factor same as TEC growth
RANK Tnfrsfl la Pos mTEC development factor receptor mTEC development ligand,
NM_033012, through RANK TEC growth membrane
RANKL NM_003701 Pos signaling factor bound
NM_138711, overexpression nuclear NM_015869, copies thymic receptor,
PPARgam NM_138712, involution, involved TEC growth transcription ma NM_005037 Neg in adipogenesis factor factor
TEC transcription
AIRE NM_000383 Pos TRA expression function factor
TRA expression
(separate from TEC transcription
Fezf2 NM_018008 Pos AIRE) function factor
HLA (e.g.,
any
variant/poly TEC
morph) function receptor
MHC I/II
and all
known TEC
alleles function receptor ligand, anderson, t-cell membrane proliferation of DN growth bound or
SCF Kitl same as Kitl Pos thymocytes factor secreted
NM_001201359, anderson, ETP t-cell
CCL25 NM_005624 Pos attractiong migration chemokine t-cell
NM_001114377, growth transcription
FoxP3 NM_014009 Pos Treg development factor factor t-cell
TCR (any growth
variant) factor receptor
NM_001278675,
NM_172390,
NM_001278673,
NM_172388,
NM_001278672,
NM_001278670,
NM_172389,
NM_172387, t-cell
NM_006162, beta selection, DN to growth transcription
Nfatcl NM_001278669 Pos SP factor factor
NM_001113178,
NM_006599,
NM_138714,
NM_138713, thymocyte survival t-cell
NM_173214, and transition from growth transcription
Nfat5 NM_173215 Pos beta selection to DP factor factor
NM_001165412, mTEC
NM_003998, differentiation and TEC growth transcription
Nfkbl NM_001319226 Pos function factor factor
NM_002502,
NM_001261403,
NM_001077494, required for normal
NM_001288724, negative selection of transcription
Nfkb2 NM_001322934 Pos CD8+ T-cell factor t-cell
beta selection, growth transcription
Id3 NM_002167 Pos positive selection factor factor
Treg function, iTreg
induction and
function,
homeostasis and life t-cell
span of naive T cells, growth transcription
Foxol NM_002015 Pos thymocyte factor factor
survival/proliferation beta(5t)/Ps TEC enzyme mbl l NM_001099780 Pos antigen presentation function (proteinase)
NM_001079821,
NM_001243133,
NM_001127461,
NM_001127462,
NM_004895, reduced thymic thymus
NLRP3 NM_183395 Neg involution in null homeostasis receptor
NM_145182, thymus
ASC NM_013258 Neg similar to Nlrp3 homeostasis cytoplasmic involved in
adipogenesis of
thymus,
overexpression
NM_181050, promotes thymocyte thymus
Axin NM_003502 Neg apoptosis homeostasis cytoplasmic thymocyte
proliferation,
protects against t-cell
NM_001083111, thymic involution in growth hormone,
GnRH NM_000825 Pos case of insult factor secreted protection against
stress induced TEC
damage (particularly
Leptin mTEC), increased thymus hormone, (TEC) NM_000230 Pos IL7 expression homeostasis secreted
DN proliferation,
protection of DP
against endotoximia
induced apoptosis, t-cell
naive T cell growth hormone,
Leptin NM_000230 Pos proliferation factor secreted
NM_000515,
NM_022560,
NM_022559,
NM_022558, restoration of HSCs
NM_022557, in bone marrow,
hGH (GH1 NM_022556, thymus recovery hormone, and GH2) NM_002059 Pos after insult secreted thymocyte
development and
proliferation, t-cell
NM_021803, accelerated thymic growth ligand,
IL21 NM_001207006 Pos recovery post GC factor secreted thymocyte survival
and proliferation; t-cell
NM_001163558, counteracts growth hormone,
Prolactin NM_000948 pos glucocorticoid factor secreted
Thyrotrop activates calcium t-cell
in (beta NM_001277991, signaling and growth hormone,
Tshb chain) NM_000549 pos cyclicAMP signaling factor secreted
downregulation of
D114 (and IL7,
Ccl25), thymocyte
survival (mediated
through TECs), TEC
NM_000044, proliferation (non thymus
AR NM_001011645 Neg cell autonomous) homeostasis receptor
NM_001244701, role in beta selection t-cell
NM_001244698, and regulation of growth transcription
Zfp3611 NM_004926 Pos Notch 1 mRNA factor factor role in beta selection t-cell
and regulation of growth transcription
Zfp3612 NM_006887 Pos Notch 1 mRNA factor factor required for T-cell t-cell
lineage commitment growth
Notch 1 NM_017617 Pos and differentiation factor receptor
NM_001318243,
NM_001318243, ligand, NM_152710, TEC proliferation TEC growth membrane
Tbata NM_001318241 Neg and function factor bound reduction in thymic ligand, glucocorticoid thymus membrane l lb-HSD2 NM_000196 Pos expression homeostasis bound
NM_003276,
NM_001307975,
thymopeot NM_001032284,
Tmpo in NM_001032283 induction of CD90 enzyme
T-cell proliferation
and funciton (in
periphery and
tissues), HLA-DR
thymosin NM_001099285, expression in human hormone,
Ptma alpha- 1 NM_002823 Pos APCs secreted thymus cellularity,
NM_000314, architecture, enzyme NM_001304717, decreased thymocyte TEC growth (phosphatas
Pten NM_001304718 pos numbers, factor e)
NM_000193,
NR_132319, TEC development, (- NR_132318, ve) modulation of TEC growth ligand,
Shh (TEC) NM_001310462 pos MHCII expression factor secreted expansion and
differentiation of
NM_000193, DN; neg regulation
NR_132319, of pre-TCR t-cell
Shh (T- NR_132318, dependent DN growth ligand, cell) NM_001310462 mixed differentiation to DP factor secreted
TEC enzyme
Prssl6 NM_005865 Pos antigen presentation function (protease) mTEC
differentiation,
NM_004620, thymic DC TEC growth
Traf6 NM_145803 pos differentiation factor enzyme
dendritic cell
activity, T cell
development,
NM_138551, thymocyte t-cell
NM_033035, progenitor and T-cell growth ligand,
Tslp NR_045089 Pos proliferation factor secreted thymocyte
proliferation and
differentiation,
deletion of t-cell
autoreactive ClassII growth ligand,
IL2 NM_000586 pos restricted thymocytes factor secreted possible role in
maintenance of
thymic
IL2 monocyte/macropha thymus ligand,
(storma) NM_000586 pos ges and cTEC homeostasis secreted differentiation of
CDl lb+ DCs from
DN thymocytes,
functions together
with IL2 and IL12 - t-cell
NM_001562, phenotypic change in growth ligand,
IL18 NM_001243211 pos thymocyte factor secreted anti-ageing effect on thymus ligand,
Fgf21 NM_019113 pos thymus homeostasis secreted
NM_019554, proliferation and TEC growth
Fspl NM_002961 pos maturation of TECs factor cytoplasmic
NM_001258036,
NM_001258035,
NM_001258034,
NM_001258033,
NM_018119, mTEC development TEC growth
Sin/Polr3e NR_047581 pos and maintenance factor enzyme
NM_080647, negative regulation
NM_080646, of Foxnl TEC growth transcription
Tbxl NM_005992 neg transcription factor factor deletion leads to transcription
Smad4 NM_005359 Pos thymus hypoplasia factor mTEC proliferation
and compartment
NM_003242, size, Treg TEC growth
Tgfbr2 NM_001024847 neg development factor receptor required for
thymocyte
proliferation (at
physiological levels), t-cell
NM_000600, causes loss of DP at growth ligand,
IL6 NM_001318095 Pos/Neg higher levels factor secreted required for
thymocyte
proliferation (at
physiological levels), t-cell
NM_002309, causes loss of DP at growth ligand,
Lif NM_001257135 neg higher levels factor secreted
NM_001190981,
NM_175767,
NM_002184, mediator of IL6,
gpl30 NR_120480 neg LPS, Lif activities receptor protection against
stress induced TEC thymus ligand,
IL10 NM_000572 Pos damage homeostasis secreted
NM_001001890, t-cell
NM_001754, IL7R expression, growth transcription
Runxl NM_001122607 Pos thymocyte survival factor factor
T-cell progenitor and
NM_001309193, thymocyte migration,
NM_001309192, differentiation and t-cell
NM_017449, interaction with growth
EphB2 NM_004442 Pos TECs factor receptor
TEC proliferation TEC growth
Cbx4 NM_003655 Pos and function factor enzyme t-cell
Ccl21 NM_002989 Pos chemokine migration chemokine positive selection
(costimulation and
thymocyte survival), t-cell ligand, thymocyte numbers growth membrane
Icaml NM_000201 Pos and proportion factor bound
NM_001199834, t-cell ligand,
NM_001078, growth membrane
Vcaml NM_080682 Pos positive selection factor bound neg regulator of
NM_005585, BMP and TGFbeta transcription
Smad6 NR_027654, signaling factor expressed in
progenitor-like TECs
in adult thymus,
important for thymus transcription
Meisl NM_002398 Pos homeostasis homeostasis factor temporarily required
during thymocyte
development for t-cell
TCR gene growth
Ragl NM_000448 Pos rearrangement factor enzyme temporarily required
during thymocyte
NM_001243786, development for t-cell
NM_001243785, TCR gene growth
Rag2 NM_000536 Pos rearrangement factor enzyme recruitment and entry
of hematopoietic t-cell
Selp P-selectin NM_003005 Pos progenitors migration receptor
E-selectin,
CD62E, recruitment and entry
ELAM-1, of hematopoietic t-cell
Sele LECAM2 NM_000450 Pos progenitors migration receptor
NM_000655, export of naive T- t-cell
Sell CD62L NR_029467 Pos cells, naive T-cells migration receptor
trafficking to
secondary lymphoid
organ
recruitment and entry
of hematopoietic
NM_031200, progenitors; DN-DP
NM_006641, transition; CD4 t-cell
Ccr9 NM_001256369 Pos differentiation migration receptor
NM_001001389,
NM_000610,
NM_001202556,
NM_001202555,
NM_001001392,
NM_001001391,
NM_001001390,
Cd44 NM_001202557 Pos receptor t-cell
NM_004119, growth
Flt3 NR_130706 Pos receptor for Flt3L factor receptor receptor for Cxcll2,
seeding of
NM_003467, progenitors to t-cell
Cxcr4 NM_001008540\ Pos thymus migration receptor migration to outer
cortex and from t-cell ligand,
Ccll9 NM_006274 Pos cortex to medulla migration secreted
NM_001301718,
NM_001301717,
NM_001301716,
NM_001301714, receptor for Cell 9 t-cell
Ccr7 NM_001838 Pos and Ccl21 migration receptor
NM_001320730, t-cell
S1PR1 S 1P1 NM_001400 Pos ETP export migration receptor
NM_000141,
NM_023029,
NM_001144918,
NM_001144916,
NM_022970,
NM_001144917,
NM_001144914,
NM_001144915,
NM_001144913,
NM_001144919, TEC growth
NM_001320658, Fgf7 and FgflO factor
Fgfr2 NM_001320654 Pos receptor receptor receptor t-cell
early stages of T-cell growth ligand,
Wnt3a NM_033131 Pos development factor secreted
Wnt3a TEC growth ligand,
(TEC) NM_033131 Pos TEC development factor secreted t-cell
growth
Fzdl NM_003505 Pos Wnt receptor factor receptor
receptor t-cell
growth
factor
Fzd2 NM_001466 Pos Wnt receptor receptor receptor t-cell
growth
NM_017412, factor
Fzd3 NM_145866 Pos Wnt receptor receptor receptor t-cell
growth
factor
Fzd4 NM_012193 Pos Wnt receptor receptor receptor t-cell
growth
factor
Fzd5 NM_003468 Pos Wnt receptor receptor receptor
NM_001317796,
NR_133921, t-cell
NM_001164616, growth
NM_001164661 factor
Fzd6 5, NM_003506 Pos Wnt receptor receptor receptor t-cell
growth
factor
Fzd7 NM_003507 Pos Wnt receptor receptor receptor t-cell
growth
factor
Fzd8 NM_031866 Pos Wnt receptor receptor receptor t-cell
growth
factor
Fzd9 NM_003508 Pos Wnt receptor receptor receptor t-cell
growth
factor
FzdlO NM_007197 Pos Wnt receptor receptor receptor promoting
thymopoiesis before t-cell
pre-TCR signalling growth
but negatively factor ligand,
Ihh NM_002181 Pos/Neg regulating later steps receptor secreted
NM_000264,
NM_001083602,
NM_001083604,
NM_001083605, t-cell
NM_001083607, receptor for growth
NM_001083606, hedgehog signalling factor
Ptchl NM_001083603 Pos ligands receptor receptor
NM_001166292, receptor for t-cell
Ptch2 NM_003738 Pos hedgehog signalling growth receptor
ligands factor
receptor
thymocyte t-cell
development and growth
differentiation, Treg factor
CD27 NM_001242 Pos survival receptor receptor thymocyte
development and t-cell ligand, differentiation, Treg growth membrane
CD70 NM_001252 Pos survival factor bound dendritic cell
activity, T cell
development, t-cell
NM_001012288, thymocyte growth
NM_022148, progenitor and T-cell factor
Crlf2 TSLP-R NR_110830 Pos proliferation receptor receptor
Assays to measure expression (level) of thymic function factors
The expression or level of a thymic function factor can refer to the level of mRNA or protein.
The level, e.g., mRNA level, of a thymic function factor can be determined by a number of assays, e.g., Northern blots, PCR, RT-PCR, or fluorescence in situ hybridization. The level, e.g., protein level, of a thymic function factor can be determined by a number of assays, e.g., Western blot, mass spectrometry (MS), liquid chromatography (LC) (e.g., LC-MS), ELISA, or histological methods (e.g., immunohistochemistry).
In embodiments, the level of a thymic function factor is determined in a sample, e.g., a sample from a subject. The sample can comprise a cell or tissue sample. In embodiments, the sample comprises a blood, serum, urine, or tissue (e.g., biopsy) sample.
Assays to measure activity of thymic function factors
The activity of a thymic function factor can include one or more of the effects listed in Table 1, corresponding to each thymic function factor. In embodiments, the activity of an enzyme thymic function factor is determined using an assay for catalytic activity of the enzyme. In embodiments, the activity of a non-enzyme thymic function factor can be determined by assessing a downstream effect of the factor. For example, if the thymic function factor is in a signaling pathway that leads to the increase or decrease of a particular molecule, e.g., polypeptide, nucleic acid, or metabolite, the activity of the factor can be measured by measuring the level of the particular molecule.
Thymic function modulators
Functions of thymic function modulators
Thymic function modulators are used in the methods (e.g., therapeutic methods or ex- vivo culture methods) described herein. In embodiments, a thymic function modulator modulates, e.g., increases or decreases, a thymic function (e.g., in vivo or ex vivo). For example, a thymic function modulator improves a thymus function, e.g., a thymus function described herein, e.g., one or more of: increases the number of T cells in a subject; increases the number and/or relative ratio of a T cell subset (e.g., Tregs, CD4 positive T cells, and/or CD8 positive T cells) in a subject, improves a T cell function in a subject; and/or increases T cell migration in a subject. In embodiments, a thymic function modulator modulates the function of dendritic cells associated with thymus tissue (e.g., modulates antigen presentation of a dendritic cell, modulates the inflammatory properties of a dendritic cell, and/or modulates the cytokines secreted by a dendritic cell). In embodiments, a thymic function modulator modulates, e.g., increases or decreases, the level and/or activity of a thymic function factor, e.g., a thymic function factor described herein, e.g., in Table 1. In embodiments, a thymic function modulator results in one or more effects listed in Table 1.
In embodiments, a thymic function modulator modulates one or more thymic function factors, e.g., one or more thymic function factors described herein, e.g., in Table 1. In embodiments, a thymic function modulator modulates the level and/or activity of a thymic function factor selected from a T cell growth factor, T cell growth factor receptor, T cell migration factor, T cell activity factor, TEC proliferation factor, TEC growth factor, TEC growth factor receptor, TEC function factor, or thymus homeostasis factor, e.g., as described in Table 1. In embodiments, a thymic function modulator modulates the level and/or activity of a thymic function factor selected from a chemokine, cytoplasmic protein, enzyme (e.g., phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, receptor (e.g., cell surface receptor or nuclear receptor), or transcription factor, e.g., as described in Table 1.
In some embodiments, one or more thymic function modulators, e.g., one, two, three, four, or five thymic function modulators (e.g., a second, third, fourth, fifth or sixth thymic function modulator) is administered to the subject. In one embodiment, administration of one or
more of the thymic function modulators increases or decreases expression of or activity level of a thymic function factor, e.g., a T cell growth factor, a T cell growth factor receptor, a T cell proliferation factor, a T cell migration factor, a T cell activity factor, a TEC proliferation factor, a TEC growth factor, a TEC growth factor receptor, a TEC function factor, or a thymus homeostasis factor.
In embodiments, a thymic function modulator increases the level and/or activity of a thymic function factor (e.g., a positive regulator of thymic function, e.g., described in Table 1) by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2- fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, increased as compared to a reference expression or activity level of the one or more thymic function factors. In
embodiments, a thymic function modulator decreases the level and/or activity of a thymic function factor (e.g., a negative regulator of thymic function, e.g., described in Table 1) by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold, decreased as compared to a reference expression or activity level of the one or more thymic function factors. In one embodiment, the reference expression or activity level is the expression or activity level of the one or more thymic function factors prior to administration of the thymic function modulator.
In embodiments, a thymic function modulator can be itself a thymic function factor described herein, e.g., in Table 1.
In embodiments, a thymic function modulator comprises a polypeptide/protein or nucleic acid molecule homologous to a thymic function modulator described herein, e.g., in Table 1. In embodiments, a thymic function modulator comprises an amino acid sequence or nucleic acid sequence that is substantially identity to, e.g., having at least 60% (e.g., at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99%, or more, e.g., 100%) identity to the amino acid sequence or nucleic acid sequence of a thymic function modulator described herein, e.g., in Table 1.
Structural characteristics of thymic function modulators
A thymic function modulator can comprise a number of different modalities. In embodiments, a thymic function modulator comprises a nucleic acid molecule (e.g., DNA molecule or RNA molecule, e.g., mRNA, guide RNA (gRNA), or inhibitory RNA molecule (e.g., siRNA, shRNA, or miRNA), or a hybrid DNA-RNA molecule), a small molecule, a
peptide, or a polypeptide (e.g., an antibody molecule, e.g., an antibody or antigen binding fragment thereof). In embodiments, the nucleic acid molecule, peptide, polypeptide, or antibody molecule can be modified. For example, the modification can be a chemical modification, e.g., conjugation to a marker, e.g., fluorescent marker or a radioactive marker. In other examples, the modification can include conjugation to a molecule that enhances the stability of the thymic function modulator (e.g., stability in vivo and/or in cell/tissue culture).
Polypeptides
In embodiments, a thymic function modulator described herein comprises a thymic function factor polypeptide or functional fragment or derivative thereof. In embodiments, a thymic function modulator is a polypeptide listed in Table 1, wherein the primary sequence of the thymic function modulator is provided by reference to accession number. Methods of making a therapeutic polypeptide are routine in the art. See, in general, Smales & James (Eds.), Therapeutic Proteins: Methods and Protocols (Methods in Molecular Biology), Humana Press (2005); and Crommelin, Sindelar & Meibohm (Eds.), Pharmaceutical Biotechnology:
Fundamentals and Applications, Springer (2013).
Preferred methods for producing a thymic function modulator polypeptide involve expression in mammalian cells, although recombinant proteins can also be produced using insect cells, yeast, bacteria, or other cells under the control of appropriate promoters. Mammalian expression vectors may comprise nontranscribed elements such as an origin of replication, a suitable promoter and enhancer, and other 5' or 3' flanking nontranscribed sequences, and 5' or 3' nontranslated sequences such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and termination sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the other genetic elements required for expression of a heterologous DNA sequence. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described in Green & Sambrook, Molecular Cloning: A Laboratory Manual (Fourth Edition), Cold Spring Harbor Laboratory Press (2012).
Various mammalian cell culture systems can be employed to express and manufacture recombinant protein. Examples of mammalian expression systems include CHO cells, COS cells, HeLA and BHK cell lines. Processes of host cell culture for production of protein therapeutics
are described in Zhou and Kantardjieff (Eds.), Mammalian Cell Cultures for Biologies
Manufacturing (Advances in Biochemical Engineering/Biotechnology), Springer (2014).
Purification of protein therapeutics is described in Franks, Protein Biotechnology:
Isolation, Characterization, and Stabilization, Humana Press (2013); and in Cutler, Protein Purification Protocols (Methods in Molecular Biology), Humana Press (2010).
Formulation of protein therapeutics is described in Meyer (Ed.), Therapeutic Protein Drug Products: Practical Approaches to formulation in the Laboratory, Manufacturing, and the Clinic, Woodhead Publishing Series (2012).
Antibodies
In embodiments, the thymic function modulator is an antibody or antigen binding fragment thereof. The making and use of therapeutic antibodies against a target antigen (e.g., a thymic function factor described herein) is known in the art. See, for example, the refernces cited hereinabove, as well as Zhiqiang An (Editor), Therapeutic Monoclonal Antibodies: From Bench to Clinic. 1st Edition. Wiley (2009) and Greenfield (Ed.), Antibodies: A Laboratory Manual. 2d ed. Spring Harbor Laboratory Press (2013) for methods of making recombinant antibodies, including antibody engineering, use of degenerate oligonucleotides, 5'-RACE, phage display, and mutagenesis; antibody testing and characterization; antibody pharmacokinetics and pharmacodynamics; antibody purification and storage; and screening and labeling techniques.
Modified mRNA
In embodiments, the thymic function modulator comprises an mRNA molecule, e.g., a modified mRNA molecule encoding a thymic function factor. In embodiments, the mRNA molecule increases the level (e.g., protein and/or mRNA level) and/or activity of a thymic function factor, e.g., a positive regulator of thymus function. In embodiments, the mRNA molecule encodes a thymic function factor or a fragment thereof. For example, the mRNA molecule encodes a polypeptide having at least 50% (e.g., at least 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, or greater) identity to the amino acid sequence of a thymic function factor listed in Table 1. In other examples, the mRNA molecule has at least 50% (e.g., at least 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, or greater) identity to the nucleic acid sequence of a thymic function factor listed in Table 1. In embodiments, the mRNA molecule encodes an amino acid
sequence differing by no more than 30 (e.g., no more than 30, 20, 10, 5, 4, 3, 2, or 1) amino acids to the amino acid sequence of a thymic function factor listed in Table 1. In some embodiments, the mRNA molecule comprises a fragment of a thymic function factor listed in Table 1. For example, the fragment comprises 10-20, 20-40, 40-60, 60-80, 80-100, 100-120, 120-140, 140- 160, 160-180, 180-200, 200-250, 250-300, 300-400, 400-500, 500-600, or more amino acids in length. In embodiments, the fragment is a functional fragment, e.g., having at least 20%, e.g., at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or greater, of an activity of a full length thymic function factor listed in Table 1. In embodiments, the mRNA molecule increases the level and/or activity of or encodes a thymic function factor (or fragment thereof) that is a positive regulator of thymus function.
The mRNA molecule can be modified, e.g., chemically. The mRNA molecule can be chemically synthesized or transcribed in vitro. The mRNA molecule can be disposed on a plasmid, e.g., a viral vector, bacterial vector, or eukaryotic expression vector. In some examples, the mRNA molecule can be delivered to cells by transfection, electroporation, or transduction (e.g., adenoviral or lentiviral transduction).
In some embodiments, the modified RNA encoding a thymic function factor of interest described herein has modified nucleosides or nucleotides. Such modifications are known and are described, e.g., in WO 2012/019168. Additional modifications are described, e.g., in
WO2015038892; WO2015038892; WO2015089511; WO2015196130; WO2015196118 and WO2015196128A2.
In some embodiments, the modified RNA encoding a polypeptide of interest described herein has one or more terminal modification, e.g., a 5'Cap structure and/or a poly-A tail (e.g., of between 100-200 nucleotides in length). The 5' cap structure may be selected from the group consisting of CapO, Capl, ARCA, inosine, Nl-methyl-guanosine, 2'fluoro- guanosine, 7-deaza- guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido- guanosine. In some cases, the modified RNAs also contain a 5 ' UTR comprising at least one Kozak sequence, and a 3 ' UTR. Such modifications are known and are described, e.g., in WO2012135805 and WO2013052523. Additional terminal modifications are described, e.g., in WO2014164253 and WO2016011306. WO2012045075 and WO2014093924
Chimeric enzymes for synthesizing capped RNA molecules (e.g., modified mRNA) which may include at least one chemical modification are described in WO2014028429.
In some embodiments, a modified mRNA may be cyclized, or concatemerized, to generate a translation competent molecule to assist interactions between poly-A binding proteins and 5 '-end binding proteins. The mechanism of cyclization or concatemerization may occur through at least 3 different routes: 1) chemical, 2) enzymatic, and 3) ribozyme catalyzed. The newly formed 5'-/3'- linkage may be intramolecular or intermolecular. Such modifications are described, e.g., in WO2013151736.
Methods of making and purifying modified RNAs are known and disclosed in the art. For example modified RNAs are made using only in vitro transcription (IVT) enzymatic synthesis. Methods of making IVT polynucleotides are known in the art and are described in WO2013151666, WO2013151668, WO2013151663, WO2013151669, WO2013151670, WO2013151664, WO2013151665, WO2013151671, WO2013151672, WO2013151667 and WO2013151736.S Methods of purification include purifying an RNA transcript comprising a polyA tail by contacting the sample with a surface linked to a plurality of thymidines or derivatives thereof and/or a plurality of uracils or derivatives thereof (polyT/U) under conditions such that the RNA transcript binds to the surface and eluting the purified RNA transcript from the surface (WO2014152031); using ion (e.g., anion) exchange chromatography that allows for separation of longer RNAs up to 10,000 nucleotides in length via a scalable method
(WO2014144767); and subjecting a modified RMNA sample to DNAse treatment
(WO2014152030).
Formulations of modified RNAs are known and are described, e.g., in WO2013090648. For example, the formulation may be, but is not limited to, nanoparticles, poly(lactic-co-glycolic acid)(PLGA) microspheres, lipidoids, lipoplex, liposome, polymers, carbohydrates (including simple sugars), cationic lipids, fibrin gel, fibrin hydrogel, fibrin glue, fibrin sealant, fibrinogen, thrombin, rapidly eliminated lipid nanoparticles (reLNPs) and combinations thereof.
Modified RNAs encoding polypeptides in the fields of human disease, antibodies, viruses, and a variety of in vivo settings are known and are disclosed in for example, Table 6 of International Publication Nos. WO2013151666, WO2013151668, WO2013151663,
WO2013151669, WO2013151670, WO2013151664, WO2013151665, WO2013151736; Tables 6 and 7 International Publication No. WO2013151672; Tables 6, 178 and 179 of International Publication No. WO2013151671; Tables 6, 185 and 186 of International Publication No WO2013151667. Any of the foregoing may be synthesized as an IVT polynucleotide, chimeric
polynucleotide or a circular polynucleotide, and each may comprise one or more modified nucleotides or terminal modifications.
Inhibitory RNA
In embodiments, the thymic function modulator comprises an inhibitory RNA molecule, e.g., that acts via the RNA interference (RNAi) pathway. For example, an inhibitory RNA molecule includes a short interfering RNA, short hairpin RNA, and/or a microRNA. A siRNA is a double- stranded RNA molecule that typically has a length of about 19-25 base pairs. A shRNA is a RNA molecule comprising a hairpin turn that decreases expression of target genes via RNAi. shRNAs can be delivered to cells in the form of plasmids, e.g., viral or bacterial vectors, e.g., by transfection, electroporation, or transduction). A microRNA is a non-coding RNA molecule that typically has a length of about 22 nucleotides. MiRNAs bind to target sites on mRNA molecules and silence the mRNA, e.g., by causing cleavage of the mRNA, destabilization of the mRNA, or inhibition of translation of the mRNA. In embodiments, the inhibitory RNA molecule decreases the level and/or activity of a negative regulator of thymic function. In other embodiments, the inhibitor RNA molecule decreases the level and/or activity of an inhibitor of a positive regulator of thymic function.
An inhibitory RNA molecule can be modified, e.g., to contain modified nucleotides, e.g., 2'-fluoro, 2'-o-methyl, 2'-deoxy, unlocked nucleic acid, 2' -hydroxy, phosphorothioate, 2'- thiouridine, 4'-thiouridine, 2'-deoxyuridine. Without being bound by theory, it is believed that certain modification can increase nuclease resistance and/or serum stability, or decrease immunogenicity .
In embodiments, the inhibitory RNA molecule decreases the level and/or activity of a thymic function factor. In embodiments, the inhibitory RNA molecule inhibits expression of a thymic function factor (e.g., inhibits translation to protein). In other embodiments, the inhibitor RNA molecule increases degradation of a thymic function factor and/or decreases the stability (i.e., half-life) of a thymic function factor. The inhibitory RNA molecule can be chemically synthesized or transcribed in vitro.
The making and use of inhibitory therapeutic agents based on non-coding RNA such as ribozymes, RNAse P, siRNAs, and miRNAs are also known in the art, for example, as described
in Sioud, RNA Therapeutics: Function, Design, and Delivery (Methods in Molecular Biology).
Humana Press (2010).
Gene Editing
In embodiments, the thymic function modulator comprises a component of a gene editing system. For example, the thymic function modulator introduces an alteration (e.g., insertion, deletion (e.g., knockout), translocation, inversion, single point mutation, or other mutation) in a thymic function factor, e.g., described in Table 1. Exemplary gene editing systems include the clustered regulatory interspaced short palindromic repeat (CRISPR) system, zinc finger nucleases (ZFNs), Transcription Activator-Like Effector-based Nucleases (TALEN). ZFNs, TALENs, and CRISPR-based methods are described, e.g., in Gaj et al. Trends Biotechnol.
31.7(2013):397-405.
In embodiments, the thymic function modulator comprises a guide RNA (gRNA) for use in a clustered regulatory interspaced short palindromic repeat (CRISPR) system for gene editing. In embodiments, the thymic function modulator comprises a zinc finger nuclease (ZFN), or a mRNA encoding a ZFN, that targets (e.g., cleaves) a nucleic acid sequence (e.g., DNA sequence) encoding a thymic function factor, e.g., a thymic function factor described in Table 1. In embodiments, the thymic function modulator comprises a TALEN, or an mRNA encoding a TALEN, that targets (e.g., cleaves) a nucleic acid sequence (e.g., DNA sequence) encoding a thymic function factor, e.g., a thymic function factor described in Table 1.
For example, the gRNA can be used in a CRISPR system to engineer an alteration in a gene (e.g., a thymic function factor, e.g., described in Table 1). In other examples, the ZFN and/or TALEN can be used to engineer an alteration in a gene (e.g., a thymic function factor, e.g., described in Table 1). Exemplary alterations include insertions, deletions (e.g., knockouts), translocations, inversions, single point mutations, or other mutations. The alteration can be introduced in the gene in a cell, e.g., in vitro, ex vivo, or in vivo. In some examples, the alteration increases the level and/or activity of a thymic function factor, e.g., a positive regulator of thymic function, e.g., described in Table 1. In other examples, the alteration decreases the level and/or activity of (e.g., knocks down or knocks out) a thymic function factor, e.g., a negative regulator of thymic function, e.g., described in Table 1. In yet another example, the
alteration corrects a defect (e.g., a mutation causing a defect), in a thymic function factor, e.g., described in Table 1.
CRISPR refers to a set of (or system comprising a set of) clustered regularly interspaced short palindromic repeats. A CRISPR system refers to a system derived from CRISPR and Cas (a CRISPR-associated protein) or other nuclease that can be used to silence or mutate a gene described herein (e.g., a thymic function factor or thymic function modulator, e.g., described herein).
The CRISPR system is a naturally occurring system found in bacterial and archeal genomes. The CRISPR locus is made up of alternating repeat and spacer sequences. In naturally-occurring CRISPR systems, the spacers are typically sequences that are foreign to the bacterium (e.g., plasmid or phage sequences).
The CRISPR system has been modified for use in gene editing (e.g., changing, silencing, and/or enhancing certain genes) in eukaryotes. See, e.g., Wiedenheft et al. (2012) Nature 482: 331-8. For example, such modification of the system includes introducing into a eukaryotic cell a plasmid containing a specifically-designed CRISPR and one or more appropriate Cas proteins. In embodiments, in a CRISPR system for use described herein, e.g., in accordance with one or more methods described herein, the spacers of the CRISPR are derived from a target gene sequence, e.g., a sequence from a thymic function factor or thymic function modulator, e.g., described herein.
The CRISPR locus is transcribed into RNA and processed by Cas proteins into small RNAs that comprise a repeat sequence flanked by a spacer. The RNAs serve as guides to direct Cas proteins to silence specific DNA/RNA sequences, depending on the spacer sequence. See, e.g., Horvath et al. (2010) Science 327: 167-170; Makarova et al. (2006) Biology Direct 1: 7; Pennisi (2013) Science 341: 833-836. In some examples, the CRISPR system includes the Cas9 protein, a nuclease that cuts on both strands of the DNA. See, e.g., i.d.
In certain embodiments, the CRISPR system is used to edit (e.g., to add or delete a base pair) a target gene, e.g., a thymic function factor or thymic function modulator, e.g., described herein. In other embodiments, the CRISPR system is used to introduce a premature stop codon, e.g., thereby decreasing the expression of a target gene, e.g., a thymic function factor or thymic function modulator, e.g., described herein. In yet other embodiments, the CRISPR system is used to turn off a target gene (e.g., a thymic function factor or thymic function modulator, e.g.,
described herein) in a reversible manner, e.g., similarly to RNA interference. In embodiments, the CRISPR system is used to direct Cas to a promoter of a thymic function factor or thymic function modulator, e.g., described herein, for example, thereby blocking an RNA polymerase sterically.
In embodiments, a CRISPR system can be generated to edit a thymic function factor or thymic function modulator (e.g., described herein), using technology described in, e.g., U.S. Publication No.20140068797, Cong (2013) Science 339: 819-823, Tsai (2014) Nature
Biotechnol., 32:6 569-576, U.S. Patent No.: 8,871,445; 8,865,406; 8,795,965; 8,771,945; and 8,697,359.
In some embodiments, the CRISPR interference (CRISPRi) technique can be used for transcriptional repression of specific genes, e.g., a gene encoding a thymic function modulator or thymic function factor described herein. In CRISPRi, an engineered Cas9 protein (e.g., nuclease-null dCas9, or dCas9 fusion protein, e.g., dCas9-KRAB or dCas9-SID4X fusion) can pair with a sequence specific guide RNA (sgRNA). The Cas9-gRNA complex can block RNA polymerase, thereby interfering with transcription elongation. The complex can also block transcription initiation by interfering with transcription factor binding. The CRISPRi method is specific with minimal off-target effects and is multiplexable, e.g., can simultaneously repress more than one gene (e.g., using multiple gRNAs). Also, the CRISPRi method permits reversible gene repression.
In embodiments, CRISPR-mediated gene activation (CRISPRa) can be used for transcriptional activation, e.g., of one or more genes described herein, e.g., genes encoding a thymic function modulator or thymic function factor described herein. In the CRISPRa technique, dCas9 fusion proteins recruit transcriptional activators. For example, dCas9 can be used to polypeptides (e.g., activation domains) such as VP64 or the p65 activation domain (p65D) and used with sgRNA (e.g., a single sgRNA or multiple sgRNAs), to activate a gene or genes, e.g., endogenous gene(s). Multiple activators can be recruited by using multiple sgRNAs - this can increase activation efficiency. A variety of activation domains and single or multiple activation domains can be used. In addition to engineering dCas9 to recruit activators, sgRNAs can also be engineered to recruit activators. For example, RNA aptamers can be incorporated into a sgRNA to recruit proteins (e.g., activation domains) such as VP64. In some examples, the synergistic activation mediator (SAM) system can be used for transcriptional activation. In
SAM, MS2 aptamers are added to the sgRNA. MS2 recruits the MS2 coat protein (MCP) fused to p65AD and heat shock factor 1 (HSF1).
The CRISPRi and CRISPRa techniques are described in greater detail, e.g., in
Dominguez et al. Nat. Rev. Mol. Cell Biol. 17(2016):5-15, incorporated herein by reference. In addition, dCas9-mediated epigenetic modifications and simultaneous activation and repression using CRISPR systems, as described in Dominguez et al., can be used to modulate a thymic function modulator or thymic function factor described herein.
Epigenetic modifying agents
In embodiments, the thymic function modulator comprises an epigenetic modifying agent. An epigenetic modifying agent is an agent that modifies chromatin structure, e.g., directly and/or indirectly, and in some cases affects gene expression and function. For example, an epigenetic modifying agent modifies an epigenetic status of a cell (e.g., phenotype or gene expression in the cell that is caused by mechanisms other than alterations in DNA sequence). For example, an epigenetic status of a cell includes DNA methylation, histone modification(s) and RNA-associated silencing. Without wishing to be bound by theory, it is believed that epigenetic alterations in the genome can contribute to certain diseases, e.g., cancer initiation and progression. For example, abnormal DNA methylation and histone hypoacetylation in promoter regions of important genes can lead to gene silencing.
In embodiments, an epigenetic modifying agent involves sequence-specific targeting of an epigenetic enzyme (e.g., an enzyme that generates or removes epigenetic marks, e.g., acetylation and/or methylation, e.g., histone modifying enzyme). In embodiments, an epigenetic modifying agent comprises a DNA-sequence-specific targeting system in which an epigenetic enzyme is linked (e.g., fused) to a DNA binding domain. In embodiments, such an epigenetic modifying agent modulates (e.g., downregulates or upregulates) gene expression, e.g., expression of a thymus function factor or thymus function modulator described herein. Exemplary epigenetic enzymes include DNA methyltransferases, DNA methylases, histone
methyltransferases, histone deacetylase (e.g., HDAC1, HDAC2, HDAC3), sirtuin 1, 2, 3, 4, 5, 6, or 7, lysine- specific histone demethylase 1 (LSDl), histone-lysine-N-methyltransferase (Setdbl), euchromatic histone-lysine N-methyltransferase 2 (G9a), histone-lysine N-methyltransferase (SUV39H1), enhancer of zeste homolog 2 (EZH2), viral lysine methyltransferase (vSET),
histone methyltransferase (SET2), and protein-lysine N-methyltransferase (SMYD2). Examples of such epigenetic modifying agents are described, e.g., in de Groote et al. Nuc. Acids Res. (2012): 1-18.
In embodiments, an epigenetic modifying agent is a small molecule. Exemplary small molecule epigenetic modifying agents are described, e.g., in Lu et al. J. Biomolecular Screening 17.5(2012):555-71, e.g., at Table 1 or 2, incorporated herein by reference. In embodiments, an epigenetic modifying agent comprises vorinostat, romidepsin. In embodiments, an epigenetic modifying agent comprises an inhibitor of class I, II, III, and/or IV histone deacetylase (HDAC). In embodiments, an epigenetic modifying agent comprises an activator of SirTI. In
embodiments, an epigenetic modifying agent comprises Garcinol, Lys-CoA, C646, (+)-JQI, I- BET, BICI, MS 120, DZNep, UNC0321, EPZ004777, AZ505, AMI-I, pyrazole amide 7b, benzo[d] imidazole 17b, acylated dapsone derivative (e.e.g, PRMTI), methylstat, 4,4'-dicarboxy- 2,2'-bipyridine, SID 85736331, hydroxamate analog 8, tanylcypromie, bisguanidine and biguanide polyamine analogs, UNC669, Vidaza, or decitabine.
In embodiments, an epigenetic modifying agent comprises a construct described in Koferle et al. Genome Medicine 7.59(2015): 1-3 (e.g., at Table 1), incorporated herein by reference.
In embodiments, an epigenetic modifying agent inhibits DNA methylation, e.g., is an inhibitor of DNA methyltransferase (e.g., is 5-azacitidine and/or decitabine). In embodiments, an epigenetic modifying agent modifies histone modification, e.g., histone acetylation, histone methylation, histone sumoylation, and/or histone phosphorylation. In embodiments, the epigenetic modifying agent is an inhibitor of a histone deacetylase (e.g., is vorinostat and/or trichostatin A). In embodiments, the epigenetic modifier comprises sodium phenyl butyrate (SDB), lipoic acid (LA), quercetin, valproic acid, hydralazine, bactrim, green tea extract (e.g., epigallocatechin gallate (EGCG)), curcumin, sulforphane and/or allicin/diallyl disulfide. In embodiments, an epigenetic modifying agent modifies, e.g., increases or decreases, the expression level of a thymic function factor (e.g., a thymic function factor described herein), or a thymic function modulator (e.g., a thymic function modulator described herein).
In embodiments, the thymic function modulator comprises an aptamer. An aptamer can be made up of nucleic acids (e.g., DNA, RNA, modified DNA, modified RNA, or combinations thereof) and/or peptides. Aptamers form three-dimensional structures that bind specifically to a
target molecule, inhibiting or activating the target molecule. For example, an aptamer can be generated using systematic evolution of ligands using exponential enrichment (SELEX). In embodiments, the aptamer binds to a thymic function factor, e.g., described in Table 1. For example, the aptamer decreases the activity of a thymic function factor, e.g., a negative regulator of thymic function, e.g., described in Table 1. In other examples, the aptamer increases the activity and/or stability of a thymic function factor, e.g., a positive regulator of thymic function, e.g., described in Table 1.
In embodiments, the thymic function modulator comprises an antibody molecule or an mRNA encoding an antibody molecule. In embodiments, the antibody molecule binds to a thymic function factor, e.g., described in Table 1. For example, the antibody molecule decreases the activity of a thymic function factor, e.g., a negative regulator of thymic function, e.g., described in Table 1. In other examples, the antibody molecule increases the activity and/or stability of a thymic function factor, e.g., a positive regulator of thymic function, e.g., described in Table 1.
In embodiments, the thymic function modulator comprises a peptide or polypeptide, e.g., a thymic function factor or fragment thereof (e.g., functional fragment thereof) described in Table 1. In embodiments, the peptide or polypeptide comprises an amino acid sequence having at least 50% (e.g., at least 50%, 60%, 70%, 80%, 90%, 95%, or more) identity to an amino acid sequence of a thymic function factor described in Table 1, e.g., a positive regulator of thymic function described in Table 1. In embodiments, a peptide has a molecular weight between about 700 to about 5000 Daltons. In embodiments, a polypeptide has a molecular weight between about 5000 and about 500,000 Daltons, e.g., between about 5000 and about 150,000 Daltons. Peptides and polypeptides can be naturally occurring, recombinant or chemically synthesized.
In embodiments, the thymic function modulator comprises a small molecule. For example, the small molecule binds to a thymic function factor, e.g., described in Table 1. For example, the small molecule inhibits the activity of a thymic function factor, e.g., a negative regulator of thymic function, e.g., described in Table 1. For example, the small molecule increases the activity of a thymic function factor, e.g., a positive regulator of thymic function, e.g., described in Table 1. A small molecule has a molecular weight of between about 50 and about 1000 Daltons, e.g., between about 100 Daltons and about 700 Daltons.
Measurement of thymus function
Methods described herein may include the assessment of certain thymic activities, structure, functions or characteristics. For example, methods described herein can modulate (e.g., increase or decrease, as desired) T cell exhaustion, TILs, T-cell diversity, T cell clonality, thymocytes, thymic epithelial cells, thymic stromal cells, and thymus size. Accordingly, subjects being treated may be assessed for one or more such thymic activities, functions or parameter before, during and/or after treatment. In other embodiments, a cell culture/cell(s)/preparation thereof produced using a method described herein can be assessed for thymus function ex vivo using one or more of the methods described herein, e.g., assessed prior to administration into a subject.
In some embodiments, patients are assessed before treatment, e.g., to establish a baseline level of a particular thymic parameter. In some such instances, a patient may be selected for treatment based on a pre-treatment assessment described herein. In some embodiments, a patient is assessed after a first administration of the therapy, e.g., one or more times (e.g., 2, 3, 4, 5, 7, 10, 15 or more times) during the period encompassing the treatment regimen. In some such embodiments, a patient may be monitored for disease treatment or progression based on assessments during the period encompassing the treatment regimen, e.g., where an increase in a thymic function parameter is intended by treatment, such assessments may be used to confirm the effect of treatment, or to determine whether to stop or continue treatment. In other embodiments, a patient is assessed after the period encompassing a treatment regimen is complete. The results of such assessments may be used, e.g., to determine if the patient should undergo a different treatment, continue with another round of the same treatment regimen, or another action determined by the patient' s health care provider.
Thymus function (e.g., extent of thymic involution, thymic damage, thymic regeneration, or decrease/reverse in thymic involution or damage) can be determined a number of methods.
In some embodiments, an increase in thymus tissue size/mass after treatment in a subject is indicative of a decrease/reverse in thymic involution.
Thymus size
Generally speaking, the size and cellular composition of a human thymus is proportional to its output and level of activity. Thymus size can be assessed by direct visualization in vivo, ex
vivo, or intraoperatively, as well as through a wide variety of histological processing techniques known to the art, including but not limited to hematoxylin and eosin staining. Thymus size can also be assessed using biomedical imaging techniques such as ultrasound, magnetic resonance imaging (MRI or MR imaging), computed tomography (CT), and position emission tomography (PET) (PMID: 21700977). Ultrasound can be used to measure the size and/or shape of the thymus. For example, ultrasound can be used to determine the size and/or shape of each of the two lobes of the thymus. Ultrasound permits the imaging of individual parts of the thymus, e.g., medulla, cortex, interlobular septum, and blood vessels. See, e.g., Han et al. Pediatr. Radiol. 31(2001):474-79; and Nasseri et al. RadioGraphics 30(2010):413-28. The size of the thymus can be expressed, e.g., in terms of volume and/or a Thymus index, e.g., as described in Hasselbalch et al. Eur. Radiol. 6.5(1996):700-03; and Varga et al. Surg. Radiol. Anat. 33(2011):689-95.
Recently, 18F-FDG PET imaging is an important tool for the visualization and staging of human cancer. In infants and young adults, the thymus's extensive cellularity and metabolic activity results in physiologic uptake of FDG, although this disappears during adolescence as the thymus involutes. (PMID 8896924) In contrast, transient thymic hyperplasia has been sporadically observed following chemotherapy, particularly for testicular carcinoma or malignant lymphoma; additionally, a retrospective study showed that in a subset of adult patients who experience chemotherapy-induced thymic hyperplasia, the hyperplasia is detectible via increased FDG uptake, rendering thymus FDG uptake an imaging biomarker for enhanced thymic cellularity (PMID 11337547).
In certain embodiments, thymus size is increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to prior to treatment.
In some embodiments, anterior mediastinal mass is a marker of thymic function (e.g., extent of thymic involution or extent of decrease/reverse in thymic involution). A larger, longer, thicker, denser, and/or more opaque anterior mediastinal mass is indicative of a decrease/reverse in thymic involution. Accordingly, methods described herein include in some embodiments measuring the size, (e.g., length, width, and/or thickness), opacity, and/or density of the anterior mediastinal shadow in a subject, e.g., before, during, and/or after treatment with a therapy, e.g., a cell culture, cell(s), or preparation thereof, e.g., described herein. Anterior mediastinal shadow can be measured by imaging techniques such as ultrasound, X-ray, CT scan, MRI, or PET (e.g.,
FDG avidity via PET). In some embodiments, a treatment, e.g., described herein (e.g., cell culture, cell(s), or preparation thereof, and/or second therapeutic agent or procedure, as described herein), increases the size (e.g., length, width, and/or thickness), opacity, and/or density of the anterior mediastinal shadow in a subject, compared to a reference value. In embodiments, the treatment, e.g., described herein, increases the size, opacity, and/or density of the anterior mediastinal shadow by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60-fold, 80- fold, 100-fold, or more, compared to a reference value. In embodiments, an increase (e.g., of at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold, or more) in size, opacity, and/or density of the anterior mediastinal shadow in a subject (compared to a reference value) is indicative of an improvement in thymic function, e.g., a decrease or reverse in thymic involution.
In embodiments, the reference value is the size (e.g., length, width, and/or thickness), opacity, and/or density of the anterior mediastinal shadow in the subject prior to administration with a treatment, e.g., described herein.
Thymic stromal cells
Another marker of thymic function, e.g., thymic involution, is the level of stromal cells in the thymus. Stromal cells in the thymus include dendritic cells and epithelial cells of the thymic medulla and cortex. Stromal cells are involved in the selection of a self-tolerant and functional T cell repertoire.
Thymic stromal cells are the non-thymocyte cells within the thymus that mediate the thymus's system for 'training' T lineage progenitor T cells as developing thymocytes for proper binding of a T cell receptor recognizing 'self in the context of a peptide; this compartment includes fibroblasts, epithelium, endothelium, and dendritic cells (Gray et al., J Immun., 2007). The main stromal compartments responsible for interacting with developing thymocytes are lined with TECs. Among other cell types, thymic stromal cells also comprise fibroblasts;
fibroblasts are also known to play a role in guiding thymocyte development. Thymic stromal cells are heterogeneous and can be assessed by determining the relative or absolute quantity of the subsets comprising thymic stromal cells (e.g., fibroblasts, TECs, endothelium). For example,
the stromal cell subset comprising thymic fibroblasts can be assessed through the use of the monoclonal antibody MTS-15 as known to the art (Gray et al., J. Immun., 2007).
In certain embodiments, thymic stromal cells (e.g., one or more or all of: fibroblasts, TECs, endothelium) are increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to prior to treatment.
In embodiments, a treatment, e.g., described herein, increases the level of stromal cells (e.g., dendritic cells, medulla epithelial cells, and/or cortex epithelial cells) in the thymus of a subject, e.g., by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value. In embodiments, a treatment, e.g., described herein, increases the percentage of stromal cells (e.g., dendritic cells, medulla epithelial cells, and/or cortex epithelial cells) in a population of cells in a thymic sample, e.g., by at least 1.25- fold, 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value.
In embodiments, an increase (by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40- fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value) in the level of stromal cells in the thymus in a subject after administration of a treatment, e.g., described herein, is indicative of an improvement in thymic function, e.g., a decrease or reverse in thymic involution. In embodiments, an increase (by at least 1.25-fold, 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5- fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value) in the percentage of stromal cells (e.g., dendritic cells, medulla epithelial cells, and/or cortex epithelial cells) in a population of cells in a thymic sample is indicative of an improvement in thymic function, e.g., a decrease or reverse in thymic involution.
In embodiments, the reference value is the level of the stromal cells (e.g., dendritic cells, medulla epithelial cells, and/or cortex epithelial cells) in the subject prior to administration with a treatment, e.g., described herein. In embodiments, the reference value is the percentage of stromal cells (e.g., dendritic cells, medulla epithelial cells, and/or cortex epithelial cells) in a population of cells in a thymic sample from the subject prior to administration with a treatment, e.g., described herein.
The level of stromal cells can be determined by identifying/quantifying one or more markers of stromal cells (e.g, dendritic cells, medulla epithelial cells, and/or cortex epithelial cells). For example, the level of stromal cells can be determined by using flow cytometry, e.g., FACS. For example, the level of stromal cells can be determined (e.g., using FACS) by using one or more of the cell surface markers shown in Table 2. In embodiments, the level of stromal cells is determined in a sample from the subject, e.g., a blood or tissue sample from the subject.
Table 2: Exemplary FACS/surface markers for thymic stromal cells
Another marker of thymic function, e.g., thymic involution, is the level of adipocytes in the thymus. As a thymus ages or involutes, thymic tissue degenerates into adipose tissue.
Without being bound by theory, it is believed that a decrease or reverse in thymic involution is characterized, in part, by a decrease in the level and/or size of adipocytes in the thymus.
In embodiments, a treatment, e.g., described herein, decreases the level and/or size of adipocytes in the thymus of a subject, e.g., by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-
fold, 40-fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value. In embodiments, a decrease (by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60- fold, 80-fold, 100-fold, or more, compared to a reference value) in the level and/or size of adipocytes in the thymus in a subject after administration of a treatment, e.g., described herein, is indicative of an improvement in thymic function, e.g., a decrease or reverse in thymic involution. In embodiments, the reference value is the level and/or size of adipocytes in a thymic samples from the subject prior to administration with a treatment, e.g., described herein. The size of adipocytes can be the average size of adipocytes, e.g., in a sample containing a population of adipocytes, or the size of an individual adipocyte.
The level of adipocytes can be determined by identifying/quantifying one or more markers of adipocytes. For example, the level and/or size of adipocytes can be determined by using flow cytometry, e.g., FACS. In other examples, the level and/or size of adipocytes can be determined using histological methods, e.g., in situ hybridization or immunohistochemistry. In yet other embodiments, the level of adipocytes can be determined by using PPARy staining (e.g., to identify adipogenic fibroblasts), LipidTOX Green (Invitrogen), Oil Red O staining, and/or magnetic resonance imaging (MRI). In embodiments, the level of adipocytes is determined in a sample from the subject, e.g., a blood or tissue sample (e.g., biopsy, e.g., thymus biopsy) from the subject.
Thymocytes
Thymocytes are T-cells and T-cell progenitors found in the thymus. In the thymus, under the influence of the thymic stromal microenvironment, immature thymocytes acquire various cell surface molecules useful in their future role as mature T cells. Thymocytes can be assessed by multiple methods as described in the art. For example, thymocytes can be assessed by assaying for cell surface expression of developmentally regulated thymocyte markers, using labeled antibodies that specifically bind to these markers. For example, the most immature CD4-CD8- double-negative (DN) thymocytes give rise to CD4+CD8+ double-positive (DP) thymocytes, which give rise to mature CD4+CD8- single-positive (SP) and CD4-CD8+ SP T cells. The DN population can be further subdivided by the expression of CD44 and CD25: CD44+CD25- (DN1) cells differentiate into CD44+CD25+ (DN2) cells, which give rise to CD44-CD25+
(DN3) cells, which finally become the most mature CD44-CD25- (DN4) DN population. The DN4 cells may pass through an intermediate population expressing either coreceptor alone before becoming DP cells. This intermediate population, most commonly expressing CD8, is known as immature single positive (ISP) cells. Progression beyond the DN3 stage is dependent on successful rearrangement of a TCRP-chain gene and pre-TCR signaling, whereas
differentiation from DP to mature SP cell is dependent on the expression and positive selection of an apTCR (Von Boehmer et al., Immunol. Rev. 191: 62, 2003; Ceredig and Rolink, Nat. Rev. Immunol. 2: 888, 2002). Additionally, the cellularity of the thymus (including thymocytes) can be assessed using clinical imaging modalities such as MRI, CT, or PET, as described in the art (Brink et al., J. Nuc. Med., 2001; Ackman and Wu, Am. J. Roent, 2011).
In certain embodiments, thymocytes (e.g., one or more of: CD4+CD8+ DP thymocytes; CD4+CD8- SP thymocytes; CD4-CD8+ SP T cells; CD44+CD25- DN1 cells; CD44+CD25+ DN2 cells; to CD44-CD25+ DN3 cells; CD44-CD25- DN4) are increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to prior to treatment.
Thymic epithelial cells
Thymic epithelial cells or TECs are epithelial cells located in the thymus, including cortical thymic epithelial cells (cTECs) and medullary TECs (mTECs). They comprise the stromal compartment of the thymus responsible for guiding developing thymocytes through various developmental stages and to maturity. Thymocytes can be assessed by multiple methods as described in the art. For example, TECs can be assessed by assaying for cell surface expression of developmentally regulated TEC markers using labeled antibodies that specifically bind these markers; such cell surface markers include Keratin 8 (K8), K5, EpCAM, MHC class I, MHC class II, CD45, CD80, CD86, CD90, CDl lc, CCL25, RANK, RANKL and CXCL12 (Gray et al., Immun. Meth., 2008). Other markers of TECs are intracellular or secreted and can be assessed using intracellular staining or other methods known to the art. Such markers include AIRE, FezF2, FoxNl, Hoxa3, proteasome subunit β5ί, proteasome subunit β5ί, BMP4, retinoic acid, Wnt, Shh, FGF, and SCF. In some case the absence of a particular marker can be useful in assessing the identity of a cell as a TEC, for example, CD45. Additionally, the cellularity of the
thymus (including thymic epithelium) can be assessed using clinical imaging modalities such as MRI, CT, or PET, as described in the art (Brink et al., J. Nuc. Med., 2001; Ackman and Wu, Am. J. Roent., 2011).
In certain embodiments, thymic epithelial cells are increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to prior to treatment.
T cell function/output
A measure of thymic activity is T cell output. T cell maturation takes place in the thymus. Hematopoietic progenitor cells (e.g., a CD34 positive hematopoietic stem cell) enter the thymus, where they proliferate to generate a large population of immature thymocytes.
Immature thymocytes make distinct T cell receptor via gene rearrangement. Some T cell receptors are functional (e.g., recognize specific cell surface molecules, e.g., foreign antigens) and some T cell receptors are autoreactive (e.g., recognize self-peptides). During T cell maturation in the medulla of the thymus, immature thymocytes undergo positive selection and negative selection based on their T cell receptor specificity. These newly generated T cells are exported into the periphery and circulate through the lymphoid tissues and blood. In
embodiments, the recently exported T cells are CD4+ and CD8+. In embodiments, recently exported T cells are referred to as recent thymic emigrants and typically have undergone no more than a few cellular divisions after leaving the thymus. It is believed that the number of T cells exported into the periphery, i.e., T cell output, e.g., recent thymic emigrants, decreases during the process of thymic involution.
T cell output, e.g., over a period of time (e.g., T cell output per day, per hour, or per 12 hours) can be determined, e.g., by measuring one or more markers of recent thymic emigrants. Exemplary markers of recent thymic emigrants (RTEs) include chTl+, CD45RA, and CD31 (PECAM-1), In embodiments, a RTE has the following expression pattern: CD3+ CD62L+ CD45RA+ CD31+ CD44_/1°. In embodiments, a RTE can be distinguished from an older non- RTE naive CD4+ T cell, e.g., using TPK7 as a marker. See, e.g., Haines et al. J. Exp. Med. 206.2(2009):275-85. In other embodiments, a RTE can be distinguished from a mature naive T cell, e.g., by using Rag2 as a marker. See, e.g., Houston Jr. et al. J. Immunol. 181(2008):5213- 17. Another measure of T cell output, e.g., recent thymic emigrants, is the concentration of T
cell receptor excision circles (TRECs). TRECs are extrachromosomal nonreplicative DNA byproducts generated during T-cell receptor (TCR) rearrangement. TRECs are expressed only in thymus -originated T cells, each of which is believed to contain a single TREC. TRECs are exported into the periphery from the thymus, and it is believed that TREC levels in the periphery are an indicator of the number of recent thymic emigrants, which is a measure of T cell output and/or T-cell recovery (e.g., after hematopoietic cell transplantation). TREC concentration can be measured using PCR, real-time PCR, quantitative-competitive PCR, or PCR-ELISA. T cell output and measurement of recent thymic emigrant and/or TREC concentration is described, e.g., in Ye et al. J. Immunol. 168(2002):4968-79 or in http://www.mayomedicallaboratories.com/test- catalog/Clinical+and+Interpretive/87959 (accessed as of June 9, 2016).
In embodiments, a treatment, e.g., described herein (e.g., a cell culture, cell(s), or preparation thereof and/or a second therapeutic agent or procedure, as described herein), increases the T cell output (e.g., number of recent thymic emigrants, e.g., concentration of TRECs) in a subject, e.g., by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60- fold, 80-fold, 100-fold, or more, compared to a reference value. In embodiments, an increase (by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3- fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value) in the T cell output (e.g., number of recent thymic emigrants, e.g., concentration of TRECs) in a subject after administration of a treatment, e.g., described herein, is indicative of an improvement in thymic function, e.g., a decrease or reverse in thymic involution. In embodiments, the reference value is the T cell output (e.g., number of recent thymic emigrants, e.g., concentration of TRECs) in a sample from the subject prior to
administration with a treatment, e.g., described herein.
T cell output, e.g., markers of recent thymic emigrants, e.g., concentration of TRECs, can be determined in a sample from a subject, e.g., a blood (peripheral blood) or tissue sample.
Additional indicators of thymic function (e.g., extent of thymic involution, thymic damage, thymic regeneration, or decrease/reverse in thymic involution or damage) include T cell diversity, TCR repertoire diversity, T cell clonality, and/or T cell diversity.
In embodiments, a treatment, e.g., described herein, increases the T cell diversity, TCR repertoire diversity, and/or T cell clonality in a subject, e.g., by at least 10%, e.g., at least 10%,
20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10- fold, 15-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value. In embodiments, an increase (by at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 10-fold, 15-fold, 20-fold, 40- fold, 60-fold, 80-fold, 100-fold, or more, compared to a reference value) in the T cell diversity, TCR repertoire diversity, and/or T cell clonality in a subject after administration of a treatment, e.g., described herein, is indicative of an improvement in thymic function, e.g., a decrease or reverse in thymic involution. In embodiments, the reference value is the T cell diversity, TCR repertoire diversity, and/or T cell clonality in a sample from the subject prior to administration with a treatment, e.g., described herein.
T cell exhaustion
The invention provides, inter alia, methods of decreasing T cell exhaustion. T cell exhaustion, also referred to as T cell dysfunction, refers to dysfunctional state of T cells indicated by reduced or absent production of effector cytokines IFNg, TNFa, IL-2, effector molecules perforin, granzyme A, B, or K, reduced ability of cells to proliferate, and increased expression of co-inhibitory receptors PD-1, LAG-3, TEVI-3, CTLA-4, CD160, 2B4 (CD244), BTLA, or TIGIT as described in the art (PMID: 26205583, PMID:21739672).
T cell exhaustion can be assessed by the following methods: T cells are stained for the expression of above mentioned surface receptors, or reactivated ex vivo with cognate peptide, PMA + Ionomycin, or anti-CD3, to assess their ability to produce cytokines and other effector molecules, as well as their ability to proliferate as measured by the increase of Ki-67 expression, incorporation of BrdU, or dilution of a cell dye such as CSFE or CellTrace Violet.
In certain embodiments, T cell exhaustion is increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to a reference level, e.g., the extent of T cell exhaustion prior to treatment.
Memory T cell response
In embodiments, a composition or method described herein stimulates a robust memory T cell response. This memory T cell response will aid in the clearance of pathogens or tumor cells and will prevent the occurrence of relapse.
During a T cell response to a viral infection or a tumor, antigen- specific CD 8 T cells will be activated by antigen-presenting cells and will differentiate into effector T cells. Effector CD8 T cells proliferate rapidly, produce pro-inflammatory cytokines, and kill infected target cells or tumor cells using cytotoxic molecules such as granzymes and perforin. The number of antigen- specific T cells responding to a pathogen peaks at day 8 after the initial infection and then the contraction phase of the T cell response begins. During contraction, the majority of T cells die and 5-10% persist as memory cells (PMID: 23080391). Before the contraction phase begins, T cells have already entered a molecular program of cellular death during the contraction phase or persist as memory cells. The antigen- specific cells that will eventually die during contraction are termed "short-lived effector cells" (SLECs) and the cells that will persist are termed "memory- precursor effector cells" (MPECs). During an infection, these cells can be differentiated using the cell surface markers KLRG1 and CD127 (IL-7Ra). SLECs will be KLRG1+ CD127- and MPECs will be KLRG1- CD127+ (PMID: 23080391). An increase in the percentage of cells in the MPEC population indicates a stronger memory T cell response and greater protective immunity.
In certain embodiments, memory T cells are increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to a reference level, e.g., the level of memory T cells prior to treatment. In some embodiments, MPECs comprise between 1-20%, between 2-20%, between 5-20%, between 2-15%, between 5-15%, between 7- 20%, between 7-15%, between 10-20% of T cells in a treated subject.
Tumor infiltrating lymphocytes (TILs)
Tumor infiltrating lymphocytes (TIL) are populations of immune cells that are associated with tumor tissue. TIL can be made up of lymphocytes such as CD4 T cells, CD8 T cells and NK cells, and also myeloid cells such as macrophages, dendritic cells, and myeloid-derived suppressor cells (MDSCs). These populations of cells can be enriched from single-cell
suspensions of tumor tissue using density gradient centrifugation. The presence of TIL in tumors is associated with better prognosis, particularly for CD8 T cells. TILS can be assessed, identified, and/or phenotyped by direct antibody labeling and flow cytometric analysis. CD45 is often used to identify hematopoietic cells from the tumor, which can then be phenotyped for more parameters such as CD3, CD4, CD8, CDl lb, CDl lc, NK1.1. Better pheno type and function of CD8 T cells in tumors is associated with good responses to immunomodulatory antibody therapy (PD-1 and CTLA-4 pathways) and can be assessed using flow cytometry markers that have been described previously (PMID: 25754329; PMID: 23197535).
In certain embodiments, TILs are increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to prior to treatment.
T cell diversity
T cell diversity refers to the range of phenotypically, genetically, epigenetically, biochemically, and/or functionally distinct T cell populations present within a given sample or subject. T cell diversity can be assessed through a wide variety of methods known to the art. For example, T cell diversity can be assessed through qualitative and/or quantitative comparison of T cell receptor repertoire, as described herein. Importantly, T cell diversity can also be assessed by methods known to the art that do not involve and that are independent of TCR analysis. For example, high-resolution mass spectrometry can be used to map the proteome from cytotoxic T lymphocytes and use this information to identify different functional subgroups that vary in population size and cytotoxic efficacy (PMID: 26551880) Additionally, it is known to the art that engagement of different metabolic pathways and properties across subsets of T-cell populations can lead to functionally distinct T-cell populations; thus, T cell diversity can also be assessed through quantitative or qualitative assessment of such metabolic pathways and properties through a variety of methods known to the art (PMID 23746840, PMID 26261266). The diversity of cells can also be assessed from blood samples or other tissues such as biopsied tumor, using flow cytometry or mass cytometry (CyTOF), by staining cell surface markers. For example, CD4 T cells can be divided into naive (CD4+CCR7+CD45RA+CD45RO-), TH1 (CD4+CXCR3+CCR6-CD 161 -) , TH17 (CD4+CCR6+CD 161 +CXCR3 -) , TH2
(CD4+CRTH2+CXCR3 -) , Treg (CD4+CD1271oCD25+), memory (CD4+CD45RA-CD45RO+),
TCM (CD4+CCR7+CD45RA-CD45RO+), TEM (CD4+CCR7-CD45RA-CD45RO+), TEMRA (CD4+CCR7-CD45RA+CD45RO-), Trl: (CD49b and Lag3 co-expression), Tfh (CXCR5, PD-1, BCL6, FoxP3-), and Tfr (CXCR5, PD-1, BCL6, FoxP3+), and CD8 T cells can be similarly divided into naive (CD8+CCR7+CD45RA+CD45RO-), TCM (CD8+CCR7+CD45RA- CD45RO+), TEM (CD8+CCR7-CD45RA-CD45RO+), TEMRA (CD8+CD45RA+CCR7- CD45RO-), Tel (IFNg expression following restimulation) Tc2 (CRHT2+) and Tel 7 (CCR5, CCR6, CD161) as known to art (PMID: 23624599, 26146074, 25177353, 7525836, 11069080, 21706005). Following treatment with the inventions described herein, the distribution of the different subsets of these cells can be measurably altered, thereby quantitatively impacting the diversity of the T cells in the patient.
In certain embodiments, T cell diversity is increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to a reference level, e.g., the T cell diversity prior to treatment.
TCR repertoire diversity
TCR repertoire diversity refers to the number of different T cell receptors (TCR) in a population of T cells; sources of diversity within TCR repertoire include unique alpha and beta TCR subunits, genetic differences stemming from V-J (TCR alpha) and V-D-J (TCR beta) recombination, as well as different terminal deoxynucleotidyl transferase (TdT) - introduced nucleotides at DNA junctions, resulting in sequence variation. (Murphy et al., Janeway's
Immunobiology, 8th Edition, 2012). Because T-cells expand clonally, in some cases a given TCR can be shared by multiple T-cells that have expanded from a common parent cell; in this situation and in similar situations, TCR repertoire diversity can additionally refer to the number of different clonal populations of T-cells that harbor distinct TCRs within a sample. An increase in TCR repertoire diversity is an indicator of either the presence of or an increased potential for a robust antigen- specific T cell response to a pathogen or tumor, as increased diversity suggests that more T cells are capable of responding to the pathogen or tumor, which is beneficial for ensuring effective control of the pathogen or tumor. Increases in repertoire diversity also suggest an environment more favorable for effective immunity, as subdominant clones with weaker TCR affinity for their antigen are also able to become activated and proliferate.
TCR repertoire diversity can be assessed by methods known to art including RNA- Sequencing, DNA- sequencing, TCR-targeted sequencing, and TCR probe-based PCR. For example, TCR repertoire profiling can measure the distribution of individual T cell clones in a population. This is done by amplifying the CDR3 region of the TCR alpha and TCR beta chains from T cell genomic DNA and next-generation sequencing the region. Since each clonal population of T cells has a unique T cell receptor, analysis of deep sequencing data from a TCR repertoire profile can yield information about the total number of different T cell clones and T- cell receptors found in the population. Both of these metrics can be measured from a single sample, given that the sample is sequenced deeply enough and the amount of input T cell genomic DNA is standardized. (US 20100035764, PMID: 26404496, PMID: 2343517, PMID: 24329790).
In certain embodiments, T cell repertoire diversity is increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to a reference level, e.g., the T cell repertoire diversity prior to treatment..
T cell clonality
T cell clonality refers to the absolute or relative size of a clonal T cell population or of several clonal T cell populations, including peripheral blood mononuclear cells, TILs, or other tissue-derived immune cells, or the magnitude of a T cell expansion giving rise to said clonal population. For example, during the course of a response to a particular antigen, a T cell that is specific for said antigen will undergo a series of receptor-mediated reactions, resulting in the division of the cell into daughter cells and establishing a clonal population of T cells expressing the same TCR. In embodiments, an increase TCR clonality is a good indicator of a robust antigen-specific T cell response to a pathogen or tumor. The term "T cell clonality" can be used to refer to the absolute or relative size of a specific T cell clonal population, or it can be used to refer to multiple clonal T cell populations simultaneously. Increases in T cell clonality can also suggest that T cells are expanding vigorously after antigen recognition, indicating that they are not functionally suppressed (e.g., exhausted). Accordingly, in some embodiments, an increase in T cell clonality (e.g., of disease-specific T cells, e.g., cancer- specific T cells) can be desirable. In some cases, a subject can achieve a state of T cell clonality in which clonal populations of T cells
specific to a particular target or set of targets (e.g., cytomegalovirus or Epstein-Barr Virus) represent a disproportionately large portion of the total T-cell pool. In such cases, for example, a decrease in T cell clonality (e.g., for certain T cell populations) may be desirable.
T cell clonality can be assessed by performing T cell spectratyping on a population of T cells, performing tetramer staining on a population of T cells, sequencing at least one TCR subunit from a population of cells, staining a population of T cells with an anti-TCR antibody, performing flow cytometry, or a combination thereof. TCR sequence can be assessed by methods known to art including RNA-Sequencing, DNA-sequencing, TCR-targeted sequencing, and TCR probe-based PCR (US 20100035764 Al, PMID: 26404496, PMID: 2343517, PMID: 24329790).
TCR-Immunosequencing is a platform technology that allows the enumeration, specification and quantification of each and every T-cell in any biologic sample of interest. It is based on bias-controlled multiplex PCR and high throughput sequencing and is highly accurate, standardized, and sensitive. See, e.g., Kirsch. J. Immunother Cancer. 3.29(2015); or Carlson et al. Nat. Commun. 4(2013):2680, both incorporated herein by reference. Without wishing to be bound by theory, it is believed that the average clonal size of a naive cell is about 100-200 cells. Recent thymic emigrants in the newborn undergo three to four divisions in the periphery after TCRA gene rearrangement, thereby establishing a minimal clonal size of 10 cells. Qi et al. have described that there is an increase in T-cell clonality in the naive repertoire of the elderly; the contribution of clonally expanded T cells to the observed repertoire increased by a factor of >100 for naive CD8 and of >10 for naive CD4 T cells compared with young adults. See Qi et al. Proc. Natl. Acad. Sci. USA. 111.36(20140: 13139-44.
In certain embodiments, T cell clonality is increased or decreased in a subject, as determined by these methods, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% compared to a reference level, e.g., the clonality prior to treatment. In embodiments, the T cell clonality is increased or decreased, e.g., as determined by TCR-immunosequencing, by 1.5-fold to 1000-fold, e.g., 1.5- fold to 10-fold, 10-fold to 20-fold, 20-fold to 50-fold, 50-fold to 100-fold, 100-fold to 250-fold, 250-fold to 500-fold, or 500-fold to 1000-fold, compared to a reference level, e.g., the clonality prior to treatment.
Other markers of thymic structure/function include the formation of a plasma cell, development of an antigen- specific T cell, and/or formation of a thymic organoid. Yet another
marker of thymic structure/function comprises the formation of, or modulation (e.g., increase or decrease) in quantity, size, function, and/or distribution of, Hassall's corpuscles in the cell(s)/tissue(s)/organoid(s), compared to before the culture step(s).
The formation of a plasma cell (e.g., polyclonal plasma cell) can be determined by detection (e.g., using flow cytometry, e.g., FACS, and/or immunohistochemistry) of one or more surface markers, e.g., CD138, CD38, CD45, CD19, and/or the presence of kappa and/or lambda cytoplasmic immunoglobulin light chains in the cells. In embodiments, high expression of CD38 and CD138 (in conjunction with scatter properties of cells), e.g., in flow cytometric methods or immunohistochemical methods, can indicate presence of polyclonal plasma cells. Without wishing to be bound by theory, it is believed that CD45 and CD 19 are expressed on normal plasma cells; abnormal plasma cells lack CD19 and variably express CD45. Clonality can be confirmed based on the presence of either kappa or lambda cytoplasmic immunoglobulin light chains (or both) in the cells. In other embodiments, plasma cells (e.g., polyclonal plasma cells) can be detected using morphological analysis, e.g., in smear slides (e.g., stained with Giemsa). For example, mature plasma cells can be detected via their eccentric nuclei and basophilic cytoplasm with perinuclear halos. In some examples, morphological analysis is combined with cellular marker staining (e.g., CD138 or other cellular marker(s)).
Antigen-specific T cells can be identified and/or quantified. In embodiments, cells, e.g., T cells, are analyzed by in vitro stimulation of T cells, followed by identification of cells that are activated using one of the methods described herein. Exemplary methods include flow cytometry, intracellular cytokine staining (ICS), enzyme-linked immunospot (ELISpot), carboxyfluorescein succinimidyl ester (CFSE)-based methods, TCR sequencing, mass spectrometry based methods (e.g., CyTOF), and tetramer staining (e.g., detection of peptide- MHC multimers). In embodiments, pre-enrichment (e.g., magnetic pre-enrichment) can be used to pre-enrich rare antigen-specific T cells, e.g., in order to achieve a higher signal-to-noise ratio, increased sensitivity, and/or improved detection of antigen-specific T cells, e.g., within the naive and/or Treg compartment. ICS detects antigen-induced secretion of cytokines by blocking cytokine secretion by cells (e.g., trapping in Golgi/endoplasmic reticulum). ICS may provide more flexibility than ELISpot and can be performed on cryopreserved cells as well as fresh samples. ICS can be combined with MHC multimer staining and flow cytometry. ICS works well with Thl cells. ICS can detect a limited number of cytokines and does not permit analysis
of live cells. ICS typically provides supporting evidence of antigen specificity (e.g., in combination with another method, e.g., described herein). ELISpot detects antigen-induced secretion of cytokines using an enzyme linked immunosorbent assay (ELISA) based method. ELISpot is highly reproducible and sensitive and is suited for high-throughput analysis. ELISpot detects secreted cytokines at a single cell level, measures one or two parameters at a time, and requires cell purification to identify the source of the cytokine. ELISpot works well with Thl cells and does not permit analysis of live cells. CFSE based methods utilize the dye, 5,6- carboxyfluorescein diacetate succinimidyl ester, which is distributed evenly between daughter cells (of proliferating activated T-cells). Flow cytometry can identify antigen- specific T cells through antibodies specific for surface and/or cytoplasmic markers. Flow cytometry can be used to detect rare T cell populations and provides a quantitative analysis of lymphocytes expressing a specific TCR. For example, CD 154 (CD40L) is expressed after 5-7 hours of TCR stimulation by all naive and memory CD4 T-cells. Similarly, CD137 is expressed by Treg cells after 5-7 hours of antigen stimulation. Flow cytometry can detect these markers. In TCR-seq methods, TCR clones are sequenced; this provides comprehensive information about antigen-activated T cells. CyTOF is a mass spectrometry based approach that identifies antigen specificity; it allows analysis of over 40 parameters at a single cell level with moderate throughput. Detection of peptide-MHC multimers permits direct identification of T cells according to TCR binding, independently of functional status of T cells or antigen presenting cells (APCs). In this method, up to 100 different multimers can be combined in cytometric analysis using barcoding. For example, the peptide-MHC multimer method requires knowledge of antigens and epitopes, and works for pathogens with low antigen complexity and peptides. In some examples, differences in TCR specificities among individuals or within an individual, e.g., at different stages of disease, can be detected using the peptide-MHC multimer method.
Thymic organoids can be detected by the detection of one or more thymus cell markers, e.g., as described in Table 2 or Table 4, or the detection of a thymus structure, e.g., cortex and/or medulla.
Hassall's corpuscles are histologically distinct groups of epithelial cells present in the thymic medulla that are known to engage dendritic cells and facilitate production of CD4+ CD25+ FoxP3+ regulatory T cells (i.e., natural or thymic Tregs, nTregs.) See, e.g., Watanabe et al. Nature. 436(2005): 1181-85; or Skogberg et al. J. Immunol. 193(2014):2187-95, both
incorporated herein by reference. Therefore, changing the quantity, size, function, or distribution of Hassall's corpuscles can change the rate of generation of nTregs, their molecular properties, and their population in the bloodstream. In embodiments, a change in Hassall's corpuscles (e.g., in an ex vivo culture or in a subject treated with a therapy described herein) can be detected histologically and/or through a thymus exosome profile, e.g., as described in Skogberg et al. J. Immunol. 193(2014):2187-95, incorporated herein by reference. In embodiments, a subject treated with a therapy described herein, e.g., a cell culture/cell(s)/preparation described herein, a change in Hassall's corpuscles can be detected, e.g., by detecting a change in the number of sjTREC+, FoxP3+, and/or nTreg cells in the bloodstream of the subject. In other examples, a change in Hassall's corpuscles can be detected, e.g., by detecting a serum biomarker such as a secreted thymus exosome with distinct molecular properties.
Combinations
Combinations of agents used in methods such as ex vivo methods
In accordance with any method described herein, a method (e.g., ex vivo method described herein) can comprise contacting a source cell with a combination of thymic function modulators, e.g., thymic function modulators described herein. Combinations can include two or more, e.g., two, three, four, five, six, seven, eight, nine, ten or more thymic function modulators, e.g., thymic function factors described in Table 1 or modulators thereof.
In embodiments, combinations can include one or more of the following and/or modulators thereof:
(i) a chemokine listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional chemokine listed in Table 1 ;
(ii) a cytoplasmic protein listed in Table 1 with a chemokine, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional cytoplasmic protein listed in Table l;
(iii) an enzyme (phosphatase, protease, or proteinase) listed in Table 1 with a chemokine, cytoplasmic protein, hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional enzyme listed in Table 1 ;
(iv) a hormone (e.g., secreted hormone) listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional hormone (e.g., secreted hormone) listed in Table 1;
(v) a ligand (e.g., membrane bound or secreted ligand) listed in Table 1 with a
cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional ligand (e.g., membrane bound or secreted ligand) listed in Table 1 ;
(vi) a matrix protein listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional matrix protein listed in Table 1 ;
(vii) a transcription factor listed in Table 1 with a cytoplasmic protein, enzyme
(phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, receptor (e.g., cell surface receptor or nuclear receptor) or additional transcription factor listed in Table 1 ;
and/or
(viii) a receptor (e.g., cell surface receptor or nuclear receptor) listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, or additional receptor (e.g., cell surface receptor or nuclear receptor) listed in Table 1.
In other embodiments, combinations can include one or more of the following and/or modulators thereof:
(i) a T-cell activity factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, or additional T-cell activity factor listed in Table 1 ;
(ii) a T-cell growth factor listed in Table 1 with a T-cell activity factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, or additional T-cell growth factor listed in Table 1 ;
(iii) a T-cell growth factor receptor listed in Table 1 with a T-cell growth factor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional T-cell growth factor receptor listed in Table 1 ;
(iv) a T-cell migration factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional T-cell migration factor listed in Table 1 ;
(v) a TEC function factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, T-cell migration factor, or additional TEC function factor listed in Table 1 ;
(vi) a TEC growth factor listed in Table 1 with a T-cell growth factor, T-cell growth
factor receptor, T-cell migration factor, TEC function factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional TEC growth factor listed in Table 1 ;
(vii) a TEC growth factor receptor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional TEC growth factor receptor listed in Table 1 ;
(viii) a TEC proliferation factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC
growth factor receptor, thymus homeostasis factor, T-cell activity factor, or additional TEC proliferation factor listed in Table 1 ; or
(ix) a thymus homeostasis factor listed in Table 1 with a T-cell growth factor, T-cell
growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, T-cell activity factor, or additional thymus homeostasis factor listed in Table 1.
Combinations of agents used in methods such as treatment/use methods
Methods described herein can include administration of a cell culture, cell(s), or preparation thereof in combination with a second therapeutic agent or procedure. In
embodiments, the second therapeutic agent comprises one or more (e.g., any combination of) thymic function modulators, e.g., thymic function factors described in Table 1 or modulators thereof. Combinations can include two or more, e.g., two, three, four, five, six, seven, eight, nine, ten or more thymic function modulators.
In embodiments, combinations can include any one or more of the following or modulators thereof:
(ix) a chemokine listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional chemokine listed in Table 1 ;
(x) a cytoplasmic protein listed in Table 1 with a chemokine, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional cytoplasmic protein listed in Table l ;
(xi) an enzyme (phosphatase, protease, or proteinase) listed in Table 1 with a chemokine, cytoplasmic protein, hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional enzyme listed in Table 1 ;
(xii) a hormone (e.g., secreted hormone) listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), ligand (e.g., membrane bound or
secreted ligand), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional hormone (e.g., secreted hormone) listed in Table 1;
(xiii) a ligand (e.g., membrane bound or secreted ligand) listed in Table 1 with a
cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), matrix protein, transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional ligand (e.g., membrane bound or secreted ligand) listed in Table 1 ;
(xiv) a matrix protein listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), transcription factor, receptor (e.g., cell surface receptor or nuclear receptor) or additional matrix protein listed in Table 1 ;
(xv) a transcription factor listed in Table 1 with a cytoplasmic protein, enzyme
(phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, receptor (e.g., cell surface receptor or nuclear receptor) or additional transcription factor listed in Table 1 ;
and/or
(xvi) a receptor (e.g., cell surface receptor or nuclear receptor) listed in Table 1 with a cytoplasmic protein, enzyme (phosphatase, protease, or proteinase), hormone (e.g., secreted hormone), ligand (e.g., membrane bound or secreted ligand), matrix protein, transcription factor, or additional receptor (e.g., cell surface receptor or nuclear receptor) listed in Table 1.
In other embodiments, combinations can include any one or more of the following or modulators thereof:
(x) a T-cell activity factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, or additional T-cell activity factor listed in Table 1 ;
(xi) a T-cell growth factor listed in Table 1 with a T-cell activity factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC
growth factor receptor, TEC proliferation factor, thymus homeostasis factor, or additional T-cell growth factor listed in Table 1 ;
(xii) a T-cell growth factor receptor listed in Table 1 with a T-cell growth factor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional T-cell growth factor receptor listed in Table 1 ;
(xiii) a T-cell migration factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional T-cell migration factor listed in Table 1 ;
(xiv) a TEC function factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, T-cell migration factor, or additional TEC function factor listed in Table 1 ;
(xv) a TEC growth factor listed in Table 1 with a T-cell growth factor, T-cell growth
factor receptor, T-cell migration factor, TEC function factor, TEC growth factor receptor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional TEC growth factor listed in Table 1 ;
(xvi) a TEC growth factor receptor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC proliferation factor, thymus homeostasis factor, T-cell activity factor, or additional TEC growth factor receptor listed in Table 1 ;
(xvii) a TEC proliferation factor listed in Table 1 with a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, thymus homeostasis factor, T-cell activity factor, or additional TEC proliferation factor listed in Table 1 ; or
(xviii) a thymus homeostasis factor listed in Table 1 with a T-cell growth factor, T-cell
growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, T-cell activity factor, or additional thymus homeostasis factor listed in Table 1.
In embodiments, methods described herein (e.g., ex vivo methods or treatment/use methods) can comprise use of (e.g., administration of, or use of in an ex vivo method) one or more thymic function modulators, e.g., described herein, with one or more other therapy/agent. For example, methods can include use of a one or more of: a thymus homeostasis factor, a T-cell growth factor, T-cell growth factor receptor, T-cell migration factor, TEC function factor, TEC growth factor, TEC growth factor receptor, TEC proliferation factor, T-cell activity factor listed in Table 1, or a modulator thereof, optionally in combination with one or more other therapy/agent.
In embodiments, the combination of thymic function modulators and/or other therapies/agents can be formulated together or separately.
In addition, methods described herein can include use of (e.g., administration of, or use of in an ex vivo method) more than one thymic function modulator, e.g., thymic function modulator described herein. Methods described herein can also include use of a thymic function modulator (e.g., described herein) in combination with a different therapy or agent.
Other therapies or agents suitable for use in combination with a thymic function modulator described herein (e.g., in a method of use/treatment or an ex vivo method described herein) include but are not limited to a surgery, radiation, antimicrobial, or chemotherapy.
Exemplary antimicrobials include antibacterial, antiviral, antifungal, antimycobacterial, antihelmintic and/or antiprotozoan pharmaceutical compositions. In embodiments, antimicrobial compositions include Penicillins, Macrolides, Ketolides, Cephalosporins, and/or Streptomycin. In embodiments, an antimicrobial drug is selected from the group consisting of penicillin, amoxicillin, oxacillin, dicloxoacilline, clavulinic acid with a penicillin, bicillin, ticarcillin, piperacillin, taxobactam, cephalexin, cefazolin, cephaclor, ceftibuten, cefuroxime, cefprozil, cefotaxime, ceftazidime, cefepime, cifdinir, ceftriaxone, cefditoren, cefpodoxime, aztreonam, ertapenem, cefoxitin, meropenem, imipenem, erythromycin, clarithromycin, azithromycin, telithromycin, clindamycin, daptomycin, cycloserine, quinupristin, dalfopristin, streptomycin, vancomycin, linezolid and combinations thereof. In embodiments, an antimicrobial composition comprises penicillin, amoxicillin, oxacillin, dicloxoacilline, clavulinic acid with a penicillin, bicillin, ticarcillin, piperacillin, taxobactam, cephalexin, cefazolin, cephaclor, ceftibuten, cefuroxime, cefprozil, cefotaxime, ceftazidime, cefepime, cifdinir, ceftriaxone, cefditoren, cefpodoxime, aztreonam, ertapenem, cefoxitin, meropenem, imipenem, erythromycin,
clarithromycin, azithromycin, telithromycin, clindamycin, daptomycin, cycloserine, quinupristin, dalfopristin, streptomycin, vancomycin, linezolid, albendazole and mebendazole. In
embodiments, exemplary antimicrobial compositions are described in Table 3.
Table 3: Exemplary antimicrobial compositions
A. Antibacterial Drugs
Penicillins, e.g., benzylpenicillin, amoxicillin, ticarcillin,
piperacillin; Cephalosporins, e.g., cefpodoxime, cefuroxime, cefazolin,
cefalor, ceftibuten, cefprozil, cefotaxime, ceftazidime, dephaloexin,
cefepime, cefdinir, ceftriaxone, cefditoren; Macrolides, e.g.,
erythromycin, clarithromycin, spiramycin, roxithromycin, azithromycin;
Carbapenems, e.g., imipenen, meropenem; β-lactams, e.g., meropenem,
Monobactams (e.g., aztreonam), ertapenem, cefoxitin, imipenem;
Ketolides, e.g., telithromycin; Glycopeptides, e.g., vancomycin;
Lincosamides, e.g., clindamycin, lincomycin; Cyclic lipopeptide
antibacterial agents, e.g., daptomycin; Streptogamins, e.g.,
quinupristin, dalfopristin; Tetracyclines, e.g., doxycycline,
minocycline, tigecycline; Diarylquinoline; Oxazolidinones, e.g.,
linezolid.
B. Antimycobacterial Drugs
Rifampin, Rifabutin, Cycloserine, Isoniazid, Ethambutol,
Pyrazinamide.
C. Antiviral Drugs
Cidefovir, Foscarnet, Ganciclovir, Valganciclovir, Formivirisen,
Zidovudine, Zalcitabine, Didanosine, Stavudine, Lanivudine, Tenovir,
Emtricitabine, Nevirapine.
D. Antifungal Drugs
Fluconazole, Voriconazole, Itraconazole, Caspofungin,
Clotrimazole, Amphotericin B, Micafungin, Terbinafine, Naftifine,
Natamycin, Butenafine, Amorolfine, Ravuconazole, Posaconazole,
Flucytosine, Econazole, Enilaconazole, Miconazole, Oxiconazole,
Saperconazole, Sulconazole, Terconazole, Tioconazole, Nikkomycin Z,
Anidulafungin (LY303366), Nystatin, Pimaricin, Griseofulvin, Ciclopirox,
Haloprogin, Tolnaftate, Undecylenate.
E. Anthelmintic Drugs
[Mebendazole, Niclosamide, Praziquantel, Pyrantel, Thiabendazole,
Albendazole, diethyl carbamazine, Ivermectin, Benzimidazole,
Praziquantal/B enzimidazole combination .
F. Antiprotozoan Drugs
Pyrimethamine, Sulfadiazine, Clindamycin, Mebendazole,
Thiabendazole, Chloroquine
Exemplary chemotherapies include but are not limited to cisplatin, vinorelbine, etoposide, vinblastine, gemcitabine, docetaxel, pemetrexed, carboplatin, paclitaxel, albumin- bound paclitaxel, irinotecan, mitomycin, ifosfamide, erlotinib, bevacizumab, cetuximab, crizotinib, afatinib, ceritinib, ramucirumab, nivolumab, ceritinib, ramucirumab, topotecan, temozolomide, cyclophosphamide, doxorubicin, vincristine, or any combination thereof, e.g., for use in treating or in a subject having a cancer, e.g., lung cancer, e.g,. non-small cell lung cancer (NSCLC). In embodiments, a chemotherapy includes but is not limited to doxorubicin, cyclophosphamide, paclitaxel, doxetaxel, 5-fluorouracil, epirubicin, methotrexate, trastuzumab, pertuzumab, carboplatin, fluorouracil, or any combination thereof, e.g., for use in treating or in a subject having a cancer, e.g., a breast cancer. In embodiments, a chemotherapy includes but is not limited to cyclophosphamide, etoposide, busulfan, fludarabine, carmustine, etoposide, cytosine arabinoside, melphalan, thiotepa, anti-thymocyte globulin, or any combination thereof, e.g., for use in treating or in a subject having a hematological cancer, e.g., a lymphoma or leukemia, e.g., non-Hodgkin or Hodgkin lymphoma or in a subject who has had, is undergoing, or will undergo a cell transplant, e.g., hematopoietic cell transplant. In embodiments, one or more of chemotherapy, e.g., described herein, is combined with irradiation (e.g., total body irradiation or total lymphoid irradiation). Additional chemotherapeutic agents are described below.
In embodiments, the two or more treatments in the combination therapy are administered after the subject has been diagnosed with the disorder and before the disorder has been cured or eliminated or treatment has otherwise ceased. In some embodiments, the administration of the combination of treatments is simultaneous or concurrent, e.g., delivery of the second treatment begins while the delivery of one treatment is still ongoing, such that there is an overlap in administration. In other embodiments, the administration of the combination of treatments is sequential, e.g., delivery of a second treatment begins after delivery of one treatment ceases.
The two or more treatments (e.g., cell culture/cell(s)/preparation thereof, and/or thymic function modulators, and/or other agents/therapies) can be administered simultaneously, in the same or in separate compositions, or sequentially. For sequential administration, a cell culture/cell(s)/preparation thereof described herein can be administered first, a different therapy (e.g., thymic function modulator) can be administered second, or the order of administration can be reversed. In embodiments in which more than one thymic function modulator is administered in combination with a cell culture/cell(s)/preparation thereof, one thymic function modulator described herein can be administered first, and a different thymic function modulator can be administered second, or the order of administration can be reversed. In other embodiments, one thymic function modulator described herein can be administered first, and a different therapy/agent can be administered second, or the order of administration can be reversed.
In embodiments, treatment can be more effective due to the combination of treatments. In embodiments, a second treatment is more effective when administered in combination with the first treatment than in the absence of the first treatment. For example, an equivalent effect is seen with a lower dose of the second treatment, or the second treatment reduces a symptom to a greater degree, than if the second treatment were administered in the absence of the first treatment. In other examples, the combination of treatment reduces a symptom to a greater degree than either treatment delivered in the absence of the other. The effect of the multiple (e.g., two or more, e.g., three, four, five or more) treatments can be partially additive, wholly additive, or greater than additive. In some cases, the effect of the combination is synergistic.
Coupled thymic function modulators
In embodiments of any method or composition described herein, two or more thymic function modulators can be coupled together by a covalent bond, non-covalent bond, or chemical linkage, e.g., separated by a linker. In embodiments, the thymic function modulators are nucleic acid molecules (e.g., mRNAs, siRNAs, dsRNAs, shRNAs, miRNAs, or modified versions thereof) and disposed on a single nucleic acid molecule or on separate nucleic acid molecules. In the case where the thymic function modulators are disposed on the same nucleic acid molecule, e.g., mRNA, they can be separated by an IRES, e.g., they are translated into separate polypeptides. In embodiments, the thymic function modulators are polypeptides and are
disposed on a single polypeptide or on separate polypeptides. In the case where the thymic function modulators are disposed on a single polypeptide, they can be separated by a linker, e.g., peptide or chemical linker. In embodiments, the linker is a cleavable linker.
For example, a peptide linker can be a sequence of amino acids that physically connects polypeptide domains. For example, a peptide linker comprises one or more of the amino acids glycine and serine (e.g., comprises repetitive modules of glycine and serine). An exemplary peptide linker is (GGGGS)3. In other embodiments, a peptide linker comprises (GGGXX)nGGGGS and GGGGS(XGGGS)n wherein n is greater than or equal to 1 , and wherein X is an amino acid which reduces or eliminates the addition of a post-translational modification to the polypeptide upon expression in a host cell. In one embodiment, the peptide linker comprises the amino acid sequence (GGGGA)nGGGGS. In another embodiment, the peptide linker comprises the amino acid sequence (GGGGQ)2GGGGS. In yet another embodiment, the peptide linker comprises the amino acid sequence (GGGPS)2GGGGS. In still another
embodiment, the peptide linker comprises the amino acid sequence GGGGS(PGGGS)2. In a further embodiment, the peptide linker consists of the amino acid sequence (GGGGA)2GGGGS. In another embodiment, the peptide linker consists of the amino acid sequence
(GGGGQJ2GGGGS. In another embodiment, the peptide linker consists of the amino acid sequence (GGGPS)2GGGGS. In another embodiment, the peptide linker consists of the amino acid sequence GGGGS(PGGGS)2.
In embodiments, a peptide linker comprises a cleavable amino acid sequence, e.g., a protease or peptidase cleavage recognition sequence. For example, the protease or peptidase cleavage recognition sequence is cleavable by Factor XIa/FVIIa, matrix metalloprotease-1, HIV- 1 protease, NS3 protease, Factor Xa, furin, or cathepsin B. See, e.g., Chen et al. Adv. Drag Deliv. Rev. 65.10(2013): 1357-69 (e.g., at Table 3), incorporated herein by reference.
In embodiments, a peptide linker comprises a sequence described in Chen et al. Adv. Drug Deliv. Rev. 65.10(2013): 1357-69 (e.g., at Table 3), incorporated herein by reference.
Peptide linkers described herein can be of varying lengths. In one embodiment, a peptide linker is from about 5 to about 75 amino acids in length. In another embodiment, a peptide linker is from about 5 to about 50 amino acids in length. In another embodiment, a peptide linker is from about 10 to about 40 amino acids in length. In another embodiment, a 15 peptide linker is from about 15 to about 35 amino acids in length. In another embodiment, a
peptide linker is from about 15 to about 20- amino acids in length. In another embodiment, a peptide linker is from about 15 amino acids in length.
Peptide linkers may be attached to the N or to the C terminus (or both) of polypeptides to which they are attached.
In some embodiments, a chemical linker suitable for use in the
compositions/methods described herein is described in WO 08/109105, incorporated herein by reference. For example, a chemical linker, e.g., described in WO 08/109105, can link one or more peptides, polypeptides, antibody molecules, nucleic acid molecules, and/or small molecules. For example, a chemical linker, e.g., described in WO 08/109105, can link one or more RNA interfering molecule (e.g., siRNA, miRNA, or shRNA) and/or one or more mRNA molecule(s). Exemplary chemical linkers include but are not limited to a polymeric linking agent, e.g., a PEG, e.g., homobifunctional PEG linker, heterobifunctional PEG linker, homomultifunctional PEG linker, poly- (beta- amino ester) polymeric linker, PEG-PLGA-PEG triblock polymeric linker, e.g., as described in WO 08/109105. In some embodiments, a chemical linker comprises a polymer, e.g., a branched or unbranched hydrophilic polymer, e.g., polyamino acids, amino sugars, fatty acyl, glycerolipid, glycerophospholipid, sphinglipid, sterol lipid, prenol lipid, saccarolipid, polyketide, glucosamines, lipopolysaccarides, aminopolysaccarides, polyglutamic acids, poly(allylamines), polyethylene glycol (PEG), PEG derivatives, methoxy polyethylene glycol (mPEG), polypropylene glycol (PPG), poly(lactic acid), poly(glycolic acid), poly(ethylene-co-vinyl acetate) (EVAc), N-(2- hydroxypropyl)methacrylamides (HPMA), HPMA derivatives, poly(hydroxyalkanoates), poly(2-dimethylamino)ethyl methacrylate
(DMAEMA), poly(D,L lactic-co-glycolide) (PLGA), poly(lactic-co-glycolic acid) (PLGA), PLGA derivatives, poly(polypropylacrylic acid) (PPAA), poly(D,L-lactide)-block- methoxypolyethylene glycol (diblock), poly(ethyleneimine), poly(beta-aminoester), polyvinyl alcohol, poly(hydroxyethyl methacrylate), polyacrylamide, polyacrylic acid, polyethyloxazole, polyvinyl pyrrolidinone, and polysaccharides such as dextran, chitosan, alginates, hyaluronic acid, and any ratio of copolymers, grafted polymers, and grafted copolymers thereof, wherein said linking moiety further comprises at least two terminal reactive groups corresponding and reactive with two or more functional groups selected from the group consisting of: OH, -COOH, N-hydroxy succidimidyl ester (NHS), Imidazole amide, triazole amide, tetrazole amide, hydroxy benzotriazole ester (HOBt), l-hydroxy-7-azabenzotriazole ester (HOAt), 2,4-dinitrophenyl ester,
pentafluorophenyl ester, 2,2,2-trifluoroethyl ester, 2,2,2-trifluoroethyl thioester, acid chloride, acid bromide, 4-nitrophenyl carbonate (NPC), isocyanate, optionally substituted aldehyde, optionally substituted ketone, optionally substituted acrylate, maleimide, vinyl sulfone, and/or orthopyridyl disulfide.
Methods of treatment/use
Thymic Involution
In some aspects, featured herein are methods for decreasing or reversing thymic involution in a subject. Thymic involution is a process in which the thymus shrinks in size. Thymic involution occurs gradually with age or may be the result of a stress, e.g., trauma or disease. During the neonatal and developmental period of a mammal, the size and function of the thymus is at its greatest. Involution progresses as a mammal ages, leading to lower thymic function, e.g., less thymopoiesis (T cell maturation) and fewer naive T cells (which are self- tolerant and responsive to foreign antigens but have not been stimulated by a foreign agent). During involution, thymic tissue becomes replaced with adipose tissue. Thymic involution can also occur in a more acute fashion due to factors other than age, e.g., stresses such as therapies (e.g., chemotherapy), pregnancy, diseases or pathological conditions such as infections, and malnutrition.
Accordingly, provided herein are compositions and methods for reducing or preventing thymic involution (e.g., thymic involution from aging, from therapies, or from diseases). In embodiments, methods described herein include administering a cell culture, cell(s), or preparation thereof, e.g., described herein, to reduce or prevent thymic involution. The extent of thymic involution, e.g., before, during, and/or after treatment, can be assessed by determining thymic function, e.g., using methods described herein.
Thymus injury
Provided herein are compositions and methods for treating a thymus injury, e.g., acute or chronic thymus injury, e.g., using a cell culture, cell(s), or preparation thereof, e.g., described herein. In embodiments, a thymus injury comprises a drug-induced thymus injury or a radiotherapy induced thymus injury. In embodiments, a thymus injury includes a wounded thymus. For example, the drug can be a cytoreductive drug or a chemotherapeutic drug, e.g.,
alkylating agents such as thiotepa and CYTOXAN® cyclosphosphamide; a ky sulfonates such as busulfan, improsulfan and piposuifan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelaniine; acetogenins (especially bullatacin and bullatacinone); delta-9-tetrahydrocannabinol (dronabinol,
MARINOL®); beta-lapachone; lapachol; colchicines; betulinic acid; a camptothecin (including the synthetic analogue topotecan (H YC AMTIN® ) , CPT-11 (irinotecan, CAMPTOSAR®), acetylcarnptothecin, scopolectin, and 9-aminocamptothecin); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); podophyllotoxin;
podophyllinic acid; teniposide; cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB 1-TM1);
eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as
chlorambucil, chiornaphazine, c olophosphamide, estramustine, ifosfanide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimus ine, trofosfamide, uracil mustard; nitros ureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gamma II and calicheamicin omegall (see, e.g., Agnew, Chem. Intl. Ed. Engl., 33: 183-186 (1994)); dynemicin, including dynemicin A; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chroraophores), aciacinomysins, actinomycin, authramycin, azaserine, bleomycins,
cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including
ADRIAMYCIN®, morpholino-doxorubicin, cyanomoipholino-doxorubicin, 2-pyrroIino- doxorubicin, doxorubicin HC1 liposome injection (DOXIL®) and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, strepionigrin, streptozocin, tubercidin, ubemmex, zinostatin, zorabicin; anti-metabolites such as methotrexate, gemcitabine (GEMZAR®), tegafur (UFTORAL®), capecitabine (XELODA®), an epothilone, and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur,
cytarabine, dideoxyuridine, doxifiuridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacnne; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformiihiiie; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-(xichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine (ELDISINE®, FILDES1N®); dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C");
thiotepa; taxoids, e.g., paclitaxel (TAXOL®), albumin-engineered nanoparticle formulation of paclitaxel (ABRAXANE™), and doxetaxel (TAXOTERE®); chloranbucil; 6-thioguanine;
mercaptopurine; methotrexate; platinum analogs such as cisplatin and carbopladn; vinblastine (VELBAN®); platinum; etoposide (VP- 16); ifosfamide; mitoxantrone; vincristine
(ONCOVIN®); oxaliplatin; leucovovin; vinorelbine (NAVELBINE®); novantrone; edatrexate; daunomycin; aminopterin; cyclosporine, sirolimus, rapamycin, ibandronate; topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO); retinoids such as retinoic acid; CHOP, an abbreviation for a combined therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone, and FOLFOX, an abbreviation for a treatment regimen with oxaliplatin
(ELOXATIN™) combined with 5-FU, leucovovin; anti -estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX® tamoxifen), raloxifene (EVISTA®), droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY1 17018, onapristone, and toremifene (FARESTON®); anti-progesterones; estrogen receptor down- regulators (ERDs); estrogen receptor antagonists such as fulvestrant (FASLODEX®); agents that function to suppress or shut down the ovaries, for example, leutinizing hormone-releasing hormone (LHRH) agonists such as leuprolide acetate (LUPRON® and ELIGARD®), goserelin acetate, buserelin acetate and triptereiin; other anti-androgens such as flutamide, nilutaniide and bicalutamide; and aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles,
aminoglutethimide, megestrol acetate (MEGASE©), exemestane (AROMASIN©), formestanie, fadrozole, vorozole (RIVISOR®), letrozole (FEMARA©), and anastrozole (ARIMIDEX®); bisphosphonates such as clodronate (for example, BONEFOS® or OSTAC©), etidronate (DIDROCAL®), NE-58095, zoiedronic acid/zoledronate (ZOMETA®), alendronate
(FOSAMAX®), pamidronate (AREDIA®), tiludronate (SKELID®), or risedronate
(ACTONEL®); troxacitabine (a 1 ,3-dioxol.ane nucleoside cytosine analog); vaccines such as THERATOPE® vaccine and gene therapy vaccines, for example, ALLOVECTIN® vaccine, LEUVECTIN® vaccine, and VAXID® vaccine; topoisomerase 1 inhibitor (e.g.,
LURTOTECAN®); rmRH (e.g., ABARELIX®); iapatinib ditosylate (an ErbB-2 and EGFR dual tyrosine kinase small-molecule inhibitor also known as GW572016); CQX-2 inhibitors such as celecoxib (CELEBREX®; 4-(5-(4-niethylphenyl)-3-(trifluoromethyl)-l H-pyrazol-l- yl)benzenesulfonamide; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Exemplary chemo therapeutics are also described at
https://www.navigatingcancer.com/library/all/chemotherapy_drugs (accessed as of June 9, 2016), incorporated herein by reference.
In embodiments, a thymus injury can be acute, e.g., transient during treatment or infection or a physiological state (e.g., with a drug,radiation, Trypanosoma cruzi infection, pregnancy infection, pregnancy). For example, an acute thymus injury subsides (e.g., symptoms of thymus injury decrease in number and/or degree) within 1 year or less (e.g., 1 year, 12 months, 11 months, 10 months, 9 months, 8 months, 7 months, 6 months, 5 months, 4 months, 3 months, 2 months, 1 month, 6 weeks, 5 weeks, 4 weeks, 3 weeks, 2 weeks, 1 week, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day or less) after cessation of administration of a treatment (e.g., drug or radiation) or after resolution of an infection (e.g., Trypanosoma cruzi infection) or a physiological state (e.g., pregnancy). In other embodiments, a thymus injury can be chronic. For example, in a chronic thymus injury, symptoms and/or degree of symptoms persist for a period of time, e.g., at least 2 weeks, e.g., at least 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years, 15 years, 20 years, or more.
Replacing thymic function
Also provided herein are compositions and methods for replacing thymic function. For example, a cell culture, cell(s), or preparation thereof, e.g., described herein, is administered to a subject, e.g., in combination with a thymic transplant. In embodiments, the cell(s), e.g., in combination with the thymic transplant, increases the function/activity/lifetime of the
transplanted thymus compared to the level of function/activity/lifetime that would be seen if the thymic transplant occurred in the absence of the cell(s). Thymic function/activity can be assessed using methods described herein, e.g., in the "Measurement of thymus function" section. Exemplary dosing of the cell(s) in combination with a thymic transplant is described in greater detail in the Pharmaceutical compositions, administration, dosing section herein.
Physiological senescence
Also provided herein are compositions and methods for treating physiological senescence, e.g., reversing or delaying physiological senescence. The physiological senescence can be associated with muscle atrophy or degeneration, decrease in bone health (e.g., bone strength and/or density), immunosenescence (e.g., decrease in immune responsiveness), cardiac disease, or uncontrolled cell growth (e.g., tumorigenesis). In embodiments, treating
physiological senescence includes rejuvenating bone, muscle, and/or heart tissue. In
embodiments, senescence is characterized by a deterioration of one or more structures and/or functions of a cell, tissue, organ, or system of an organism. In embodiments, senescence can be due to aging (e.g., aging-associated senescence). In other embodiments, senescence can be non- aging associated, e.g., can be due to factors or processes other than aging/passage of time, e.g., can be therapy-induced (e.g., drug-induced, surgery-induced, and/or radiation-induced), disease- induced, and/or injury-induced. Immunosenescence is a type of senescence characterized by deterioration of the immune system, e.g., decreased immune responsiveness. Immunosenescence can be aging-associated or non-aging associated. Disease of aging can include those associated with immune aging (e.g., immunosenescence) or those not associated (directly associated) with immune aging. Accordingly, provided herein are compositions and methods for treating diseases of aging (e.g., osteoporosis, sarcopenia, amyotrophic lateral sclerosis (ALS) (e.g., sporadic or familial ALS), obesity, or diabetes). Also provided herein are compositions and methods for treating diseases of aging, e.g., immune aging (e.g., immunosenescence). For example, provided
herein is a method of reducing physiological senescence, e.g., reducing aging, e.g., rejuvenating bone and/or muscle, by administering a cell culture, cell(s), or preparation thereof, e.g., described herein. The reduction in physiological senescence/aging is at least 10%, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20- fold, 50-fold, or 100-fold, or more, compared to the extent of senescence/aging in a subject that has not been administered the cell(s) or in the subject prior to administration with the cell(s). Methods of quantifying senescence/aging include methods of assessing presence/progression of a condition/disease such as sarcopenia, osteoporosis, T-cell contraction, poor health/cardiac output, and/or reduced insulin sensitivity.
For example, the presence of or progression of osteoporosis can be detected by measuring bone density, e.g., by radiological assessments, and/or bone turnover markers. For example, bone density can be measured using dual-energy X-ray absorptiometry (DXA). For example, bone density can be measured using peripheral DXA (peripheral DXA) (which can measure bone mass at the forearm, finger, and heel), single-energy X-ray absorptiometry (SXA) (which can measure the heel or wrist), dual photon absorptiometry (DPA) (which can measure the spine, hip, or total body, single photon absorptiometry (SPA) (which can measure the wrist), quantitative computed tomography (QCT) (which can measure the spine or hip), peripheral QCT (PQCT) (which can measure the forearm), and/or quantitative ultrasound (QUS) (which can measure the heel or finger). The World Health Organization has defined threshold values for osteoporosis, where the reference measurement is derived from bone density measurements in a population of healthy young adults (T- score). Normal hip bone density corresponds to a T- score of -1 or above; osteopenia corresponds to a T-score lower than -1 and greater than -2.5; osteoporosis corresponds to a T-score of -2.5 or lower; and severe osteoporosis corresponds to a T-score of - 2.5 or lower and presence of at least one fragility fracture. See, e.g., World Health Organisation. Assessment of fracture risk and its implication to screening for postmenopausal osteoporosis: Technical report series 843. Geneva: WHO, 1994; and Kanis J. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359: 1929-36.
In some examples, sarcopenia can be diagnosed using DXA and/or measurement of gait speed. For example, sarcopenia is characterized by low muscle mass and low muscle strength and/or low physical performance. Muscle mass can be measured using computed tomography (CT), magnetic resonance imaging (MRI), DXA, bio-electrical impedance analysis (BIA),
determination of total or partial body potassium per fat-free soft tissue, and/or anthropmetry. Muscle strength can be determined by handgrip strength, knee flexion/extension, and/or peak expiratory flow. Physical performance can be determined by assessment of short physical performance battery (SPPB), usual gait speed, timed get-up-and-go test, cardiac stress test, and/or stair climb power test. See, e.g., Muscaritoli M, Anker S Argiles J, et al (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG). "Cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clinical Nutrition 29(2): 154-9; Sarcopenia: European consensus on definition and diagnosis, Report of the European Working Group on Sarcopenia in Older People," Age and Ageing Advance Access originally published online on April 13, 2010, Age and Ageing 2010 39(4):412-423; and/or Mithal A, Bonjour J-P, Boonen S, Burckhardt P, Degens H, El Hajj Fuleihan G, Josse R, Lips P, Morales Torres J, Rizzoli R, Yoshimura N, Wahl D.A., Cooper C, Dawson-Hughes B(2011) Impact of nutrition on muscle strength and performance in older adults. Osteoporosis International.
Insulin response/sensitivity and/or diabetes (e.g., Type I or Type II diabetes) can be determined by measuring fasting and 2-hour plasma glucose (both after 75 g oral tolerance test), AIC levels, islet autoantibody levels, insulin autoantibody levels, autoantibodies to GAD65, autoantibodies to tyrosine phosphatases IA-2/IA-2beta, and/or autoantibodies to zinc transporter 8 (ZnT8). See, e.g., Diabetes Care 2015;38(Suppl. 1):S8-S 16.
Obesity can be detected by basal/resting metabolic rate tests.
T cell contraction can be detected by TCR diversity analysis, e.g., spectratyping, TCR- Sequencing, and/or TREC analysis, e.g., described in greater detail herein.
ALS can be diagnosed by using electromyography (EMG) (which detects electrical activity in muscles), measuring nerve conduction velocity (NCV) (e.g., which can distinguish peripheral neuropathy or myopathy from ALS), and/or MRI (e.g., of the brain and spinal cord) (e.g., to rule out problems other than ALS, such as a spinal cord tumor, herniated disk in the neck, syringomyelia, or cervical spondylosis). In some examples, ALS is characterized by degeneration of lower motor neurons (in the spinal cord and brainstem), degeneration of upper motor neurons (in the brain), progressive spread of signs within a region to other regions, and the absence of evidence of other diseases that may explain the observed clinical/electrophysiological signs.
In other examples, provided herein is a method of treating diseases associated with aging or physiological senescence (e.g., osteoporosis, sarcopenia, ALS (e.g., sporadic or familial ALS), obesity, or diabetes), by administering a cell culture, cell(s), or preparation thereof, e.g., described herein. In embodiments, treatment results in the amelioration or disappearance of one or more symptoms of the disease.
Increasing immune response
Also provided herein are compositions and methods for increasing an immune response. In embodiments, methods described herein include administering a thymic function modulator, e.g., described herein, e.g., in Table 1, to increase an immune response in a subject. For example, the immune response is an immune response to a cancer, a vaccine response, or an immune response to an infection, e.g., chronic infection. Exemplary cancers include
hematological cancers or solid cancers. Exemplary solid cancers include uterine cancer, colon cancer, ovarian cancer, rectal cancer, skin cancer, stomach cancer, lung cancer, non-small cell carcinoma of the lung, breast cancer, cancer of the small intestine, testicular cancer, cancer of the anal region, cancer of the endocrine system, cancer of the thyroid gland, cancer of the
parathyroid gland, rectal cancer, renal-cell carcinoma, liver cancer, cancer of the esophagus, melanoma, cutaneous or intraocular malignant melanoma, uterine cancer, brain cancer, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, cancer of the adrenal gland, bone cancer, pancreatic cancer, cancer of the head or neck, epidermoid cancer, carcinoma of the endometrium, carcinoma of the vagina, cervical cancer, sarcoma, uterine cancer, stomach cancer, esophageal cancer, colorectal cancer, liver cancer, prostate cancer, carcinoma of the cervix squamous cell cancer, carcinoma of the fallopian tubes, sarcoma of soft tissue, cancer of the urethra, carcinoma of the vulva, cancer of the kidney or ureter, carcinoma of the renal pelvis, spinal axis tumor, cancer of the penis, cancer of the bladder, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, metastatic lesions of said cancers, and/or combinations thereof. In embodiments, the cancer is a hematological cancer, e.g., a leukemia or lymphoma. Exemplary hematological cancers include acute lymphoid leukemia (ALL); one or more chronic leukemias including, e.g., chronic myelogenous leukemia (CML), Chronic
Lymphoid Leukemia (CLL), B cell prolymphocytic leukemia; B-cell acute Lymphoid Leukemia ("BALL"); T-cell acute Lymphoid Leukemia ("TALL"); blastic plasmacytoid dendritic cell
neoplasm; Follicular lymphoma; diffuse large B cell lymphoma; non-Hodgkin lymphoma;
Hodgkin lymphoma; Burkitt's lymphoma; malignant lymphoproliferative conditions; Hairy cell leukemia; small cell- or large cell-follicular lymphoma; mantle cell lymphoma; MALT lymphoma; marginal zone lymphoma; multiple myeloma; myelodysplasia; myelodysplastic syndrome; Waldenstrom macroglobulinemia; plasmablastic lymphoma; and plasmacytoid dendritic cell neoplasm.
Vaccines include vaccines against an infection or cancer vaccines. For example, a vaccine comprises an antigen of interest and an adjuvant and/or matrix, e.g., carrier protein matrix, e.g., as described in US 8642042, or US 8,980,288 incorporated herein by reference. In embodiments, the antigen is derived from a pathogen, e.g., a pathogen described herein. In embodiments, the antigen is derived from a cancer, e.g., a cancer described herein. In
embodiments, the vaccine comprises an attenuated microorganism, e.g., expressing an immunogenic peptide. In some examples, cancer vaccines can include antigen presenting cells (APCs) loaded with one or more peptide epitopes from a cancer antigen, e.g., mesothelin, NY- ESO-1, Folate Binding Protein, HER2/neu, IL-13Ra2, MAGE-A1, and/or EphA2. Exemplary cancer vaccines are described in WO 2014127296 Al, US 20160114018, US 20160114017 , US 20160101169, US 20160058854 , US 20160030536 , US 20160022792 , US 20160015796, US 20150359867, US 20150306197, US 20150297698, US 20150297696, US 20150273034, US 20150258185, US 20150250864, US 20150202273, incorporated herein by reference. Infections can be acute or chronic. Infections can include bacterial infections or viral infections.
In embodiments, persistent infection is caused by a pathogen from one of the 3 major categories:
i) viruses, including the members of the Retroviridae family such as the lentiviruses (e.g. Human immunodeficiency virus (HIV) and deltaretroviruses (e.g., human T cell leukemia virus I (HTLV-I), human T cell leukemia virus II (HTLV-II)); Hepadnaviridae family (e.g. hepatitis B virus (HBV)), Flaviviridae family (e.g. hepatitis C virus (HCV)), Adenoviridae family (e.g. Human Adenovirus), Herpesviridae family (e.g. Human cytomegalovirus (HCMV), , Epstein- Barr virus, herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), human herpesvirus 6 (HHV-6), varicella- zoster virus), PapiUomaviridae family (e.g. Human Papillomavirus (HPV)), Parvoviridae family (e.g. Parvovirus B 19), Polyomaviridae family (e.g. JC virus and BK virus),
Paramyxoviridae family (e.g. Measles virus), Togaviridae family (e.g. Rubella virus) as well as other viruses such as hepatitis D virus;
ii) bacteria, such as those from the following families: Salmonella (e.g. S. enterica Typhi), Mycobacterium (e.g. M. tuberculosis and M. leprae), Yersinia (Y. pestis), Neisseria (e.g. N. meningitides, N. gonorrhea), Burkholderia (e.g. B. pseudomallei), Brucella, Chlamydia, Helicobacter, Treponema, Borrelia and Pseudomonas; and
iii) parasites, such as Leishmania, Toxoplasma, Trypanosoma, Plasmodium, Schistosoma, or Encephalitozoon.
In embodiments, a cell culture, cell(s), or preparation thereof, e.g., described herein, is administered in combination with a cancer immunotherapy. Without wishing to be bound by theory, it is believed that such a combination increases adaptive immunity in the subject, as RNAs induce an innate immunity response. In embodiments, such a combination is synergistic, e.g., in terms of the anti-cancer immune response elicited, compared to either the cell(s) or the cancer immunotherapy alone. Exemplary cancer immunotherapies include cell-based therapies (e.g., chimeric antigen receptor (CAR)-expressing immune cells), antibody therapies (e.g., cytotoxic or radioactive antibodies, cytokine therapies (e.g., interferons or interleukins), and immune checkpoint inhibitors.
Decreasing immune response
Also provided herein are compositions and methods for decreasing an immune response, e.g., to prevent rejection of a transplant, or to induce negative selection, e.g., to treat an autoimmune disease. In embodiments, methods described herein comprise administering a cell culture, cell(s), or preparation thereof, e.g., described herein. Transplants can include organ transplants, e.g., lung, heart, eye, liver, or kidney transplant. Exemplary autoimmune diseases include but are not limited to rheumatoid arthritis, juvenile oligoarthritis, collagen -induced arthritis, adjuvant-induced arthritis, Sjogren's syndrome, multiple sclerosis, experimental autoimmune encephalomyelitis, inflammatory bowel disease (for example, Crohn's disease, ulcerative colitis), autoimmune gastric atrophy, pemphigus vulgaris, psoriasis, vitiligo, type 1 diabetes, non-obese diabetes, myasthenia gravis. Grave's disease, Hashimoto's thyroiditis, sclerosing cholangitis, sclerosing sialadenitis, systemic lupus erythematosis, autoimmune thrombocytopenia purpura, Goodpasture's syndrome, Addison's disease, systemic sclerosis,
polymyositis, dermatomyositis, autoimmune hemolytic anemia, primary biliary cirrhosis, celiac disease, psoriatic arthritis, ankylosing spondylitis, Guillain-Barre syndrome, ALS, and pernicious anemia.
Subject characteristics
In accordance with any method described herein, a subject comprises a mammal, e.g., a human (e.g., a male or female of any age group, e.g., an adult subject (e.g., young adult, middle-aged adult, or senior adult) or pediatric subject (e.g., infant, child, or adolescent); primate (e.g., cynomolgus monkey or rhesus monkey); cattle; pig; horse; sheep; goat; cat; or dogs. The subject can be a subject from which a source cell is derived (e.g., for ex vivo cultures/methods) or a subject treated or to be treated with a therapy described herein.
In embodiments, the subject is an adult subject, e.g., a subject at least 18 years or older, e.g., 18, 19, 20, 21 , 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90 years or older. In embodiments, the subject is a geriatric subject, e.g., older than 60, 65, 70, 75, 80, 85, or 90 years of age. In embodiments, the subject is a pediatric subject, e.g., younger than 18 years, e.g., younger than 18, 16, 14, 12, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 year, 12 months, 11 months, 10 months, 9 months, 8 months, 7 months, 6 months, 5 months, 4 months, or younger.
In embodiments, the subject has an implanted thymus.
In embodiments, the subject has a cancer, e.g., a hematological cancers or solid cancer, such as lung cancer, non-small cell lung cancer (NSCLC), skin cancer, melanoma, cervical cancer, uterine cancer, ovarian cancer, breast cancer, pancreatic cancer, stomach cancer, esophageal cancer, colorectal cancer, liver cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, sarcoma, lymphoma, and brain cancer. In embodiments, the cancer is a solid cancer. Exemplary solid cancers include breast cancer, uterine cancer, colon cancer, ovarian cancer, rectal cancer, skin cancer, stomach cancer, non-small cell carcinoma of the lung (NSCLC), cancer of the small intestine, testicular cancer, cancer of the anal region, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, rectal cancer, renal-cell carcinoma, liver cancer, cancer of the esophagus, melanoma, cutaneous or intraocular malignant melanoma, uterine cancer, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, cancer of the adrenal gland, bone cancer, pancreatic cancer, cancer of the head or neck, epidermoid cancer, carcinoma of the endometrium, carcinoma of the vagina, carcinoma
of the cervix squamous cell cancer, carcinoma of the fallopian tubes, sarcoma of soft tissue, cancer of the urethra, carcinoma of the vulva, cancer of the kidney or ureter, carcinoma of the renal pelvis, spinal axis tumor, cancer of the penis, cancer of the bladder, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, metastatic lesions of said cancers, and/or combinations thereof. In embodiments, the cancer is a hematological cancer, e.g., a leukemia or lymphoma. Exemplary hematological cancers include acute lymphoid leukemia (ALL); one or more chronic leukemias including, e.g., chronic myelogenous leukemia (CML), Chronic Lymphoid Leukemia (CLL), B cell prolymphocytic leukemia; B-cell acute Lymphoid Leukemia ("BALL"); T-cell acute Lymphoid Leukemia ("TALL"); blastic plasmacytoid dendritic cell neoplasm; Follicular lymphoma; diffuse large B cell lymphoma; non- Hodgkin lymphoma; Hodgkin lymphoma; Burkitt's lymphoma; malignant lymphoproliferative conditions; Hairy cell leukemia; small cell- or large cell-follicular lymphoma; mantle cell lymphoma; MALT lymphoma; marginal zone lymphoma; multiple myeloma; myelodysplasia; myelodysplastic syndrome; Waldenstrom macroglobulinemia; plasmablastic lymphoma; and plasmacytoid dendritic cell neoplasm.
In embodiments, the subject has an infection, e.g., a chronic infection or acute infection. In embodiments, the infection is bacterial or viral.
In embodiments, the subject has an autoimmune disease, e.g., rheumatoid arthritis, juvenile oligoarthritis, collagen-induced arthritis, adjuvant-induced arthritis, Sjogren's syndrome, multiple sclerosis, experimental autoimmune encephalomyelitis, inflammatory bowel disease (for example, Crohn's disease, ulcerative colitis), autoimmune gastric atrophy, pemphigus vulgaris, psoriasis, vitiligo, type 1 diabetes, non-obese diabetes, myasthenia gravis, Grave's disease, Hashimoto's thyroiditis, sclerosing cholangitis, sclerosing sialadenitis, systemic lupus erythematosis, autoimmune thrombocytopenia purpura, Goodpasture's syndrome, Addison's disease, systemic sclerosis, polymyositis, dermatomyositis, autoimmune hemolytic anemia, primary biliary cirrhosis, celiac disease, psoriatic arthritis, ankylosing spondylitis, Guillain-Barre syndrome, ALS, and/or pernicious anemia.
Pharmaceutical compositions, administration, dosing
Provided herein are pharmaceutical compositions comprising a cell culture, cell(s), or preparation thereof, e.g., described herein. Pharmaceutical compositions can comprise a cell
culture, cell(s), or preparation thereof, e.g., described herein, combined with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Pharmaceutical compositions can comprise a buffer, e.g., phosphate buffered saline or neutral buffered saline; proteins; polypeptides/amino acids, such as glycine; pantioxidants; chelating agents, e.g., EDTA or glutathione; carbohydrates, e.g., glucose, sucrose, mannose, dextrans, or mannitol; adjuvants such as aluminum hydroxide; and preservatives.
Pharmaceutical compositions can further comprise a second therapeutic agent, e.g., as described herein.
Compositions described herein can be formulated for intravenous, oral, or subcutaneous administration. The administration of the compositions described herein can be carried out in manners such as by ingestion, transfusion, aerosol inhalation, injection, implantation, or transplantation. In embodiments, the compositions described herein can be administered to a subject orally or parenterally (e.g., intravenously, intramuscularly, subcutaneously, intraorbitally, intracapsularly, intraperitoneally, intrarectally, intracisternally, intratumorally, intravasally, intradermally). In embodiments, the compositions described herein can be infused or injected into the subject. In embodiments, the compositions can be administered to the site of a target tissue, for example, intravenously or intra-arterially into a blood vessel supplying a tumor. The compositions described herein can be administered directly into the thymus, lymph node, tumor, or site of infection.
The dose and dosing frequency can be determined by factors such as the condition of the patient and the type and severity of the patient's disease. In embodiments, a cell culture, cell(s), or preparation thereof, e.g., described herein, is dosed chronically, e.g., for an extended or indefinite period of time, e.g., at least 2 weeks, e.g., at least 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years, 15 years, 20 years, or more. In embodiments, a cell culture, cell(s), or preparation thereof, e.g., described herein, is dosed transiently, e.g., for a period of time no longer than 1 year, e.g., 1 year, 12 months, 11 months, 10 months, 9 months, 8 months, 7 months, 6 months, 5 months, 4 months, 3 months, 2 months, 1 month, 6 weeks, 5 weeks, 4 weeks, 3 weeks, 2 weeks, 1 week, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, or less. For example, a cell culture, cell(s), or
preparation thereof, e.g., described herein, is dosed until a thymic function improves and/or a symptom of a disease described herein subsides.
Without wishing to be bound by theory, it is believed that a cell culture, cell(s), or preparation thereof, e.g., described herein, can boost or maintain function of a transplanted thymus in a subject. Accordingly, methods described herein include dosing (e.g., long-term dosing) of a cell culture, cell(s), or preparation thereof, e.g., described herein, in a subject that has undergone, will be undergoing, or is undergoing a thymic (e.g., thymic cell and/or tissue) transplant). In embodiments, the cell culture, cell(s), or preparation thereof, e.g., described herein, is administered for an extended or indefinite period of time, e.g., at least 2 weeks, e.g., at least 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years, 15 years, 20 years, or more. In embodiments, administration of the cell culture, cell(s), or preparation thereof, e.g., described herein, commences before or after, or simultaneously with transplantation of the thymus cell/tissue. In embodiments, administration of the cell culture, cell(s), or preparation thereof, e.g., described herein, commences before, e.g., at least 1 day (e.g., at least 2, 3, 4, 5, 6, 7 days, 1, 2, 3, 4, 5, 6 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years, 15 years, 20 years, or more) before, the transplantation of the thymus cell/tissue. In embodiments, administration of the cell culture, cell(s), or preparation thereof, e.g., described herein, commences after e.g., at least 1 day (e.g., at least 2, 3, 4, 5, 6, 7 days, 1, 2, 3, 4, 5, 6 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years, 15 years, 20 years, or more) after, the transplantation of the thymus cell/tissue. In embodiments,
administration of the cell culture, cell(s), or preparation thereof, e.g., described herein, commences within 5 months, e.g., within 5 months, 4 months, 3 months, 2 months, 1 month, 6 weeks, 5 weeks, 4 weeks, 3 weeks, 2 weeks, 1 weeks, 7 days, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day, 24 h, 12 h, 6 h 3 h 1 h or less, of the transplantation of the thymus cell/tissue.
In embodiments, the pharmaceutical composition is substantially free of, e.g., there are no detectable levels of a contaminant. Exemplary contaminants include an endotoxin, replication competent lentivirus (RCL), VSV-G nucleic acid, HIV gag, p24, mycoplasma, mouse antibodies,
bovine serum albumin, bovine serum, pooled human serum, culture media components, a bacterium, vector packaging cell or plasmid components, and a fungus.
An effective amount of a cell culture, cell(s), or preparation thereof, e.g., described herein, can be determined by a physician with consideration of individual differences in disease, weight, age, extent of degeneration/infection/tumor
growth/metastasis/senescence/autoimmunity/thymic injury, and condition of the subject.
In some embodiments, the subject is assessed for the level of the cell culture, cell(s), or preparation thereof, e.g., described herein, or other agent at periodic times during the treatment regimen, e.g., to ensure that the cell culture, cell(s), or preparation thereof, e.g., described herein, or other agent is present at a threshold level over the course of the therapy. In one example, the agent is administered in a controlled release formulation. The overall period of time over which a particular treatment regimen is followed by a subject may vary depending on the response and health of the subject but typically is at least one month, 6 weeks, 2 months, 3 months, 6 months, 9 months, a year, 18 months, 2 years or more.
In certain embodiments, the agents (e.g., cell culture, cell(s), or preparation thereof, e.g., described herein, or other agents) described herein are administered in doses of 0.01-10 mg/kg, 0.05-5 mg/kg, 0.1-5 mg/kg, 0.2-5 mg/kg, 0.5-5 mg/kg, 0.5-1 mg/kg, 0.5-5 mg/kg, 0.5-10 mg/kg, 1-10 mg/kg, 1-5 mg/kg, or any combination thereof.
All references and publications cited herein are hereby incorporated by reference.
The following examples are provided to further illustrate some embodiments of the present invention, but are not intended to limit the scope of the invention; it will be understood by their exemplary nature that other procedures, methodologies, or techniques known to those skilled in the art may alternatively be used.
EXAMPLES
Example 1; Treated thymi from aged mouse donors compared to untreated thymi for reconstitution of T cell development in nude mice
The thymus organ is extracted from aged and young mice (over 18 months of age, and 6- 10 weeks of age, respectively). The organ is processed for in vitro culture of thymic epithelial cell sections as described in Kim et al. J. Immunol. 194.10(2015):4784-95; and Markert et al. Clin. Immunol. Immunopathol. 81.1(1997):26-36. A portion of the thymus tissue is cultured with a therapeutic agent and a portion cultured only in cell culturing medium. The therapeutic agent is one or more of the following molecules: KGF, FGF21, SCF, IGF-1, IL-7, IL-12, IL-21, IL-22, Flt3L, GH/Ghrelin, FOXNl or a synthetic mRNA encoding KGF, FGF21, SCF, IGF-1, IL-7, IL- 12, IL-21, IL-22, Flt3L, GH/Ghrelin, or FOXNl.
In one experiment, the cultured thymic epithelial cells (TECs) are maintained in culture and analyzed for their ability to expand and survive for extended periods of time while maintaining their functional characteristics of TEC. Functional characteristics of TEC are measured by the expression of TEC markers, such as one or more of: cytokeratins K5 and K8, FOXNl, MHC Class 2, AIRE, DLL4, CCL25, CXCL12, and/or SCF. The cells are also enumerated at sequential time points following culture and assessed for their proliferative capacity. Proliferative capacity is measured by the incorporation of a DNA intercalator, e.g., BrdU or EdU, and expression of the proliferative marker Ki-67.
TECs derived from treated thymi are expected to exhibit superior ability to be cultured and expanded in vitro (e.g., superior survival and/or proliferation) compared to the untreated thymi.
In another experiment, the thymic epithelial cells (TEC) from the first experiment (e.g., from treated or untreated thymic tissue) are then transplanted under the kidney capsule of nude mice as described in Parent et al. Cell Stem Cell. 13.2(2013):219-29; and Su et al. Sci. Rep. 5(2015):9882. 8-20 weeks following transplantation, the grafts are analyzed for the presence of thymic morphology and for expression of TEC markers, including cytokeratins K5 and K8, FOXNl, MHC Class 2, AIRE, DLL4, CCL25, CXCL12, and/or SCF. The thymus graft is analyzed for the presence and relative proportion of the different thymocyte subsets using flow cytometry, including CD4 CD8 double negative cells, CD4 CD8 double positive cells, CD4 single positive T cells, CD8 single positive T cells, and the subsets within the double negative
cell population (DN1-4 stages, as measured by their expression of cell surface molecules CD25 and CD44). Blood and secondary lymphoid organs are analyzed for successful restoration of T cell development, measured by the number of T cells and their phenotype. For example, T cell phenotype refers to the proportion of CD4+ vs. CD8+ T cells, FoxP3+ CD4+ Treg, CD44 neg. CD62L pos. naive T cells measured by flow cytometry, the diversity of T cell receptor repertoire by TCR sequencing (Han et al. Nat. Biotechnol. 32.7(2014):684-92), and/or quantification of T cell receptor excision circle (TREC) (Mensen et al. J. Translat. Med. 11.188(2013); and Al- Harthi et al. J. Immunol. Methods 237.1-2(2000): 187-97). Young thymus serves as a positive control and the old thymus as a negative control.
TECs from the treated old thymus tissue are expected to be superior to those from the untreated old tissue and more similar or better compared to TECs from the young thymus tissue in successfully engrafting to generate a functional organ and in reconstituting T cell development in nude mice.
Example 2: Treated thymi from elderly human donors compared to untreated thymi for reconstitution of T cell development in nude mice
The thymus organ is extracted from elderly and young human donors (over 65 years of age, and under 2 years of age, respectively). Organs may be derived from a necessary removal during major unrelated surgery procedure or from a cadaver. The organ is processed for in vitro culture of thymic epithelial cell (TEC) sections as described in Markert et al. Clin. Immunol. Immunopathol. 81.1(1997):26-36. A portion of the thymus tissue is cultured with a therapeutic agent and a portion cultured only in cell culturing medium. Therapeutic agent is one or more of the following molecules: KGF, FGF21, SCF, IGF-1, IL-7, IL-12, IL-21, IL-22, Flt3L,
GH/Ghrelin, FOXN1 or a synthetic mRNA encoding KGF, FGF21, SCF, IGF-1, IL-7, IL-12, IL- 21, IL-22, Flt3L, GH/Ghrelin, or FOXN1.
In a first experiment, the cultured thymic epithelial cells (TECs) are maintained in culture and analyzed for their ability to expand and survive for extended periods of time while maintaining their functional characteristics of TEC. Functional characteristics of TEC are measured by the expression of TEC markers, including cytokeratins K5 and K8, FOXN1, MHC Class 2, AIRE, DLL4, CCL25, CXCL12, and/or SCF. The cells are also enumerated at sequential time points following culture and assessed for their proliferative capacity as measured
by the incorporation of a DNA intercalator, e.g., BrdU or EdU, and expression of the proliferative marker Ki-67.
TECs derived from the treated old thymi are expected to exhibit superior ability to be cultured and expanded in vitro (e.g., superior survival and/or proliferation) compared to the untreated thymi.
In a second experiment, the thymic epithelial cells (TEC) from the first experiment (e.g., from treated or untreated thymic tissue) are then transplanted under the kidney capsule of nude mice that have been irradiated and depleted of NK cells by injecting anti-asialo-GMl as described in Khan et al. Transplantation 63.1(1997): 124-31 ; and Su et al. Sci. Rep.
5(2015):9882. 8-20 weeks following transplantation, the grafts are analyzed for the presence of thymic morphology and for expression of TEC markers, including cytokeratins K5 and K8, FOXN1, MHC Class 2, AIRE, DLL4, CCL25, CXCL12, and/or SCF. The thymus graft is analyzed for the presence and relative proportion of the different thymocytes subsets using flow cytometry, including CD4 CD8 double negative cells, CD4 CD8 double positive cells, CD4 single positive T cells, CD8 single positive T cells, and the subsets within the double negative cell population (DN1-4 stages as measured by their expression of cell surface molecules CD25 and CD44). Blood and secondary lymphoid organs are analyzed for successful restoration of T cell development, measured by the number of T cells and their phenotype. The T cell phenotype is assessed by the proportion of CD4+ vs. CD8+ T cells, FoxP3+ CD4+ Treg, CD44 neg. CD62L pos. naive T cells measured by flow cytometry, the diversity of T cell receptor repertoire by TCR sequencing (Han et al. Nat. Biotechnol. 32.7(2014):684-92), and/or quantification of T cell receptor excision circle (TREC) (Mensen et al. J. Translat. Med. 11.188(2013); and Al-Harthi et al. J. Immunol. Methods 237.1-2(2000): 187-97). Young thymus serves as a positive control and the old thymus as a negative control.
The TECs from the treated old thymus tissue are expected to be superior to TECs from untreated old tissue and more similar or better compared to the TECs from young thymus tissue in successfully engrafting to generate a functional organ and in reconstituting T cell development in nude mice.
In a third experiment, the thymic epithelial cells (TECs) from the first experiment (e.g., from treated or untreated thymic tissue) are then transplanted under the kidney capsule of NOG (NOO/Shi-Prkdcscid Il2rgtmlSu8/hc) mice (Ito et al. Blood 100.9(2002)3175-82; and Watanabe et
al. Int. Immunol. 21.7(2009):843-58) crossed to nude mice (NOG-nu/nu) or NOD/LtSz-scid (also known as NOD-SCID-hu) as described in Okamoto et al. Blood 99.8(2002):2851-58. The mice also receive autologous CD34+ stem cells from the human donor. 8-20 weeks following transplantation, the grafts are analyzed for the presence of thymic morphology and for expression of TEC markers, including cytokeratins K5 and K8, FOXN1, MHC Class 2, AIRE, DLL4, CCL25, CXCL12, and/or SCF. The thymus graft is analyzed for the presence and relative proportion of the different human thymocyte subsets using flow cytometry, including CD4 CD8 double negative cells, CD4 CD8 double positive cells, CD4 single positive T cells, CD8 single positive T cells, and the subsets within the double negative cell population (DN1-4 stages as measured by their expression of cell surface molecules CD25 and CD44). Blood and secondary lymphoid organs are analyzed for successful restoration of T cell development, measured by the number of T cells and their phenotype. The T cell phenotype is assessed by the proportion of CD4+ vs. CD8+ T cells, FoxP3+ CD4+ Treg, CD44 neg. CD62L pos. naive T cells measured by flow cytometry, the diversity of T cell receptor repertoire by TCR sequencing (Han et al. Nat. Biotechnol. 32.7(2014):684-92), and/or quantification of T cell receptor excision circle (TREC) (Mensen et al. J. Translat. Med. 11.188(2013); and Al-Harthi et al. J. Immunol. Methods 237.1- 2(2000): 187-97). Young thymus serves as a positive control and the elderly thymus as a negative control.
The TECs from treated old thymus tissue are expected to be superior to TECs from untreated old tissue and more similar or better compared to the TECs from young thymus tissue in successfully engrafting to generate a functional organ and in reconstituting T cell development in nude mice.
Example 3: Treatment of irradiation-induced lymphopenia in mice by increasing thymic T cell proliferation and survival
Cytoreductive conditioning regimens such as chemotherapy or irradiation that are used in the context of allogeneic bone marrow transplantation (BMT) elicit deficits in innate and adaptive immunity, which predispose patients to infections. As such, transplantation outcomes depend on the successful reconstruction of immune competence. Restoration of a normal peripheral T-cell pool after hematopoietic cell transplantation (HCT) is a slow process that requires de novo production of naive T cells in a functionally competent thymus.
To study reconstitution of the peripheral immune system after BMT, the well-described clinically relevant MHC-matched BMT model is used (Schroeder et al. Disease Models & Mechanisms 2011 4: 318-333). Lethally irradiated (9.5 Gy) C57BL/6 CD45.1 mice are injected intravenously with 1x10 T cell depleted bone marrow cells from C57BL/6 CD45.2 mice (Frasca et al. Bone Marrow Transplantation (2000) 25, 427-433).
Irradiated mice are injected subcutaneously, every other day for 10 days with IL-7, IL-21, and a combination thereof, at previously titrated concentration.
The kinetics of peripheral T cell reconstitution is measured by weekly flow cytometric analysis of blood cells. Tail blood samples are collected once a week starting on day 5 after BMT and are stained for CD3, CD4, CD8, CD31, CD45.1, CD45.2, TCRy5, FoxP3, CD56, CD 19, and a cell viability dye before acquisition on a flow cytometer.
Mice are euthanized at week 2, 4 or 6 post BMT for analyzing the number and
composition of thymic T cells, as well as the composition and function of peripheral immune cells. Thymi are removed, dissociated and stained for CD3, CD45.1, CD45.2, CD44, CD28, CD127, CD25, FoxP3, TCRb, CD8 and a viability dye. These markers allow the detection of newly produced donor versus host derived thymocytes at the different stages of differentiation. Cells from peripheral blood, lymph nodes and spleens are stained for CD3, CD4, CD8, CD31, CD45.1, CD45.2, TCRy5, FoxP3, CD56, CD19 and a viability dye, for assessing the amount of donor versus host derived T cells that have been newly exported from the thymus. Function of peripheral T cells is assessed by analyzing in vitro proliferation and cytokine production in response to polyclonal stimulation. For intracellular cytokine staining, splenocytes are isolated and stimulated with PMA and ionomycin in the presence of brefeldin A for 4 hours. Cells are stained for CD3, CD4, CD8, CD45.1 and CD45.2 and fixed using a fixation/permeabilization buffer (eBioscience) and processed according to manufacturer's suggestion (see eBioscience protocol B2 for intracellular staining) to determine the T cell composition in each spleen. After intracellular staining for the effector cytokines IL-17, IFNy and IL-2 that are a surrogate for T cell function, cells are acquired and analyzed by flow cytometer. Proliferation is assessed by staining T cells with a proliferation dye (CellTrace Violet) according to the manufacturer' s instructions. Labeled cells are cultured (100,000 cells/ 200 μΐ) in 96-well microtiter plates with coated CD3 antibody (1 μg/ml) and soluble CD28 antibody (1 μg/ml). Proliferation is measured
by flow cytometry on day 3 after staining with antibodies for CD3, CD4, CD8, CD45.1, and CD45.2 and a viability dye.
A treatment with IL-7 and/or IL-21 accelerates the thymic production of T cells, as reflected by an increase of thymocytes at different stages of differentiation and an accelerated reconstitution of the peripheral T cell compartment that is reflected by a faster increase of functional T cells in the periphery (blood and lymphatic organs such as spleen and lymph nodes).
Example 4: Treatment of immunodeficient mice by enhancing thymic T cell development and function
Immunodeficient mice engrafted with human immune systems provide an exciting model to study human immunobiology in an in vivo setting without placing patients at risk. Co- implantation of human hematopoietic stem cells (HSCs) with autologous fetal liver and thymic tissues into immunodeficient mice create a humanized model with optimal human T cell development. Humanized mice are generated using human HSC derived from a number of sources, including umbilical cord blood, G-CSF mobilized peripheral blood, bone marrow and fetal liver. Co-implantation of human fetal thymic tissues with autologous fetal liver derived HSC provide human thymic epithelium that is essential for T cell education. See for example, Methods Mol Biol. 2014; 1185: 267-278.
To study reconstitution of the peripheral immune system after BMT, the model described herein is used. NOO-Prkdcscid IL2rgTmlWjl (NSG) mice between 8 to 12 weeks of age are irradiated with 200 cGy, 1mm pieces of fetal thymic and liver are inserted into the kidney capsule at the posterior lateral side with a scalpel, and 2xl05 CD34+ fetal liver hematopoietic cells are injected intravenously, see, Methods Mol Biol. 2014; 1185: 267-278.
Mice are injected subcutaneously, every other day for 10 days with SCF alone, IL-7 alone, KGF alone, and a combination of SCF/IL-7/KGF, at previously titrated concentrations.
The kinetics of peripheral T cell reconstitution is measured by weekly flow cytometric analysis of blood cells. Tail blood samples are collected once a week starting on day 5 after BMT and are stained for CD3, CD4, CD8, CD31, CD45.1, CD45.2, TCRy5, FoxP3, CD56, CD 19, and a cell viability dye before acquisition on a flow cytometer.
Mice are euthanized at week 2, 4 or 6 post surgery and injection for analyzing the number and composition of transplanted T cells, as well as the composition and function of peripheral
immune cells. Tissue transplants are removed, dissociated and stained for CD3, CD29 (HLA- A2), CD44, CD28, CD127, CD25, FoxP3, TCRb, CD8 and a viability dye. These markers allow the detection of newly produced human thymocytes at the different stages of differentiation. Cells from peripheral blood, lymph nodes and spleens are stained for CD3, CD4, CD8, CD31, CD29 (HLA-A2), TCRy5, FoxP3, CD56, CD19 and a viability dye, for assessing the amount of T cells. Function of peripheral T cells is assessed by analyzing in vitro proliferation and cytokine production in response to polyclonal stimulation. For intracellular cytokine staining, splenocytes are isolated and stimulated with PMA and ionomycin in the presence of brefeldin A for 4 hours. Cells are stained for CD3, CD4, CD8 and CD29 and fixed using a
fixation/permeabilization buffer (eBioscience) and processed according to manufacturer's suggestion (see eBioscience protocol B2 for intracellular staining) to determine the T cell composition in each tissue transplant. After intracellular staining for the effector cytokines IL- 17, IFNy and IL-2 that are a surrogate for T cell function, cells are acquired and analyzed by flow cytometer. Proliferation is assessed by staining T cells with a proliferation dye (CellTrace Violet) according to the manufacturer's instructions. Labeled cells are cultured (100,000 cells/ 200 μΐ) in 96-well microtiter plates with coated CD3 antibody (1 μg/ml) and soluble CD28 antibody (1 μg/ml). Proliferation is measured by flow cytometry on day 3 after staining with antibodies for CD3, CD4, CD8 and CD29 and a viability dye.
SCF augments the number of early stage CD4-CD8- thymocytes, while IL-7 increases the number of CD4-CD8-, CD4+CD8+, CD4+CD8- and CD8+CD4- thymocytes and accelerates the reconstitution of the peripheral T cell compartment that is reflected by a faster increase of functional T cells in the periphery (blood and lymphatic organs such as spleen and lymph nodes). KGF has a positive impact on the number of thymic epithelial cells (TECs) as well as the number of thymocytes and peripheral T cells.
Claims
1. A method of providing (e.g., making/providing) a thymic culture.
2. The method of the previous claim comprising:
contacting a source cell (e.g., a population of cells, e.g., cells isolated from a thymus tissue or T cells of a subject, e.g., a cell described herein) with one or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more) thymic function modulator described herein; and
culturing the cell (e.g., a population of cells) under conditions sufficient to produce a cell (e.g., population of cells) with thymic function (e.g., cells having one or more marker of thymus function described herein).
3. A method of producing (e.g., making/providing) a cell having a thymic function.
4. The method of the previous claim comprising:
(a) providing a source cell from a subject;
(b) forming an ex vivo reaction mixture comprising the source cell and one or more thymic function modulator (e.g., a thymic function modulator described herein), thereby producing the cell having the thymic function.
5. The method of the previous claim further comprising expanding, selecting, and/or
purifying the cell having the thymic function from (b).
6. The method of the previous claim, wherein the purification or selection step comprises using a fluorescently labeled molecule (e.g., antibody or fragment thereof and/or a dye) that binds to one or more cell surface markers for thymic function.
7. The method of the previous claim, wherein the purification or selection step comprises using fluorescence activated cell sorting (FACS).
8. The method of the previous claim, wherein the purification or selection step comprises using a bead (e.g., magnetic bead) coated with an antibody (or fragment thereof) that binds to one or more cell surface markers for thymic function
9. The method of any one of the previous claims further comprising expanding the cell (e.g., population of cells) having the thymic function.
10. The method of the previous claim, wherein the expansion comprises increasing the
number of the cells by at least about 2-fold, e.g., at least about 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 50-, 100-, 1000-, 104-, 105-fold, or more.
11. The method of any one of the previous claims further comprising producing a
preparation, e.g., pharmaceutical preparation, comprising the cell having the thymic function.
12. The method of the previous claim, wherein the thymic function modulator is present in the preparation at a concentration of less than 15% by weight, e.g., less than 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, 0.01%, or less.
13. The method of the previous claim, wherein the thymic function modulator is present at no less than 0.005% (by weight) in the preparation.
14. The method of any one of the previous claims, wherein the preparation comprises 106- 1010 cells, e.g., 107-1010 cells, 108-1010 cells, 109-1010 cells, 106-107 cells, 106-108 cells, 106-109 cells, 107-109 cells, 107-108 cells, or 108-109 cells.
15. An ex vivo reaction mixture comprising a source cell and a thymic function modulator, wherein the source cell is derived from a sample from a subject.
16. A composition (e.g., pharmaceutical preparation, e.g., purified preparation) comprising a cell(s) having thymic function described herein, e.g., produced by a method described herein.
17. The composition of the previous claim comprising a thymic function modulator present at a concentration of at least 0.001% by weight (e.g., at least 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, or more).
18. The composition of the previous claim comprises a trace amount of a thymic function modulator, e.g., wherein the thymic function modulator is present at a concentration of less than 1% by weight, e.g., less than 0.5%, 0.1%, 0.05%, 0.01%, or less.
19. A method of:
(i) improving thymus function (e.g., decreasing, reversing, or preventing thymic involution, treating a thymic injury, treating a thymus related disease or condition (e.g., aging-related disease or condition), or replacing/augmenting thymic function);
(ii) modulating, e.g., treating, physiological senescence (e.g., reversing, reducing the rate of, or delaying physiological senescence;
(iii) enhancing, e.g., increasing, an immune response;
(iv) decreasing an immune response;
(v) treating an infectious disease;
(vi) preventing a transplant rejection; and/or
(vii) treating an autoimmune disease,
in a subject in need thereof, comprising
administering to the subject a thymic culture described herein or a cell or preparation thereof having thymic function as described herein, thereby performing one or more of (i)-(vii) in the subject.
20. The method of the previous claim comprises administering the cell (e.g., population of cells) having thymic function or a preparation thereof described herein to the subject.
21. The method of the previous claim, wherein the cell (e.g., population of cells) having thymic function or preparation thereof is produced using a method described herein.
22. The method of any one of the previous claims, wherein the cell(s) having thymic
function, or preparation thereof, has at least one (at least 2, 3, 4, 5, 6, 7) increased marker of thymus function described herein relative to the source cell (e.g., increased by at least 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 80%, 90%, 100% or more).
23. The method of any one of the previous claims, wherein the cell is from the same subject that is receiving the treatment for any of (i)-(vii), e.g., the cell is an autologous cell.
24. The method of any one of the previous claims further comprising obtaining the cell (e.g., population of cells) from the same subject or a different subject.
25. The composition or method of any one of the previous claims, wherein the thymic
function factor can be characterized by one or more, e.g., one, two, three, four, five, or all, of the following:
(a) increases the proliferation or cell count of stromal cells or non-adipocyte cells (e.g., as assessed by proliferation assays, e.g., Ki67 staining), e.g., by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, or more;
(b) changes the stromal/non- stromal cellular balance in the thymus (e.g., as assessed by ultrasound, histological analysis, or FDG avidity via PET imaging), e.g., an increase or decrease in the ratio of stromal to non-stromal cells, e.g., an increase of decrease in the ratio of thymic epithelial cells to thymocytes, or an increase or decrease in the ratio of adipocytes to thymocytes;
(c) increases thymic hormonal production and/or levels; wherein the thymic hormone is associated with thymic size, e.g., thymulin (e.g., as assessed by rosette inhibition assay, e.g., as described in Consolini et al.), e.g., by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, or more.
(d) changes in peripheral T cell phenotype, e.g., measuring changes in thymic emigrant profile (e.g., as assessed by comparing levels of different T cell populations, e.g., comparing percentages of T cells and clonal populations of T cells with unique TCRs that are FoxP3 positive, e.g., Tregs);
(e) polyclonality of B-cell response or emergence of a particular antibody (e.g., as assessed by changes in B-cell isotype distribution or polyclonal antibody titers to an antigen of interest, or particular set of thymus-dependent antigens); and/or
(f) changes in thymocyte flux (e.g., as assessed by determining TRECs per number of cells, e.g., over time).
26. The composition or method of any one of the previous claims, wherein the thymic
function factor comprises a T cell growth factor, a T cell growth factor receptor, a T cell proliferation factor, a T cell migration factor, a T cell activity factor, a thymic epithelial cell (TEC) proliferation factor, a thymic epithelial cell (TEC) growth factor, a thymic
epithelial cell (TEC) growth factor receptor, a thymic epithelial cell (TEC) function factor, or a thymus homeostasis factor
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662361070P | 2016-07-12 | 2016-07-12 | |
US62/361,070 | 2016-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018013589A1 true WO2018013589A1 (en) | 2018-01-18 |
Family
ID=60953406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/041566 WO2018013589A1 (en) | 2016-07-12 | 2017-07-11 | Methods and compositions for thymic transplantation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018013589A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019152767A1 (en) * | 2018-02-02 | 2019-08-08 | Wake Forest University Health Sciences | Organoids related to immunotherapy and methods of preparing and using the same |
CN110499288A (en) * | 2019-09-17 | 2019-11-26 | 青岛华赛伯曼医学细胞生物有限公司 | The kit and its application that external evoked candidate stem cell breaks up to thymus T cells |
WO2022011007A1 (en) * | 2020-07-08 | 2022-01-13 | The Jackson Laboratory | Transgenic mouse models supporting human innate immune function |
WO2022271862A1 (en) * | 2021-06-23 | 2022-12-29 | Thymmune Therapeutics, Inc. | Thymic cell compositions and methods of use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100178700A1 (en) * | 2007-05-03 | 2010-07-15 | Australian Stem Cell Centre Ltd. | Novel thymic cellular populations and uses thereof |
US20140101786A1 (en) * | 2010-12-31 | 2014-04-10 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Generation of autologous t-cells in mice |
US20160120945A1 (en) * | 2013-02-15 | 2016-05-05 | The Brigham And Women's Hospital, Inc. | Thymic Regeneration |
WO2017095940A1 (en) * | 2015-11-30 | 2017-06-08 | Flagship Pioneering, Inc. | Methods and compositions relating to chondrisomes from cultured cells |
-
2017
- 2017-07-11 WO PCT/US2017/041566 patent/WO2018013589A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100178700A1 (en) * | 2007-05-03 | 2010-07-15 | Australian Stem Cell Centre Ltd. | Novel thymic cellular populations and uses thereof |
US20140101786A1 (en) * | 2010-12-31 | 2014-04-10 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Generation of autologous t-cells in mice |
US20160120945A1 (en) * | 2013-02-15 | 2016-05-05 | The Brigham And Women's Hospital, Inc. | Thymic Regeneration |
WO2017095940A1 (en) * | 2015-11-30 | 2017-06-08 | Flagship Pioneering, Inc. | Methods and compositions relating to chondrisomes from cultured cells |
Non-Patent Citations (1)
Title |
---|
LEGRAND ET AL.: "Human Thymus Regeneration and T Cell Reconstitution", SEMINARS IN IMMUNOLOGY, vol. 19, 9 November 2007 (2007-11-09), pages 280 - 288, XP022371001 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019152767A1 (en) * | 2018-02-02 | 2019-08-08 | Wake Forest University Health Sciences | Organoids related to immunotherapy and methods of preparing and using the same |
CN110499288A (en) * | 2019-09-17 | 2019-11-26 | 青岛华赛伯曼医学细胞生物有限公司 | The kit and its application that external evoked candidate stem cell breaks up to thymus T cells |
WO2022011007A1 (en) * | 2020-07-08 | 2022-01-13 | The Jackson Laboratory | Transgenic mouse models supporting human innate immune function |
WO2022271862A1 (en) * | 2021-06-23 | 2022-12-29 | Thymmune Therapeutics, Inc. | Thymic cell compositions and methods of use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cheng et al. | Tumor‐associated macrophages in liver cancer: from mechanisms to therapy | |
US20220105133A1 (en) | Tumor infiltrating lymphocytes and methods of therapy | |
US20210179687A1 (en) | Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer | |
EP3645036A1 (en) | Cellular immunotherapy for repetitive administration | |
WO2018013589A1 (en) | Methods and compositions for thymic transplantation | |
US20200323905A1 (en) | Methods and compositions for modulating the immune system | |
CN113710691A (en) | Amplification of natural killer and chimeric antigen receptor modified cells | |
JP2024510505A (en) | Methods for tumor-infiltrating lymphocyte (TIL) expansion and gene knockout in TILs associated with CD39/CD69 selection | |
JP2017533707A (en) | Compositions and methods for stimulating and expanding T cells | |
CN114981415A (en) | Systems and methods for enhanced immunotherapy | |
US20230041057A1 (en) | Treatment methods | |
EP3402508A1 (en) | Methods and compositions for modulating thymic function | |
KR20220148859A (en) | Lymphocyte populations and methods of producing them | |
EP4031655A2 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
US20220033464A1 (en) | Methods and compositons for modulations of immune response | |
WO2018013585A1 (en) | Methods and compositions for modulating thymic function | |
JP2022512538A (en) | Anti-LMP2 TCR-T cell therapy for the treatment of EBV-related cancers | |
WO2023092097A1 (en) | Fragment consensus methods for ultrasensitive detection of aberrant methylation | |
US20210338725A1 (en) | Treatment methods | |
Wang et al. | Novel insights based on the plasticity of T cells in the tumor microenvironment | |
US20240226166A1 (en) | CD8(+) Stem-Like Chronic Memory Cell Based Therapies and Compositions Related Thereto | |
WO2023078287A1 (en) | Systems and methods for enhanced immunotherapies | |
Kerr | Modulation of T Cells to Promote an Anti-Tumor Response: Activation And Inhibition Of T Cells For Efficacy In T-Cell Lymphomas And Melanoma | |
Zanon | Stem cell-like properties of memory T cells in human immune reconstitution | |
Idri | Low-dose chemotherapy combined with NK cell-based immunotherapy as a treatment for triple negative breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17828325 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17828325 Country of ref document: EP Kind code of ref document: A1 |